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Chapter 1, summarising the comparative performance of OECD countries, and a special chapter on
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Annalisa Belloni, David Morgan, Michael Mueller, Luke Slawomirski and Marie-Clémence Canaud;
Chapter 11 by Tim Muir, Yuki Murakami, Gaétan Lafortune, Marie-Clémence Canaud and Nelly Biondi.
This publication benefited from useful comments from Francesca Colombo.HEALTH AT A GLANCE 2015 © OECD 2015 3

TABLE OF CONTENTSTable of contents
Executive summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Reader’s guide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Chapter 1. Dashboards of health indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Health status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Risk factors to health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Access to care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Quality of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Health care resources. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Chapter 2. Pharmaceutical spending trends and future challenges . . . . . . . . . . . . . . . . 29
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
One in every five health dollars is spent on pharmaceuticals . . . . . . . . . . . . . . . . . . 30
The share of private funding of pharmaceuticals increases . . . . . . . . . . . . . . . . . . . 32
Pharmaceutical expenditure growth is driven by changes in quantity, prices
and therapeutic mix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Drivers of spending growth vary across therapeutic areas. . . . . . . . . . . . . . . . . . . . . 38
New challenges in the pharmaceutical market . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Chapter 3. Health status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Life expectancy at birth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Life expectancy by sex and education level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Mortality from cardiovascular diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Mortality from cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Mortality from transport accidents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Suicide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Infant mortality. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Infant health: Low birth weight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Perceived health status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Cancer incidence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Chapter 4. Non-medical determinants of health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Tobacco consumption among adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Alcohol consumption among adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Fruit and vegetable consumption among adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Obesity among adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Overweight and obesity among children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76HEALTH AT A GLANCE 2015 © OECD 2015 5
TABLE OF CONTENTSChapter 5. Health workforce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Doctors (overall number) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Doctors by age, sex and category . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Medical graduates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
International migration of doctors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Remuneration of doctors (general practitioners and specialists) . . . . . . . . . . . . . . . 88
Nurses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Nursing graduates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
International migration of nurses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Remuneration of nurses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Chapter 6. Health care activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Consultations with doctors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Medical technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Hospital beds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Hospital discharges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Average length of stay in hospitals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Cardiac procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Hip and knee replacement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Caesarean sections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Ambulatory surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Chapter 7. Access to care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Coverage for health care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Unmet needs for medical care and dental care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Out-of-pocket medical expenditure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Geographic distribution of doctors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Waiting times for elective surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Chapter 8. Quality of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Avoidable hospital admissions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Diabetes care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Prescribing in primary care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Mortality following acute myocardial infarction (AMI) . . . . . . . . . . . . . . . . . . . . . . . . 138
Mortality following stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Waiting times for hip fracture surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Surgical complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Obstetric trauma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Care for people with mental health disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Screening, survival and mortality for cervical cancer . . . . . . . . . . . . . . . . . . . . . . . . 150
Screening, survival and mortality for breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Survival and mortality for colorectal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Childhood vaccination programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Influenza vaccination for older people . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Patient experience with ambulatory care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Chapter 9. Health expenditure and financing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Health expenditure per capita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
Health expenditure in relation to GDP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
Health expenditure by function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Financing of health care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170HEALTH AT A GLANCE 2015 © OECD 20156
TABLE OF CONTENTSExpenditure by disease and age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
Capital expenditure in the health sector . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Chapter 10. Pharmaceutical sector . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Pharmaceutical expenditure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
Financing of pharmaceutical expenditure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
Pharmacists and pharmacies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Pharmaceutical consumption. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
Share of generic market. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Research and development in the pharmaceutical sector . . . . . . . . . . . . . . . . . . . . . 188
Chapter 11. Ageing and long-term care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
Demographic trends. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
Life expectancy and healthy life expectancy at age 65 . . . . . . . . . . . . . . . . . . . . . . . 194
Self-reported health and disability at age 65 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
Dementia prevalence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
Recipients of long-term care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
Informal carers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
Long-term care workers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Long-term care beds in institutions and hospitals . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Long-term care expenditure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
Annex A. Additional information on demographic and economic context,
and health expenditure and financing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
Look for the StatLinks2at the bottom of the tables or graphs in this book. 
To download the matching Excel® spreadsheet, just type the link into your 
Internet browser, starting with the http://dx.doi.org prefix, or click on the link from 
the e-book edition.
Follow OECD Publications on:
This book has... StatLinks2
A service that delivers Excel   files from the printed page! ®
http://twitter.com/OECD_Pubs
http://www.facebook.com/OECDPublications
http://www.linkedin.com/groups/OECD-Publications-4645871
http://www.youtube.com/oecdilibrary
http://www.oecd.org/oecddirect/ 
OECD
AlertsHEALTH AT A GLANCE 2015 © OECD 2015 7

EXECUTIVE SUMMARYExecutive Summary
Health at a Glance 2015 presents cross-country comparisons of the health status of
populations and the performance of health systems in OECD countries, candidate
countries and key emerging economies. This edition offers two new features: a set of
dashboard indicators on health outcomes and health systems (presented in Chapter 1),
which summarise the comparative performance of OECD countries; and a special chapter
on recent trends in pharmaceutical spending across OECD countries. The key findings of
this publication are as follows.
New drugs will push up pharmaceutical spending unless policy adapts
● Across OECD countries, pharmaceutical spending reached around USD 800 billion in
2013. This amounts to about 20% of total health spending on average when
pharmaceutical consumption in hospital is added to the purchase of pharmaceutical
drugs in the retail sector.
● The growth of retail pharmaceutical spending has slowed down in recent years in most
OECD countries, while spending on pharmaceuticals in hospital has generally increased.
● The emergence of new high-cost, specialty medicines targeting small populations and/or
complex conditions has prompted new debate on the long-term sustainability and
efficiency of pharmaceutical spending.
Life expectancy continues to rise, but widespread differences persist across
countries and socio-demographic groups
● Life expectancy continues to increase steadily in OECD countries, rising on average by 3-
4 months each year. In 2013, life expectancy at birth reached 80.5 years on average, an
increase of over ten years since 1970. Japan, Spain and Switzerland lead a group of eight
OECD countries in which life expectancy now exceeds 82 years.
● Life expectancy in key emerging economies, such as India, Indonesia, Brazil and China,
has increased over the past few decades, converging rapidly towards the OECD average.
There has been much less progress in countries such as South Africa (due mainly to the
epidemic of HIV/AIDS) and the Russian Federation (due mainly to a rise in risk-
increasing behaviours among men).
● Across OECD countries, women can expect to live more than 5 years longer than men,
but this gap has narrowed by 1.5 years since 1990.
● People with the highest level of education can expect to live six years longer on average
than those with the lowest level. This difference is particularly pronounced for men,
with an average gap of almost eight years.HEALTH AT A GLANCE 2015 © OECD 2015 9
EXECUTIVE SUMMARYThe number of doctors and nurses has never been higher in OECD countries
● Since 2000, the number of doctors and nurses has grown in nearly all OECD countries,
both in absolute number and on a per capita basis. The growth was particularly rapid in
some countries that had fewer doctors in 2000 (e.g., Turkey, Korea, Mexico and the United
Kingdom), but there was also a strong rise in countries that already had a relatively large
number of doctors (e.g., Greece, Austria and Australia).
● Growth was pushed by increased student intakes in domestic medical and nursing
education programmes, as well as by more foreign-trained doctors and nurses working
in OECD countries in response to short-term needs.
● There are more than two specialist doctors for every generalist on average across the
OECD. In several countries, the slow growth in the number of generalists raises concerns
about access to primary care for all the population.
Out-of-pocket spending remains a barrier to accessing care
● All OECD countries have universal health coverage for a core set of services, except
Greece, the United States and Poland. In Greece, the economic crisis led to a loss in
health insurance coverage among long-term unemployed and many self-employed
workers. However, since June 2014, measures have been taken to provide the uninsured
population with access to prescribed pharmaceuticals and emergency services. In the
United States, the percentage of the population uninsured has come down from 14.4% in
2013 to 11.5% in 2014 following the implementation of the Affordable Care Act and is
expected to diminish further in 2015.
● Out-of-pocket spending by households can create barriers to health care access. On
average across OECD countries, about 20% of health spending is paid directly by patients,
ranging from less than 10% in France and the United Kingdom to over 30% in Mexico,
Korea, Chile and Greece. In Greece, the share of health spending paid directly by
households has increased by 4 percentage points since 2009, as public spending was
reduced.
● Low-income households are four to six times more likely to report unmet needs for
medical care and dental care for financial or other reasons than those with high income.
In some countries, like Greece, the share of the population reporting some unmet
medical care needs has more than doubled during the economic crisis.
Too many lives are still lost because quality of care is not improving
fast enough
● Better treatment of life-threatening conditions such as heart attack and stroke has led to
lower mortality rates in most OECD countries. On average, mortality rates following
hospital admissions for heart attack fell by about 30% between 2003 and 2013 and for
stroke by about 20%. Despite the progress achieved so far, there is still room in many
countries to improve the implementation of best practices in acute care to further
reduce mortality after heart attack and stroke.
● Survival has also improved for many types of cancer in most countries, due to earlier
diagnosis and better treatment. For example, the relative five-year survival for breast
cancer and colorectal cancer has increased from around 55% on average for people
diagnosed and followed up in the period 1998-2003 to over 60% for those diagnosed and
followed up ten years later (2008-13). Still, several countries such as Chile, Poland and theHEALTH AT A GLANCE 2015 © OECD 201510
EXECUTIVE SUMMARYUnited Kingdom are still lagging behind the best performers in survival following
diagnosis for different types of cancer.
● The quality of primary care has improved in many countries, as illustrated by the
continuing reduction in avoidable hospital admissions for chronic diseases. Still, there is
room in all countries to improve primary care to further reduce costly hospital
admissions, in the context of population ageing and a growing number of people with
one or more chronic diseases.
● Pharmaceutical prescribing practices can also be used as indicators of health care
quality. For example, antibiotics should be prescribed only where there is an evidence-
based need, to reduce the risk of antimicrobial resistance. Total volumes of antibiotic
consumption vary more than four-fold across OECD countries, with Chile, the
Netherlands and Estonia reporting the lowest, and Turkey and Greece reporting the
highest. Reducing unnecessary antibiotic use is a pressing, yet complex problem,
requiring multiple co-ordinated initiatives including surveillance, regulation and
education of professionals and patients.HEALTH AT A GLANCE 2015 © OECD 2015 11

READER’S GUIDEReader’s guide
Health at a Glance 2015 presents comparisons of key indicators of health and health
system performance across the 34 OECD countries, as well as for candidate and key
partner countries where possible (Brazil, China, Colombia, Costa Rica, India, Indonesia,
Latvia, Lithuania, the Russian Federation and South Africa). The data presented in this
publication come mainly from official national statistics, unless otherwise indicated.
Content of the publication
This new edition of Health at a Glance contains two main new features: 1) a series of
dashboards are presented in Chapter 1 to summarise, in a clear and user-friendly way, the
relative strengths and weaknesses of OECD countries on a selected set of key indicators on
health and health system performance which are presented in other chapters of this
publication; and 2) a special focus is put on the pharmaceutical sector, including an
analysis of recent trends and future challenges in the management of pharmaceutical
expenditure in Chapter 2, as well as a new chapter on the pharmaceutical sector
(Chapter 10), combining both indicators that were previously shown in other chapters and
some new indicators based on the two-page format used in most of this publication.
The general framework underlying the indicators presented in this publication
assesses the performance of health systems in the context of a broader view of public
health (Figure 0.1). It is based on a framework that was endorsed for the OECD Health Care
Quality Indicators project (Kelley and Hurst, 2006; Arah et al., 2006). This framework
recognises that the goal of health systems is to improve the health status of the population.
Many factors influence health status, including a number that fall outside health care
systems, such as the physical environment in which people live, and individual lifestyles
and behaviours. The performance of health care systems also contributes obviously to the
health status of the population. This performance includes several dimensions, including
the degree of access to care and the quality of care provided. Performance measurement
also needs to take into account the financial resources required to achieve these access and
quality goals. The performance of health systems depends also greatly on the health
workers providing the services, and the training and equipment at their disposal. Finally, a
number of contextual factors also affect the health status of the population and the
demand for and supply of health services also need to be taken into account, including the
demographic context, and economic and social development.
Health at a Glance 2015 compares OECD countries on each component of this general
framework.HEALTH AT A GLANCE 2015 © OECD 2015 13
Following the first two new chapters presenting the set of dashboards of indicators
and the special focus on pharmaceutical expenditure, Chapter 3 on health status highlights
variations across countries in life expectancy, some of the main causes of mortality and
other measures of population health status. This chapter also includes measures of
inequality in health status by education and income level for key indicators such as life
expectancy and perceived health status.
Chapter 4 on non-medical determinants of health focuses on health-related lifestyles
and behaviours, including tobacco smoking, alcohol drinking, nutrition, and overweight
and obesity problems among children and adults. Most of these factors can be modified by
public health and prevention policies.
Chapter 5 looks at the health workforce, focusing on the supply and remuneration of
doctors and nurses in OECD countries. This chapter presents trends in the number of new
graduates from medical and nursing education programmes and also features new
indicators on the international migration of doctors and nurses, highlighting the fact that
the number and share of foreign-trained doctors and nurses has increased in many OECD
countries over the past decade.
Chapter 6 on health care activities describes some of the main characteristics of health
service delivery in different OECD countries, starting with the number of consultations
with doctors (which is often the “entry point” of patients to health care systems),
hospitalisation rates, the utilisation rates of different diagnostic and surgical procedures,
as well as the development of ambulatory surgery for interventions such as cataract
surgery and tonsillectomy.
Chapter 7 on access to care presents a set of indicators related to financial access to
care, geographic access, and timely access (waiting times), as well as indicators of self-
reported unmet needs for medical care and dental care.
Figure 0.1. Conceptual framework for health system performance assessment
Source: Adapted from Kelley, E. and J. Hurst (2006).
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READER’S GUIDEChapter 8 examines quality of care or the degree to which care is delivered in
accordance with established standards and improves health outcomes. It provides
comparisons on quality of care for chronic conditions and pharmaceutical prescriptions,
acute care for life-threatening diseases such as heart attack and stroke, patient safety,
mental health care, cancer care, the prevention of communicable diseases, as well as some
important aspects of patient experiences.
Chapter 9 on health expenditure and financing compares how much OECD countries
spend on health, both on a per capita basis and in relation to GDP. The chapter also
provides an analysis of the different types of health services and goods consumed across
OECD countries. It also looks at how these health services and goods are paid for and the
mix between public funding, private health insurance and direct out-of-pocket payments
by households in different countries.
Chapter 10 is a new chapter on the pharmaceutical sector, which combines some
indicators that were previously shown in other chapters and some new indicators. The
chapter begins by comparing recent trends and levels of pharmaceutical expenditure
across countries and how these expenditure are paid for, and then goes on to compare the
consumption of certain high-volume pharmaceutical drugs and the share of the generic
market in different countries. It concludes by reviewing spending on research and
development (R&D) to develop new products in the pharmaceutical sector.
Chapter 11 focuses on ageing and long-term care, starting by a review of demographic
trends which highlights the steady growth in the share of the population aged over 65 and
80 in all OECD countries. The chapter presents the most recent data on life expectancy and
life expectancy free of disability at age 65, along with data on self-reported health and
disability status, as important factors affecting the current and future demand for long-
term care. It then focuses on people currently receiving long-term care at home or in
institutions and people providing formal or informal care, and concludes with a review of
levels and trends in long-term care expenditure in different countries.
A statistical annex provides additional information on the demographic and economic
context within which health and long-term care systems operate.
Presentation of indicators
With the exception of the first two chapters, each of the indicators covered in the rest
of the publication is presented over two pages. The first provides a brief commentary
highlighting the key findings conveyed by the data, defines the indicator and signals any
significant national variation from the definition which might affect data comparability.
On the facing page is a set of figures. These typically show current levels of the indicator
and, where possible, trends over time. Where an OECD average is included in a figure, it is
the unweighted average of the OECD countries presented, unless otherwise specified.
Data limitations
Limitations in data comparability are indicated both in the text (in the box related to
“Definition and comparability”) as well as in footnotes to figures.
Data sources
Readers interested in using the data presented in this publication for further analysis
and research are encouraged to consult the full documentation of definitions, sources and
methods presented in OECD Health Statistics on OECD.Stat (http://stats.oecd.org/index.aspx,HEALTH AT A GLANCE 2015 © OECD 2015 15
READER’S GUIDEthen choose “Health”). More information on OECD Health Statistics is available at
www.oecd.org/health/health-data.htm.
Population figures
The population figures presented in the Annex and used to calculate rates per capita
throughout this publication come from the OECD Historical Population Data and
Projections (as of end of May 2015), and refer to mid-year estimates. Population estimates
are subject to revision, so they may differ from the latest population figures released by the
national statistical offices of OECD member countries.
Note that some countries such as France, the United Kingdom and the United States
have overseas colonies, protectorates or territories. These populations are generally
excluded. The calculation of GDP per capita and other economic measures may, however,
be based on a different population in these countries, depending on the data coverage.
OECD country ISO codes
Partner country ISO codes
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Dashboards of health indicators
This chapter presents, for the first time, a set of dashboards which are designed to
shed light on how well OECD countries do in promoting the health of their
population and improving their health system performance. These dashboards do
not have the ambition of identifying which countries have the best health system
overall. They summarise some of the relative strengths and weaknesses of countries
on a selected set of indicators on health and health system performance, to help
identify possible priority areas for actions. These dashboards, which take the form
of summary tables, highlight how well OECD countries are doing along five
dimensions: 1) health status; 2) risk factors to health; 3) access to care; 4) quality of
care; and 5) health care resources. For each of these five dimensions, a selected set
of key indicators are presented. The selection of these indicators is based on three
main criteria: 1) policy relevance; 2) data availability; and 3) data interpretability
(i.e., no ambiguity that a higher/lower value means a better/worse performance).
There is, however, one exception to the application of this third criterion: for the fifth
dashboard on health care resources, more health spending or more human or
physical resources does not necessarily mean better performance. This is why the
ranking of countries is displayed differently.
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities.The use of such data by the OECD is without prejudice to the status of the Golan Heights,
East Jerusalem and Israeli settlements in theWest Bank under the terms of international law.17
1. DASHBOARDS OF HEALTH INDICATORSAcross the OECD, policy makers have a keen interest to understand how good the health
of their people is, and how well their health systems are able to deliver good results. A look
at indicators contained in this publication shows that much progress has already been
achieved. People in OECD countries are living longer than ever before, with life expectancy
now exceeding 80 years on average, thanks to improvements in living conditions and
educational attainments, but also to progress in health care. In most countries, universal
health coverage provides financial protection against the cost of illness and promotes
access to care for the whole population. The quality of care has also generally improved, as
illustrated by the reduction in deaths after heart attacks and strokes, and the earlier
detection and improved treatments for serious diseases such as diabetes and cancer. But
these improvements have come at a cost. Health spending now accounts for about 9% of
GDP on average in OECD countries, and exceeds 10% in many countries. Higher health
spending is not a problem if the benefits exceed the costs, but there is ample evidence of
inequities and inefficiencies in health systems which need to be addressed. There is also a
need to achieve a proper balance between spending on disease prevention and treatment.
Despite these improvements, important questions about how successful countries are
in achieving good results on different dimensions of health system performance remain.
What are the main factors explaining differences in health status and life expectancy
across OECD countries? Is the increase in certain risk factors such as inactivity and obesity
offsetting some of the gains from the reduction in other risk factors like smoking? To what
extent do all citizens have adequate and timely access to care, and good financial
protection against the cost of health care? What do we know about the quality and safety
of care provided to people with different health conditions?What are the financial, human
and technical resources allocated to health systems in different countries? And how does
this translate into beneficial activities and better health outcomes?
Answering these questions is by no mean an easy task. But the dashboards presented
in this chapter can help shed light on how well countries do in promoting the health of
their population and on several dimensions of health system performance. These
dashboards do not have the ambition of identifying which countries have the best health
system overall. However, they summarise some of the relative strengths and weaknesses
of OECD countries on a selected set of indicators on health and health system
performance, and can be useful to identify possible priority areas for actions.
These dashboards, which take the form of summary tables, highlight how well OECD
countries are doing along five dimensions: 1) health status; 2) risk factors to health;
3) access to care; 4) quality of care; and 5) health care resources. For each of these five
dimensions, a selected set of key indicators (ranging from 4 to 7) are presented in a
summary table. The selection of these indicators is based on three main criteria: 1) policy
relevance; 2) data availability; and 3) data interpretability (i.e., no ambiguity that a higher/
lower value means a better/worse performance). There is, however, one notable exception
to the application of this third criterion: for the fifth dashboard on health care resources,HEALTH AT A GLANCE 2015 © OECD 201518
1. DASHBOARDS OF HEALTH INDICATORSmore health spending or more human or physical resources does not necessarily mean
better performance. This is why the ranking of countries is displayed differently (through
different colours) in this last dashboard. Box 1.1 at the end of this chapter summarises
some of the main limitations in interpreting these dashboards.
In most of the dashboards, countries are classified in three groups: 1) top third
performer; 2) middle third performer; and 3) bottom third performer. In addition, the
specific ranking of countries is indicated in each cell to provide further information on how
close countries may be to the other group.The ranking is based on the number of countries
for which data are available for each indicator (with a maximum of 34, when all countries
are covered), with countries separated in three equal groups. For the first indicator related
to access to care (the percentage of the population with health coverage), the grouping of
countries is based on a different method because most countries are at or close to 100%
coverage: the top countries are defined as those with a population coverage rate between
95% and 100%, themiddle countries with a coverage between 90% and 95%, and the bottom
countries with a coverage of less than 90%.The availability of comparable data is also more
limited for indicators of access to care, either because of a lack of harmonisation in survey
instruments (for indicators related to unmet care needs) or limitations in administrative
data (for indicators on waiting times).
Health status
The broad measures of population health status shown in Table 1.1, such as life
expectancy at various ages, are not only related to health spending and the performance of
health systems, but also to a wide range of non-medical determinants of health (with some
of the lifestyle and behavioural factors presented in Table 1.2). Countries that perform well
on life expectancy at birth for men and women usually also tend to do well on life
expectancy at older ages, and typically have lower rates of mortality from cardiovascular
diseases (the main causes of death in nearly all OECD countries).
Japan, Spain, Switzerland, Italy and France are among the countries that have the
highest life expectancy at birth and at older ages, although France does not perform so well
in terms of life expectancy at birth for men, reflecting higher mortality rates among
younger and middle-aged men.
Mexico, Hungary, the Slovak Republic and Turkey have the lowest life expectancy at
birth and older ages, although Turkey has achieved huge gains in longevity over the past
few decades and is quickly moving towards the OECD average (see the first indicator on life
expectancy in Chapter 3 for trends over time).
While higher health spending per capita is generally associated with higher life
expectancy, this relationship is less pronounced in countries with the highest health
spending per capita. Japan, Spain and Korea stand out as having relatively high life
expectancies, and the United States relatively low life expectancies, given their levels of
health spending (see Table 1.5). Life expectancy in the United States is lower than in most
other OECD countries because of higher mortality rates from various health-related
behaviors (including higher calorie consumption and obesity rates, higher consumption of
legal and illegal drugs, higher deaths from road traffic accidents and homicides), adverse
socio-economic conditions affecting a large segment of the US population, and poor access
and co-ordination of care for certain population groups.HEALTH AT A GLANCE 2015 © OECD 2015 19
1. DASHBOARDS OF HEALTH INDICATORSRisk factors to health
Most countries do not performwell for at least one or more indicators of risk factors to
health, whether that is the proportion of their population smoking tobacco, alcohol
consumption, or overweight and obesity among children and adults (Table 1.2). This
highlights the importance of countries putting a higher priority on health promotion and
disease prevention policies to reduce modifiable risk factors to health and mortality from
related diseases.
The United States, Canada, Australia and Mexico have achieved remarkable progress
over the past few decades in reducing tobacco smoking among adults and have very low
rates now, but they face the challenge of tackling relatively high rates of overweight and
obesity among children and adults. Some countries like Italy and Portugal currently have a
relatively low rate of obesity among adults, but the current high rate of overweight and
obesity among children is likely to translate into higher rates among adults in the future.
Other countries like Turkey and Greece have relatively low levels of alcohol consumption,
but still have a way to go to reduce tobacco smoking. Alcohol consumption remains high in
Austria, Estonia, the Czech Republic, Hungary, France and Germany, although the overall
level of consumption has come down in many of these countries over the past few decades
(see the indicator on alcohol consumption in Chapter 4).
Access to care
Most OECD countries have achieved universal (or near-universal) coverage of health
care costs for a core set of services, with the exception of Greece, the United States and
Poland, where a sizeable proportion of the population is still not covered (Table 1.3). In the
United States, the percentage of the population uninsured has started to decrease
significantly in 2014, following the implementation of the Affordable Care Act which is
designed to expand health insurance coverage. In Greece, the response to the economic
crisis has reduced health insurance coverage among people who have become long-term
unemployed, and many self-employed workers have also not renewed their health
insurance plans because of reduced disposable income. However, since June 2014,
uninsured people are covered for prescribed pharmaceuticals and for services in
emergency departments in public hospitals, as well as for non-emergency hospital care
under certain conditions.
The financial protection that people have against the cost of illness depends not only
on whether they have a health insurance, but also on the range of goods and services
covered and the extent to which these goods and services are covered. In countries like
France and the United Kingdom, the amount that households have to pay directly for
health services and goods as a share of their total consumption is relatively low, because
most such goods and services are provided free or are fully covered by public and private
insurance, with only small additional payments required. Some other countries, such as
Korea and Mexico, have achieved universal (or quasi-universal) health coverage, but a
relatively small share of the cost of different health services and goods are covered,
leaving a significant amount to be paid by households. Direct out-of-pocket payments
can create financial barriers to health care, dental care, prescribed pharmaceutical drugs
or other health goods or services, particularly for low-income households. The share of
household consumption spent on direct medical expenditure is highest in Korea,
Switzerland, Portugal, Greece and Mexico, although some of these countries have put in
place proper safeguards to protect access to care for people with lower income.HEALTH AT A GLANCE 2015 © OECD 201520
1. DASHBOARDS OF HEALTH INDICATORSAccess to health care may be restricted not only because of financial reasons, but also
because of geographic barriers, waiting times and other reasons. In Europe, around 3% of
the population on average in countries that are OECD members reported unmet needs for
medical examination due to cost, travel distance or waiting lists in 2013, according to the
EU-SILC survey. The share of the population reporting such unmet medical care needs was
highest in Greece and Poland, and lowest in the Netherlands and Austria. In nearly all
countries, a higher proportion of the population reports some unmet needs for dental care,
reflecting that public coverage for dental care is generally lower. People in Portugal, Iceland,
Italy and Greece reported the highest rates of unmet needs for dental care among
European countries that are OECD members in 2013.
Waiting times for different health services indicate the extent to which people have
timely access to care for specific interventions such as elective surgery. Denmark, Canada
and Israel have relatively low waiting times for interventions such as cataract surgery and
knee replacement among the limited group of countries that provide these data, while
Poland, Estonia and Norway have relatively long waiting times.
Quality of care
Improving quality of care is a high priority in most OECD countries. Based on the
available data, no country consistently performs in the top group on all indicators of
quality of care (Table 1.4), even those that spend much more on health. This suggests that
there is room for improvement in all countries in the governance of health care quality and
prevention, early diagnosis and treatment of different health problems.
The United States is doing well in providing acute care for people having a heart attack
or a stroke and preventing them from dying, but is not performing very well in preventing
avoidable hospital admissions for people with chronic conditions such as asthma and
diabetes. The reverse is true in Portugal, Spain and Switzerland, which have relatively low
rates of hospital admissions for certain chronic conditions, but relatively high rates of
mortality for patients admitted to hospital for a heart attack or stroke.
Finland and Sweden do relatively well in having high survival of people following
diagnosis for cervical, breast or colorectal cancer, while the survival for these types of
cancer remains lower in Chile, Poland, the Czech Republic, the United Kingdom and
Ireland. An important pillar to achieve progress in the fight against cancer is to establish a
national cancer control plan to focus political and public attention on performance in
cancer prevention, early diagnosis and treatment.
Health care resources
Higher health spending is not always closely related to a higher supply of health
human resources or to a higher supply of physical and technical equipment in health
systems.
The United States continues to spend much more on health per capita than all other
OECD countries, but is not in the top group in terms of the number of doctors or nurses per
population. Following the United States, the next biggest spenders on health are
Switzerland, Norway, the Netherlands and Sweden, whereas the lowest per capita
spenders are Mexico and Turkey (Table 1.5). Health spending per capita is also relatively
low in Chile, Poland and Korea, although it has grown quite rapidly over the past decade.
Greece, Austria and Norway have the highest number of doctors per capita, while
Switzerland, Norway and Denmark have the highest number of nurses. The mix between
different categories of health workers varies widely, with some countries choosing to haveHEALTH AT A GLANCE 2015 © OECD 2015 21
1. DASHBOARDS OF HEALTH INDICATORSrelatively more doctors (such as Greece and Austria) and others opting to rely more on
nurses and other health care providers to deliver some services (such as Finland and the
United States).
Some Central and Eastern European countries such as Hungary, Poland and the Slovak
Republic continue to have a relatively high number of hospital beds, reflecting an excessive
focus of activities in hospital. The number of hospital beds per capita is lowest in Mexico,
Chile, Sweden, Turkey, Canada and the United Kingdom. Relatively low number of hospital
beds may not create any capacity problem if primary care systems are sufficiently
developed to reduce the need for hospitalisation.
The availability of expensive technological equipment such as MRI and CT scanners is
highest in Japan and the United States, and much lower in Mexico, Hungary, Israel and the
United Kingdom.There is no ideal number of MRI units or CT scanners per population, and
there is also evidence in many countries of inappropriate and excessive use of these
expensive diagnostic technologies.
Higher health spending and other human or technical resources are not always
correlated with greater access to care or higher quality of care, as shown by the lack of any
consistent correlation in countries’ relative position between health spending and various
indicators of access or quality of care. For example, Norway has high levels of health
spending and also relatively high numbers of doctors and nurses, and does generally well
on many indicators of quality of care, but still faces some persisting issues in terms of
access to care, for instance, on waiting times for elective surgery. On the other hand, the
Czech Republic spends much less on health and is achieving good results for several
indicators on access to care, but could improve public health and prevention programmes
and improve the quality of care for people who have chronic diseases such as diabetes. The
performance of health systems in achieving the key policy goals of universal access and
quality depends not only on allocating more money on health care, but also on making a
more rational use of resources and providing the right incentives to ensure the best value
for money spent.HEALTH AT A GLANCE 2015 © OECD 201522
1. DASHBOARDS OF HEALTH INDICATORSTable 1.1. Health status
* Life expectancy at 65 is not presented in chapter 3 on health status, but rather in chapter 11 on ageing and long-
term care.
** Mortality from cardiovascular diseases includes deaths from ischemic heart diseases and cerebrovascular diseases
shown in Chapter 3, as well as other cardiovascular diseases.
Source: Health at a Glance 2015.
1 2 http://dx.doi.org/10.1787/888933281467
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Note: Countries are listed in alphabetical order. The number in the cell indicates the position of each country among all countries 
for which data is available. For the mortality indicator, the top performers are countries with the lowest rates.  HEALTH AT A GLANCE 2015 © OECD 2015 23
1. DASHBOARDS OF HEALTH INDICATORSTable 1.2. Risk factors
* Data on obesity in adults are based on measured height and weight for all the countries marked with an *. These
result in more accurate data and higher obesity rates compared with all other countries that are providing self-
reported height and weight.
** Data on overweight or obesity in children are all based on measured data, but refer to different age groups across
countries.
Source: Health at a Glance 2015.
1 2 http://dx.doi.org/10.1787/888933281473
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Note: Countries are listed in alphabetical order. The number in the cell indicates the position of each country among all countries for which
data is available.     HEALTH AT A GLANCE 2015 © OECD 201524
1. DASHBOARDS OF HEALTH INDICATORSTable 1.3. Access to care
* Unmet medical or dental care needs may be for financial reasons, waiting times or long distance to travel to get
access to services. The data only cover European countries because they are based on the EU-SILC survey.
** The ranking for the Netherlands is overrated as it excludes compulsory co-payments to health insurers (if these
were included, this would move the Netherlands in the middle third category).
Source: Health at a Glance 2015.
1 2 http://dx.doi.org/10.1787/888933281483
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United States
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 pocket medical 
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Waiting times 
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1. DASHBOARDS OF HEALTH INDICATORSTable 1.4. Quality of care
Source: Health at a Glance 2015.
1 2 http://dx.doi.org/10.1787/888933281494
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Italy
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Portugal
Slovak Rep.
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United States
Indicator
Asthma and 
COPD hospital 
admission
Diabetes 
hospital 
admission 
Case-fatality 
for AMI 
(admission-
based)
Cervical
cancer
survival
Case-fatality 
for ischemic 
stroke 
(admission-
based)
Breast
cancer
survival
Colorectal
cancer
survival
Note: Countries are listed in alphabetical order. The number in the cell indicates the position of each country among all countries for which
data is available. For the indicators of avoidable hospital admissions and case-fatality rates, the top performers are countries with the 
lowest rates.  
 Top third performers
 Middle third performers
 Bottom third performersHEALTH AT A GLANCE 2015 © OECD 201526
1. DASHBOARDS OF HEALTH INDICATORSTable 1.5. Health care resources
* Data for most countries marked with an * do not include MRI units and CT scanners installed outside hospitals,
leading to an under-estimation. In Australia and Hungary, the data only include MRI units and CT scanners eligible
for public reimbursement, also leading to an under-estimation.
Source: Health at a Glance 2015.
1 2 http://dx.doi.org/10.1787/888933281500
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Note: Countries are listed in alphabetical order. The number in the cell indicates the position of each country among all countries for 
which data is available. Although countries are ranked from highest health spending or availability of resources to lowest, this does not 
necessarily mean better performance.   
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1. DASHBOARDS OF HEALTH INDICATORS
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theBox 1.1. Limitations in the interpretation and use of the dashboards
The previous dashboards should be interpreted and used with caution for several reasons:
● Due to limitations in data availability, the indicators selected on each topic do not generally provid
complete coverage of all important aspects related to this topic. For instance, the indicators of hea
status relate solely to mortality because mortality data are more widely available and comparable acr
countries than morbidity data.While life expectancy undoubtedly is a key indicator of health status,
lack of indicators about the physical and mental health status of people while they are alive is
important limitation. The same limitations also apply to the dashboards on risk factors (which o
include some risk factors to health), access to care and quality of care.
● There are limitations in data comparability for some indicators which should be kept in mind
interpreting the ranking of countries. One notable example is the indicator on obesity rates amo
adults, which in several countries are based on self-reported height and weight, resulting in an und
estimation compared to those countries that provide more reliable data based on measured obesity.
● The grouping of countries in three groups (tertiles) is based on a simple method using only the po
estimates of each country and dividing them in three equal groups. It does not take into account
distribution of the data around the OECD average, nor the confidence intervals for those indicat
where these have been calculated (notably for several indicators of quality of care).
● These dashboards only present the current situation and in this respect may hide the progress that so
OECD countries might have achieved over time and the fact that theymay bemoving quickly towards
OECD average. These key trends are discussed in the publication.
Because of these limitations in data availability, comparability and statistical significance, there is
attempt to calculate any summary indicator of performance for each of the dimensions or acro
dimensions. These dashboards should be used to get a first impression on the relative strengths a
weaknesses of different OECD countries on the set of indicators selected. It should be complemented b
more in-depth review of the data and the factors influencing the cross-country variations presented in
following chapters of this publication.HEALTH AT A GLANCE 2015 © OECD 201528
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Pharmaceutical spending trends
and future challenges
Across OECD countries, pharmaceutical spending reached around USD 800 billion
in 2013, accounting for about 20% of total health spending on average when
pharmaceutical consumption in hospital is added to the purchase of pharmaceutical
drugs in the retail sector. This chapter looks at recent trends in pharmaceutical
spending across OECD countries. It examines the drivers of recent spending trends,
highlighting differences across therapeutic classes. It shows that while the
consumption of medicines continues to increase and to push pharmaceutical
spending up, cost-containment policies and patent expiries of a number of top-
selling products have put downward pressure on pharmaceutical prices in recent
years. This resulted in a slower pace of growth over the past decade.
The chapter then looks at emerging challenges for policy makers in the management
of pharmaceutical spending. The proliferation of high-cost specialty medicines will
be a major driver of health spending growth in the coming years. While some of
these medicines bring great benefits to patients, others provide only marginal
improvements. This challenges the efficiency of pharmaceutical spending.
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities.The use of such data by the OECD is without prejudice to the status of the Golan Heights,
East Jerusalem and Israeli settlements in theWest Bank under the terms of international law.29
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESIntroduction
Pharmaceutical spending across OECD countries reached around USD 800 billion in
2013, accounting for about 20% of total health spending on average when pharmaceutical
consumption in hospitals is added to the purchase of pharmaceutical drugs in the retail
sector. Retail pharmaceutical spending growth has slowed down inmost OECD countries in
the last decade, while spending on pharmaceuticals used in hospital has increased in most
countries where this information is available. Current market developments, such as the
multiplication of high-cost medicines targeting small populations and/or complex
conditions, have prompted new debates on the sustainability and efficiency of
pharmaceutical spending. Will OECD countries be able to afford access to these high-cost
medicines to all patients who need them and at what price? Will they get value for the
money they will spend?
This chapter looks first at recent trends in pharmaceutical spending and financing
across OECD countries. Then, it examines the drivers of recent spending trends,
highlighting differences across drug classes. Finally, it focuses on current and predicted
trends in pharmaceutical markets and associated challenges in the management of
pharmaceutical expenditure.
One in every five health dollars is spent on pharmaceuticals
In 2013, OECD countries spent an average of more than 500 USD per person on retail
pharmaceuticals1 (Figure 2.1). In the United States, the level of spending was twice the
OECD average, and more than 35% higher than in Japan, the next highest spender. At the
other end of the scale, Denmark spent less than half the OECD average.
The data on pharmaceutical spending shown in Figure 2.1 only include those
purchased in the retail sector, as many countries are not able to supply data on the cost of
pharmaceuticals consumed in hospitals and other health care facilities. In those countries
that are able to supply these data, the inclusion of pharmaceutical expenditure in hospital
and other facilities adds another 10% on top of the retail pharmaceutical spending in the
case of Germany, Canada and Australia, and more than 25% in countries such as Spain,
Czech Republic and Portugal (Figure 2.2). Such differences stem from the budgetary and
distributional channels within a country. On average, the use of pharmaceuticals in
hospitals and other health care facilities raises the pharmaceutical bill by around 20%,
meaning that a little more than one health dollar in five goes towards purchasing
pharmaceuticals.
Prior to 2005, spending on retail pharmaceuticals grew at a faster rate than other key
components of health care, such as inpatient and outpatient care, and was a major
contributor in driving up overall health expenditures (see Figure 2.3). Over the subsequent
decade, however, retail pharmaceutical spending growth was seriously affected by patent
expiries of several blockbuster drugs and cost-containment policies, particularly as a
consequence of the economic crisis. As a result, retail pharmaceutical spending decreased
dramatically in some countries, for example in Portugal, Denmark and Greece.HEALTH AT A GLANCE 2015 © OECD 201530
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGES
3
280639
4
% GDPFigure 2.1. Expenditure on retail pharmaceuticals per capita and as a share of GDP, 201
(or nearest year)
1. Includes medical non-durables.
2. Excludes over-the-counter drugs (OTC).
Source: OECD Health Statistics 2015
1 2 http://dx.doi.org/10.1787/888933
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2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESOver the same period, spending on hospital medicines grew faster in several countries
(see Figure 2.4). The multiplication of specialty drugs2 offers a partial explanation, as these
are often delivered in a hospital setting (including in an outpatient department) rather
than dispensed via pharmacies (Hirsch et al., 2014) and are coming to the market with
increasingly high prices.
The share of private funding of pharmaceuticals increases
Private funding in the purchasing of pharmaceuticals is greater than for other
categories of health care. On average in OECD countries, 43% of retail pharmaceutical
Figure 2.3. Average annual growth in pharmaceutical and total health expenditure
per capita, in real terms, average across OECD countries, 1990 to 2013
(or nearest year)
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933280658
Figure 2.4. Annual average growth in retail and hospital pharmaceutical
expenditure, in real terms, 2005 and 2013 (or nearest year)
Note: OECD estimates for Portugal exclude expenditure on other medical products from reported total and retail
spending.
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933280663
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ries,
280679
5
-15
-10
-5
0
5
10
15
%
%spending is paid for from private sources (private health insurance or out-of-pocket),
compared with 21% for inpatient and outpatient care. Most of the private spending for
drugs (37%) comes directly from households’ pockets, reflecting both the high cost-sharing
requirements and the extent of self-consumption of over-the-counter (OTC)medicines (see
the indicator on pharmaceutical expenditure in Chapter 10). Countries such as France,
Germany and Japan report a relatively low private share of pharmaceutical spending of
around 25-30%, whereas the United States and Canada (both countries where private
health insurance plays a large role in financing pharmaceutical spending), as well as
Poland (where spending on OTC drugs is significant), all report more than 60% of the
pharmaceutical bill being covered by private sources.
In a majority of OECD countries, private spending on pharmaceuticals has grown
faster than public spending over the last decade (Figure 2.5). In particular, since 2009,
private spending on drugs did not decline to the same extent as public spending. This
is due in part to an observed shift of some of the cost-burden to households. For
example, in Hungary, the out-of-pocket share of spending on prescribed medicines rose
from 40% to 45% between 2010 and 2013 (Figure 2.6). The Czech Republic and Slovak
Republic also reported increases in the households' share of medicines to 38% and 33%
respectively.
The trends in public and private spending are partly explained by a range of policy
measures adopted by countries to contain public spending on pharmaceuticals, such as
increases in cost-sharing, as well as the increasing use of OTC drugs (usually not
reimbursed) compared with prescription drugs (usually reimbursed) in several countries. In
Slovenia, Poland and Spain, the OTC share of pharmaceutical spending has significantly
increased.
Figure 2.5. Annual growth in public and total retail pharmaceutical spending, OECD count
2005-2013
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933
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2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESPharmaceutical expenditure growth is driven by changes in quantity, prices
and therapeutic mix
The increasing demand for medicines and the introduction of new drugs into the
market are the main drivers of spending growth. At the same time, the availability of
generics and biosimilars combined with the introduction and strengthening of cost-
containment policies have exerted a downward pressure on spending in recent years
(Belloni et al., forthcoming).
An increasing demand for pharmaceuticals and new treatment opportunities push
pharmaceutical spending up
The quantity of drugs consumed has increased over time in many therapeutic classes.
Between 2000 and 2013, among countries for which data are available, the use of
antihypertensive, antidiabetic and anti-depressant medications nearly doubled, while the
use of cholesterol-lowering drugs tripled (see indicator on “Pharmaceutical consumption”
in Chapter 10). These trends reflect an increasing demand for pharmaceuticals, resulting
from the rising prevalence of chronic diseases, population ageing, changes in clinical
practices and coverage extensions, as well as new treatment opportunities.
The prevalence of many chronic diseases, such as cancer, diabetes and mental illness has
increased, leading to an increased demand for medical treatments. Improvements in
diagnosis, leading to earlier recognition of conditions and earlier treatment with
medicines, as well as the development of more medicines (both prescribed and OTC) to
treat common conditions have also contributed to increase the consumption of medicines.
Population ageing also increases the demand for pharmaceutical treatments. With age,
the tendency to develop health conditions which require some kind of medication
increases. As shown in Figure 2.7 for Korea and the Netherlands, per capita spending on
pharmaceuticals increases rapidly with age.
Figure 2.6. Expenditure on retail pharmaceuticals by type of financing, 2013
(or nearest year)
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933280689
100
90
80
70
60
50
40
30
20
10
0
82 80
75 71 69 68 68 67 67 66 65 62
58 57 55 54 53 52 52 49 48
43 43
38 36 34 32
5
1
7
1
14
1 2
5
1 1 2
27
5 6
30 36
13
19 18
28
17
32 32 33 33 33 33
38
42
37
44 46 47 48 46 50
25
45
51
58
34 30
68
Public Private insurance Private out-of-pocket Other
% of  retail pharmaceutical expenditure
Lu
xe
mb
ou
rg
Ne
the
rla
nd
s
Ge
rm
an
y
Ja
pa
n
Fra
nc
e
Sp
ain
Au
str
ia
Slo
va
k R
ep
.
Gr
ee
ce
Be
lgi
um
Sw
itz
erl
an
d
Cz
ec
h R
ep
.
No
rw
ay
OE
CD
26
Ko
rea
Es
ton
ia
Fin
lan
d
Sw
ed
en
Po
rtu
ga
l
Au
str
ali
a
Slo
ve
nia
Hu
ng
ary
De
nm
ark
Ice
lan
d
Ca
na
da
Un
ite
d S
tat
es
Po
lan
dHEALTH AT A GLANCE 2015 © OECD 201534
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGES
ds,
280694
 to
 84
    
Ov
er 
85New and innovative drugs expand treatment options and increase treatment costs. New
drugs can be new chemical entities or new formulations of existing drugs. Both categories
may increase treatment options, for instance, for previously unmet needs or for new
population targets (e.g. children), increasing the quantity of drugs consumed. While the
approval of new drugs in existing market segments can increase competition and lead to
potential savings, usually new drugs offering therapeutic advantages for patients are
priced higher than their competitors and contribute significantly to pharmaceutical
spending growth.
In recent years, the proliferation of specialty pharmaceuticals with high prices, in
particular oral cancer drugs and immune modulators,3 has played an increasing role in
pharmaceutical spending growth (Express Scripts, 2015; Trish et al., 2014). In the United
States, specialty drugs represented just 1% of total prescriptions but accounted for 25% of
total prescription drug spending in 2012 (Express Scripts, 2015).
Changes in clinical practice guidelines also influence the consumption of pharmaceuticals
upward. Updated guidelines have often recommended earlier treatments, higher dosages
or longer treatment durations for secondary prevention or management of chronic
diseases, leading to increases in volume consumed. This is the case for instance for
guidelines for cholesterol-lowering drugs (e.g. statins), one of the fastest-growing
therapeutic classes of prescription drugs all over the world. Prescription guidelines have
been updated several times since the end of the 1990s, recommending wider screening and
lower lipid level targets as an indication for prescription in Canada, the United Kingdom
and the United States (CIHI, 2012; ACC/AHA, 2014; NICE, 2014).
In a few countries, coverage expansion has contributed to pharmaceutical spending
growth. In the United States, Medicare Part D was introduced in 2006 and the Affordable
Care Act was implemented in 2014, contributing to a substantial reduction in the number
of people uninsured. In Korea, with the establishment of the National Health Insurance
Figure 2.7. Per capita spending on retail pharmaceuticals by age, Korea and the Netherlan
2011
Source: OECD Database on Expenditure by Disease, Age and Gender (unpublished).
1 2 http://dx.doi.org/10.1787/888933
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2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGES(NHI) in 1989 and successive steps in coverage expansion, pharmaceutical spending
increased rapidly – at a rate of more than 10% each year on average between 2000 and 2004
(Yang et al., 2008) and continued to grow since then, albeit at a slower rate.
Cost-containment policies and patent losses have put downward pressure on
spending growth
Pharmaceutical policies have the potential to influence spending trends and the
efficiency (cost-effectiveness) of pharmaceutical spending. In recent years, and in
particular after the economic crisis in 2008, OECD countries have implemented or
strengthened a number of cost-containment policies (Table 2.1).
Since 2008, price cuts have been very common. At least one third of OECD countries
implemented measures to reduce regulated prices of pharmaceuticals. They most often
imposed cuts on ex-factory prices of on-patent and/or generic drugs (e.g. Greece, Ireland,
Portugal and Spain), but many of these countries also reduced distribution margins at least
for some categories of medicines. Germany increased temporarily the mandatory rebates
imposed on pharmaceutical companies from 6% to 16% between 2010 and 2013. In
April 2014, the mandatory rebate was set at 7% for all medicines except generics. In
Canada, several provinces and territories entered in joint price negotiations for brand-
name drugs covered by public plans. Finally, five countries changed VAT rates imposed on
Table 2.1. Pharmaceutical cost-containment policies introduced since 2008
in a selection of OECD countries
Policies Examples Extent of implementation
Pricing policies One-off cut in ex-factory prices of on-patent
medicines
Austria, Belgium, Czech Republic, France, Germany,
Greece, Ireland, Italy, Portugal, Spain, Switzerland,
United Kingdom
Implementation of external price referencing or
change in the method or basket of countries
Greece, Portugal, Slovak Republic, Spain, Switzerland
Reduction in value-added tax (VAT) rates Austria, Czech Republic, Greece
Reduction of mark-ups for distributors Czech Republic, Estonia, Greece, Hungary, Ireland,
Portugal, Spain
Increase of rebates paid by manufacturers or
distributors
Germany
Extra-ordinary price reviews Greece, Ireland, Portugal, Slovak Republic, Spain,
Switzerland
Pressure on prices of branded medicines (e.g. group
purchasing or negotiation)
Canada
Reimbursement policies Change in the reference price system (max.
reimbursement price by cluster)
Estonia, Greece, Ireland, Portugal, Slovak Republic,
Spain
Delisting of products Czech Republic, Greece, Ireland, Portugal, Spain
Increase in cost-sharing Austria, Czech Republic, Estonia, France, Greece,
Ireland, Italy, Portugal, Slovenia, Slovak Republic,
Spain, Sweden
Introduction of health-technology assessment (HTA)
to inform coverage/pricing decisions
Germany
Managed-entry agreements Belgium, Italy, United Kingdom
Policies to exploit the potential
of off-patent drugs
Implementation of voluntary or mandatory International
Non-proprietary Name (INN) prescribing
Belgium, Estonia, France, Italy, Luxembourg,
Portugal, Slovak Republic, Spain
Incentives for physicians to prescribe generics Belgium, France, Greece, Hungary, Japan
Incentives for pharmacists to dispense generics Belgium, France, Ireland, Japan
Incentives and information for patients to purchase
generics
Austria, Estonia, France, Iceland, Ireland,
Luxembourg, Portugal, Spain
Pressure on generic prices (e.g. tendering, price cuts) Canada, France, Greece, Portugal
Source: Belloni et al. (forthcoming), complemented by Thomson et al. (2014) on cost-sharing policies.HEALTH AT A GLANCE 2015 © OECD 201536
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESmedicine, either to reduce pharmaceutical spending (e.g. Austria, Czech Republic and
Greece) or to increase public revenues (e.g. Estonia, Portugal) resulting in increased spending.
Greece, Portugal, the Slovak Republic, Spain and Switzerland reformed their external
reference price system, expanding or reducing the basket of countries used for international
benchmarking or revising the method for setting prices. For example, the Slovak Republic
included Greece in the basket of benchmarked countries in 2010.
A range of policy measures have shifted some of the burden of pharmaceutical spending to
private payers (households or complementary private insurance).These rarely took the form
of delisting products (i.e. excluding them from reimbursement), with the notable
exceptions of Greece, where 49 medicines were delisted after a price review in 2011, Czech
Republic, Ireland, Portugal and Spain. At least a dozen of countries introduced or increased
user charges for retail prescription drugs (Austria, Czech Republic, Estonia, France, Greece,
Ireland, Italy, Portugal, Slovak Republic, Slovenia, Spain and Sweden) (see Thomson et al.,
2014; and Belloni et al., forthcoming).
Some countries decided to give a greater role to health technology assessment (HTA) in their
reimbursement and/or pricing process. In Germany, for instance, a new law, which took
effect in January 2011, introduced a systematic and formal assessment of the “added
therapeutic benefit” of new medicines after market entry to allow negotiation of a
reimbursement price where needed. Expected savings for health insurance funds are up to
several million Euros for some individual products (Henschke, 2013).
In parallel, many OECD countries have introduced or expanded the use of managed
entry agreements (MEAs), which are arrangements between the manufacturer and the
payer that allow coverage of drugs subject to defined conditions. Managed-entry
agreements cover a wide range of contractual arrangements, which can be just financial
or performance-based (i.e. reimbursement and pricing conditions are linked to observed
performance of a product in real life). They take the form of price-volume agreements,
coverage with evidence development, performance-based outcome guarantees, patient
access scheme, etc. Their implementation varies across countries. The United
Kingdom, Italy, Germany and Poland have taken the lead in using these arrangements
(Ferrario and Kanavos, 2013). In Italy, the amounts recouped by the government from
manufacturers through performance-based arrangements are modest and represent 5%
of total expenditure for the relevant indications. This is due, at least partly, to high
administrative and management costs of the scheme (Garattini et al., 2015, Navarria et
al., 2015, van de Vooren et al., 2014). Their impact in other jurisdictions has not yet been
evaluated.
Since the onset of the economic crisis, several countries have strengthened their generic
policies (see Table 2.1 and Figures 10.12 and 10.13 in Chapter 10). While no formal
evaluation is available, these policies – associated with the “patent cliff” – have certainly
contributed to the significant increase in the generic market share observed over the past
decade in most countries.
From the mid-2000s, a number of blockbuster drugs lost patent protection, contributing to
the decline of pharmaceutical spending growth. Several products worth more than
USD 30 billion a year in US sales lost their patents in 2011-12, among which Plavix®
(antiplatelet agent), Lipitor® (anti-cholesterol) and Actos® (diabetes), which accounted
together for nearly USD 15 billion in sales (Managed Care, 2011).
Patent expiries offer huge opportunities to make savings without affecting the quality
of care. In the United States, for instance, where the generic market is very dynamic, theHEALTH AT A GLANCE 2015 © OECD 2015 37
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESprice of a generic drug is on average 80 to 85 % lower than that of the brand name product.
In 2012, 84% of all prescriptions filled in the United States were for generic drugs (IMS
Institute for Healthcare Informatics, 2013, see also indicator on “Share of generic market”
in Chapter 10).
Biosimilars can also lead to significant savings, although the potential is perhaps not
as high as with generics of small molecules, due to longer and costlier development and
production costs. Entry barriers are higher: Europe established a pathway for the
approval of biosimilars in 2005, Japan approved biosimilars’ regulation in 2009 and Korea
in 2010. The United States approved the legislative framework for licensing follow-on
biologic products in 2010, but the FDA only recently approved the first biosimilar in March
2015. In addition, countries’ regulations often restrict market growth potential and price
competition. In many countries, prescribing by International Non-proprietary
Names (INN) is not allowed, patients cannot be switched to a biosimilar and substitution
by the pharmacist is not allowed (European Biopharmaceutical Enterprises, 2015).
Drivers of spending growth vary across therapeutic areas
All the drivers of spending growth listed before interact differently across therapeutic
classes, leading to contrasting trends.
In the case of antidiabetic medicines for instance, where use has been steadily
increasing in line with the increasing prevalence of type-2 diabetes, the existence of long-
standing treatments with generic versions resulted in a 'cost of treatment' which remained
relatively stable over a number of years. However, the arrival of new and more expensive
treatments in recent years significantly increased the average daily treatment cost. The
shift from existing medications to new drugs has therefore been the main contributor to
pharmaceutical spending growth in this therapeutic class in the recent period, as shown
for Denmark between 2005 and 2013 in Figure 2.8.
Figure 2.8. Annual growth in sales, volumes and cost per defined daily dosage
(DDD) of antidiabetic drugs, Denmark, 2005-13
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933280701
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2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESBy contrast, in the class of cholesterol lowering medications, the expiry of the patent
for some of the top selling statins in themid-2000s and the introduction of generics has led
to a pattern of decreasing treatment costs in many countries in recent years. For example,
costs per defined daily dose (DDD) typically fell by more than 10% per year, on average,
since 2005 in Germany (Figure 2.9).
The high price of new drugs has been the main driver of spending growth in other
therapeutic areas.
In the area of cancer for instance, the price of specialty medicines has steadily
increased, especially since 2000. In the United States, the median monthly price of cancer
treatment for Medicare patients has increased from around USD 5 000 in 2000-05 to around
USD 10 000 in 2010-15.4 In 2012, 12 out of 13 cancer-approved drugs cost more than
USD 100 000 per year (Light and Kantarjian, 2013). These price increases are observed
everywhere. In Australia, the average reimbursement price per anticancer prescription
drug more than doubled in real terms between 1999-2000 and 2011-12, while the price of
all other prescription drugs only increased by about one-third during that period (Karikios
et al., 2014).
Treatment costs for multiple sclerosis and pulmonary hypertension are also very
high and increasing (Lotvin et al., 2014). The first generation of multiple sclerosis therapies,
originally costing USD 8 000 to USD 11 000 per year in 1993-96, now cost about USD 60 000
per year, reflecting an increase five to seven times higher than prescription drug inflation
over the period 1993-2013. Newer therapies entered the market with a cost 25%-60% higher
than existing ones (Hartung et al., 2015).
In 2013 and 2014, new treatments for hepatitis C became available, posing an
unprecedented challenge to many OECD countries. These medicines represent a great
medical advancement: they are much better tolerated than previous treatments and reach
cure rates of 95% or higher for sub-groups of patients with hepatitis C. For these target
groups, these treatments are even cost-effective. The immediate budget impact of treating
the entire population affected proved to be unaffordable for OECD countries, due to high
prices and high prevalence of the disease. In reaction, many countries sought to reach
Figure 2.9. Annual growth in sales, volumes and cost per defined daily dosage
(DDD) of lipid-lowering drugs, Germany, 2005-13
Source: OECD Health Statistics 2015.
1 2 http://dx.doi.org/10.1787/888933280715
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2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESagreements with manufacturers to limit the budget impact and to recommend priority use
for the most severely affected patients, generating frustration for physicians, patients and
decision makers alike.
Orphan drugs5 also typically have high prices. The median cost per patient and per
year is 19 times higher for an orphan drug than for a non-orphan drug (EvaluatePharma,
2014). The premium for ultra-rare indications is very high. The number of newly approved
molecular entities classified as orphans has been increasing since the implementation of
policies designed to encourage their development and medicines with orphan designation
now account for one-third of new chemical entities approved by the FDA (IMS Institute for
Healthcare Informatics, 2014).
New challenges in the pharmaceutical market
Changes in the pharmaceutical market, with the increased availability of high-cost
drugs, suggest that future pharmaceutical spending growth may pick up again, instead of
continuing its recent path, at least in some countries. Countries will face a number of
challenges to make new high-cost medicines available to patients, contain spending
growth and ensure value for money.
The IMS Institute for Healthcare Informatics predicts worldwide pharmaceutical
sales6 to be 30% higher in 2018 than in 2013 (IMS Institute for Healthcare Informatics, 2014).
The average annual growth rate is slightly higher than in previous years due to a smaller
number of patent expiries and a higher number of new specialty drugs. Emerging markets,
in addition to the United States, are expected to contribute most of this growth, while
European markets will make more modest contributions.
The United States is the largest pharmaceutical market, accounting for one third of
global sales, and is expected to continue to grow. The IMS Institute for Healthcare
Informatics predicted peaks in US spending growth of 14% in 2014 and 8% in 2015, followed
by annual growth rates of 4-5% until 2018. According to CMS projections, prescription drug
spending is expected to grow at an average annual rate of over 6% per year between 2016
and 2024 (Keehan, 2015).
The largest European markets are predicted to experience lower levels of growth.
According to the IMS Institute for Healthcare Informatics, the top 5 European markets
(Germany, France, the United Kingdom, Italy and Spain) will see annual growth rates of
between 1 and 4% during the period 2014 to 2018. Pharmaceutical spending in the United
Kingdom and Germany should experience the highest growth, while France and Spain will
have zero to negative growth (IMS Institute for Healthcare Informatics, 2014). In an earlier
study, Urbinati et al. (2014) had predicted a decrease in pharmaceutical spending in all
European countries studied – except Poland – between 2012 and 2016.
Specialty drugs will continue to be a major contributor to pharmaceutical spending growth.
Since 2010, one out of every two FDA approvals is a specialty drug and, as the population
ages, the number of patients eligible for specialty drugs such as treatments for rheumatoid
arthritis and cancer is increasing (Lotvin et al., 2014). Increased spending on these drugs is
projected to account for 53% of total growth in North America between 2013 and 2018,
while in Europe it is expected to account for 94% of the (much slower) growth over the same
period (IMS Institute for Healthcare Informatics, 2014). The huge contribution of specialty
medicines to pharmaceutical spending growth is explained by the fact that there will be
more of them, priced at very high levels, with more patients needing them.HEALTH AT A GLANCE 2015 © OECD 201540
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESCancer is the therapeutic area with the highest expected spending growth, driven by
new drug approvals and the increasing incidence of cancer worldwide (IMS Institute for
Healthcare Informatics, 2014). Many orphan drugs approvals are also expected in the years
to come. Their predicted budget impact by 2020 in several European countries ranges
from 4-5% to 9-11% of pharmaceutical spending, depending on the success rate of
products in development (Schey et al., 2011; Hutchings et al., 2014). Another study
estimated that the share of orphan drugs in the worldwide pharmaceutical market for
non-generic prescription drugs is expected to increase from 14% in 2014 to 19% in 2020
(EvaluatePharma, 2014).
High prices of drugs are an important barrier to access, and this does not concern
developing countries only. The results of a recent survey conducted among policy makers
(reported inWHO, 2015) show that policy makers in European countries consider the high
price of drugs as the main challenge to provide access to new medicines given the
budgetary constraints they have. Many drugs, including drugs providing important
benefits, are not available at all, or not accessible to all patients who need them. For
example, as already noted, a lot of countries restricted access to the new hepatitis C
treatments to the most severely affected patients and a few countries have not yet
reimbursed the new medicines at all (e.g. Poland).
A further challenge is that high prices of new medicines do not always appear to be
justified by high clinical benefits (Howard et al., 2015; Light and Kantarjian, 2013). For
example, many new cancer drugs provide small added benefits over existing ones. Among
the 12 new anticancer drugs approved by the FDA in 2012, only one provides survival gains
that exceed two months. Sometimes cancer drugs are used for several indications with
varying levels of efficacy, but the price is usually unique (Bach, 2014). Examining the launch
prices of cancer drugs approved between 1995 and 2013, Howard et al. (2015) observed that
patients and insurers paid USD 54 100 for a year of life gained in 1995, USD 139 100 a
decade later and USD 207 000 in 2013 for the same benefit (in constant 2013 dollars,
adjusting earlier costs for inflation).
Similarly, many orphan drugs do not pass the test of cost-effectiveness. In the
Netherlands, medicines used for the treatment of Pompe’s and Fabry’s disease have been
assessed to cost several million Euros per QALY gained, which triggered a discussion about
the opportunity to maintain health insurance coverage of these products. However, they
were not delisted, since these medicines are used for severe diseases for which no
alternative treatment is available (van den Brink, 2014).
Conclusions
Retail pharmaceutical spending has increased at a slower pace than before or even
decreased in recent years due to patent losses of several blockbusters and cost-
containment policies, while pharmaceutical spending in hospital has increased in most
countries for which data are available.
New high-cost specialty drugs are coming to the market and are expected to account
for 50% or more of pharmaceutical spending growth in the near future. Their increasing
availability, combined with population ageing, suggests that pharmaceutical expenditure
may pick up again after the recent stagnation or decline.
Pharmaceutical spending growth is not necessarily a problem in itself. Medicines play
an important role in the management of a number of chronic diseases (e.g. diabetes,
asthma) and, in some circumstances, they prevent complications and the use of costly
health care services. However, the increasing availability and sky-rocketing prices of newHEALTH AT A GLANCE 2015 © OECD 2015 41
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESmedicines, especially in cancer, hepatitis C, pulmonary hypertension and multiple
sclerosis, or for rare diseases, have raised a number of questions about accessibility, budget
impact and the legitimacy of such high prices.
While some of these high-price medicines bring great benefits to patients, others
provide only marginal improvement of patients’ outcomes. In reality, prices seem more
determined bymarket conditions (high unmet medical need, small population target) than
by any conception of value in terms of clinical or wider benefits for patients. Many of these
medicines are not cost-effective, according to standard thresholds. This challenges both
the static and dynamic efficiency of pharmaceutical spending and raises questions about
the best ways to align societies’ interests with those of pharmaceutical companies and
investors.
Notes
1. Retail pharmaceuticals are delivered to patients via community pharmacies and other retail outlets.
Pharmaceuticals are also consumed in other care settings – primarily the hospital sector – where by
convention the pharmaceuticals used are considered as an input to the overall service treatment
and not separately accounted. That said, health accounts do allow for an additional reporting item
to report a total pharmaceutical spending estimate covering all modes of provision. Currently only
about one-third of OECD countries submit such figures.
2. Specialty medicines include most injectable and biologic agents used to treat complex conditions
such as rheumatoid arthritis, multiple sclerosis and cancer and often require special handling or
delivery mechanisms.
3. Biologics used in the treatment of certain types of immunologic and inflammatory diseases,
including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.
4. https://www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs.
5. Orphan drugs refer to medicines developed for rare conditions. The United States and the
European Union have implemented policies to encourage private investments in R&D for rare
diseases (e.g. increased market exclusivity) and have consequently defined criteria to be met by a
medicine to be granted an “orphan drug status”. In the European Union, those criteria are: the
severity of the disease; the fact that it serves an unmet need; and either prevalence below one in
2 000 or a negative expected return on investment.
6. IMS data report market sales at ex-manufacturer prices and do not reflect off-invoice discounts
and rebates (IMS Institute for Healthcare Informatics, 2014). By contrast, pharmaceutical spending,
as reported in the System of Health Accounts, are estimated at retail prices (includingVAT) and are
in principle net of off-invoice discounts and rebates. Both sets of data are not directly comparable
but are expected to show more or less consistent trends.
References
ACC/AHA – American College of Cardiology/American Heart Association (2014), “2013 ACC/AHA
Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults”, Journal of the American College of Cardiology, Vol. 63(25_PA), pp. 2889-2934.
Bach, P.B. (2014), “Indication-Specific Pricing for Cancer Drugs”, Journal of American Medical Association,
Vol. 312, No. 16, pp. 1629-1630.
Belloni, A., D. Morgan and V. Paris (forthcoming), “Pharmaceutical Expenditure and Policies: Past
Trends and Future Challenges”, OECD Health Working Papers, OECD Publishing.
CIHI – Canadian Institute for Health Information (2012), Drivers of Prescription Drug Spending in Canada,
Canadian Institute for Health Information, Ottawa, Ontario.
European Biopharmaceutical Enterprises (2015), “What Pricing and Reimbursement Policies to Use for
Off-patent Biologicals? Results from the EBE 2014 Biological Medicines Policy Survey”, Gabi Journal,
Vol. 4, No. 1, pp. 17-24.
EvaluatePharma (2014), “Budget-busters: The Shift to High-priced Innovator Drugs in the USA”.HEALTH AT A GLANCE 2015 © OECD 201542
2. PHARMACEUTICAL SPENDING TRENDS AND FUTURE CHALLENGESEvaluatePharma (2014), Orphan Drug Report 2014,
http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf.
Express Scripts (2015), The 2014 Drug Trend Report Highlights, March.
Ferrario, A. and P. Kanavos (2013),Managed Entry Agreements for Pharmaceuticals: The European Experience,
EMINet.
Garattini, L., A. Curto and K. van de Vooren (2015), “Italian Risk-sharing Agreements on Drugs: Are
TheyWorthwhile?”, European Journal of Health Economics, Vol. 16, pp. 1-3.
Hartung, D. et al. (2015), “The Cost of Multiple Sclerosis Drugs in the US and the Pharmaceutical
Industry – Too Big to Fail?”, Neurology, Vol. 84, May 26, pp. 1-8.
Henschke, C., L. Sundmacher and R. Busse (2013), “Structural Changes in the German Pharmaceutical
Market: Price Setting Mechanisms Based on the Early Benefit Evaluation”, Health Policy, Vol. 109,
pp. 263-269.
Hirsch, B.R., S. Balu and K.A. Schulman (2014), “The Impact of Specialty Pharmaceuticals As Drivers of
Health Care Costs”, Health Affairs, Vol. 33, No. 10, pp. 1714-1720.
Howard, D. et al. (2015), “Pricing in the Market for Anticancer Drugs”, Journal of Economic Perspectives,
Vol. 29, No. 1, pp. 139-162.
Hutchings, A. et al. (2014), “Estimating the Budget Impact of Orphan Drugs in Sweden and France 2013-
2020”, Orphanet Journal of Rare Diseases, Vol. 9, pp. 9-22.
IMS Institute for Healthcare Informatics (2013), Declining Medicine Use and Costs: For Better or For Worse?
– A Review of the Use of Medicines in the United States in 2012.
IMS Institute for Healthcare Informatics (2014), Medicine Use and Shifting Costs of Healthcare. A Review of
the Use of Medicines in the United States in 2013, April 2014.
Karikios, D.J. et al. (2014), “Rising Cost of Anticancer Drugs in Australia”, Internal Medical Journal, Vol. 44,
No. 5, pp. 458-463.
Keehan, S.K. et al. (2015), “National Health Expenditure Projections, 2014-24: Spending Growth Faster
Than Recent Trends”, Health Affairs, Vol. 34, No. 8, pp. 1407-1417.
Light, D.W. and H. Kantarjian (2013), “Market Spiral Pricing of Cancer Drugs”, Cancer, Vol. 15,
No. 119(22), pp. 3900-3902, November.
Lotvin, A.M. et al. (2014), “Specialty Medications: Traditional and Novel Tools Can Address Rising
Spending on These Costly Drugs”, Health Affairs, Vol. 33, No. 10, pp. 1736-1744.
Managed Care® (2011), “Patent Cliff: Billions To Be Saved – Starting Now”,
http://www.managedcaremag.com/content/patent-cliff-billions-be-saved-%E2%80%94-starting-now.
Navarria, A. et al. (2015), “Do Current Performance-based Schemes in Italy ReallyWork? ‘Success Fee’:
A Novel Measure for Cost-containment of Drug Expenditure”, Value in Health, Vol. 18, pp. 131-136.
NICE – National Institute for Health and Care Excellence (2014), “NICE Clinical Guideline 181, Lipid
Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary
and Secondary Prevention of Cardiovascular Disease”, July 2014.
Schey, C., T. Milanova and A. Hutchings (2011), “Estimating the Budget Impact of Orphan Medicines in
Europe: 2010-2020”, Orphanet Journal of Rare Diseases, Vol. 6, No. 62, pp. 1-10.
Thomson, S. et al. (2014), “Economic Crisis, Health Systems and Health in Europe: Impact and
Implications for Policy”, WHO Regional Office for Europe and European Observatory on Health
Systems and Policies.
Trish, E., G. Joyce and D.P. Goldman (2014), “Specialty Drug Spending Trends Among Medicare and
Medicare Advantage Enrollees, 2007-11”, Health Affairs, Vol. 33, No. 11, November, pp. 2018-2024.
van den Brink, R. (2014), “Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the
Netherlands”, Orphanet Journal of Rare Diseases,Vol. 9, Suppl. 1, O17.
van de Vooren, K. et al. (2014), “Market-access Agreements for Anti-cancer Drugs”, Journal of the Royal
Society of Medicine, Vol. 108, No. 5, pp. 166-170.
WHO – World Health Organization (2015), “Access to New Medicines in Europe: Technical Review of
Policy Initiatives and Opportunities for Collaboration and Research”, WHO Regional Office for
Europe, Copenhagen.
Yang B., E. Bae and J. Kim (2008), “Economic Evaluation and Pharmaceutical Reimbursement Reform In
South Korea’s National Health Insurance”, Health Affairs, Vol. 27, No. 1, pp. 179-187.HEALTH AT A GLANCE 2015 © OECD 2015 43

HEALTH AT A GLANCE 2015 © OECD 2013. HEALTH STATUS
Life expectancy at birth
Life expectancy by sex and education level
Mortality from cardiovascular diseases
Mortality from cancer
Mortality from transport accidents
Suicide
Infant mortality
Infant health: Low birth weight
Perceived health status
Cancer incidence
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities. The use of such data by the OECD is without prejudice to the status of the Golan
Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of
international law.5 45
3. HEALTH STATUSLife expectancy at birthLife expectancy at birth continues to increase steadily in
OECD countries, going up on average by 3 to 4 months each
year, with no sign of slowing down. These gains in longe-
vity can be attributed to a number of factors including
improved lifestyle and better education, and progress in
health care.
In 2013, life expectancy on average across OECD countries
reached 80.5 years, an increase of more than ten years
since 1970 (Figure 3.1). Japan, Spain and Switzerland lead a
large group of 25 OECD countries in which life expectancy
at birth now exceeds 80 years. A second group, including
the United States, Chile and a number of Central and
Eastern European countries, has a life expectancy between
75 and 80 years.
Among OECD countries, Mexico had the lowest life expec-
tancy in 2013, still slightly below 75 years. Since 2000, life
expectancy in Mexico has increased more slowly than in
other OECD countries, with a gain of just over a year (from
73.3 to 74.6 years) compared with an average gain of more
than three years across OECD countries. The gap in longe-
vity between Mexico and other OECD countries has there-
fore widened from about four years to six years between
2000 and 2013. The slow progress in life expectancy in
Mexico is due to a number of factors, including harmful
health-related behaviours such as poor nutrition and very
high obesity rates, a lack of progress in reducing mortality
from cardiovascular diseases, very high death rates from
road traffic accidents and homicides, as well as persistent
barriers of access to high-quality care.
In the United States, the gains in life expectancy over the
past few decades have also beenmore modest than inmost
other OECD countries. While life expectancy in the United
States used to be one year above the OECD average in 1970,
it is now more than one year below the average. Many
factors can explain these lower gains in life expectancy,
including: 1) the highly fragmented nature of the US health
system, with relatively few resources devoted to public
health and primary care, and a large share of the popula-
tion uninsured; 2) health-related behaviours, including
higher calorie consumption per capita and greater obesity
rates, higher consumption of prescription and illegal drugs,
more deaths from road traffic accidents and higher homi-
cide rates; and 3) adverse socio-economic conditions
affecting large segments of the US population, with higher
rates of poverty and income inequality than in most other
OECD countries (National Research Council and Institute of
Medicine, 2013).
Although the life expectancy in partner countries such as
India, Indonesia, Brazil and China remains well below the
OECD average, these countries have achieved considerable
gains in longevity over the past decades, with the level
converging rapidly towards the OECD average. There has
been much less progress in countries such as South Africa
(due mainly to the epidemic of HIV/AIDS), and the Russian
Federation (due mainly to the impact of the economic
transition in the 1990s and a rise in risk increasing behaviours
among men, notably rising alcohol consumption).
Higher national income (as measured by GDP per capita) is
generally associated with higher life expectancy at birth,
although the relationship is less pronounced at the highest
levels of national income (Figure 3.2). There are also notable
differences in life expectancy between countries with
similar income per capita. For example, Japan, Spain and
Italy have higher, and the United States and the Russian
Federation have lower life expectancies than would be pre-
dicted by their GDP per capita alone.
Figure 3.3 shows the relationship between life expectancy
at birth and current health expenditure per capita (excluding
capital investments) across OECD, candidate and partner
countries. Higher health spending per capita is generally
associated with higher life expectancy at birth, although
this relationship tends to be less pronounced in countries
with the highest health spending per capita. Japan, Spain
and Korea stand out as having relatively high life expec-
tancies, and the United States and the Russian Federation
relatively low life expectancies, given their levels of health
spending.
Variation in life expectancy across countries can be
explained by many factors beyond national income and
total health spending.
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Definition and comparability
Life expectancy at birth measures how long, on average,
people would live based on a given set of age-specific
death rates. However, the actual age-specific death
rates of any particular birth cohort cannot be known in
advance. If age-specific death rates are falling (as has
been the case over the past decades), actual life spans
will be higher than life expectancy calculated with
current death rates.
The methodology used to calculate life expectancy
can vary slightly between countries. This can change
a country’s estimates by a fraction of a year.
Life expectancy at birth for the total population is calcu-
lated by the OECD Secretariat for all OECD countries,
using the unweighted average of life expectancy of
men and women.HEALTH AT A GLANCE 2015 © OECD 201546
3. HEALTH STATUS
Life expectancy at birthInformation on data for Israel: http://oe.cd/israel-disclaimer
3.1. Life expectancy at birth, 1970 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3.2. Life expectancy at birth and GDP per capita, 2013
(or latest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280727
0 10 000 20 000 30 000 40 000 50 000 60 000 70 000
R² = 0.58
65
70
75
80
85
AUS
AUT
BEL
BRA
CAN
CHL
CHN
COL
CZE
DNK
EST
FIN
FRA
DEU
GRC
HUN
ISL
IND
IDN
IRL
ISR
ITA JPN
KOR
LVA LTU
MEX
NLD
NZL
NOR
POL
PRT
RUS
SVK
SVN
ESP
SWE CHE
TUR
GBR USA
GDP per capita (USD PPP)
Life expectancy in years
3.3. Life expectancy at birth and health spending
per capita, 2013 (or latest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280727
R² = 0.51
65
70
75
80
85
0 2 000 4 000 6 000 8 000 10 000
AUS
AUT
BEL
BRA
CAN
CHL
CHNCOL
CRI
CZE
DNK
EST
FIN
FRA
DEU
GRC
HUN
ISL
IND
IDN
IRL
ISR ITA
JPN
KOR
LVA LTU
LUX
MEX
NLD
NZL NOR
POL
PRT
RUS
SVK
SVN
ESP
SWE CHE
TUR
GBR
USA
Health spending per capita (USD PPP)
Life expectancy in yearsHEALTH AT A GLANCE 2015 © OECD 2015 47
3. HEALTH STATUSLife expectancy by sex and education levelThere remain large gaps in life expectancy between women
and men in all OECD countries. On average across OECD
countries, life expectancy at birth for women reached 83.1
years in 2013, compared with 77.8 years for men, a gap of
5.3 years (Figure 3.4).
The gender gap in life expectancy increased substantially
in many OECD countries during the 1970s and early 1980s
to reach a peak of almost seven years in the mid-1980s, but
it has narrowed during the past 25 years, reflecting higher
gains in life expectancy among men than among women.
This can be attributed at least partly to the narrowing of
differences in risk-increasing behaviours, such as smoking,
accompanied by sharp reductions in mortality rates from
cardiovascular diseases among men.
In 2013, the life expectancy for women in OECD countries
ranged from less than 80 years in Turkey, Hungary and
Mexico to more than 85 years in Japan, Spain, France, Italy
and Switzerland. Life expectancy for men ranged from less
than 75 years in Mexico, Hungary, Estonia, the Slovak
Republic, Poland and Turkey to over 80 years in Switzerland,
Iceland, Italy, Israel, Japan, Spain, Sweden and Australia.
In the United States, the life expectancy for both women
and men is now slightly shorter than the OECD average,
and the gap with leading countries has been widening. The
life expectancy for US men in 2013 was 4.3 years shorter
than in Switzerland (up from less than three years in 1970);
for US women, it was 5.4 years shorter than in Japan in
2013 (there was no gap in 1970). Possible explanations for
this slower progress are provided under the indicator “Life
expectancy at birth”.
Among OECD countries, the gender gap in life expectancy is
relatively narrow in Iceland, Israel, Sweden, the Netherlands,
New Zealand and the United Kingdom (a gap of less than
four years), but much larger in Estonia (around nine years),
Poland (around eight years), the Slovak Republic and Hungary
(around seven years).
Life expectancy in OECD countries varies not only by gender,
but also by socio-economic status as measured, for
instance, by education level (Figure 3.5). Higher education
level not only provides the means to improve the socio-
economic conditions in which people live and work, but
may also promote the adoption of healthier lifestyles and
facilitate access to appropriate health care. On average
among 15 OECD countries for which recent data are available,
people with the highest level of education can expect to live
six years longer than people with the lowest level of educa-
tion at age 30 (53 years versus 47 years). These differences
in life expectancy by education level are particularly
pronounced for men, with an average gap of almost
eight years. The differences are especially large in Central
and Eastern European countries (Czech Republic, Estonia,
Hungary and Poland), where the life expectancy gap
between higher and lower educated men is more than
ten years. This is largely explained by the greater preva-
lence of risk factors among men, such as tobacco and alco-
hol use. Differences in other countries such as Portugal,
Sweden, Switzerland and Italy are less pronounced.
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Definition and comparability
Life expectancy at birth measures how long, on aver-
age, people would live based on a given set of age-
specific death rates. However, the actual age-specific
death rates of any particular birth cohort cannot be
known in advance. If age-specific death rates are fall-
ing (as has been the case over the past decades),
actual life spans will be higher than life expectancy
calculated with current death rates.
The methodology used to calculate life expectancy
can vary slightly between countries. This can change
a country’s estimates by a fraction of a year.
To calculate life expectancies by education level,
detailed data on deaths by sex, age and education
level are needed. However, not all countries have
information on education as part of their deaths data.
Data linkage to another source (e.g. a census) which
does have information on education may be required
(Corsini, 2010).HEALTH AT A GLANCE 2015 © OECD 201548
3. HEALTH STATUS
Life expectancy by sex and education levelInformation on data for Israel: http://oe.cd/israel-disclaimer
3.4. Life expectancy at birth by sex, 2013 (or latest year)
Note: Countries are ranked in descending order of life expectancy for the whole population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3.5. Gap in life expectancy at age 30 by sex and educational level, 2012 (or latest year)
Note: The figures show the gap in the expected years of life remaining at age 30 between adults with the highest level (“tertiary education”) and the
lowest level (“below upper secondary education”) of education.
Source: Eurostat database complemented with national data for Israel, Mexico and Netherlands.
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3. HEALTH STATUSMortality from cardiovascular diseasesDespite substantial declines in recent decades, cardiovas-
cular diseases remain the main cause of mortality in most
OECD countries, accounting for nearly one-third (32.3%) of
all deaths in 2013. Prospects for further reductions may be
hampered by a rise in certain risk factors such as obesity
and diabetes (OECD, 2015). Cardiovascular diseases cover a
range of illnesses related to the circulatory system, includ-
ing ischemic heart disease (often referred to as heart
attack) and cerebrovascular diseases such as stroke.
Ischemic heart disease (IHD) is caused by the accumulation
of fatty deposits lining the inner wall of a coronary artery,
restricting blood flow to the heart. IHD alone was responsi-
ble for nearly 20% of all deaths in OECD countries in 2013.
However, mortality from IHD varies considerably across
countries (Figure 3.6). Central and Eastern European coun-
tries report the highest IHD mortality rates; Japan, France
and Korea report the lowest rates. Across OECD countries,
IHD mortality rates in 2013 were around 84% higher for
men than women.
IHD mortality rates have declined in nearly all OECD coun-
tries, with an average reduction of 45% since 1990, contrib-
uting greatly to gains in life expectancy, particularly among
men. The decline has been most remarkable in Denmark,
the Netherlands, and Norway, where rates fell by two-
thirds or more. Declining tobacco consumption contributed
significantly to reducing the incidence of IHD (see Indicator
“Tobacco consumption among adults” in Chapter 4), and con-
sequently to reducingmortality rates. Improvements inmed-
ical care have also contributed to reducedmortality rates (see
the indicators on “Cardiac procedures” in Chapter 6 and
“Mortality following acute myocardial infarction” in
Chapter 8).
In Korea, IHD mortality rates have increased substantially
since 1990, although they remain low compared with
nearly all other OECD countries and have started to fall
after peaking in 2006. The initial rise in IHD mortality rates
in Korea has been attributed to changes in lifestyle and
dietary patterns as well as environmental factors at the
time of birth, with people born between 1940 and 1950 facing
higher relative risks. In 2006, Korea introduced a Compre-
hensive Plan to tackle cardiovascular diseases that encom-
passed prevention and primary care as well as better acute
care, contributing to the reduction in mortality in recent
years (OECD, 2012).
Cerebrovascular disease was the underlying cause for
about 7% of all deaths in OECD countries in 2013. Cerebro-
vascular disease refers to a group of diseases that relate to
problems with the blood vessels that supply the brain.
Common manifestations of cerebrovascular disease
include ischemic stroke, which develops when the brain's
blood supply is blocked or interrupted, and haemorrhagic
stroke which occurs when blood leaks from blood vessels
into the surface of the brain. In addition to being an impor-
tant cause of mortality, the disability burden from stroke
and other cerebrovascular diseases is also substantial
(Murray et al., 2015).
There are large variations in cerebrovascular disease mor-
tality rates across countries (Figure 3.7). The Slovak Repub-
lic and Hungary report a cerebrovascular mortality that is
more than three times higher than that of Switzerland,
Canada and France, and have the highest mortality rates
for both IHD and cerebrovascular disease. The high preva-
lence of risk factors common to both diseases (such as
smoking and high blood pressure) may explain this link.
Since 1990, cerebrovascular disease mortality has
decreased in all OECD countries, although to a lesser extent
in Poland and the Slovak Republic. On average, the mortal-
ity burden from cerebrovascular disease has halved across
OECD countries. In Estonia, Luxembourg and Portugal, the
rates have been cut by at least two-thirds, although in Estonia
this is partly due to a change in death recording practices
with a greater recording of other related causes of death
such as hypertension. As with IHD, the reduction inmortal-
ity from cerebrovascular disease can be attributed at least
partly to a reduction in risk factors as well as improve-
ments in medical treatments (see indicator “Mortality
following stroke” in Chapter 8), but rising obesity and diabe-
tes threatens progress in tackling cerebrovascular disease
(OECD, 2015).
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Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database.
Deaths from ischemic heart disease are classified to
ICD-10 codes I20-I25, and cerebrovascular disease to
I60-I69.HEALTH AT A GLANCE 2015 © OECD 201550
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Mortality from cardiovascular diseasesInformation on data for Israel: http://oe.cd/israel-disclaimer
3.6. Ischemic heart disease mortality, 2013 and change 1990-2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3.7. Cerebrovascular disease mortality, 2013 and change 1990-2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3. HEALTH STATUSMortality from cancerCancer is the second leading cause of mortality in OECD
countries after cardiovascular diseases, accounting for 25%
of all deaths in 2013, up from 15% in 1960. In a number of
countries, cancer is now the most frequent cause of death.
The rising share of deaths due to cancer reflects the fact
that mortality from other causes, particularly cardiovascu-
lar diseases, has been declining more rapidly than mortal-
ity from cancer.
There are more than 100 different types of cancers, with
most named for the organ in which they start. For a large
number of cancer types, the risk of developing the disease
rises with age.While genetics is a risk factor, only about 5%
to 10% of all cancers are inherited. Modifiable risk factors
such as smoking, obesity, lack of exercise and excess sun
exposure, as well as environmental exposures, explain up
to 90-95% of all cancer cases (Anand et al., 2008). Preven-
tion, early detection and treatment remain at the forefront
in the battle to reduce the burden of cancer (OECD, 2013).
In 2013, the average rate of mortality attributable to cancer
across OECD countries was just over 200 per 100 000 popula-
tion (Figure 3.8). Mortality due to cancer was lowest in
Mexico, Turkey, Finland, Switzerland and Japan, with rates
less than 180 per 100 000 population. Hungary, Slovenia,
the Slovak Republic and Denmark bear the highest cancer
mortality burden, with rates in excess of 240 per
100 000 population.
Mortality due to cancer is consistently higher for men than
for women in all countries. The gender gap is particularly
wide in Korea, Turkey, Estonia, Spain and Portugal, with
rates among men more than twice those for women. This
gender gap can be explained partly by the greater preva-
lence of risk factors among men, notably smoking rates.
Among men, lung cancer imposes the highest mortality
burden, accounting for 26% of all cancer-related deaths
(Figure 3.9). In Turkey, Greece, Poland, Hungary and
Belgium, this percentage was over 30%. For women, lung
cancer accounted for 17% of all cancer-related deaths. In
many countries, lung cancer mortality rates for men have
decreased over the last 20 years. But lung cancer mortality
has risen for women in several countries such as France
and Spain where it has more than doubled since 1990.
These conflicting trends are, to a large degree, explained by
the high number of females who started smoking several
decades later than males (in the 1980s and 1990s).
Breast cancer is the second most common cause of cancer
mortality in women in many OECD countries. While there
has been an increase in the incidence of breast cancer over
the past decade, mortality has declined in most countries
due to earlier diagnosis and better treatment. Mortality
from breast cancer increased somewhat in Korea and
Japan, although the rates there remained the lowest in
2013. Mortality rates from breast cancer in 2013 were high-
est in Denmark, Hungary, Belgium, Ireland, Slovenia and
the Netherlands (see indicator “Screening, survival and
mortality for breast cancer” in Chapter 8).
Colorectal cancer is a major cause of cancer mortality
among both men and women (second-highest cause of
cancer mortality in men and third in women). In 2013,
colorectal cancer mortality was lowest in Mexico and
Turkey, and highest in Hungary and the Slovak Republic
(see indicator “Survival and mortality for colorectal cancer”
in Chapter 8).
Prostate cancer has become the most common cancer
among men in many OECD countries, particularly among
men aged 65 years and over. Mortality from prostate cancer
remains lower than for lung cancer in all countries except
in Chile and Mexico, where it is the leading cause of cancer
deaths in men, and in some Nordic countries (Iceland,
Norway and Sweden) where mortality from prostate and
lung cancer are almost equal. Mortality rates from prostate
cancer in 2013 were lowest in Japan and Korea, and highest
in Estonia and Iceland.
In most OECD countries, cancer-related mortality rates
have fallen since 1990. On average, rates fell by 17%
between 1990 and 2013. Substantial declines in mortality
from stomach cancer, colorectal cancer, lung cancer for
men, breast, cervical and ovarian cancer for women, as
well as prostate cancer for men contributed to this reduc-
tion. However, these gains were partially offset by increases
in the number of deaths due to cancer of the liver, skin and
pancreas for both sexes, as well as lung cancer for women.
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Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database. Deaths from all
cancers are classified to ICD-10 codes C00-C97. The
international comparability of cancer mortality data
can be affected by differences in medical training
and practices as well as in death certification across
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Mortality from cancerInformation on data for Israel: http://oe.cd/israel-disclaimer
3.8. Cancer mortality, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280758
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3.9. Main causes of cancer deaths among men and women in OECD countries, 2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3. HEALTH STATUSMortality from transport accidentsInjuries from transport accidents – most of which are due
to road traffic – are a major public health problem in OECD
countries, causing the premature deaths of more than
100 000 people in 2013 (more than 1% of all deaths). Almost
three-quarters of these deaths occurred among men. In
addition, more than 5 million people were injured in road
accidents. The direct and indirect financial costs of trans-
port accidents are substantial, with estimates ranging from
1 to 3% of GDP annually (OECD/ITF, 2015).
Most fatal traffic injuries occur in passenger vehicles,
although other road users also face substantial risks. In
Korea, Japan, Israel and Poland, pedestrians account for
over one third of all road user fatalities. Cyclists in the
Netherlands and motorcyclists in Greece, Italy and France
account for over one fourth of road traffic accident deaths
in these countries (OECD/ITF, 2015).
The average OECD mortality rate due to transport acci-
dents was 7 per 100 000 population in 2013 (Figure 3.10).
There is considerable variation between countries with
transport accidents claiming more than five times as
many lives per 100 000 population in Mexico compared to
the United Kingdom and Sweden. Mortality rates from road
transport accidents were also relatively high in Korea, Chile
and the United States.
Much transport accident injury and mortality is prevent-
able. Road safety for car occupants has increased greatly
over the past decades in many countries through improve-
ments of road systems, education and prevention cam-
paigns as well as vehicle design. In addition, the adoption
of new laws and regulations and the enforcement of these
laws to improve compliance with speed limits, seatbelt use
and drink-driving rules have had a major impact on reduc-
ing the burden of road transport accidents.
As a result, deaths due to transport accidents have
decreased in almost all countries over the last few decades.
Since 1990, the average OECD mortality rate due to transport
accidents has fallen by more than 70% (Figure 3.11). These
gains are even more impressive when considering the
increase in the number of vehicle kilometers travelled over
this period (OECD/ITF, 2015). Chile is the only country
where deaths due to transport accidents have increased. In
1990, Chile’s mortality rate was comparatively low, but then
rose during the 1990s as the economy and the number of
vehicles grew and has remained relatively high since then
(Nghiem et al., 2013).
Declines in mortality rates for vulnerable road users such
as pedestrians, cyclists and motorcyclists were substan-
tially less than those for car occupants. Reductions in
deaths among pedestrians, cyclists and motorcyclists have
levelled-off and some increases have been recorded. As a
consequence, road safety priorities in many countries have
recently shifted to vulnerable road users in urban areas
(OECD/ITF, 2015).
The economic crisis has contributed to the reduction in
road traffic deaths in many countries, by reducing the dis-
tance travelled (especially by young men and by trucks).
However, this impact is likely to be short-lived and, over the
longer term, effective road safety policies will remain the
primary contributor to reduced mortality (OECD/ITF, 2015).
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Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database.
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Mortality from transport accidentsInformation on data for Israel: http://oe.cd/israel-disclaimer
3.10. Transport accident mortality, 2013 (or nearest year)
1. Three-year average.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en and Ministry of Health for New Zealand.
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3.11. Trends in transport accident mortality, selected OECD countries, 1990-2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3. HEALTH STATUSSuicideSuicide is a significant cause of death in many OECD coun-
tries, accounting for over 150 000 deaths in 2013. A complex
set of reasons may explain why some people choose to
attempt or commit suicide. A high proportion of people
who have attempted or committed suicide are suffering
from psychiatric disorders such as severe depression, bipolar
disorder and schizophrenia. The social context in which an
individual lives is also important. Low income, alcohol and
drug abuse, unemployment and social isolation are all
associated with higher rates of suicide.
Figure 3.12 shows that suicide rates in 2013 were lowest in
Turkey, Greece, Mexico, Italy and Israel, at seven or fewer
deaths per 100 000 population, although the number of sui-
cides in certain countries may be under-reported because
of the stigma associated with the act or data unreliability
associated with reporting criteria (see “Definition and com-
parability”). Korea had the highest suicide rate with nearly
30 deaths per 100 000 population, followed by Japan,
Hungary and Slovenia with nearly 20 deaths per 100 000
population. Mortality rates from suicide are three-to-four
times greater for men than for women across OECD coun-
tries (Figure 3.12). In Poland and the Slovak Republic, men
are seven times more likely to commit suicide than
women.The gender gap is narrower for attempted suicides,
reflecting the fact that women tend to use less fatalmethods
than men. Suicide is also related to age, with young people
aged under 25 and elderly people especially at risk. While
suicide rates among the latter have generally declined over
the past two decades, less progress has been observed
among younger people.
Since 1990, suicide rates have decreased by around 30%
across OECD countries, with the rates being halved in
countries such as Hungary and Finland (Figure 3.13). In
Estonia, after an initial rise in the early 1990s, the rates
have also fallen sharply. On the other hand, death rates
from suicides have increased in Korea and Japan. In Japan,
there was a sharp rise in the mid-to-late 1990s, coinciding
with the Asian financial crisis, but rates have started to
come down in recent years. In Korea, suicide rates rose
steadily over the past two decades peaking around 2010,
before starting to come down (Lim et al., 2014). Suicide is
the number one cause of death among teenagers in Korea.
Suicide is often linked with depression and the abuse of alco-
hol and other substances. Early detection of these psycho-
social problems in high-risk groups by families and health
professionals is an important part of suicide prevention
campaigns, together with the provision of effective support
and treatment. Many countries are developing national
strategies for prevention, focusing on at-risk groups. Mental
health services in Korea lag behind those of other countries
with fragmented support, focused largely around institutions,
and insufficient or ineffective support services provided to
those who remain in the community. Further efforts are
also needed to remove the stigma associated with seeking
care (OECD, 2014).
Previous studies have shown a strong link between adverse
economic conditions and higher levels of suicide (Van Gool
and Pearson, 2014). Suicide rates rose slightly at the start of
the economic crisis in 2008-2009 in a number of countries,
but this trend did not persist in most. In Greece, suicide
rates were stable in 2009 and 2010, but have increased since
2011 (Figure 3.13). All countries need to continuemonitoring
developments closely in order to be able to respond quickly,
including monitoring high-risk populations such as the
unemployed and those with psychiatric disorders (see
indicator “Mental health care” in Chapter 8).
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Definition and comparability
The World Health Organization defines suicide as an
act deliberately initiated and performed by a person in
the full knowledge or expectation of its fatal outcome.
Comparability of data between countries is affected by
a number of reporting criteria, including how a per-
son’s intention of killing themselves is ascertained,
who is responsible for completing the death certifi-
cate, whether a forensic investigation is carried out,
and the provisions for confidentiality of the cause of
death. Caution is required therefore in interpreting
variations across countries.
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is theWHOMortality Database. Deaths from sui-
cide are classified to ICD-10 codes X60-X84.HEALTH AT A GLANCE 2015 © OECD 201556
3. HEALTH STATUS
SuicideInformation on data for Israel: http://oe.cd/israel-disclaimer
3.12. Suicide, 2013 (or nearest year)
1. Three-year average.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280778
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3.13. Trends in suicide, selected OECD countries, 1990-2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280778
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3. HEALTH STATUSInfant mortalityInfant mortality, the rate at which babies and children of
less than one year of age die, reflects the effect of economic
and social conditions on the health of mothers and new-
borns, the social environment, individual lifestyles as well
as the characteristics and effectiveness of health systems.
In most OECD countries, infant mortality is low and there is
little difference in rates (Figure 3.14). In 2013, the average in
OECD countries was less than four deaths per 1 000 live
births, with rates being the lowest in Iceland, Slovenia,
Finland, Estonia and Japan. A small group of OECD coun-
tries still have comparatively high infant mortality (Mexico,
Turkey and Chile), although in these three countries infant
mortality has reduced considerably over the past few
decades (Figure 3.15).
In some large partner countries (India, South Africa and
Indonesia), infant mortality remains above 20 deaths per
1 000 live births. In India, one-in-twenty-five children die
before their first birthday, although the rates have fallen
sharply over the past few decades. Infant mortality rates
have also reduced greatly in Indonesia.
In OECD countries, around two-thirds of the deaths that
occur during the first year of life are neonatal deaths (i.e.,
during the first four weeks). Birth defects, prematurity and
other conditions arising during pregnancy are the main
factors contributing to neonatal mortality in developed
countries. With an increasing number of women deferring
childbearing and a rise in multiple births linked with fertil-
ity treatments, the number of pre-term births has tended
to increase (see indicator “Infant health: low birthweight”). In
a number of higher-income countries, this has contributed to
a levelling-off of the downward trend in infant mortality
over the past few years. For deaths beyond a month (post-
neonatal mortality), there tends to be a greater range of
causes – the most common being SIDS (sudden infant
death syndrome), birth defects, infections and accidents.
In the United States, the reduction in infant mortality has
been slower than in most other OECD countries. In 2000,
the US rate was below the OECD average, but it is now
higher (Figure 3.14). One of the explanations that have been
given for that the high rate of infant mortality in the United
States is that it is based on a more complete registration of
very premature and low birth weight babies than in many
other countries (Joseph et al., 2012). In order to remove the
impact of differences in registration practices of very small
babies, the figures shown in Figure 3.14 for a majority of
countries (including the United States) exclude deaths of
babies of less than 22 weeks of gestation period or
500 grams birth weight. The rate in the United States none-
theless remains higher than the OECD average, especially
for post-neonatal mortality (deaths after onemonth) which
is greater in the United States than in most other OECD
countries. There are large differences in infant mortality
among racial groups in the United States, with Black
womenmore likely to give birth to low birth weight infants,
and with infant mortality more than double that for White
women (10.9 vs. 5.1 in 2012) (NCHS, 2015).
Many studies use infant mortality as a health outcome to
examine the effect of a variety of medical and non-medical
determinants of health. Although most analyses show that
higher health spending tends to be associated with lower
infant mortality, the fact that some countries with a high
level of health expenditure do not exhibit low levels of
infant mortality suggests that more health spending is not
necessarily required to obtain better results (Retzlaff-Roberts
et al., 2004).
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Definition and comparability
The infant mortality rate is the number of deaths of
children under one year of age, expressed per
1 000 live births. Some of the international variation
in infant mortality rates is related to variations in reg-
istering practices for very premature infants. While
some countries register all live births including very
small babies with low odds of survival, several coun-
tries apply a minimum threshold of a gestation period
of 22 weeks (or a birth weight threshold of 500 grams)
for babies to be registered as live births (Euro-Peristat,
2013). To remove this data comparability limitation,
the data presented in this section are now based on a
minimum threshold of 22 weeks of gestation period
(or 500 grams birth weight) for a majority of OECD
countries that have provided these data. However, the
data for some countries (e.g., Canada and Australia)
continue to be based on all registered live births,
resulting in some over-estimation.HEALTH AT A GLANCE 2015 © OECD 201558
3. HEALTH STATUS
Infant mortalityInformation on data for Israel: http://oe.cd/israel-disclaimer
3.14. Infant mortality, 2013 (or nearest year)
Note: The data for most countries are based on a minimum threshold of 22 weeks of gestation period (or 500 grams birthweight) to remove the impact
of different registration practices of extremely premature babies across countries.
1. Three-year average (2011-13).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280782
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3.15. Trends in infant mortality, selected OECD countries, 2000-13
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3. HEALTH STATUSInfant health: Low birth weightLow birth weight – defined as newborns weighing less than
2 500 grams – is an important indicator of infant health
because of the close relationship between birth weight and
infant morbidity and mortality. There are two categories of
low birth weight babies: those occurring as a result of
restricted foetal growth and those resulting from pre-term
birth. Low birth weight infants have a greater risk of poor
health or death, require a longer period of hospitalisation
after birth, and are more likely to develop significant
disabilities. Risk factors for low birth weight include mater-
nal smoking, excessive alcohol consumption, poor nutri-
tion, low body mass index, lower socio-economic status, and
having had in-vitro fertilisation treatment and multiple
births.
One in 15 babies born in OECD countries in 2013 – or 6.6% of
all births – weighed less than 2 500 grams at birth
(Figure 3.16). The proportions of low-weight births were
lowest in Nordic countries (Iceland, Finland, Sweden,
Norway, with the exception of Denmark) and Estonia, with
less than 5% of live births defined as low birth weight.
Japan, had the highest proportion of low birth weight
infants among OECD countries, with rates close to 10%,
followed by Greece, Hungary and Portugal.
Despite the widespread use of a 2 500 grams limit for low
birth weight, physiological variations in size occur across
different countries and population groups, and these need
to be taken into account when interpreting differences
(Euro-Peristat, 2013). Some populations may have lower
than average birth weights than others because of genetic
differences.
In almost all OECD countries, the proportion of low birth
weight infants has increased over the past two decades,
mainly due to increases in pre-term births (Euro-Peristat,
2013). There are several reasons for this rise, including a
growing number of multiple pregnancies mainly as a result
of the rise in fertility treatment, and a rise in maternal age
(Delnord et al., 2015). Another factor which may explain the
rise in low birth weight infants is the increased use of deliv-
ery management techniques such as induction of labour
and caesarean delivery, which have increased the survival
rates of low birth weight babies.
Korea, Greece, Spain, Portugal and Japan have seen large
increases of low birth weight babies over the past two
decades, although the proportions remain below the OECD
average in Korea (Figure 3.17). In Japan, this increase can be
explained by changes in obstetric interventions, in particu-
lar the greater use of caesarean sections, along with
changes in maternal socio-demographic and behavioural
factors (Yorifuji et al., 2012). In Greece, the rise in the pro-
portion of low birth weight babies started in the mid-1990s,
well before the economic crisis, and peaked in 2010. Some
researchers have suggested that the high rates of low birth
weight babies between 2009 and 2012 were linked to the
economic crisis and its impact on unemployment rates and
lowering family incomes in Greece (Kentikelenis, 2014). In
2013, the rate came down to levels observed before the crisis.
Comparisons of different population groups within coun-
tries indicate that the proportion of low birth weight
infants may also be influenced by differences in education
level, income and associated living conditions. In the
United States, there are marked differences in the proportion
of low birth weight infants among racial groups, with black
infants having a rate almost double that of white infants
(13% versus 7% in 2013) (NCHS, 2015). Similar differences
have also been observed among the indigenous and non-
indigenous populations in Australia, Mexico and New
Zealand, often reflecting the disadvantaged living condi-
tions of many of these mothers.
The proportion of low birth weight infants is also generally
higher among women who smoke than for non-smokers.
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Definition and comparability
Low birth weight is defined by the World Health
Organization (WHO) as the weight of an infant at birth
of less than 2 500 grams (5.5 pounds) irrespective of
the gestational age of the infant. This threshold is
based on epidemiological observations regarding the
increased risk of death to the infant and serves for
international comparative health statistics.The number
of low weight births is expressed as a percentage of
total live births.HEALTH AT A GLANCE 2015 © OECD 201560
3. HEALTH STATUS
Infant health: Low birth weightInformation on data for Israel: http://oe.cd/israel-disclaimer
3.16. Low birth weight infants, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280794
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3.17. Trends in low birth weight infants, selected OECD countries, 1990-2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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3. HEALTH STATUSPerceived health statusMost OECD countries conduct regular health surveys which
allow respondents to report on different aspects of their
health. A commonly asked question relates to self-
perceived health status, of the type: “How is your health in
general?”. Despite the subjective nature of this question,
indicators of perceived general health have been found to
be a good predictor of people’s future health care use and
mortality (DeSalvo et al., 2005).
For the purpose of international comparisons, cross-country
variations in perceived health status are difficult to interpret
because responses may be affected by the formulation of
survey questions and responses, and by social and cultural
factors. In addition, since older people report poor health
more often than younger people, countries with a larger
proportion of aged persons will also have a lower propor-
tion of people reporting to be in good health.
With these limitations in mind, in almost all OECD coun-
tries, a majority of adults reports being in good health
(Figure 3.18). New Zealand, Canada, the United States and
Australia are the four leading countries, with more than
85% of people reporting to be in good health. However, the
response categories offered to survey respondents in these
four countries are different from those used in European
countries and Asian OECD countries, which introduce an
upward bias (see box on “Definition and comparability”).
On the other hand, less than half of adults in Japan, Korea
and Portugal rate their health as being good. The propor-
tion is also relatively low in Estonia, Hungary, Poland, Chile
and the Czech Republic, where less than 60% of adults con-
sider themselves to be in good health.
In all OECD countries, men are more likely than women to
report being in good health, except inAustralia, New Zealand,
Canada and United Kingdom where the proportion is
almost equal. As expected, people’s rating of their own
health tends to decline with age. In many countries, there
is a particularly marked decline in how people rate their
health after age 45 and a further decline after age 65
(OECD, 2015).
There are large disparities in self-reported health across
different socio-economic groups, as measured by income
or education level. Figure 3.19 shows that, in all countries,
people with a lower level of income tend to report poorer
health than people with higher income, although the gap
varies. On average across OECD countries, nearly 80% of
people in the highest income quintile report being in good
health, compared with just over 60% for people in the low-
est income group. These disparities may be explained by
differences in living and working conditions, as well as
differences in lifestyles (e.g., smoking, harmful alcohol
drinking, physical inactivity, and obesity problems). In
addition, people in low-income householdsmay have limited
access to certain health services for financial or other reasons
(see Chapter 7 on “Access to care”). A reverse causal link is
also possible, with poor health status leading to lower
employment and lower income.
Greater emphasis on public health and disease prevention
among disadvantaged groups, and improving access to
health services may contribute to further improvements in
population health status in general and reducing health
inequalities.
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Definition and comparability
Perceived health status reflects people’s overall percep-
tion of their health. Survey respondents are typically
asked a question such as: “How is your health in
general? very good, good, fair, poor, very poor”.
Caution is required in making cross-country compari-
sons of perceived health status, for at least two reasons.
First, people’s assessment of their health is subjective
and can be affected by cultural factors. Second, there
are variations in the question and answer categories
used to measure perceived health across surveys and
countries. In particular, the response scale used in the
United States, Canada, New Zealand, Australia and
Chile is asymmetric (skewed on the positive side),
including the following response categories: “excellent,
very good, good, fair, poor”. The data in OECD Health
Statistics refer to respondents answering one of the
three positive responses (“excellent, very good or
good”). By contrast, in most other OECD countries, the
response scale is symmetric, with response categories
being: “very good, good, fair, poor, very poor”. The
data reported from these countries refer only to the
first two categories (“very good, good”). In Israel, the
scale is symmetric but there is no middle category
related to “fair” health. Such differences in response
categories biases upward the results from those
countries that are using an asymmetric scale or a
symmetric scale but without any middle category.
Self-reported health by income level is reported for
the first quintile (lowest 20% of income group) and
the fifth quintile (highest 20%). Depending on the
surveys, the income may relate either to the individ-
ual or the household (in which case the income is
equivalised to take into account the number of persons
in the household).HEALTH AT A GLANCE 2015 © OECD 201562
3. HEALTH STATUS
Perceived health statusInformation on data for Israel: http://oe.cd/israel-disclaimer
3.18. Perceived health status among adults, 2013 (or nearest year)
1. Results for these countries are not directly comparable with those for other countries, due to methodological differences in the survey
questionnaire resulting in an upward bias. In Israel, there is no category related to fair health.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en (EU-SILC for European countries).
1 2 http://dx.doi.org/10.1787/888933280801
3.19. Perceived health status by income level, 2013 (or nearest year)
Note: Countries are ranked in descending order of perceived health status for the whole population.
1. Results for these countries are not directly comparable with those for other countries, due to methodological differences in the survey
questionnaire resulting in an upward bias. In Israel, data by income group relate to the employed population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en (EU-SILC for European countries).
1 2 http://dx.doi.org/10.1787/888933280801
0
10
20
30
40
60
50
100
80
90
70
90 89 88 85 82 81 81 80 77 76 76 74 74 74 72 72 72 69 69 68 67 66 66 65 65 65
60 59 58 57
53
46
35 35
8 9 9 11 14 15 16
18 16 19 17 16 18 20 21 20 22 22
21 24 21 22 27 25
29
28
35
27 27 31
35
49 49
2 3 3 4 4 4 4
20
6 8 5 9 11 8 8 8 8 9 9 12 9 13 12
8 11
7
13
6
14 16 16 19 15 16
% of population aged 15 years and over
Fair Bad or very badGood or very good
Ne
w 
Ze
ala
nd
1
Ca
na
da
1
Un
ite
d S
tat
es
1
Au
str
ali
a1
Ire
lan
d
Sw
ed
en
Sw
itz
erl
an
d
Isr
ae
l1
Ice
lan
d
No
rw
ay
Ne
the
rla
nd
s
Be
lgi
um
Gr
ee
ce
Un
ite
d K
ing
do
m
Lu
xe
mb
ou
rg
De
nm
ark
Sp
ain
OE
CD
33
Au
str
ia
Tu
rke
y
Fra
nc
e
Ita
ly
Slo
va
k R
ep
.
Ge
rm
an
y
Slo
ve
nia
Fin
lan
d
Cz
ec
h R
ep
.
Ch
ile
1
Po
lan
d
Hu
ng
ary
Es
ton
ia
Po
rtu
ga
l
Ja
pa
n
Ko
rea
0
10
20
30
40
60
50
100
80
90
70
94 9
5 96
93 91 89 89
96
82
85 84
86
83
89
80
83
81
79 8
0
76
74 7
4
78 77 76 7
7 77
67
69 69
78
62
40
42
87
79
73
83
77
70 69
84
73
67 66
58
75
64
67 67
69
62
60 6
1 62 6
3
60
52 52
49 48
54 5
4
53
39 4
0
28
31
% of population aged 15 years and over reporting to be in good health
Lowest incomeHighest income
Ne
w 
Ze
ala
nd
1
Ca
na
da
1
Un
ite
d S
tat
es
1
Au
str
ali
a1
Ire
lan
d
Sw
ed
en
Sw
itz
erl
an
d
Isr
ae
l1
Ice
lan
d
No
rw
ay
Ne
the
rla
nd
s
Be
lgi
um
Gr
ee
ce
Un
ite
d K
ing
do
m
Lu
xe
mb
ou
rg
De
nm
ark
Sp
ain
OE
CD
33
Au
str
ia
Tu
rke
y
Fra
nc
e
Ita
ly
Slo
va
k R
ep
.
Ge
rm
an
y
Slo
ve
nia
Fin
lan
d
Cz
ec
h R
ep
.
Ch
ile
1
Po
lan
d
Hu
ng
ary
Es
ton
ia
Po
rtu
ga
l
Ja
pa
n
Ko
reaHEALTH AT A GLANCE 2015 © OECD 2015 63
3. HEALTH STATUSCancer incidenceIn 2012, an estimated 5.8 million new cases of cancer were
diagnosed in OECD countries, 54% (around 3.1 million)
occurring in men and 46% (around 2.7 million) in women.
The most common were breast cancer (12.9% of all new
cancer cases) and prostate cancer (12.8%), followed by lung
cancer (12.3%) and colorectal cancer (11.9%). These four
cancers represented half of the estimated overall burden of
cancer in OECD countries (Ferlay et al., 2014).
Large variations exist in cancer incidence across OECD
countries. Cancer incidence rates are highest in Denmark,
Australia, Belgium, Norway, United States, Ireland, Korea,
Netherlands and France registering more than 300 new
cancer cases per 100 000 population in 2012 (Figure 3.20).
The lowest rates were reported in some Latin American
and Mediterranean countries such as Mexico, Greece, Chile
and Turkey, with around 200 new cases or less per
100 000 population. These variations reflect not only varia-
tions in the prevalence of risk factors for cancer, but also
national policies regarding cancer screening and differ-
ences in quality of reporting.
Cancer incidence was higher for men in all OECD countries
in 2012 except in Mexico. However, the gender gap varies
widely across countries. In Turkey, Estonia and Spain, inci-
dence among men were around 60% higher than among
women, whereas in the United Kingdom, Denmark and Ice-
land, the gap was less than 10%.
Breast was by far the most common primary sites in
women (28% on average), followed by colorectal (12%), lung
(10%), and cervical (3%). The causes of breast cancer are not
fully understood, but the risk factors include age, family
history, breast density, exposure to oestrogen, being over-
weight or obese, alcohol intake, radiation and hormone
replacement therapy. Incidence rates in 2012 were highest
in Belgium, Denmark and Netherlands, with rates 25% or
more than the OECD average (Figure 3.21). Chile and Mexico
had the lowest rate, followed by Turkey and Greece. The
variation in breast cancer incidence across OECD countries
may be at least partly attributed to variation in the extent
and type of screening activities. Although mortality rates
for breast cancer have declined in most OECD countries
since the 1990s due to earlier detection and improvements
in treatments, breast cancer continues to be the leading
cause of death from cancer among women (see Indicator
“Mortality from cancer” in Chapter 3 and “Screening, survival
andmortality from breast cancer” in Chapter 8).
Prostate cancer has become the most commonly diagnosed
cancer among men in almost all OECD countries, except in
Hungary, Poland, Turkey and Greece where lung cancer is
still predominant, and in Japan and Korea where colorectal
cancer is the main cancer among men. On average across
OECD countries, prostate cancer accounted for 24% of all
new cancer diagnoses in men in 2012, followed by lung
(14%) and colorectal (12%). Similar to breast cancer, the
causes of prostate cancer are not well-understood but age,
ethnic origin, family history, obesity, lack of exercise and
poor nutrition are the main risk factors. Incidence in 2012
was highest in Norway, Sweden, Australia and Ireland, with
rates more than 50% higher than the OECD average
(Figure 3.22). Greece had the lowest rates, followed by
Mexico, Korea and Japan. Prostate cancer incidence rates
have increased in most OECD countries since the late 1990s
with increased use of prostate specific antigen (PSA) tests
having led to greater detection (Ferlay et al., 2014). Differ-
ences between countries’ rates can be partly attributed to
differences in the use of PSA testing. Mortality rates from
prostate cancer have decreased in some OECD countries as
a consequence of early detection and improvements in
treatments (see indicator “Mortality from cancer”).
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Definition and comparability
Cancer incidence rates are based on numbers of new
cases of cancer registered in a country in a year per
100 000 population. The rates have been directly age-
standardised based on Segi’s world population to
remove variations arising from differences in age struc-
tures across countries and over time. The data come
from the International Agency for Research on Cancer
(IARC), GLOBOCAN 2012, available at globocan.iarc.fr.
GLOBOCAN estimates for 2012 may differ from
national estimates due to differences in methods.
Cancer registration is well established in most OECD
countries, although the quality and completeness of
cancer registry datamay vary. In some countries, cancer
registries only cover subnational areas. The interna-
tional comparability of cancer incidence data can also
be affected by differences in medical training and
practice.
The incidence of all cancers is classified to ICD-10
codes C00-C97 (excluding non-melanoma skin
cancer C44). Breast cancer corresponds to C50, and
prostate cancer to C61.HEALTH AT A GLANCE 2015 © OECD 201564
3. HEALTH STATUS
Cancer incidenceInformation on data for Israel: http://oe.cd/israel-disclaimer
3.20. All cancers incidence, men and women, 2012
Source: International Agency for Research on Cancer (IARC), GLOBOCAN 2012. 1 2 http://dx.doi.org/10.1787/888933280811
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3.21. Breast cancer incidence, women, 2012
Source: International Agency for Research on Cancer (IARC), GLOBOCAN
2012. 1 2 http://dx.doi.org/10.1787/888933280811
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3.22. Prostate cancer incidence, men, 2012
Source: International Agency for Research on Cancer (IARC), GLOBOCAN
2012. 1 2 http://dx.doi.org/10.1787/888933280811
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4. NON-MEDICAL DETERMINANTS OF HEALTHTobacco consumption among adultsTobacco kills nearly 6 million people each year, of whom
more than 5 million are from direct tobacco use and more
than 600 000 are non-smokers exposed to second-hand
smoke (WHO, 2015). Tobacco is a major risk factor for at
least two of the leading causes of premature mortality –
cardiovascular diseases and cancer, increasing the risk of
heart attack, stroke, lung cancer, cancers of the larynx and
mouth, and pancreatic cancer, among others. In addition, it
is a dominant contributing factor for respiratory diseases
such as chronic obstructive pulmonary disease (US DHHS,
2014). Smoking in pregnancy can lead to low birth weight
and illness among infants. Smoking remains the largest
avoidable risk factor for health in OECD countries and
worldwide.
The proportion of daily smokers in the adult population
varies greatly, even between neighboring countries
(Figure 4.1). Nineteen of 34 OECD countries had less than
20% of the adult population smoking daily in 2013. Rates
were lowest in Sweden, Iceland, Mexico and Australia (less
than 13%). Rates were also less than 13% in Brazil, Colombia,
and India, although the proportion of smokers among men
is high, up to 23% in India. On the other hand, smoking
rates remain high in Greece in both men and women, and
in Latvia and Indonesia where more than one in two men
smoke daily. Smoking prevalence is higher among men
than among women in all OECD countries except in Sweden
and Iceland.The gender gap in smoking rates is particularly
large in Korea, Japan, and Turkey, as well as in the Russian
Federation, India, Indonesia, Latvia, Lithuania, SouthAfrica
and China (Figure 4.1).
Smoking rates across most OECD countries have shown a
marked decline, although other forms of smokeless
tobacco use, such as snuff in Sweden, are not taken into
account. On average, smoking rates have decreased by
about one fourth since 2000, from 26% in 2000 to 20% in
2013. Large reductions occurred in Norway, Iceland, Swe-
den, Denmark and Ireland, as well as in India.
In the period that followed World War II, smoking rates
were very high among men (50% or more) in most OECD
countries through to the 1960s and 1970s, while the 1980s
and the 1990s were characterised by a marked downturn in
tobacco consumption. Non-OECD countries and emerging
economies stand at an earlier phase of the evolution of
smoking, with high rates and a wide gender gap. In OECD
countries, much of the decline in tobacco use can be attrib-
uted to policies aimed at reducing tobacco consumption
through public awareness campaigns, advertising bans,
increased taxation, and restriction of smoking in public
spaces and restaurants, in response to rising rates of
tobacco-related diseases. More stringent policies and
higher level of taxes have led to bigger reductions in smok-
ing rates between 1996 and 2011 in OECD countries (OECD,
2015). As governments continue to reinforce their anti-
tobacco policies, new strategies such as plain packaging for
tobacco products aimed to restrict branding have been
implemented (e.g. in Australia) and are being adopted by an
increasing number of countries.
Several studies provide strong evidence of socio-economic
differences in smoking and mortality (Mackenbach et al.,
2008). People in less affluent social groups have a greater
prevalence and intensity of smoking, a higher all-cause
mortality rate and lower rates of cancer survival (Woods et
al., 2006). The influence of smoking as a determinant of
overall health inequalities is such that, if the entire popula-
tion was non-smoking, mortality differences between
social groups would be halved (Jha et al., 2006).
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Definition and comparability
The proportion of daily smokers is defined as the per-
centage of the population aged 15 years and over who
report smoking every day. International comparability
is limited due to the lack of standardisation in the
measurement of smoking habits in health interview
surveys across OECD countries. Variations remain in
the age groups surveyed, the wording of questions,
response categories and survey methodologies (e.g. in
a number of countries, respondents are asked if they
smoke regularly, rather than daily). Self-reports of
behaviours may also suffer from social desirability bias
that may potentially limit cross-country comparisons.HEALTH AT A GLANCE 2015 © OECD 201568
4. NON-MEDICAL DETERMINANTS OF HEALTH
Tobacco consumption among adultsInformation on data for Israel: http://oe.cd/israel-disclaimer
4.1. Daily smoking in adults, 2013 (or nearest year)
Note: Countries are ranked in ascending order of smoking rates for the whole population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280827
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4.2. Change in daily smoking in adults, 2000 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280827
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4. NON-MEDICAL DETERMINANTS OF HEALTHAlcohol consumption among adultsThe health burden related to harmful alcohol consump-
tion, both in terms of morbidity and mortality, is consider-
able in most parts of the world (Rehm et al., 2009; WHO,
2014; OECD, 2015). Alcohol use is associated with numerous
harmful health and social consequences, including an
increased risk of a range of cancers, stroke, and liver cirrhosis,
among others. Foetal exposure to alcohol increases the risk
of birth defects and intellectual impairment. Alcohol also
contributes to death and disability through accidents and
injuries, assault, violence, homicide and suicide. The use of
alcohol is estimated to cause more than 3.3 million deaths
worldwide per year, and accounts for 5.1% of the global
burden of disease (WHO, 2014). Health care costs associated
with excessive drinking in the United States are estimated
at USD 25.6 billion (Bouchery et al., 2011). In the Russian
Federation, alcoholmisusewas amajor contributing factor to
the sharp rise in premature mortality and decline in life
expectancy during the 1990s (OECD, 2012). The use of alco-
hol also has broader societal consequences, accounting for
large losses in work productivity through absenteeism and
premature mortality, as well as injuries and death among
non-drinkers (e.g. because of traffic accidents caused by
drivers under the influence of alcohol).
Alcohol consumption, as measured by recorded data on
annual sales, stands at 8.9 litres per adult, on average,
across OECD countries, based on the most recent data
available (Figure 4.3).Austria, Estonia and the Czech Republic,
as well as Lithuania, reported the highest consumption of
alcohol with 11.5 litres or more per adult per year in 2013.
Low alcohol consumption was recorded in Turkey and
Israel, as well as in Indonesia and India, where religious
and cultural traditions restrict the use of alcohol in some
population groups.
Although average alcohol consumption has gradually
fallen in many OECD countries since 2000, it has risen in
Poland, Sweden and Norway, as well as in Latvia, Lithuania
and the Russian Federation. However, national aggregate
data does not permit to identify individual drinking patterns
and the populations at risk. OECD analysis based on individ-
ual-level data show that hazardous drinking and heavy epi-
sodic drinking are on the rise in young people and women
especially. Men of low socioeconomic status are more likely
to drink heavily than those of a higher socioeconomic status,
while the opposite is observed in women (OECD, 2015).
Alcohol consumption is highly concentrated, as the large
majority of alcohol is drunk by the 20% of the population
who drink the most (Figure 4.4), with some variation across
countries. The 20% heaviest drinkers in Hungary consume
about 90% of all alcohol consumed, while in France the
share is about 50%.
In 2010, the World Health Organization endorsed a global
strategy to combat the harmful use of alcohol, through
direct measures such as medical services for alcohol-
related health problems, and indirect measures such as the
dissemination of information on alcohol-related harm
(WHO, 2010). The OECD used this as a starting point to
identify a set of policy options to be assessed in an economic
evaluation, and showed that several policies have the
potential to reduce heavy drinking, regular or episodic, as
well as alcohol dependence. Governments seeking to tackle
binge drinking and other types of alcohol abuse can use a
range of policies that have proven to be effective, including
counselling heavy drinkers, stepping up enforcement of
drinking-and-driving laws, as well as raising taxes, raising
prices, and increasing the regulation of the marketing of
alcoholic drinks (OECD, 2015).
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Definition and comparability
Alcohol consumption is defined as annual sales of
pure alcohol in litres per person aged 15 years and
over. The methodology to convert alcoholic drinks to
pure alcohol may differ across countries. Official statis-
tics do not include unrecorded alcohol consumption,
such as home production. WHO produces estimates
for unrecorded alcohol consumption.
Survey-based estimates of the amount of alcohol
drunk by the 20% heaviest drinkers rely on the data
analysis of the latest available national health surveys
for 13 OECD countries. The list of surveys is provided
in Table A.1 in Annex A in the publication Tackling
Harmful Alcohol Use – Economics and Public Health Policy
(OECD, 2015).HEALTH AT A GLANCE 2015 © OECD 201570
4. NON-MEDICAL DETERMINANTS OF HEALTH
Alcohol consumption among adultsInformation on data for Israel: http://oe.cd/israel-disclaimer
4.3. Alcohol consumption among adults, 2000 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; WHO for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888933280835
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4.4. Share of total alcohol consumed by the 20% of the population who drink the most, 2012 (or nearest year)
Source: OECD (2015), Tackling Harmful Alcohol Use – Economics and Public Health Policy.
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4. NON-MEDICAL DETERMINANTS OF HEALTHFruit and vegetable consumption among adultsNutrition is an important determinant of health. Insuffi-
cient consumption of fruit and vegetables is one factor that
can play a role in increased risk of morbidity (Bazzano et
al., 2003; Riboli and Norat, 2003). Food insecurity, that is the
inability to afford enough food for a healthy and active life,
is also associated with adverse health effects (Seligman et
al., 2010). Proper nutrition assists in preventing a number of
chronic conditions, including cardiovascular disease,
hypertension, type-2 diabetes, stroke, certain cancers,
musculoskeletal disorders and a range of mental health
conditions.
In response to a health survey question asking “How often
do you eat fruit?”, the percentage of adults consuming fruit
daily varied from about 30% in Finland, to 94% in Australia
(Figure 4.5). Across the 29 countries providing data, on
average 55% of men and 66% of women reported to eat fruit
daily. Women reported eating fruit more often than men in
all countries except in Switzerland, with the largest gender
differences in Germany, Slovenia, and Iceland (20 percentage
points or more). In Australia, Greece, Mexico, and the United
Kingdom, gender differences were much smaller, under
5 percentage points.
Persons aged 65 and over were more likely to eat fruit than
those in younger age group; with the lowest consumption
in people aged 15-24 years. Fruit consumption also varies
by education level, generally being highest among persons
with higher educational levels.
Daily vegetable consumption ranged from around 33% in
men in Slovenia to nearly 100% in Korea, with Australia and
New Zealand at about the same levels, but counting pota-
toes as vegetables (Figure 4.6). The average across 29 OECD
countries was 61% for men and 70% for women. Again,
more women than men reported eating vegetables daily in
all countries, except in Korea, Australia and Mexico where
vegetable consumption is not significantly different
between men and women. In Sweden, Switzerland, Norway,
Germany and Slovenia, gender differences exceeded
16 percentage points.
Patterns of vegetable consumption across age groups and
by level of education are similar to those observed for fruit.
Older persons are more likely to eat vegetables daily. Highly
educated persons eat vegetables more often.
The availability of fruit and vegetables is the most impor-
tant determinant of consumption. Despite large variations
between countries, vegetable, and especially fruit, availabi-
lity is higher in Southern European countries, with cereals
and potatoes more available in Central and Eastern Euro-
pean countries. Fruit and vegetable availability also tends
to be higher in families where household heads have a
higher level of education (Elmadfa, 2009).
The promotion of fruit and vegetable consumption, especially
in schools and at the workplace, features in the EU platform
for action on diet, physical activity and health (European
Commission, 2014).
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Definition and comparability
Estimates of daily fruit and vegetable consumption
are derived from national and European Health Inter-
view Survey questions. Typically, respondents were
asked “How often do you eat fruit (excluding juice)?”
and “How often do you eat vegetables or salad
(excluding juice and potatoes)?”.
Data for Greece and Switzerland include juices as a
portion of fruit, and juices and soups as a portion of
vegetable. Data for Australia, Greece, New Zealand,
and the United Kingdom include potatoes as vegetables.
Data rely on self-reporting, and are subject to errors in
recall. The same surveys also ask for information on
age, sex and educational level. Data are not age stan-
dardised, with aggregate country estimates representing
crude rates among respondents aged 15 years and over
in all countries, except Germany and Australia which is
18 years and over.HEALTH AT A GLANCE 2015 © OECD 201572
4. NON-MEDICAL DETERMINANTS OF HEALTH
Fruit and vegetable consumption among adultsInformation on data for Israel: http://oe.cd/israel-disclaimer
4.5. Daily fruit eating among adults, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280841
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Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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4. NON-MEDICAL DETERMINANTS OF HEALTHObesity among adultsObesity is a known risk factor for numerous health prob-
lems, including hypertension, high cholesterol, diabetes,
cardiovascular diseases, respiratory problems (asthma),
musculoskeletal diseases (arthritis) and some forms of
cancer. The rise in overweight and obesity is a major public
health concern, threatening progress in tackling cardiovas-
cular diseases (OECD, 2015).
Estimates of obesity and overweight are derived either
from health examinations or self-reports, the former being
higher and more reliable. Based on the latest available
surveys, more than half (53.8%) of the adult population in
OECD countries are overweight or obese. In countries
where height and weight are measured (as opposed to self-
reported), this proportion is even greater, at 57.5%. The
prevalence of overweight and obesity among adults
exceeds 50% in no less than 22 of 34 OECD countries. In
contrast, overweight and obesity rates are much lower in
Japan and Korea and in some European countries (France
and Switzerland), although even in these countries rates
are increasing.
The prevalence of obesity, which presents even greater
health risks than overweight, varies about six fold across
OECD countries, from a low of 5% in Japan and Korea, to
over 32% in Mexico and the United States (Figure 4.7).
Across OECD countries, 19% of the adult population are
obese. Obesity rates in men and women are similar in most
countries. However, in Chile, Mexico and Turkey, as well as
Colombia, the Russian Federation and South Africa, a
greater proportion of women are obese, while the reverse is
true in Slovenia.
The prevalence of obesity has increased over the past
decade in all OECD countries (Figure 4.8). In 2013, at least
one in five adults was obese in twelve OECD countries,
compared to one in eight a decade ago. Since 2000, obesity
rates have increased by a third or more in 14 countries. The
rapid rise occurred regardless of where levels stood a
decade ago. Obesity increased by around 45% in both
Denmark and Australia, even though the current rate in
Denmark is only half that of Australia.
The rise in obesity has affected all population groups,
regardless of sex, age, race, income or education level, but to
varying degrees. Evidence from Canada, the United Kingdom,
France, Italy, Mexico, Spain, Switzerland and the United
States shows that obesity tends to be more common in
lower educated groups, especially in women (OECD, 2014).
Rates of overweight and obesity vary by education level and
socioeconomic status, and these disparities are significant
in women while less clear-cut in men (Devaux and Sassi,
2013).
A number of behavioural and environmental factors have
contributed to the long-term rise in overweight and obesity
rates in industrialised countries, including the widespread
availability of energy dense foods and more time spent being
physically inactive. These factors have created obesogenic
environments, putting people, and especially those socially
vulnerable, more at risk of obesity.
A growing number of countries have adopted policies to
prevent obesity from spreading further. The policy mix
includes, for instance, public awareness campaigns, health
professionals training, advertising limits or bans on
unhealthy food, taxations and restrictions on sales of certain
types of food and beverages, and nutrition labelling. Better
informed consumers, making healthy food options available,
encouraging physical activity and focussing on vulnerable
groups are some of the areas in which progress has been
made (European Commission, 2014).
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Definition and comparability
Overweight and obesity are defined as excessive
weight presenting health risks because of the high
proportion of body fat. The most frequently used
measure is based on the bodymass index (BMI), which
is a single number that evaluates an individual’s weight
in relation to height (weight/height2, with weight in
kilograms and height in metres). Based on the WHO
classification (WHO, 2000), adults with a BMI from 25
to 30 are defined as overweight, and those with a BMI
of 30 or over as obese. This classification may not be
suitable for all ethnic groups, who may have equiva-
lent levels of risk at lower or higher BMI. The thresholds
for adults are not suitable to measure overweight and
obesity among children.
For most countries, overweight and obesity rates are
self-reported through estimates of height and weight
from population-based health interview surveys.
However, around one-third of OECD countries derive
their estimates from health examinations. These dif-
ferences limit data comparability. Estimates from
health examinations are generally higher, and more
reliable than estimates from health interviews. Note
that the OECD average is based on both types of esti-
mates (self-reported and measured) and, thus, may be
underestimated.HEALTH AT A GLANCE 2015 © OECD 201574
4. NON-MEDICAL DETERMINANTS OF HEALTH
Obesity among adultsInformation on data for Israel: http://oe.cd/israel-disclaimer
4.7. Obesity among adults, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280857
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4.8. Increasing obesity among adults in OECD countries, 2000 and 2013 (or nearest years)
1. Data are based on measurements rather than self-reported height and weight.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280857
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4. NON-MEDICAL DETERMINANTS OF HEALTHOverweight and obesity among childrenChildren who are overweight or obese are at greater risk of
poor health in adolescence, as well as in adulthood. Among
young people, orthopaedic problems and psychosocial
problems such as low self-image, depression and impaired
quality of life can result from being overweight. Excess
weight problems in childhood are associated with an
increased risk of being an obese adult, at which point
cardiovascular disease, diabetes, certain forms of cancer,
osteoarthritis, a reduced quality of life and premature
death become health concerns (Lobstein, 2010; Currie et al.,
2012).
Overweight (including obesity) rates based on measured
(rather than self-reported) height and weight are about 24%
for boys and 22% for girls, on average, in OECD countries,
although rates are measured in different age groups in dif-
ferent countries (Figure 4.9). Boys tend to carry excess
weight more often than girls, with the largest gender differ-
ences observed in China, Denmark, Iceland, Korea and
Poland. In contrast, Ireland and South Africa show larger
overweight rates among girls. More than one in three chil-
dren are overweight in Brazil, Chile, Greece, Italy, Mexico,
New Zealand, United Kingdom (England) and the United
States, and about one in three boys in Spain, and one in
three girls in Portugal.
Child obesity has increased in the past few decades world-
wide and seems to be stabilising in high-income countries
(Ng et al., 2014; Lobstein et al., 2015). Self-reported over-
weight rates (including obesity) across OECD countries
slightly increased between 2001-02 and 2009-10 from 13%
to 15% in 15-year-olds (Figure 4.10). The largest increases
during this period were in the Czech Republic, Estonia,
Poland and Slovenia, all greater than 5%. Significant reduc-
tions in the proportion of overweight or obese children at
age 15 were only observed in Denmark and the United
Kingdom between 2001-02 and 2009-10, although non-
response rates to questions about self-reported height and
weight may bias the results downward.
Childhood is an important period for forming healthy
behaviours, and the increased focus on obesity has stimu-
lated the implementation of many community-based
initiatives in OECD countries in recent years. Studies show
that locally focussed interventions, targeting children up to
12 years of age can be effective in changing behaviours.
Schools provide opportunities to ensure that children
understand the importance of good nutrition and physical
activity, and can benefit from both. Teachers and health
professionals are often involved as providers of health and
nutrition education, and the most frequent community-
based initiatives target professional training, the social or
physical environment, and actions for parents (Bemelmans
et al., 2011).
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Definition and comparability
Estimates of overweight and obesity are based on body
mass index (BMI) calculations using either measured or
self-reported height and weight, the latter possibly
under-estimating obesity and overweight. Overweight
and obese children are those whose BMI is above a set
of age- and sex-specific cut-off points (Cole et al.,
2000).
Measured data are gathered by the World Obesity
Federation (WOF, former IASO) from different national
studies, except for Germany (data come from the
2003-06 KIGGS survey) and Korea (based on the 2013
KNHANES survey). The estimates are based on
national surveys of measured height and weight among
children at various ages. Caution is therefore needed
in comparing rates across countries. Definitions of over-
weight and obesity among children may sometimes
vary among countries, although whenever possible
the IOTF BMI cut-off points are used.
Self-reported data are from the Health Behaviour in
School-aged Children (HBSC) surveys undertaken
between 2001-02 and 2009-10. Data are drawn from
school-based samples of 1 500 in each age group (11-,
13-and 15-year-olds) in most countries. Self-reported
height and weight are subject to under-reporting,
missing data and error, and require cautious inter-
pretation.HEALTH AT A GLANCE 2015 © OECD 201576
4. NON-MEDICAL DETERMINANTS OF HEALTH
Overweight and obesity among childrenInformation on data for Israel: http://oe.cd/israel-disclaimer
4.9. Measured overweight (including obesity) among children, 2013 (or nearest year)
Source: World Obesity Federation (2015), KIGGS (2003-06) for Germany and KNHANES (2013) for Korea.
1 2 http://dx.doi.org/10.1787/888933280866
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4.10. Change in self-reported overweight among 15-year-olds, 2001-02, 2005-06 and 2009-10
Source: Currie et al. (2004); Currie et al. (2008); Currie et al. (2012).
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Doctors (overall number)
Doctors by age, sex and category
Medical graduates
International migration of doctors
Remuneration of doctors (general practitioners and specialists)
Nurses
Nursing graduates
International migration of nurses
Remuneration of nurses
The statistical data for Israel are supplied by and under the responsibility of the relevant
Israeli authorities. The use of such data by the OECD is without prejudice to the status of
the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the
terms of international law.5 79
5. HEALTH WORKFORCEDoctors (overall number)The number of doctors per capita varies widely across
OECD countries. In 2013, Greece had the highest number
(with 6.3 doctors per 1 000 population), followed by Austria.
Turkey and Chile had the lowest number among OECD
countries, with slightly less than two doctors per
1 000 population. The OECD average was just over three
doctors per 1 000 population. The number of doctors per
capita is much lower in some partner countries. There was
less than one doctor per 1 000 population in Indonesia,
India and South Africa. In China, the number of doctors per
capita is still about half the OECD average, but it has grown
significantly since 2000 (Figure 5.1).
Since 2000, the number of doctors has grown in nearly all
OECD countries, both in absolute number and on a per cap-
ita basis. The growth rate was particularly rapid in some
countries which started with lower levels in 2000 (Turkey,
Korea and Mexico), but also in countries which already had
a large number such as Greece and Austria. In Greece, the
number of doctors per capita increased strongly between
2000 and 2008, but has stabilised since then. The number of
doctors has also increased strongly in Australia and the
United Kingdom (Figure 5.2), driven mainly by a strong rise
in the number of graduates from domestic medical educa-
tion programmes (see indicator on medical graduates).
On the other hand, the number of physicians per capita
remained fairly stable between 2000 and 2013 in Estonia,
France, Israel and the Slovak Republic. In France, the number
of doctors increased by 10%, more or less at the same pace
as the population size.
The number of doctors has continued to grow in most
OECD countries following the 2008-09 recession, although
the growth slowed down in some countries such as Greece.
In the United Kingdom, the growth did not slow down
much; there were 15% more employed doctors in 2013 than
in 2008 (Figure 5.2).
Projecting the future supply and demand of doctors is
challenging given the high levels of uncertainty concerning
their retirement and migration patterns and their demand
(Ono, Lafortune and Schoenstein, 2013). In Australia, a
recent projection exercise based on a status quo policy
scenario estimated that there may be an over-supply of
doctors by 2017 before moving to an under-supply from
2020 to 2030. This projection exercise explored different
scenarios that may either mitigate or exacerbate these
imbalances. If the demand for doctors is growing at a
slightly slower pace than projected because of slower GDP
growth, the projected shortage in the next decade may
disappear and there may be a slight over-supply of doctors
by 2030. On the other hand, if there is a sharp reduction in
the number of immigrant doctors, a growing number of
domestic medical graduates would be required to close any
projected gap (HealthWorkforce Australia, 2014).
Many countries have anticipated the upcoming retirement
of a significant number of doctors by increasing their train-
ing efforts over the past decade to ensure that there would
be enough new doctors to replace those who will retire. In
some countries where domestic training efforts increased
(e.g., the United Kingdom and the Netherlands), there have
been recent concerns of possible surpluses of certain catego-
ries of doctors in the years ahead. This has led to recom-
mendations to reduce slightly student intakes in medical
schools and post-graduate training programmes for certain
specialties (CfWI, 2012; ACMMP, 2014).
In many countries, current concerns focusses more specif-
ically on shortages of general practitioners (see the indica-
tor related to doctors by age, sex and category) or the
undersupply of doctors in rural and remote regions (see the
indicator on the geographic distribution of doctors in
Chapter 7).
References
ACMMP (2014), The 2013 Recommendations for Medical Special-
ist Training, Utrecht.
CfWI – Centre for Workforce Intelligence (2012), A Strategic
Review of the Future HealthcareWorkforce: Informing Medical
and Dental Student Intakes, London.
Health Workforce Australia (2014), Australia’s Future Health
Workforce – Doctors, Canberra.
Ono, T., G. Lafortune and M. Schoenstein (2013), “Health
Workforce Planning in OECD Countries: A Review of 26
Projection Models from 18 Countries”, OECD HealthWork-
ing Papers, No. 62, OECD Publishing, Paris,
http://dx.doi.org/10.1787/5k44t787zcwb-en.
Definition and comparability
The data for most countries refer to practising doctors,
defined as the number of doctorswho are providing care
directly to patients. In many countries, the numbers
include interns and residents (doctors in training).
The numbers are based on head counts. The data for
Ireland are based on estimations. Several countries
also include doctors who are active in the health sector
even though they may not provide direct care to
patients, adding another 5-10% of doctors. Portugal
reports the number of physicians entitled to practice,
resulting in a larger over-estimation of the number
of practicing doctors of about 30%. Belgium and
Luxembourg set a minimum threshold of activities
for doctors to be considered to be practising, thereby
resulting in an under-estimation compared with other
countries which do not set suchminimum thresholds.
Data for India are likely over-estimated as they are
based on medical registers which are not updated to
account for migration, retirement or death, nor do
they take into account doctors registered in multiple
states.HEALTH AT A GLANCE 2015 © OECD 201580
5. HEALTH WORKFORCE
Doctors (overall number)Information on data for Israel: http://oe.cd/israel-disclaimer
5.1. Practising doctors per 1 000 population, 2000 and 2013 (or nearest year)
1. Data include not only doctors providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
(adding another 5-10% of doctors).
2. Data refer to all doctors licensed to practice (resulting in a large over-estimation of the number of practising doctors in Portugal, of around 30%).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280876
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5.2. Evolution in the number of doctors, selected OECD countries, 2000 to 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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5. HEALTH WORKFORCEDoctors by age, sex and categoryBeyond the overall number of doctors, the age and gender
composition of themedical workforce and themix between
different categories of doctors also have important implica-
tions on the supply of medical services. The ageing of doc-
tors in OECD countries has, for many years, raised concerns
that there may not be sufficient new recruits to replace
them, although there is evidence that the retirement of
doctors often only occurs gradually and that their retire-
ment age is increasing (Pong, 2011). The rising share of
female doctors may affect the overall supply of medical
services, as women tend to work fewer hours than men,
although it appears that working time preferences are
becoming more similar among new generations of men
and women doctors. The growing imbalance in favour of
greater specialisation over general medicine raises con-
cerns inmany countries about access to primary care for all
the population.
In 2013, on average across OECD countries, one-third of all
doctors were over 55 years of age, up from one-fifth in 2000
(Figure 5.3).While these doctors might be expected to retire
over the next ten years, a growing number of doctors con-
tinue to practice after 65 years. In Israel and Italy, almost
half (49%) of all doctors were over 55 years of age in 2013,
but in Israel this high share may be due partly to the fact
that these numbers relate to all doctors licensed to practice
(and some of them may no longer be practicing). By con-
trast, only about 15% of doctors in the United Kingdom and
Korea were aged over 55 due to large numbers of new grad-
uates entering medical practice over the past decade (see
the indicator on medical graduates).
Pension reforms, as well as a possible greater willingness
and capacity of many doctors to work longer, are likely to
have a significant impact on future replacement needs.
Several OECD countries have reformed their pension sys-
tems and increased the retirement age to take into account
longer life expectancy. While few studies have examined
the impact of these pension reforms specifically on doc-
tors, it is likely that they will prolong working lives after age
65 in the coming years.
In 2013, 45% of doctors on average across OECD countries
were women, up from 38% in 2000 and 29% in 1990
(Figure 5.4). At least half of all doctors now are women in
10 countries. By contrast, only about one-in-five doctors in
Japan and Korea were women in 2013.
The balance between generalists and specialists has
changed over the past few decades, with the number of
specialists increasing much more rapidly, raising concerns
in many countries about shortages of general practitioners.
On average across OECD countries, generalists made up
only about 30% of all physicians in 2013; there were more
than two specialists for every generalist (Figure 5.5). Medi-
cal specialists greatly outnumber generalists in Central and
Eastern European countries and in Greece. Some countries
such as France, Canada and Australia have been able to
maintain a more equal balance between specialists and
generalists. In Ireland and Portugal, most generalists are
not really general practitioners, but rather non-specialist
doctors working in hospitals or other settings. In some
countries such as the United States, general internal medi-
cine doctors are categorised as specialists although their
practice is often very similar to that of general practitio-
ners, resulting in some underestimation of the capacity to
provide generalist care.
In most OECD countries, specialists earnmore than general
practitioners, providing financial incentives for doctors to
specialise (see indicator on the remuneration of doctors). In
response to concerns about shortages of general practitio-
ners, many countries have taken steps to improve the num-
ber of training places in general medicine. For example, in
France, about 50% of all post-graduate medical training
places are reserved for general medicine (DREES, 2014). In
Canada, the number of post-graduate training places in
family medicine more than doubled between 2000 and
2013, as part of a national effort to strengthen access to pri-
mary care for the whole population (CAPER, 2015). How-
ever, for these training policies to have lasting effects on
the composition of the medical workforce, they need to be
complemented by other measures to improve the employ-
ment and remuneration conditions of general practitioners
in order to attract and retain a sufficient number of new
doctors.
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Definition and comparability
The definition of doctors is provided under the previ-
ous indicator. In some countries, the data are based
on all doctors licensed to practice, not only those
practising (e.g., Ireland and Portugal). Not all countries
are able to report all their physicians in the two broad
categories of specialists and generalists. This may be
due to the fact that specialty-specific data are not
available for doctors in training or for those working in
private practice.HEALTH AT A GLANCE 2015 © OECD 201582
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Doctors by age, sex and categoryInformation on data for Israel: http://oe.cd/israel-disclaimer
5.3. Share of doctors aged 55 years and over, 2000 and 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280883
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5.4. Share of female doctors, 2000 and 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280883
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5.5. Generalists and specialists as a share of all doctors, 2013 (or nearest year)
1. Generalists include general practitioners/family doctors and other generalist (non-specialist) medical practitioners.
2. Specialists include paediatricians, obstetricians/gynaecologists, psychiatrists, medical, surgical and other specialists.
3. In Ireland and Portugal, most generalists are not GPs (“family doctors”), but rather non-specialist doctors working in hospitals or other settings. In
Portugal, there is some double-counting of doctors with more than one specialty.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280883
%
0
20
40
60
80
100
5 1
2 12 1
4 15 16 16 1
9 19 20 2
0 22 23 2
7 27 27 28 2
9 29 3
1 31 31 3
3 35 3
6 38 4
2 44 4
5 47 47 4
9 51
60
61
58
88 8
6 85
54
61
80
42
63
40
75 7
7 73 73
45
58
71
62
70 69 69
52
65
45
61 5
8 56 47
53 53 5
1 52 4
0
Generalists¹ Specialists² Medical doctors not further defined
Gr
ee
ce
OE
CD
33
Hu
ng
ary
Un
ite
d S
tat
es
Slo
va
k R
ep
.
Po
lan
d
Sw
ed
en
Ice
lan
d
Cz
ec
h R
ep
.
De
nm
ark
Sp
ain
No
rw
ay
Slo
ve
nia Ita
ly
Es
ton
ia
Ko
rea
Ne
w 
Ze
ala
nd
Sw
itz
erl
an
d
Un
ite
d K
ing
do
m
Lu
xe
mb
ou
rg
Tu
rke
y
Isr
ae
l
Au
str
ia
Me
xic
o
Fin
lan
d
Be
lgi
um
Ge
rm
an
y
Ne
the
rla
nd
s
Au
str
ali
a
Fra
nc
e
Ca
na
da
Ch
ile
Po
rtu
ga
l3
Ire
lan
d3HEALTH AT A GLANCE 2015 © OECD 2015 83
5. HEALTH WORKFORCEMedical graduatesThe number of new medical graduates in a given year
reflects to a large extent government decisions taken a few
years earlier on the number of students admitted in medi-
cal schools (so-called numerus clausus policies). Since 2000,
most OECD countries have increased the number of stu-
dents admitted to medical education in response to con-
cerns about current or possible future shortages of doctors
(OECD, forthcoming), but large variations remain across
countries.
In 2013, there were on average about 12 new medical grad-
uates per 100 000 population across OECD countries
(Figure 5.6). This proportion was highest in Ireland,
whereas Israel and Japan had the lowest number of new
medical graduates relative to their population. In Ireland,
the number of medical graduates increased strongly in
2013 due at least partly to the opening of new Graduate
Entry Programmes a few years earlier, allowing students
with an undergraduate degree in another discipline to
obtain a medical degree in four years only. In Israel, the low
number of domestic medical graduates is compensated by
the high number of foreign-trained doctors. About one-
third of foreign-trained doctors in Israel are in fact people
who were born in the country but have pursued their study
abroad before coming back. The situation is quite different
in Japan, where there are very few foreign-trained doctors.
Since 2008, the Japanese government decided to increase
intakes in medical education in response to current and
projected shortages of doctors, which should lead to a
growing number of medical graduates in the coming years.
Following the expansion of the numerus clausus in most
countries over the past fifteen years, the number of medi-
cal graduates has increased, though at different paces
(Figure 5.7). In Australia, the number of medical graduates
increased by two-and-a-half times between 2000 and 2013.
Most of this growth reflects an increase in the number of
domestic students, but there has also been a growing num-
ber of international students in medical schools in Australia.
In the United Kingdom, the number of medical graduates
doubled between 2000 and 2013, reflecting an effort to
increase the domestic supply and rely less on foreign-
trained doctors. Most of the increase in admission in med-
ical schools occurred between 2000 and 2004. In 2013, the
number of graduates decreased slightly for the first time,
and so did the number of students admitted in medical
schools following a 2% reduction in medical school intakes
based on a projected oversupply of doctors in the coming
years (Department of Health, 2012).
In France, the number of medical graduates has increased
steadily since 2006 following a large increase in the numerus
clausus between 2000 and 2006. However, the number of
graduates should stabilize in the coming years, as admis-
sion quotas have remained fairly stable over the past few
years.
In the United States, the increase in admission intakes to
medical schools occurred a bit later than in several other
countries, mainly after 2005, so the number of medical
graduates has only started to go up recently. In addition to
the growing number of medical graduates from American
universities, there has also been a growing number of
American students who have gone to study abroad (notably
in Caribbean countries), with the intention of coming back
to complete their post-graduate training and practice in the
United States. This is expected to create additional pres-
sures to increase the number of residency posts to allow
both domestic graduates and US foreign-trained graduates
to complete their post-graduate training.
In Nordic countries, there has been a fairly steady rise in
the number of medical graduates, with the number of grad-
uates in Finland and Norway rising by about 50% between
2000 and 2013. Many Norwegian students also go to study
medicine abroad, notably in Germany, Poland and Hungary,
with the intention of coming back to practice in their
country.
There has also been a strong rise in the number of medical
graduates in the Czech Republic, Hungary and Poland. This
sharp increase can be explained partly by the growing
number of international students choosing these countries
to purse their medical studies. International students
accounted for about 30% of all medical graduates in the
Czech Republic in recent years.
This growing internationalisation of medical education,
combined with the international migration of already
trained doctors, makes it more difficult for national gov-
ernments to set their own domestic numerus clausus poli-
cies, given that these policies may be affected by policies
and actions taken by actors in other countries (OECD, forth-
coming).
References
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Definition and comparability
Medical graduates are defined as the number of stu-
dents who have graduated from medical schools in a
given year.The data forAustria and the United Kingdom
exclude foreign graduates, while other countries
include them. In Denmark, the data refer to the num-
ber of new doctors receiving an authorisation to prac-
tice, which may result in an over-estimation if these
include a certain number of foreign-trained doctors.HEALTH AT A GLANCE 2015 © OECD 201584
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Medical graduatesInformation on data for Israel: http://oe.cd/israel-disclaimer
5.6. Medical graduates, 2013 (or nearest year)
1. In Denmark, the number refers to new doctors receiving an authorisation to practice, which may result in an over-estimation if these include
foreign-trained doctors.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280892
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5.7. Evolution in the number of medical graduates, selected OECD countries, 2000 to 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280892
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5. HEALTH WORKFORCEInternational migration of doctorsThe international migration of doctors and other health
workers is not a new phenomenon, but has drawn a lot of
attention in recent years because of concerns that it might
exacerbate shortages of skilled health workers in certain
countries, particularly in some developing countries that
are already suffering from critical workforce shortages. The
Global Code of Practice on the International Recruitment of
Health Personnel, adopted by the World Health Assembly
in May 2010, was designed to respond to these concerns. It
provides an instrument for countries to promote a more
ethical recruitment of health personnel, encouraging coun-
tries to achieve greater “self-sufficiency” in the training of
health workers, while recognising the basic human right of
every person to migrate.
There are significant differences across OECD countries in
the proportion of doctors trained abroad. In 2013, the share
of foreign-trained doctors ranged from less than 3% inTurkey,
Poland, Estonia, the Netherlands and the Czech Republic to
more than 40% in Israel and New Zealand (Figure 5.8). The
very high proportion of foreign-trained doctors in Israel
reflects not only the importance of immigration in this
country, but also that a large number of new licenses are
issued to people born in Israel but trained abroad (one-third
in 2013). Norway, Ireland and Australia also have a high
share of foreign-trained doctors, although in Norway
roughly half of foreign-trained doctors are people whowere
born in the country but went to pursue their medical stud-
ies in another country. The share of foreign-trained doctors
in the United Kingdom, Switzerland, the United States,
Sweden and Canada varies between 23% and 30%.
Since 2000, the number and share of foreign-trained doc-
tors has increased in many OECD countries (Figure 5.9),
contributing to the overall rise in the number and density
of doctors. In the United States and the United Kingdom,
the share has remained relatively stable over time, but the
absolute number of doctors trained abroad has continued
to increase more or less at the same pace as the number of
domestically-trained doctors (OECD, forthcoming). Sweden
has experienced a strong rise in the number and share of
foreign-trained doctors, with most of these foreign-trained
doctors coming from Germany, Poland and Iraq. The num-
ber and share of foreign-trained doctors has also increased
in France and Germany, though at a slower pace. In France,
the rise is partly due to a fuller recognition of the qualifica-
tions of foreign-trained doctors who were already working
in the country, as well as the inflow of doctors from new EU
member states, notably Romania.
In absolute numbers, the United States has by far the high-
est number of foreign-trained doctors, with more than
200 000 doctors trained abroad in 2013. Following the
United States is the United Kingdom with more than
48 000 foreign-trained doctors in 2014. The composition of
migration flows by country of origin depends on several
factors, including: i) the importance of migratory ties;
ii) language; and iii) recognition of qualifications.
Figure 5.10 provides an illustration of the distribution of the
countries of training for the two main OECD receiving
countries, the United States and the United Kingdom.
Nearly 50% of foreign-trained doctors in the United States
come from Asian countries, with doctors coming from
India representing by far the largest number, followed by
the Philippines and Pakistan. More than 10% of doctors
were trained in the Caribbean Islands, but in many cases
these were American students who went to study abroad
and then came back to the United States to complete their
post-graduate training and practice. Most foreign-trained
doctors in the United Kingdom also came fromAsian coun-
tries, with India also leading by a wide margin, although a
growing number of foreign-trained doctors in the United
Kingdom come from other EU countries.
Even if smaller countries inAfrica,Asia or Central and Eastern
Europe lose a small number of doctors in absolute terms,
this may nonetheless have a large impact on their health
systems. There is growing recognition that OECD countries
should avoid actively recruiting from countries that are suf-
fering from acute shortages of doctors.
References
OECD (forthcoming), Health Workforce Policies in OECD Coun-
tries: Right Jobs, Right Skills, Right Places (preliminary title),
Chapter on “Changing patterns in the internationalmigra-
tion of doctors and nurses”, OECD Publishing, Paris.
Definition and comparability
The data relate to foreign-trained doctors working in
OECD countries measured in terms of total stocks.
The OECD health database also includes data on the
annual flows for most of the countries shown here, as
well as by country of origin. The data sources in most
countries are professional registries or other adminis-
trative sources.
The main comparability limitation relates to differ-
ences in the activity status of doctors. Some registries
are regularly updated, making it possible to distin-
guish doctors who are still actively working in health
systems, while other sources include all doctors
licensed to practice, regardless of whether they are
still active or not. The latter will tend to over-estimate
not only the number of foreign-trained doctors, but
also the total number of doctors (including the
domestically-trained), making the impact on the
share unclear. The data source in some countries
includes interns and residents, while these physicians
in training are not included in other countries. Because
foreign-trained doctors are often over-represented in the
categories of interns and residents, this may result in an
under-estimation of the share of foreign-trained doctors
in countries where they are not included (e.g., France,
Hungary, Poland and Switzerland).
The data for Germany and Spain is based on national-
ity (or place of birth in the case of Spain), not on the
place of training.HEALTH AT A GLANCE 2015 © OECD 201586
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International migration of doctorsInformation on data for Israel: http://oe.cd/israel-disclaimer
5.8. Share of foreign-trained doctors in OECD countries, 2013 (or nearest year)
1. In Germany and Spain, the data is based on nationality (or place of birth in Spain), not on the place of training.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280906
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5.9. Evolution in the share of foreign-trained doctors, selected OECD countries, 2000 to 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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5. HEALTH WORKFORCERemuneration of doctors (general practitioners and specialists)The remuneration level for different categories of doctors
has an impact on the financial attractiveness of different
medical specialties. In many countries, governments influ-
ence the level and structure of physician remuneration by
being one of the main employers of physicians or pur-
chaser of their services, or by regulating their fees.
OECD data on physician remuneration distinguishes
between salaried and self-employed physicians, although
in some countries this distinction is increasingly blurred,
as some salaried physicians are allowed to have a private
practice and some self-employed doctors may receive part
of their remuneration through salaries. A distinction is also
made between general practitioners and all other medical
specialists combined, though there may be wide differ-
ences in the income of different medical specialties.
As expected, the remuneration of doctors (both generalists
and specialists) is much higher than that of the average
worker in all OECD countries (Figure 5.11). Self-employed
general practitioners in Australia earned about two times
the average wage in 2013 (although this is an under-
estimation as it includes the remuneration of physicians in
training), whereas in Austria, Canada, Denmark, the
Netherlands, Luxembourg and the United Kingdom, self-
employed GPs earned about three times the average wage
in the country.
In most countries, GPs earn less than specialists, and in
many cases much less. In Canada and the Netherlands,
self-employed specialists earned about 4.5 times the aver-
age wage in 2013, in Germany, it was over five times, while
in Belgium and Luxembourg, they earned more than
six times the average wage (although in Belgium their
remuneration include practice expenses, thereby resulting
in an over-estimation). In France, self-employed specialists
earned almost four times the average wage, compared with
just over two times for salaried specialists and self-
employed GPs. The income gap between GPs and special-
ists is particularly large in Belgium and the Netherlands.
In many OECD countries, the income gap between general
practitioners and specialists has continued to widen over
the past decade, reducing the financial attractiveness of
general practice (Figure 5.12). Since 2005, the remuneration
of specialists has risen faster than that of general practitio-
ners in Canada, Finland, France, Hungary, Iceland, Israel,
Luxembourg and Mexico. On the other hand, in Austria,
Belgium and the Netherlands, the gap has narrowed
slightly, as the income of GPs grew faster than that of spe-
cialists.
In many OECD countries, the economic crisis which started
in 2008-09 had a significant impact on the remuneration of
doctors and other health workers. Several European coun-
tries hard hit by the recession either froze or cut down, at
least temporarily, the wages or fees of doctors in efforts to
reduce cost while protecting access to care for the popula-
tion. This has been the case in countries such as Estonia,
France, Ireland, Italy and Slovenia, where doctors saw their
remuneration decrease in nominal terms in certain years
after the crisis. However, in more recent years, the remu-
neration of doctors and other health workers have started
to rise again (OECD, forthcoming).
Reference
OECD (forthcoming), Health Workforce Policies in OECD Coun-
tries: Right Jobs, Right Skills, Right Places (preliminary title),
Chapter on “Trends in health labour markets following
the economic crisis and current policy priorities to
address health workforce issues”, OECD Publishing,
Paris.
Definition and comparability
The remuneration of doctors refers to average gross
annual income, including social security contribu-
tions and income taxes payable by the employee. It
should normally exclude practice expenses for self-
employed doctors.
A number of data limitations contribute to an under-
estimation of remuneration levels in some countries:
1) payments for overtime work, bonuses, other sup-
plementary income or social security contributions
are excluded in some countries (Austria, Ireland for
salaried specialists and Italy); 2) incomes from private
practices for salaried doctors are not included in some
countries (e.g. Czech Republic, Hungary, Iceland, Ireland
and Slovenia); 3) informal payments, which may be
common in certain countries (e.g. Greece and Hungary),
are not included; 4) data relate only to public sector
employees who tend to earn less than those work-
ing in the private sector in Chile, Denmark, Greece,
Hungary, Iceland, Ireland, Norway, the Slovak Republic
and the United Kingdom; and 5) physicians in training
are included in Australia, the Czech Republic and the
United Kingdom for specialists.
The data for some countries include part-time workers,
while in other countries the data refer only to doctors
working full time.
In Belgium, the data for self-employed doctors include
practice expenses, resulting in an over-estimation.
The income of doctors is compared to the average
wage of full-time employees in all sectors in the
country. The source for the average wage of workers
in the economy is the OECD Labour Force Statistics
Database.HEALTH AT A GLANCE 2015 © OECD 201588
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Remuneration of doctors (general practitioners and specialists)Information on data for Israel: http://oe.cd/israel-disclaimer
5.11. Remuneration of doctors, ratio to average wage, 2013 (or nearest year)
1. Physicians in training included (resulting in an underestimation).
2. Practice expenses included (resulting in an over-estimation).
3. Specialists in training included (resulting in an underestimation).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280919
5.12. Growth in the remuneration of GPs and specialists, 2005-2013 (or nearest year)
1. The growth rate for the Netherlands and for Luxembourg is for self-employed GPs and specialists.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280919
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5. HEALTH WORKFORCENursesNurses greatly outnumber physicians in most OECD coun-
tries. Nurses play a critical role in providing health care not
only in traditional settings such as hospitals and long-term
care institutions but increasingly in primary care (espe-
cially in offering care to the chronically ill) and in home
care settings.
There are concerns in many countries about current and
possible future shortages of nurses, given that the demand
for nurses is expected to rise in a context of population age-
ing and the retirement of the current “baby-boom” genera-
tion of nurses. These concerns have prompted actions in
many countries to increase the training of new nurses (see
the indicator on nursing graduates), combined with efforts
to increase the retention rate of nurses in the profession.
The latter has increased in recent years in many countries
either because of the impact of the economic crisis that
have prompted more nurses to stay or come back in the
profession, or following deliberate efforts to improve their
working conditions (OECD, forthcoming).
On average across OECD countries, there were around
nine nurses per 1 000 population in 2013, up from less than
eight nurses in 2000, so the number of nurses has gone up
both in absolute terms and on a per capita basis (Figure 5.13).
In 2013, the number of nurses per capita was highest in
Switzerland, Norway, Denmark, Iceland and Finland, with
more than 14 nurses per 1 000 population. The number of
nurses per capita in OECD countries was lowest in Turkey
(with less than 2 nurses per 1 000 population), and Mexico
and Greece (with between 2 and 4 nurses per 1 000 popula-
tion). With regards to partner countries, the number of
nurses per capita was generally low compared with the
OECD average. In 2013, Colombia, Indonesia, South Africa,
India and Brazil had fewer than 1.5 nurse per 1 000 popula-
tion, although numbers have been growing quite rapidly in
Brazil in recent years.
The number of nurses per capita increased in almost all
OECD countries since 2000. This was the case in countries
that already had a high density of nurses in 2000 such as
Switzerland, Norway and Denmark, but also in Korea,
Portugal and France which used to have a relatively low
density of nurses but have converged towards the OECD
average (in the case of Korea and Portugal) or have now
moved beyond the OECD average (in the case of France).
The number of nurses per capita declined between 2000
and 2013 in Israel, as the size of the population grew more
rapidly than the number of nurses. It also declined in the
Slovak Republic, in both absolute numbers and on a per
capita basis.
In 2013, there were about three nurses per doctor on aver-
age across OECD countries, with about half of the countries
reporting between two to four nurses per doctor (Figure 5.14).
The nurse-to-doctor ratio was highest in Finland, Japan,
Ireland and Denmark (with at least 4.5 nurses per doctor). It
was lowest in Greece (with only about half a nurse per doc-
tor) and in Turkey and Mexico (with only about one nurse
per doctor).
In response to shortages of doctors and to ensure proper
access to care, some countries have developed more
advanced roles for nurses. Evaluations of nurse practitio-
ners from the United States, Canada, and the United King-
dom show that advanced practice nurses can improve
access to services and reduce waiting times, while deliver-
ing the same quality of care as doctors for a range of
patients, including those with minor illnesses and those
requiring routine follow-up. Existing evaluations find a
high patient satisfaction rate, while the impact on cost is
either cost-reducing or cost-neutral. The implementation
of new advanced practice nursing roles may require
changes to legislation and regulation to remove any barrier
to extensions in their scope of practice (Delamaire and
Lafortune, 2010).
References
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ences in 12 Developed Countries”, OECD Health Working
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Definition and comparability
The number of nurses includes those employed in
public and private settings providing services directly
to patients (“practising”) and in some cases also those
working as managers, educators or researchers.
In those countries where there are different levels of
nurses, the data include both “professional nurses”
who have a higher level of education and perform
higher level tasks and “associate professional nurses”
who have a lower level of education but are nonethe-
less recognised and registered as nurses. Midwives, as
well as nursing aids who are not recognised as nurses,
should normally be excluded. However, about half of
OECD countries include midwives because they are
considered as specialist nurses.
Austria reports only nurses working in hospital,
resulting in an under-estimation.HEALTH AT A GLANCE 2015 © OECD 201590
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NursesInformation on data for Israel: http://oe.cd/israel-disclaimer
5.13. Practising nurses per 1 000 population, 2000 and 2013 (or nearest year)
1. Data include not only nurses providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
2. Data in Chile refer to all nurses who are licensed to practice (less than one-third are professional nurses with a university degree).
3. Austria reports only nurses employed in hospital.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280929
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5.14. Ratio of nurses to physicians, 2013 (or nearest year)
Note: For those countries which have not provided data for practising nurses and/or practising physicians, the numbers relate to the same concept
(“professionally active” or “licensed to practice”) for both nurses and physicians, for the sake of consistency. The ratio for Portugal is understimated
because the number of doctors includes all licensed to practise.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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5. HEALTH WORKFORCENursing graduatesMany OECD countries have taken steps over the past
decade or so to increase the number of students admitted
in nursing schools in response to concerns about current or
possible future shortages of nurses (OECD, forthcoming).
Nonetheless, there are wide variations across countries in
training efforts of new nurses, which may be explained by
differences in the current number and age structure of the
nursing workforce (and hence the replacement needs), in
the capacity of nursing schools to take on more students,
as well as the future employment prospects of nurses.
In 2013, there were on average nearly 50 new nurse gradu-
ates per 100 000 population across OECD countries, up
from about 40 in 2003. Korea and Denmark had the highest
number of new nurse graduates relative to their popula-
tion, with these two countries graduating more than
90 new nurses per 100 000 population in 2013. Mexico,
Luxembourg and the Czech Republic had the lowest number,
with less than 15 nurse graduates per 100 000 population
(Figure 5.15).
Over the past decade, the number of nursing graduates has
increased in all OECD countries, but at different rates
(Figure 5.16). In the United States, following a marked
decrease in student intakes during the 1990s, the number
of students admitted to nursing schools started to increase
strongly in the early 2000s, in response to concerns about a
potential significant shortage of nurses in the coming
years. Between 2003 and 2013, the number of nursing grad-
uates increased by 70% (from 119 000 to over 200 000 per
year since 2010). Given this strong rise in admission and
graduation numbers, the most recent projections from the
US Department of Health and Human Services estimate
that there may be an over-supply of registered nurses and
licensed practical nurses in the United States by 2025, if
student admissions and nurse retention rates remain at
their current level (Health and Human Services, 2014).
In France, the number of graduates from nursing schools
also increased strongly over the past decade, by 50% overall
between 2003 and 2013.The numerus clausus set by the French
Ministry of Health to control entry in nursing education
programmes increased substantially since 1999, with the
number of places growing by nearly 70% (rising from
around 18 400 places in 1999 to over 31 000 in 2013). Most of
the growth occurred in the academic year of 2000/2001
when the annual quota was increased by 43%, driven by a
projected reduction in the supply of nurses resulting from
the reduction of working time to 35 hours per week, as well
as amore general concern about the anticipated retirement
of a large number of nurses.
In Germany, there has been a big increase in the number of
nurse graduates in recent years, related at least partly to a
greater offer of registered nurse training programmes in
several universities, in addition to the programmes tradi-
tionally offered in vocational nursing schools (Cassier-
Woidasky, 2013).
The increase in the number of nursing graduates has been
much more modest in Japan and Norway. In Japan, the
number of nursing graduates rose by only 13% between
2003 and 2013, but this number has gone up further in 2014.
In Norway, this slow increase might be explained by a sig-
nificant proportion of Norwegian students who choose to
go abroad to pursue nursing studies, and then come back to
their home country to work (see the indicator on interna-
tional migration of nurses).
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Definition and comparability
Nursing graduates refer to the number of students
who have obtained a recognised qualification
required to become a licensed or registered nurse.
They include graduates from both higher level and
lower level nursing programmes. They exclude gradu-
ates from Masters or PhD degrees in nursing to avoid
double-counting nurses acquiring further qualifica-
tions.
The data for Denmark and the United Kingdom are
based on the number of new nurses receiving an
authorisation to practice.HEALTH AT A GLANCE 2015 © OECD 201592
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Nursing graduatesInformation on data for Israel: http://oe.cd/israel-disclaimer
5.15. Nursing graduates, 2013 (or nearest year)
1. In Denmark, the number refers to new nurses receiving an authorisation to practice, which may result in an over-estimation if these include
foreign-trained nurses.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280939
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5.16. Evolution in the number of nursing graduates, selected OECD countries, 2003 to 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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5. HEALTH WORKFORCEInternational migration of nursesIn nearly all OECD countries, the proportion of foreign-
trained nurses is much lower than that of foreign-trained
doctors. However, given that the overall number of nurses
is usuallymuch greater than the number of doctors, the abso-
lute number of foreign-trained nurses tends to be greater
than that of foreign-trained doctors (OECD, forthcoming).
OECD countries vary widely in the number and share of
foreign-trained nurses working in their health system
(Figure 5.17). While there are almost no foreign-trained
nurses working in countries such as Estonia, Turkey, Slovenia
and the Netherlands, these make up nearly 25% of the
nursing workforce in New Zealand, and between 10% and
20% of the nursing workforce in Switzerland, Australia, the
United Kingdom and Israel. The share of foreign-trained
nurses also exceeds 5% in Norway, Canada, the United States,
Germany and Italy. In absolute numbers, the United States
has by far the highest number of foreign-trained nurses
(with almost 250 000 nurses trained abroad in 2013), followed
by the United Kingdom (86 000 foreign-trained nurses in
2014) and Germany (70 000 foreign-trained nurses in 2010,
latest year available).
The number and share of foreign-trained nurses has
increased over the past ten years in several OECD coun-
tries, including New Zealand, Australia, Canada and Italy
(Figure 5.18). In Italy, the increase in the immigration of for-
eign-trained nurses since 2000 was primarily driven by the
arrival of a large number of nurses trained in Romania, who
are now accounting for nearly half of all foreign-trained
nurses (Figure 5.19). The movement of Romanian nurses to
Italy preceded Romania’s entry in the European Union in
2007, but has continued since then.
In the United Kingdom, in 2014, nearly half of all foreign-
trained nurses came fromAsian countries, mainly from the
Philippines (26%) and India (19%). But a growing number of
foreign-trained nurses also come from other EU countries,
such as Spain, Portugal, Romania and Poland. In 2014, more
than 5 600 nurses trained in Spain were working in the
United Kingdom, and there were also more than
4 000 nurses trained in Portugal and Romania, and over
2 500 nurses trained in Poland.
In other EU countries such as France and Belgium, the per-
centage of nurses trained abroad remains low compared
with the United Kingdom, but their numbers have
increased rapidly. The number of foreign-trained nurses
more than doubled in France between 2000 and 2013. About
half of these foreign-trained nurses received their diploma
from Belgium (in many cases, these were French citizens
who went to study to Belgium before coming back), but
there has also been a strong growth in the number of
nurses trained in Portugal (with the number rising to over
1 100 in 2013, up from less than 100 in 2008) and in Spain
(rising to over 1 600 in 2013, up from 1 100 in 2008). In
Belgium, there has been a strong rise in the number of
nurses trained in Romania (exceeding 1 000 in 2014, up
from 150 in 2008), Portugal (with the number reaching 500
in 2014, up from 10 only in 2008) and to a lesser extent
Spain (with the number reaching 300 in 2014, up from
about 50 in 2008).
In 2014, more than 6 500 nurses trained in Portugal and
more than 9 200 nurses trained in Spain were working in
other EU countries, with a majority of them working in the
United Kingdom.
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Definition and comparability
The data relate to foreign-trained nurses working in
OECD countries measured in terms of total stocks.
The OECD health database also includes data on the
annual flows for most of the countries shown here, as
well as by country of origin. The data sources in most
countries are professional registries or other adminis-
trative sources.
The main comparability limitation relates to differ-
ences in the activity status of nurses. Some registries
are regularly updated, making it possible to distin-
guish nurses who are still actively working in health
systems, while other sources include all nurses
licensed to practice, regardless of whether they are
still active or not. The latter will tend to over-estimate
the number of foreign-trained nurses, although it will
also over-estimate the total number of nurses (includ-
ing the domestically-trained), so the impact on the
share is not clear.
The data for some regions in Spain is based on nation-
ality or country of birth, not the place of training.HEALTH AT A GLANCE 2015 © OECD 201594
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International migration of nursesInformation on data for Israel: http://oe.cd/israel-disclaimer
5.17. Share of foreign-trained nurses in OECD countries, 2013 (or nearest year)
1. Data for some regions in Spain relate to foreign nationality or country of birth, not the place of training.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280940
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5.18. Evolution in the share of foreign-trained nurses, selected OECD countries, 2000 to 2013 (or nearest year)
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5. HEALTH WORKFORCERemuneration of nursesThe remuneration level of nurses is one of the factors
affecting their job satisfaction and the attractiveness of the
profession. It also has a direct impact on costs, as wages
represent one of the main spending items in health
systems.
The data presented in this section generally focus on the
remuneration of nurses working in hospitals, although the
data coverage differs for some countries (see the box on
“Definition and comparability”).
The data are presented in two ways. First, it is compared
with the average wage of all workers in each country, pro-
viding some indication of the relative financial attractive-
ness of nursing compared to other occupations. Second,
the remuneration level in each country is converted into a
common currency, the US dollar, and adjusted for purchas-
ing power parity, to provide an indication of the relative
economic well-being of nurses compared with their coun-
terparts in other countries.
In most countries, the remuneration of hospital nurses was
at least slightly above the average wage of all workers in
2013 (Figure 5.20). In Israel and Luxembourg, the income of
nurses was respectively 60% and 40% greater than the aver-
age wage. In Spain and the United States, it was about 30%
greater than the average wage, while in Greece, Australia
and Germany it was 20% higher. In other countries, the sal-
ary of hospital nurses is roughly equal to the average wage
in the economy. In the Slovak Republic, Hungary and
France, it is about 10% lower.
When converted to a common currency (and adjusted for
purchasing power parity), the remuneration of nurses was
at least four times higher in Luxembourg than in Hungary,
the Slovak Republic and Estonia (Figure 5.21). Nurses in the
United States also had relatively high earnings compared
with their counterparts in other countries, which explains,
at least partly, the ability of the United States to attract
many nurses from other countries.
In many countries, the remuneration of nurses has been
affected by the economic crisis in 2008, but to varying
degrees (Figure 5.22). Outside Europe, the growth in the
remuneration of nurses in countries such as the United
States, Australia and New Zealand slowed down temporar-
ily following the economic crisis, while the crisis did not
appear to have any effect on the growth rate in nurse remu-
neration level in Mexico. In Europe, following the economic
crisis, the remuneration of nurses was cut down in some
countries, such as in Hungary and Italy, and has been fro-
zen in Italy over the past few years. In Greece, the remuner-
ation of nurses has been reduced on average by 20%
between 2009 and 2013.
Some Central and Eastern European countries have intro-
duced a series of measures in recent years to increase the
retention of nurses and other health workers, including pay
raise despite tight budget constraints. In Hungary, a staged
increase of 20% in the salaries of nurses and doctors was
introduced in 2012, phased over a three-year period. In the
Czech Republic, nurses also benefitted from a pay increase
following protests of hospital workers in 2011 (although
their pay raise was lower than that for doctors), accompa-
nied by some improvement in other aspects of their working
conditions (OECD, forthcoming).
References
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Definition and comparability
The remuneration of nurses refers to average gross
annual income, including social security contribu-
tions and income taxes payable by the employee. It
should normally include all extra formal payments,
such as bonuses and payments for night shifts and
overtime. In most countries, the data relate specifi-
cally to nurses working in hospitals, although in Canada
the data also cover nurses working in other settings.
In some federal states, such as Australia, Canada and
the United States, the level and structure of nurse
remuneration is determined at the sub-national level,
which may contribute to variations across jurisdic-
tions.
Data refer only to registered (“professional”) nurses in
Australia, Canada, Chile, Ireland and the United
States, resulting in an overestimation compared to
other countries where lower-level nurses (“associate
professional”) are also included. Data for New Zealand
relate to nurses employed by publically funded district
health boards, and includes registered nurses, health
assistants, nurse assistants, and enrolled nurses.
These latter three categories have a different and
significantly lower salary structure than registered
nurses.
The data relate to nurses working full time, with the
exception of Belgium where part-time nurses are also
included (resulting in an under-estimation). The data
for some countries do not include additional income
such as overtime payments and bonuses (e.g., Italy
and Slovenia). Informal payments, which in some
countries represent a significant part of total income,
are not reported.
The income of nurses is compared to the average
wage of full-time employees in all sectors in the coun-
try. The source for the average wage of workers in the
economy is the OECD Labour Force Statistics Database.HEALTH AT A GLANCE 2015 © OECD 201596
5. HEALTH WORKFORCE
Remuneration of nursesInformation on data for Israel: http://oe.cd/israel-disclaimer
5.20. Remuneration of hospital nurses, ratio to average
wage, 2013 (or nearest year)
1. Data refer to registered (“professional”) nurses in the United States,
Australia, Canada and Ireland (resulting in an over-estimation).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280951
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5.21. Remuneration of hospital nurses, USD PPP, 2013
(or nearest year)
1. Data refer to registered (“professional”) nurses in the United States,
Ireland, Australia, Canada and Chile (resulting in an over-estimation).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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5.22. Evolution in the remuneration of hospital nurses, selected OECD countries, 2005-13 (or nearest year)
1. Index for France, 2006 = 100.
2. Index for Greece, 2009 = 100.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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The statistical data for Israel are supplied by and under the responsibility of the relevant
Israeli authorities. The use of such data by the OECD is without prejudice to the status of
the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the
terms of international law.5 99
6. HEALTH CARE ACTIVITIESConsultations with doctorsConsultations with doctors can take place in doctors’
offices or clinics, in hospital outpatient departments or, in
some cases, in patients’ own homes. In many countries
(e.g., Denmark, Italy, Netherlands, Norway, Portugal, Slovak
Republic, Spain and United Kingdom), patients are required
or given incentives to consult a general practitioner (GP)
about any new episode of illness. The GP may then refer
them to a specialist, if indicated. In other countries,
patients may approach specialists directly.
In 2013, the number of doctor consultations per person
ranged from over 12 in Korea and Japan, to less than three
in Mexico, Finland and Sweden, as well as in South Africa
and Brazil (Figure 6.1). The OECD average was about
6.5 consultations per person per year, with most countries
reporting between five and eight consultations. Cultural
factors appear to play a role in variations across countries,
although certain health system characteristics may also be
important. Some countries where doctors receive fee-for-
service tend to have above-average consultation rates (e.g.
Japan and Korea), while countries withmostly salaried doc-
tors tend to have below-average rates (e.g. Mexico, Finland
and Sweden). However, there are examples of countries
such as Switzerland and the United States where doctors
are paid mainly by fee-for-service and where consultation
rates are below average, suggesting that other factors are
also important.
In Sweden and Finland, the low number of doctor consulta-
tions may also be explained partly by the fact that nurses
and other health professionals play an important role in
providing primary care to patients in health centres, less-
ening the need for consultations with doctors (Delamaire
and Lafortune, 2010).
The average number of doctor consultations per person has
increased in many OECD countries since 2000. This was
particularly the case in Korea, partly explained by the rapid
increase in the number of physicians during that period. In
some other countries, the number of consultations with
doctors per person fell. This was the case in Japan, the
Czech Republic and the Slovak Republic, although the num-
ber remains well above average in these three countries.
Information on the number of doctor consultations per
person can be used to estimate the annual numbers of con-
sultations per doctor. This indicator should not be taken as
a measure of doctors’ productivity, since consultations can
vary in length and effectiveness, and because it excludes
the work doctors do on hospital inpatients, administration
and research. Keeping these reservations in mind, the esti-
mated number of consultations per doctor is highest in
Korea and Japan, followed by Turkey and Hungary
(Figure 6.2). On the other hand, the estimated number of
consultations per doctor was lowest in Sweden and Finland,
where consultations with doctors in both primary care set-
tings and hospitals tend to be concentrated more for
patients with more severe and complex cases.
The number and type of doctor consultations can vary
among different population groups in each country. An
OECD study found that the probability of a visit to the GP
tends to be equally distributed in most countries, but in
nearly all countries, higher income people are more likely
to see a specialist than those with low income, and also
more frequently (Devaux and de Looper, 2012).
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Definition and comparability
Consultations with doctors refer to the number of
contacts with physicians, including both generalists
and specialists. There are variations across countries
in the coverage of these consultations, notably in out-
patient departments of hospitals. The data come
mainly from administrative sources, although in
some countries (Ireland, Israel, Italy, Netherlands,
New Zealand, Spain, Switzerland and United Kingdom)
the data come from health interview surveys. Esti-
mates from administrative sources tend to be higher
than those from surveys because of problems with
recall and non-response rates.
In Hungary, the figures include consultations for diag-
nostic exams such as CT and MRI scans (resulting in
an over-estimation). The figures for the Netherlands
exclude contacts for maternal and child care. The data
for Portugal exclude visits to private practitioners,
while those for the United Kingdom exclude consulta-
tions with specialists outside hospital outpatient
departments (resulting in an under-estimation). In
Germany, the data include only the number of cases of
physicians’ treatment according to reimbursement
regulations under the Social Health Insurance Scheme
(a case only counts the first contact over a three-
month period, even if the patient consults a doctor
more often, leading to an under-estimation). Tele-
phone contacts are included in some countries (e.g.
Ireland, Spain and United Kingdom). In Turkey, a
majority of consultations with doctors occur in outpa-
tient departments in hospitals.HEALTH AT A GLANCE 2015 © OECD 2015100
6. HEALTH CARE ACTIVITIES
Consultations with doctorsInformation on data for Israel: http://oe.cd/israel-disclaimer
6.1. Number of doctor consultations per person, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280967
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6.2. Estimated number of consultations per doctor, 2013 (or nearest year)
1. In Chile, data for the denominator include all doctors licensed to practice.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESMedical technologiesNew medical technologies are improving diagnosis and
treatment, but they are also increasing health spending.
This section presents data on the availability and use of
two diagnostic technologies: computed tomography (CT)
scanners and magnetic resonance imaging (MRI) units.
CT and MRI exams help physicians diagnose a range of
conditions. Unlike conventional radiography and
CT scanning, MRI exams do not expose patients to ionising
radiation.
The availability of CT scanners and MRI units has
increased rapidly in most OECD countries over the past two
decades. Japan has, by far, the highest number of MRI and
CT scanners per capita, followed by the United States for MRI
units and by Australia for CT scanners (Figures 6.3 and 6.4).
Greece, Iceland, Italy, Korea and Switzerland also has
significantly more MRI and CT scanners per capita than the
OECD average. The number of MRI units and CT scanners
per population is the lowest in Mexico, Hungary, Israel and
the United Kingdom.
There is no general guideline or benchmark regarding the
ideal number of CT scanners or MRI units per population.
However, if there are too few units, this may lead to access
problems in terms of geographic proximity or waiting
times. If there are too many, this may result in an overuse
of these costly diagnostic procedures, with little if any
benefits for patients.
Data on the use of these diagnostic scanners are available
for a smaller group of countries, excluding Japan. Based on
this more limited country coverage, the number of MRI
exams per capita is highest in Turkey and the United
States, followed by France, Luxembourg and Belgium
(Figure 6.5). In the United States, the (absolute) number of
MRI exams more than doubled between 2000 and 2013. In
Turkey, it has grown even faster, by two-and-a-half times
between 2008 and 2013. In this country, there is growing
evidence that MRI exams are being systematically
prescribed for patients with various health problems,
resulting in overuse of these tests. The number of CT
exams per capita is highest in the United States, followed
by Luxembourg, France and Greece (Figure 6.6). However, in
Greece, the number of CT exams decreased by over 40%
between 2008 and 2012, while the number of MRI exams
also came down by about 30%.
There are large variations in the use of CT and MRI scan-
ners not only across countries, but also within countries.
For example, in Belgium, there was almost a two-fold vari-
ation in MRI and CT exams between provinces with the
highest and lowest rates in 2010. In the United Kingdom
(England), the utilisation of both types of diagnostic exams
is generally much lower, but the variation across regions is
greater, with almost a four-fold difference between the
Primary Care Trusts that had the highest rates and lowest
rates of MRI and CT exams in 2010/11. In Canada, there has
been a strong rise in the use of both MRI and CT exams in
all parts of the country over the past decade, but there con-
tinues to be wide variations across provinces (OECD, 2014).
Clinical guidelines have been developed in several OECD
countries to promote a more rational use of MRI and CT
exams. In the United Kingdom, the National Institute for
Health and Clinical Excellence (NICE) has issued a number
of guidelines on the appropriate use of MRI and CT exams
(NICE, 2012). In the United States, a “ChoosingWisely” cam-
paign was launched in 2012, led by professional medical
associations, to develop clear guidelines for doctors and
patients to reduce the use of unnecessary diagnostic tests
and procedures. The guidelines include, for instance,
avoiding imaging studies such as MRI, CT or X-rays for
patients with acute low back pain without specific indica-
tions (Choosing Wisely, 2015). A similar “Choosing Wisely”
campaign was launched in Canada in 2014, and work has
also started in several other OECD countries to produce
similar clear guidelines and recommendations to promote
a more proper use of diagnostic tests and other procedures.
It is still too early to tell to what extent these campaigns
will succeed in reducing the overuse of MRI and CT exams.
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Definition and comparability
The data in most countries cover MRI units and CT
scanners installed both in hospitals and the ambula-
tory sector, but the coverage is more limited in some
countries. MRI units and CT scanners outside hospi-
tals are not included in Belgium, Germany, Portugal
and Switzerland (for MRI units). For Australia and
Hungary, the number of MRI units and CT scanners
includes only those eligible for public reimbursement.
Similarly, MRI and CT exams performed outside
hospitals are not included inAustria, Germany, Ireland,
Portugal, Switzerland and the United Kingdom. Further-
more, MRI and CT exams for Ireland only cover public
hospitals. In Australia, the data only include exams
for private patients (in or out of hospitals), while in
Korea and the Netherlands, they only include publicly
financed exams.HEALTH AT A GLANCE 2015 © OECD 2015102
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Medical technologiesInformation on data for Israel: http://oe.cd/israel-disclaimer
6.3. MRI units, 2013 (or nearest year)
1. Equipment outside hospital not included.
2. Only equipment eligible for public reimbursement.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280972
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6.4. CT scanners, 2013 (or nearest year)
1. Equipment outside hospital not included.
2. Only equipment eligible for public reimbursement.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6.5. MRI exams, 2013 (or nearest year)
1. Exams outside hospital not included (in Ireland, exams in private
hospital also not included).
2. Exams on public patients not included.
3. Exams privately-funded not included.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280972
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6.6. CT exams, 2013 (or nearest year)
1. Exams outside hospital not included (in Ireland, exams in private
hospital also not included).
2. Exams on public patients not included.
3. Exams privately-funded not included.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESHospital bedsThe number of hospital beds provides a measure of the
resources available for delivering services to inpatients in
hospitals. This section presents data on the number of hos-
pital beds overall and for different types of care (curative
care, psychiatric care, long-term care and other functions).
It also includes an indicator of bed occupancy rates focus-
sing on curative care beds.
Among OECD countries, the number of hospital beds per
capita is highest in Japan and Korea, with 11 beds or more
per 1 000 population in 2013 (Figure 6.7). In Japan and Korea
hospitals have so-called “social admissions”, that is, a signifi-
cant part of hospital beds are devoted to long-term care.
The number of hospital beds is also well above the OECD
average in the Russian Federation, and in Germany and
Austria. On the other hand, some of the large partner coun-
tries in Asia (India and Indonesia) have very few hospital
beds compared with the OECD average. This is also the case
for countries in Latin America (Colombia, Mexico, Chile and
Brazil).
The number of hospital beds per capita has decreased over
the past decade in most OECD countries, falling on average
from 5.5 per 1 000 population in 2000 to 4.8 in 2013. This
reduction has been driven partly by progress in medical
technology which has enabled a move to day surgery and a
reduced need for hospitalisation. In many European coun-
tries, the financial and economic crisis which started in
2008 also provided a further stimulus to reduce hospital
capacity as part of policies to reduce public spending on
health. Only in Korea and Turkey has the number of hospital
beds per capita grown since 2000.
More than two-thirds of hospital beds (69%) are allocated
for curative care on average across OECD countries
(Figure 6.8). The rest of the beds are allocated for psychiatric
care (14%), long-term care (13%) and other types of
care (4%). However, in some countries, the share of beds
allocated for psychiatric care and long-term care is much
greater than the average. In Korea, 35% of hospital beds are
allocated for long-term care. In Finland, this share is also
relatively high (27%) as local governments (municipalities)
use beds in health care centres (which are defined as
hospitals) for at least some of the needed long-term care in
institutions. In Belgium and Norway, about 30% of hospital
beds are devoted to psychiatric care.
In several countries, the reduction in the number of hospital
beds has been accompanied by an increase in their occu-
pancy rates. The occupancy rate of curative care beds stood
at 77% on average across OECD countries in 2013, slightly
above the 2000 level (Figure 6.9). Israel and Ireland had the
highest rate of hospital bed occupancy at approximately
94%, followed by Norway and Canada at around 90%. In the
United Kingdom, Belgium and France, the bed occupancy
rate remained relatively stable during that period.
References
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Definition and comparability
Hospital beds are defined as all beds that are regularly
maintained and staffed and are immediately available
for use. They include beds in general hospitals, mental
health hospitals, and other specialty hospitals. Beds
in residential long-term care facilities are excluded
(OECD, 2015).
Curative care beds are accommodating patients
where the principal intent is to do one or more of the
following: manage labour (obstetric), treat non-mental
illness or injury, and perform surgery, diagnostic or
therapeutic procedures.
Psychiatric care beds are accommodating patients
with mental health problems. They include beds in
psychiatric departments of general hospitals, and all
beds in mental health hospitals.
Long-term care beds are accommodating patients
requiring long-term care due to chronic impairments
and a reduced degree of independence in activities of
daily living. They include beds in long-term care
departments of general hospitals, beds for long-term
care in specialty hospitals, and beds for palliative care.
The occupancy rate for curative (acute) care beds is
calculated as the number of hospital bed-days related
to curative care divided by the number of available
curative care beds (multiplied by 365).HEALTH AT A GLANCE 2015 © OECD 2015104
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Hospital bedsInformation on data for Israel: http://oe.cd/israel-disclaimer
6.7. Hospital beds per 1 000 population, 2000 and 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280981
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6.8. Hospital beds by function of health care, 2013 (or nearest year)
Note: Countries ranked from highest to lowest total number of hospital beds per capita.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESHospital dischargesHospital discharge rates measure the number of patients
who leave a hospital after staying at least one night.
Together with the average length of stay, they are impor-
tant indicators of hospital activities. Hospital activities are
affected by a number of factors, including the capacity of
hospitals to treat patients, the ability of the primary care
sector to prevent avoidable hospital admissions, and the
availability of post-acute care settings to provide rehabilita-
tive and long-term care services.
In 2013, hospital discharge rates were highest in Austria
and Germany, followed by Lithuania, the Russian Federation,
the Czech Republic and Hungary (Figure 6.10). They were
the lowest in Colombia, Mexico, South Africa, Brazil and
Canada. In general, those countries that have more hospi-
tal beds tend to have higher discharge rates. For example, the
number of hospital beds per capita inAustria and Germany is
more than two-times greater than in Canada and Spain,
and discharge rates are also more than two-times larger
(see indicator on “Hospital beds”).
Across OECD countries, themain conditions leading to hos-
pitalisation in 2013 were circulatory diseases, pregnancy
and childbirth, injuries and other external causes, diseases
of the digestive system, cancers, and respiratory diseases.
Austria and Germany have the highest discharge rates for
both circulatory diseases and cancers, followed by Hungary
and Estonia for circulatory diseases (Figure 6.11), and
Greece and Hungary for cancers (Figure 6.12). While the
high rates of hospital discharges for circulatory diseases in
Hungary and Estonia are associated with lots of people
having heart and other circulatory diseases (see indicator
on “Mortality from cardiovascular diseases” in Chapter 3),
this is not the case for Germany andAustria. Similarly, can-
cer incidence is not higher in Austria, Germany or Greece
than in most other OECD countries (see indicator on “Cancer
incidence” in Chapter 3). In Austria, the high discharge rate
is associated with a high rate of hospital readmissions for
further investigation and treatment of cancer patients
(European Commission, 2008).
Trends in hospital discharge rates vary widely across OECD
countries. Since 2000, discharge rates have increased in
some countries where discharge rates were low in 2000 and
have increased rapidly since then (e.g. Korea andTurkey) as
well as in other countries such as Germany where it was
already above-average. In other countries (e.g. Belgium,
Czech Republic and Japan), they have remained relatively
stable, while in other countries (including Canada, Finland,
France, Italy and Spain), discharge rates fell between 2000
and 2013.
Trends in hospital discharges reflect the interaction of several
factors. Demand for hospitalisation may grow as popula-
tions’ age, given that older population groups account for a
disproportionately high percentage of hospital discharges.
However, population ageing alone may be a less important
factor in explaining trends in hospitalisation rates than
changes in medical technologies and clinical practices. The
diffusion of new medical interventions often gradually
extends to older population groups, as interventions
become safer and more effective for people at older ages.
But the diffusion of new medical technologies may also
involve a reduction in hospitalisation if it involves a shift
from procedures requiring overnight stays in hospitals to
same-day procedures. In the group of countries where dis-
charge rates have decreased since 2000, there has been a
strong rise in the number of day surgeries (see indicator on
“Ambulatory surgery”).
Hospital discharge rates vary not only across countries, but
alsowithin countries. In several OECD countries (e.g., Canada,
Finland, Germany, Italy, Portugal, Spain and the United
Kingdom), hospital medical admissions (excluding admis-
sions for surgical interventions) vary by more than two-
times across different regions in the country (OECD, 2014).
References
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Definition and comparability
Discharge is defined as the release of a patient who
has stayed at least one night in hospital. It includes
deaths in hospital following inpatient care. Same-day
discharges are usually excluded, with the exceptions
of Chile, the Slovak Republic, Turkey and the United
States which include some same-day separations.
Healthy babies born in hospitals are excluded from
hospital discharge rates in several countries
(e.g. Australia, Austria, Canada, Chile, Estonia, Finland,
Greece, Ireland, Luxembourg, Mexico, Spain). These
comprise some 3-10% of all discharges. The data for
Canada also excludeunhealthy babies born inhospitals.
Data for some countries do not cover all hospitals. For
instance, data for Denmark, Ireland, Mexico, New
Zealand and the United Kingdomare restricted to public
or publicly-funded hospitals only. Data for Portugal
relate only to public hospitals on the mainland
(excluding the Islands of Azores and Madeira). Data
for Canada, Ireland and the Netherlands include only
acute care/short-stay hospitals. Data for France and
Japan refer to acute care hospitalisations.HEALTH AT A GLANCE 2015 © OECD 2015106
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Hospital dischargesInformation on data for Israel: http://oe.cd/israel-disclaimer
6.10. Hospital discharges, 2013 (or nearest year)
1. Excludes discharges of healthy babies born in hospital (between 3-10% of all discharges).
2. Includes same-day discharges.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280996
0
50
100
150
200
250
300
26
6
25
2
23
5
21
3
20
4
20
2
19
9
19
6
18
2
17
5
17
3
17
3
17
2
17
2
17
1
17
0
16
7
16
6
16
6
16
3
16
2
16
1
15
9
15
5
14
6
14
1
14
0
13
9
13
5
12
9
12
5
12
4
11
9
11
3
11
1
99 95
83
56 53 48
34
Per 1 000 population
Au
str
ia¹
Ge
rm
an
y
Lit
hu
an
ia
Ru
ss
ian
 Fe
d.
Cz
ec
h R
ep
.
Hu
ng
ary
Gr
ee
ce
¹
Slo
va
k R
ep
.²
Slo
ve
nia
No
rw
ay
Fin
lan
d¹
Au
str
ali
a¹
La
tvi
a
De
nm
ark
Es
ton
ia¹
Be
lgi
um
Po
lan
d
Sw
itz
erl
an
d
Fra
nc
e
Sw
ed
en
Ko
rea
Tu
rke
y²
Isr
ae
l
OE
CD
34
Ne
w 
Ze
ala
nd
Ice
lan
d
Lu
xe
mb
ou
rg¹
Ch
ina
Ire
lan
d¹
Un
ite
d K
ing
do
m
Un
ite
d S
tat
es
²
Ita
ly
Ne
the
rla
nd
s
Po
rtu
ga
l
Ja
pa
n
Sp
ain
¹
Ch
ile
¹ ²
Ca
na
da
¹
Br
az
il
So
uth
 Af
ric
a
Me
xic
o¹
Co
lom
bia
6.11. Hospital discharges for circulatory diseases, 2013
(or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280996
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6.12. Hospital discharges for cancers, 2013
(or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933280996
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6. HEALTH CARE ACTIVITIESAverage length of stay in hospitalsThe average length of stay in hospitals (ALOS) is often
regarded as an indicator of efficiency. All other things being
equal, a shorter stay will reduce the cost per discharge and
shift care from inpatient to less expensive post-acute set-
tings. However, shorter stays tend to be more service inten-
sive and more costly per day. Too short a length of stay
could also cause adverse effects on health outcomes, or
reduce the comfort and recovery of the patient. If this leads
to a greater readmission rate, costs per episode of illness
may fall only slightly, or even rise.
In 2013, the average length of stay in hospitals for all causes
across OECD countries was about eight days (Figure 6.13).
Turkey and Mexico had the shortest stays, with about four
days (half the OECD average), whereas Japan and Korea had
the longest stays, with over 16 days (more than double the
OECD average). Across OECD countries, the average length
of stay has fallen from an average of almost 10 days in 2000
to 8 days in 2013. But there are a few exceptions to this gen-
eral pattern, with the average length of stay increasing in
Korea, but also in Hungary and Luxembourg, where it is
now above the OECD average.
Focusing on average length of stay for specific diseases or
conditions can remove some of the effect of different case
mix and severity. Figure 6.14 shows that average length of
stay following a normal delivery was slightly less than
three days on average in 2013, down frommore than three-
and-a-half days in 2000. This ranged from less than
two days in Mexico, Turkey, the United Kingdom, Iceland,
Canada, New Zealand and the Netherlands, to five days or
more in the Slovak Republic and Hungary.
The average length of stay following acute myocardial
infarction was around seven days on average in 2013. It was
shortest in some of the Nordic countries (Denmark, Norway
and Sweden), Turkey and the Slovak Republic, at fewer than
five days, and highest in Korea and Germany, at more than
ten days (Figure 6.15).
Several factors can explain these cross-country variations.
Differences in the clinical need of the patient may obvi-
ously play a role, but these variations also likely reflect dif-
ferences in clinical practices and payments systems. The
combination of an abundant supply of beds with the struc-
ture of hospital payments may provide hospitals with
incentives to keep patients longer. A growing number of
countries (France, Germany, Poland) have moved to pro-
spective payment methods often based on diagnosis-
related groups (DRGs) to set payments based on the esti-
mated cost of hospital care for different patient groups in
advance of service provision. These payment methods
have the advantage of encouraging providers to reduce the
cost of each episode of care. In Switzerland, the cantons
which moved from per diem payments to diagnosis-related
groups (DRG) based payments, have experienced a reduc-
tion in their hospital lengths of stay (OECD andWHO, 2011).
Most countries are seeking to reduce average length of stay
whilst maintaining or improving the quality of care. A
diverse set of policy options at clinical, service and system
level are available to achieve these twin aims. Strategic
reductions in hospital bed numbers alongside development
of community care services can be expected to shorten
average length of stay, such as seen in Denmark’s quality-
driven reforms of the hospital sector (OECD, 2013). Other
options include promoting the uptake of less invasive sur-
gical procedures, changes in hospital payment methods,
the expansion of early discharge programmes which enable
patients to return to their home to receive follow-up care,
and support for hospitals to improve the co-ordination of
care across diagnostic and treatment pathways.
References
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Definition and comparability
Average length of stay refers to the average number of
days that patients spend in hospital. It is generally
measured by dividing the total number of days stayed
by all inpatients during a year by the number of
admissions or discharges. Day cases are excluded.The
data cover all inpatient cases (including not only cura-
tive/acute care cases) for most countries, with the
exceptions of Canada, Japan and the Netherlands
where the data still refer to curative/acute care only
(resulting in an under-estimation).
Discharges and average length of stay of healthy
babies born in hospitals are excluded in several coun-
tries (e.g. Australia, Austria, Canada, Chile, Estonia,
Finland, Greece, Ireland, Luxembourg, Mexico, Spain),
resulting in a slight over-estimation (e.g., the inclu-
sion of healthy newborns would reduce the ALOS by
0.5 day in Canada).HEALTH AT A GLANCE 2015 © OECD 2015108
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Average length of stay in hospitalsInformation on data for Israel: http://oe.cd/israel-disclaimer
6.13. Average length of stay in hospital, 2000 and 2013 (or nearest year)
1. Data refer to average length of stay for curative (acute) care (resulting in an under-estimation).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281004
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6.14. Average length of stay for normal delivery, 2013
(or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281004
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6.15. Average length of stay for acute myocardial
infarction (AMI), 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESCardiac proceduresHeart diseases are a leading cause of hospitalisation and
death in OECD countries (see indicator on “Mortality from
cardiovascular diseases” in Chapter 3). Coronary artery
bypass graft and angioplasty have revolutionised the treat-
ment of ischemic heart diseases in the past few decades. A
coronary bypass is an open-chest surgery involving the
grafting of veins and/or arteries to bypass one or multiple
obstructed arteries. A coronary angioplasty is a much less
invasive procedure involving the threading of a catheter
with a balloon attached to the tip through the arterial sys-
tem to distend the coronary artery at the point of obstruc-
tion; the placement of a stent to keep the artery open
accompanies the majority of angioplasties.
In 2013, Germany, Hungary and Austria had the highest
rates of coronary revascularisation procedures, while the
rates were lowest in Mexico and Chile (Figure 6.16).
A number of reasons can explain cross-country variations
in the rate of coronary bypass and angioplasty, including:
1) differences in the capacity to deliver and pay for these
procedures; 2) differences in clinical treatment guidelines
and practices; and 3) differences in coding and reporting
practices. However, the large variations in the number of
revascularisation procedures across countries do not seem
to be closely related to the incidence of ischemic heart
disease (IHD), as measured by IHD mortality (see Figure 3.6
in Chapter 3). For example, IHD mortality in Germany is
slightly below the OECD average, but Germany has the
highest rate of revascularisation procedures.
National averages can hide important variations in utilisa-
tion rates within countries. For example, in Germany, the
rate of coronary bypass surgery and angioplasty is nearly
three times higher in certain regions compared with oth-
ers. There are also wide variations in the use of these revas-
cularisation procedures across regions in other countries
such as Finland, France and Italy (OECD, 2014).
The use of angioplasty has increased rapidly over the past
20 years in most OECD countries, overtaking coronary
bypass surgery as the preferred method of revascularisa-
tion around the mid-1990s – about the same time that the
first published trials of the efficacy of coronary stenting
began to appear. On average across OECD countries, angio-
plasty now accounts for 78% of all revascularisation proce-
dures (Figure 6.17), and is equal or exceeds 88% in Korea,
Estonia, France and Spain. In many OECD countries, the
growth in angioplasty was more rapid between 2000 and
2006 than afterwards. In the United States, the share of
angioplasty increased quickly between 2000 and 2006, but
has fallen slightly since then. Part of the explanation for
this slight reduction may be due to the fact that the data
reported by the United States do not cover the growing
number of angioplasties carried out as day cases (without
any overnight stay in hospital). In addition, the greater use
of drug-eluting stents in the United States as well as in
other countries reduces the likelihood that the same
patient will need another angioplasty (Epstein et al., 2011).
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Definition and comparability
The data for most countries cover both inpatient and
day cases, with the exception of Chile, Denmark,
Iceland, Norway, Portugal, Switzerland and the United
States, where they only include inpatient cases
(resulting in some under-estimation in the number of
coronary angioplasties; this limitation in data cover-
age does not affect the number of coronary bypasses
since nearly all patients are staying at least one night
in hospital after such an operation). Some of the vari-
ations across countries may also be due to the use of
different classification systems and different codes
for reporting these two procedures.
In Ireland, Mexico, New Zealand and the United
Kingdom, the data only include activities in publicly-
funded hospitals, resulting in an under-estimation (it
is estimated that approximately 15% of all hospital
activity in Ireland is undertaken in private hospitals).
Data for Portugal relate only to public hospitals on the
mainland. Data for Spain only partially include activi-
ties in private hospitals.HEALTH AT A GLANCE 2015 © OECD 2015110
6. HEALTH CARE ACTIVITIES
Cardiac proceduresInformation on data for Israel: http://oe.cd/israel-disclaimer
6.16. Coronary revascularisation procedures, 2013 (or nearest year)
Note: Some of the variations across countries are due to different classification systems and recording practices.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281011
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6.17. Coronary angioplasty as a share of total revascularisation procedures, 2000 to 2013 (or nearest years)
Note: Revascularisation procedures include coronary bypass and angioplasty.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281011
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6. HEALTH CARE ACTIVITIESHip and knee replacementSignificant advances in surgical treatment have provided
effective options to reduce the pain and disability associ-
ated with certain musculoskeletal conditions. Joint
replacement surgery (hip and knee replacement) is consid-
ered the most effective intervention for severe osteoarthri-
tis, reducing pain and disability and restoring some
patients to near normal function.
Osteoarthritis is one of the ten most disabling diseases in
developed countries. Worldwide estimates show that 10%
of men and 18% of women aged over 60 years have symp-
tomatic osteoarthritis, including moderate and severe
forms (WHO, 2014). Age is the strongest predictor of the
development and progression of osteoarthritis. It is more
common in women, increasing after the age of 50 espe-
cially in the hand and knee. Other risk factors include obe-
sity, physical inactivity, smoking, excess alcohol and
injuries. While joint replacement surgery is mainly carried
out among people aged 60 and over, it can also be per-
formed among people at younger ages.
In 2013, Switzerland, Germany and Austria had the highest
rates of hip replacement, while the United States had the
highest rate of knee replacement, followed by Austria,
Finland and Germany (Figures 6.18 and 6.19). Differences in
population structure may explain part of these variations
across countries, and age standardisation reduces to some
extent the cross-country variations. Still, large differences
persist and the country ranking does not change signifi-
cantly after age standardisation (McPherson et al., 2013;
OECD, 2014).
National averages can mask important variations in hip
and knee replacement rates within countries. In Australia,
Canada, Germany, France and Italy, the rate of knee
replacement is more than two times higher in certain
regions compared with others, even after age-standardisa-
tion (OECD, 2014).
The number of hip and knee replacements has increased rap-
idly since 2000 in most OECD countries (Figures 6.20
and 6.21). On average, the rate of hip replacement
increased by about 35% between 2000 and 2013 and the rate
of knee replacement nearly doubled. In France, the growth
rate for both interventions was slightly lower, but still the
hip replacement rate increased by about 15% while the
knee replacement rate rose by nearly 90% between 2000
and 2013. In Germany, these surgical activity rates appear
to have stabilised in recent years and even come down
slightly in 2013.
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Definition and comparability
Hip replacement is a surgical procedure in which the
hip joint is replaced by a prosthetic implant. It is gen-
erally conducted to relieve arthritis pain or treat
severe physical joint damage following hip fracture.
Knee replacement is a surgical procedure to replace
the weight-bearing surfaces of the knee joint in order
to relieve the pain and disability of osteoarthritis. It
may also be performed for other knee diseases such
as rheumatoid arthritis.
Classification systems and registration practices vary
across countries, which may affect the comparability
of the data. Some countries only include total hip
replacement (e.g. Estonia), while most countries also
include partial replacement. In Ireland, Mexico, New
Zealand and the United Kingdom, the data only
include activities in publicly-funded hospitals (it is
estimated that approximately 15% of all hospital
activity is undertaken in private hospitals). Data for
Portugal relate only to public hospitals on the main-
land. Data for Spain only partially include activities in
private hospitals.HEALTH AT A GLANCE 2015 © OECD 2015112
6. HEALTH CARE ACTIVITIES
Hip and knee replacementInformation on data for Israel: http://oe.cd/israel-disclaimer
6.18. Hip replacement surgery, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281026
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6.19. Knee replacement surgery, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6.20. Trend in hip replacement surgery, selected OECD
countries, 2000 to 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6.21. Trend in knee replacement surgery, selected OECD
countries, 2000 to 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESCaesarean sectionsRates of caesarean delivery have increased in nearly all
OECD countries, although in a few countries this trend has
reversed at least slightly in the past few years. Reasons for
the increase include the rise in first births among older
women and in multiple births resulting from assisted
reproduction, malpractice liability concerns, scheduling
convenience for both physicians and patients, and the pref-
erences of some women to have a caesarean section. None-
theless, caesarean delivery continues to result in increased
maternal mortality, maternal and infant morbidity, and
increased complications for subsequent deliveries, raising
questions about the appropriateness of caesarean delivery
that may not be medically required.
In 2013, caesarean section rates were lowest in Nordic
countries (Iceland, Finland, Sweden and Norway), Israel
and the Netherlands, with rates ranging from 15% to 16.5%
of all live births (Figure 6.22). They were highest in Turkey,
Mexico and Chile, with rates ranging from 45% to 50%.
Caesarean rates have increased since 2000 in most OECD
countries, with the average rate going up from 20% in 2000
to 28% in 2013 (Figure 6.23). The growth rate has been par-
ticularly rapid in those countries that have the highest
rates now (Turkey, Mexico and Chile), as well as in Poland,
the Slovak Republic and the Czech Republic which used to
have relatively low rates. In some countries, however, the
growth rate has slowed down since the mid-2000s and it
has even come down slightly in Israel, Finland and Sweden.
In Italy also, caesarean rates have come down significantly
in recent years, although they remain very high. The rates
have also come down in Spain.
There can be substantial variations in caesarean rates
across regions and hospitals within the same country. In
Italy, there continues to be huge variations in caesarean
rates, driven by very large rates in the south of the country.
In Spain also, there are large variations across regions
(OECD, 2014).
In several countries, there is evidence that private hospitals
tend to perform more caesarean sections than public hos-
pitals. In France, private for-profit hospitals authorised to
provide maternity care for pregnancies without complica-
tions have caesarean rates as high as public hospitals
which have to deal with more complicated cases (FHF,
2008). In Switzerland, caesarean sections have been found
to be substantially higher in private clinics (41%) than in
public hospitals (30.5%) (OFSP, 2013).
A number of countries have taken different measures to
reduce unnecessary caesarean sections. Public reporting,
provider feedback, the development of clearer clinical
guidelines, and adjustments to financial incentives have
been used to try to reduce the inappropriate use of caesar-
eans. In Australia, where caesarean section rates are high
relative to most OECD countries, a number of States have
developed clinical guidelines and required reporting of hos-
pital caesarean section rates, including investigation of
performance against the guidelines. These measures have
discouraged variations in practice and contributed to slow-
ing down the rise in caesarean sections. Other countries
have reduced the gap in hospital payment rates between a
caesarean section and a normal delivery, with the aim to
discourage the inappropriate use of caesareans (OECD,
2014).
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Definition and comparability
The caesarean section rate is the number of caesarean
deliveries performed per 100 live births.
In Mexico, the number of caesarean sections is esti-
mated based on public hospital reports and data
obtained from National Health Surveys. Estimation is
required to correct for under-reporting of caesarean
deliveries in private facilities. The combined number
of caesarean deliveries is then divided by the total
number of live births as estimated by the National
Population Council.HEALTH AT A GLANCE 2015 © OECD 2015114
6. HEALTH CARE ACTIVITIES
Caesarean sectionsInformation on data for Israel: http://oe.cd/israel-disclaimer
6.22. Caesarean section rates, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281033
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6.23. Changes in caesarean section rates, 2000 to 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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6. HEALTH CARE ACTIVITIESAmbulatory surgeryIn the past few decades, the number of surgical procedures
carried out on a same-day basis has increased markedly
in OECD countries. Advances in medical technologies,
particularly the diffusion of less invasive surgical
interventions and better anaesthetics, have made this
development possible. These innovations have improved
patient safety and health outcomes, and have also in many
cases reduced the unit cost per intervention by shortening
the length of stay in hospitals. However, the impact of the
rise in same-day surgeries on health spending depends not
only on changes in their unit cost, but also on the growth in
the volume of procedures performed. There is also a need
to take into account any additional cost related to post-
acute care and community health services following the
interventions.
Cataract surgery and tonsillectomy (the removal of tonsils,
glands at the back of the throat, mainly performed on
children) provide good examples of high-volume surgeries
which are now carried out mainly on a same-day basis in
many OECD countries.
Day surgery now accounts for over 90% of all cataract
surgeries in a majority of OECD countries (Figure 6.24). In
several countries, nearly all cataract surgeries are performed
as day cases. However, the use of day surgery is still relatively
low in Poland, Hungary and the Slovak Republic, where
they still account for less than half of all cataract surgeries.
While this may be partly explained by limitations in the
data coverage of outpatient activities in hospital or outside
hospital, this may also reflect more advantageous reim-
bursement for inpatient stays or constraints on the develop-
ment of day surgery. In Hungary, the government recently
abolished the budget cap on the number of same-day surgery
that can be performed in hospital; this is expected to lead to a
steady increase in the number of cataract and other surgeries
performed as day cases.
The number of cataract surgeries performed on a same-day
basis has grown very rapidly since 2000 in many countries,
such as Portugal and Austria (Figure 6.24). Whereas fewer
than 10% of cataract surgeries in Portugal were performed
on a same-day basis in 2000, this proportion has increased
to 92%. In Austria, the share of cataract surgeries per-
formed as day cases increased from 1% only in 2000 to 67%
in 2013. The number of cataract surgeries carried out as day
cases has also risen rapidly in France, Ireland, Switzerland
and Luxembourg, although there is still room for further
development.
Tonsillectomy is one of the most frequent surgical proce-
dures on children, usually performed on children suffering
from repeated or chronic infections of the tonsils or suffer-
ing from breathing problems or obstructive sleep apnea
due to large tonsils. Although the operation is performed
under general anaesthesia, it is now carried out mainly as a
same-day surgery in many countries, with children returning
home the same day (Figure 6.25). This is the case in Finland
(where the share of same-day surgery has increased greatly
since 2000), Canada, Belgium, the Netherlands, Sweden and
Norway, where more than half of all tonsillectomy are
now performed on a same-day basis. This proportion is
much lower in Austria (where virtually no tonsillectomy
is performed on a same-day basis), Luxembourg, Ireland
and Germany. These large differences in the share of same-
day surgery may reflect variations in the perceived risks of
postoperative complications, or simply clinical traditions of
keeping children for at least one night in hospital after the
operation.
In some countries, there has been a strong rise however in
the share of tonsillectomy performed as day surgery since
2000. Beyond Finland which is now leading the way, the
share of same-day surgery has increased rapidly over the
past decade in the United Kingdom, Denmark, Portugal and
Italy. In France, there has virtually been no increase in the
share of day surgery for tonsillectomy since 2000, while this
share has decreased slightly in Israel and Switzerland.
There appears to be ample room for further growth in day
surgery for tonsillectomy in these countries to reduce cost
without affecting patient outcomes.
Definition and comparability
Cataract surgery consists of removing the lens of the
eye because of the presence of cataracts which are
partially or completely clouding the lens, and replacing
it with an artificial lens. It is mainly performed on
elderly people. Tonsillectomy consists of removing the
tonsils, glands at the back of the throat. It is mainly
performed on children.
The data for several countries do not include outpa-
tient cases in hospital or outside hospital (i.e., patients
who are not formally admitted and discharge), leading
to some under-estimation. In Ireland, Mexico, New
Zealand and the United Kingdom, the data only include
cataract surgeries carried out in public or publicly-
funded hospitals, excluding any procedures performed
in private hospitals (in Ireland, it is estimated that
approximately 15% of all hospital activity is under-
taken in private hospitals). Data for Portugal relate only
to public hospitals on the mainland. Data for Spain only
partially include activities in private hospitals.HEALTH AT A GLANCE 2015 © OECD 2015116
6. HEALTH CARE ACTIVITIES
Ambulatory surgeryInformation on data for Israel: http://oe.cd/israel-disclaimer
6.24. Share of cataract surgeries carried out as ambulatory cases, 2000 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281044
6.25. Share of tonsillectomy carried out as ambulatory cases, 2000 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281044
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Coverage for health care
Unmet needs for medical care and dental care
Out-of-pocket medical expenditure
Geographic distribution of doctors
Waiting times for elective surgery
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities. The use of such data by the OECD is without prejudice to the status of the Golan
Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of
international law.5 119
7. ACCESS TO CARECoverage for health careHealth care coverage through public or private health
insurance promotes access to medical goods and services,
and provides financial security against unexpected or serious
illness. However, the percentage of the population covered by
such insurance does not provide a complete indicator of
accessibility, since the range of services covered and the
degree of cost-sharing applied to those services also affects
access to care.
Most OECD countries have achieved universal (or near-
universal) coverage of health care costs for a core set of
services, which usually include consultations with doctors
and specialists, tests and examinations, and surgical and
therapeutic procedures (Figure 7.1). Generally, dental care
and pharmaceutical drugs are partially covered, although
there are a number of countries where these services must
be purchased separately (OECD, 2015).
Three OECD countries do not have universal (or near-uni-
versal) health coverage: Greece, the United States and
Poland. In Greece, the economic crisis has reduced health
insurance coverage among people who have become long-
term unemployed, and many self-employed workers have
also decided not to renew their health insurance plan
because of reduced disposable income. However, since
June 2014, uninsured people are covered for prescribed
pharmaceuticals and for services in emergency depart-
ments in public hospitals, as well as for non-emergency
hospital care under certain conditions (Eurofound, 2014). In
the United States, coverage is provided mainly through
private health insurance, and 54% of the population had this
for their basic coverage in 2014. Publicly financed coverage
insured 34.5% of the population (the elderly, people with
low income or with disabilities), leaving 11.5% of the popu-
lation without insurance. The percentage of the population
uninsured decreased from 14.4% in 2013 to 11.5% in 2014,
following the implementation of the Affordable Care Act
which is designed to expand health insurance coverage
(Cohen and Martinez, 2015). In Poland, a tightening of the
law in 2012 made people lose their social health insurance
coverage if they fail to pay their contribution. However, it is
common for uninsured people who needmedical care to go
to emergency services in hospital, where they will be
encouraged to get an insurance.
Basic primary health coverage, whether provided through
public or private insurance, generally covers a defined
“basket” of benefits, in many cases with cost-sharing. In
some countries, additional health coverage can be purchased
through private insurance to cover any cost-sharing left
after basic coverage (complementary insurance), add
additional services (supplementary insurance) or provide
faster access or larger choice to providers (duplicate insur-
ance). Among the 34 OECD countries, nine have private
coverage for over half of the population (Figure 7.2).
Private health insurance offers 95% of the French population
complementary insurance to cover cost-sharing in the social
security system. The Netherlands has the largest supple-
mentary market (86% of the population), followed by
Israel (83%), whereby private insurance pays for prescrip-
tion drugs and dental care that are not publicly reimbursed.
Duplicate markets, providing faster private-sector access to
medical services where there are waiting times in public
systems, are largest in Ireland (45%) and Australia (47%).
The population covered by private health insurance has
increased in some OECD countries over the past decade,
whereas it has decreased in others. It increased in some
Nordic countries such as Denmark where one-third of the
population now has a private health insurance (up from
less 10% in 2005) and in Finland where the growth has been
more modest, but remains almost non-existent in other
Nordic countries. Private health insurance coverage has
also increased in Australia and Korea, but it has come
down in Ireland, New Zealand and the United Kingdom
(Figure 7.3).
The importance of private health insurance is linked to sev-
eral factors, including gaps in access to publicly financed ser-
vices, government interventions directed at private health
insurance markets, and historical development.
References
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Definition and comparability
Coverage for health care is defined here as the share
of the population receiving a core set of health care
goods and services under public programmes and
through private health insurance. It includes those
covered in their own name and their dependents. Public
coverage refers both to government programmes,
generally financed by taxation, and social health
insurance, generally financed by payroll taxes. Take-
up of private health insurance is often voluntary,
although it may be mandatory by law or compulsory
for employees as part of their working conditions.
Premiums are generally non-income-related, although
the purchase of private coverage can be subsidised by
government.HEALTH AT A GLANCE 2015 © OECD 2015120
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Coverage for health careInformation on data for Israel: http://oe.cd/israel-disclaimer
7.1. Health insurance coverage for a core set of services,
2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281052
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7.2. Private health insurance coverage, by type, 2013
(or nearest year)
Note: Private health insurance can be both duplicate and supplementary
in Australia; both complementary and supplementary in Denmark and
Korea; and duplicate, complementary and supplementary in Israel and
Slovenia.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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7.3. Evolution in private health insurance coverage, 2005 to 2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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7. ACCESS TO CAREUnmet needs for medical care and dental careAccess to health care may be prevented for a number of
reasons related either to the functioning of the health care
system itself (like the cost of a doctor visit or medical
treatment, the distance to the closest health care facility, or
waiting lists) or to personal reasons (like fear of not being
understood by the doctor or not having the time to seek
care). People who forgo health care when they need it may
jeopardize their health status. Any inequalities in unmet
care needs may result in poorer health status and increase
health inequalities.
Around 3% of the population on average across Europe
reported unmet needs for medical care due to cost, travel-
ling distance and waiting lists in 2013, according to the
European Union “Statistics on Income and Living Conditions”
survey. But there are large variations across countries
(Figure 7.4). Larger shares of the population report unmet
needs in Latvia, Greece, Poland and Estonia, while less
than 1% of the population reported unmet needs in the
Netherlands, Austria, Spain, Luxembourg and the Czech
Republic. Unmet needs for medical examination are consis-
tently higher among people in low income groups compared
with those in high income groups (Figure 7.4). The gap was
particularly large in 2013 in Latvia, Italy and Greece.
A higher proportion of the population in European coun-
tries reports some unmet needs for dental care than for
medical care, reflecting the fact that public coverage for
dental care is generally lower in most countries. Latvia
(18.9%), Portugal (14.3%), Iceland (11.1%) and Italy (10%),
reported the highest rates of unmet needs for dental care
among European countries in 2013 (Figure 7.5). In these
countries, there were large inequalities in unmet dental
care needs between low and high income groups. On aver-
age across European countries covered under this survey,
nearly 10% of low income people reported having some
unmet needs for dental care, compared with 1.6% for high
income people.
Countries participating in the Commonwealth Fund Inter-
national Health Policy Survey, and other countries using
the same survey module, collect data on unmet care needs
for doctor visits, medical care and prescribed pharmaceutical
drugs due to cost. As expected, the results from these surveys
show consistently higher unmet care needs for financial
reasons among low income people compared with high
income people (Figure 7.6). The largest proportions of
unmet care needs in 2013 were found in the United States,
while the United Kingdom had the lowest rates, followed by
Sweden. There were large gaps in unmet care needs
between high and low income people in the Czech Republic,
France and the United States.
It is important to consider self-reported unmet care needs
in conjunction with other indicators of potential barriers to
access, such as the extent of health insurance coverage and
the amount of out-of-pocket payments. For instance, the
rate of unmet care needs decreased in Germany, following
the abolition of a quarterly fee of EUR 10 charged to
patients.
Strategies to improve access to care for disadvantaged or
underserved populations need to tackle both financial and
non-financial barriers, as well as promoting an adequate
supply and proper distribution of doctors, dentists and
other medical practitioners (see the indicator on “Geographic
distribution of doctors”).
Definition and comparability
Data on unmet care needs come from two main
sources. First, the European Union Statistics on
Income and Living Conditions survey (EU-SILC) ask
survey respondents whether there was a time in the
previous 12 months when they felt they needed a
medical or dental examination but did not receive it,
followed by a question as to why the need for care was
unmet (with the reasons including that care was too
expensive, the waiting time was too long, the travel-
ling distance to receive care was too far, a lack of time,
or that they wanted to wait and see if problem got
better on its own). The data presented in Figures 7.4
and 7.5 cover unmet care needs due to cost, waiting
time and travelling distance.
The second source is the 2013 Commonwealth Fund
International Health Policy Survey which asks
whether people did not visit a doctor when they had a
medical problem, skipped a medical test, treatment,
or follow-up that was recommended by a doctor, or
did not fill prescription for medicines or skipped
doses because of cost in the past year. This survey was
carried out in eleven countries. Similar questions
were also asked in the national survey in the Czech
Republic a few years earlier (2010).HEALTH AT A GLANCE 2015 © OECD 2015122
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Unmet needs for medical care and dental careInformation on data for Israel: http://oe.cd/israel-disclaimer
7.4. Unmet care needs for medical examination,
by income level, 2013
Note: Unmet care needs for following reasons: too expensive, too far to
travel, or waiting time.
Source: EU-SILC 2013.
 2 http://dx.doi.org/10.1787/888933281066
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7.5. Unmet care needs for dental examination,
by income level, 2013
Note: Unmet care needs for following reasons: too expensive, too far to
travel, or waiting time.
Source: EU-SILC 2013.
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7. ACCESS TO CAREOut-of-pocket medical expenditureFinancial protection through public or private health insur-
ance substantially reduces the amount that people pay
directly for medical care, yet in some countries the burden
of out-of-pocket spending can still create barriers to health
care access and use. Households that face difficulties pay-
ing medical bills may delay or even forgo needed health
care. On average across OECD countries, 19% of health
spending is paid directly by patients (see indicator
“Financing of health care” in Chapter 9 on “Health expen-
diture”).
In contrast to publicly-funded care, out-of-pocket pay-
ments rely on people’s ability to pay. If the financing of
health care becomes more dependent on out-of-pocket
payments, the burden shifts, in theory, towards those who
use services more, and possibly from high to low income
households, where health care needs are higher. In practice,
many countries have policies in place to protect certain
population groups from excessive out-of-pocket payments.
These consist in partial or total exemptions for social assis-
tance beneficiaries, seniors, or people with chronic diseases
or disabilities by capping direct payments, either in absolute
terms or as a share of income (Paris et al., 2010; OECD,
2015).
The burden of out-of-pocket medical spending can be mea-
sured either by its share of total household income or its
share of total household consumption. The share of house-
hold consumption allocated to medical spending varied
considerably across OECD countries in 2013, ranging from
less than 1.5% of total household consumption in countries
such as Turkey, the Netherlands, France and the United
Kingdom, to more than 4% in Korea, Switzerland and
Greece (Figure 7.7). On average across OECD countries, 2.8%
of household spending went towards medical goods and
services.
Health systems in OECD countries differ in the degree of
coverage for different health services and goods. In most
countries, the degree of coverage is higher for hospital care
and doctor consultations than for pharmaceuticals, dental
care and eye care (Paris et al., 2010; OECD, 2015). Taking into
account these differences and also the relative importance
of these different spending categories, there are significant
variations between OECD countries in the breakdown of
themedical costs that households have to bear themselves.
In most OECD countries, curative care (including both
inpatient and outpatient care) and pharmaceuticals are the
two main spending items for out-of-pocket expenditure
(Figure 7.8). On average, these two components account for
two-thirds of all medical spending by households, but the
importance varies between countries. In Luxembourg,
Belgium and Switzerland, household payments for inpa-
tient and outpatient curative care account for close to 50%
of total household outlays. In other countries such as
Poland, the Czech Republic, Hungary and Canada, half of
out-of-pocket payments or more are for pharmaceuticals.
In some of these countries, in addition to co-payments for
prescribed pharmaceuticals, spending on over-the-counter
medicines for self-medication has been historically high.
Payments for dental treatment also play a significant part
in household medical spending, accounting for 20% of all
out-of-pocket expenditure across OECD countries. In
Estonia, Norway, Denmark and Spain, this figure reaches
30% or more. This can at least partly be explained by the
limited public coverage for dental care in these countries
compared with a more comprehensive coverage for other
categories of care. The significance of therapeutic appliances
(eye-glasses, hearing aids, etc.) in households’ total medical
spending differs widely, but is as much as 33% in the
Netherlands. The average across OECD countries was 13%.
More than half of this relates to eye-care products. In many
countries, public coverage is limited to a contribution to the
cost of lenses. Frames are often exempt frompublic coverage,
leaving private households to bear the full cost if they are
not covered by complementary private insurance.
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Definition and comparability
Out-of-pocket payments are expenditures borne
directly by a patient where neither public nor private
insurance cover the full cost of the health good or
service. They include cost-sharing and other expen-
diture paid directly by private households and should
also include estimations of informal payments to
health care providers. Only expenditure for medical
spending (i.e. current health spending less expenditure
for the health part of long-term care) is presented
here, because the capacity of countries to estimate
private long-term care expenditure varies widely.
Household final consumption expenditure covers all
purchases made by resident households to meet their
everyday needs such as food, clothing, rent or health
services.HEALTH AT A GLANCE 2015 © OECD 2015124
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Out-of-pocket medical expenditureInformation on data for Israel: http://oe.cd/israel-disclaimer
7.7. Out-of-pocket medical spending as a share of final household consumption, 2013 (or nearest year)
Note: This indicator relates to current health spending excluding long-term care (health) expenditure.
1. The value for the Netherlands is underestimated as it excludes compulsory co-payments by patients to health insurers (if these were taken into
account this would double the share).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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7.8. Shares of out-of-pocket medical spending by services and goods, 2013 (or nearest year)
Note: This indicator relates to current health spending excluding long-term care (health) expenditure.
1. Including rehabilitative and ancillary services.
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7. ACCESS TO CAREGeographic distribution of doctorsAccess to medical care requires an adequate number and
proper distribution of doctors in all parts of the country.
Any shortage of doctors in certain regions can increase
travel times or waiting times for patients, and result in
unmet care needs. The uneven distribution of doctors is an
important policy issue in most OECD countries, especially
in those countries with remote and sparsely populated
areas, and those with deprived urban regions which may
also be underserved.
The overall number of doctors per capita varies across OECD
countries from lows of about two per 1 000 population in
Chile,Turkey and Korea, to highs of five and more in Greece
and Austria (see the indicator on “Doctors” in Chapter 5).
Beyond these cross-country differences, the number of
doctors per capita also often varies widely across regions
within the same country (Figure 7.9). A common feature in
many countries is that there tends to be a concentration of
physicians in capital cities. For example, Austria, Belgium,
the Czech Republic, Greece, Mexico, Portugal, the Slovak
Republic and the United States have a much higher density
of doctors in their national capital region.
The density of physicians is consistently greater in urban
regions, reflecting the concentration of specialised services
such as surgery and physicians’ preferences to practice in
urban settings. There are large differences in the density of
doctors between predominantly urban and rural regions in
France, Australia and Canada, although the definition of
urban and rural regions varies across countries. The distri-
bution of physicians between urban and rural regions is
more equal in Japan and Korea, but there are generally
fewer doctors in these two countries (Figure 7.10).
Doctors may be reluctant to practice in rural regions due to
concerns about their professional life (including their
income, working hours, opportunities for career develop-
ment, isolation from peers) and social amenities (such as
educational opportunities for their children and profes-
sional opportunities for their spouse).
A range of policy levers may influence the choice of prac-
tice location of physicians, including: 1) the provision of
financial incentives for doctors to work in underserved
areas; 2) increasing enrolments in medical education
programmes of students coming from specific social or
geographic background, or decentralising the location of
medical schools; 3) regulating the choice of practice location
of doctors (for new medical graduates or foreign-trained
doctors); and 4) re-organising health service delivery to
improve the working conditions of doctors in underserved
areas and find innovative ways to improve access to care
for the population.
Many OECD countries provide different types of financial
incentives to attract and retain doctors in underserved
areas, including one-time subsidies to help them set up
their practice and recurrent payments such as income
guarantees and bonus payments (Ono et al., 2014).
In France, the Ministry of Health launched at the end of
2012 a “Health Territory Pact” to promote the recruitment
and retention of doctors and other health workers in
underserved regions. This Pact includes a series of measures
to facilitate the establishment of young doctors in under-
served areas, to improve their working conditions (notably
through the creation of new multi-disciplinary medical
homes allowing physicians and other health professionals
to work in the same location), to promote tele-medicine,
and to accelerate the transfer of competences from doctors
to other health care providers (Ministry of Health, 2015). The
first results from this programmeare promising, although it is
still too early to reach any definitive conclusions on the cost-
effectiveness of various measures.
In Germany, the number of practice permits for new ambu-
latory care physicians in each region is regulated, based on
a national service delivery quota.
The effectiveness and cost of different policies to promote
a better distribution of doctors can vary significantly, with
the impact likely to depend on the characteristics of each
health system, the geography of the country, physician
behaviours, and the specific policy and programme design.
Policies should be designed with a clear understanding of the
interests of the target group in order to have any significant
and lasting impact (Ono et al., 2014).
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Definition and comparability
Regions are classified in two territorial levels. The
higher level (Territorial Level 2) consists of large
regions corresponding generally to national adminis-
trative regions. These broad regions may contain a
mix of urban, intermediate and rural areas. The lower
level is composed of smaller regions classified as pre-
dominantly urban, intermediate or rural regions,
although there are variations across countries in the
classification of these regions.HEALTH AT A GLANCE 2015 © OECD 2015126
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Geographic distribution of doctorsInformation on data for Israel: http://oe.cd/israel-disclaimer
7.9. Physician density, by Territorial Level 2 regions, 2013 (or nearest year)
Source: OECD Regions at a Glance 2015.
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7. ACCESS TO CAREWaiting times for elective surgeryLong waiting times for health services is an important policy
issue in many OECD countries (Siciliani et al., 2013). Long
waiting times for elective (non-emergency) surgery, such as
cataract surgery, hip and knee replacement, generates dissat-
isfaction for patients because the expected benefits of
treatments are postponed, and the pain and disability
remains.While longwaiting times is considered an important
policy issue in many countries, this is not the case in others
(e.g., Belgium, France, Germany, Japan, Korea, Luxembourg,
Switzerland, United States).
Waiting times is the result of a complex interaction
between the demand and supply of health services, where
doctors play a critical role on both sides. The demand for
health services and elective surgery is determined by the
health status of the population, progress in medical tech-
nologies (including the increase ease of many procedures
like cataract which can now be performed as day surgery),
patient preferences (including their weighting of the
expected benefits and risks), and the extent of cost-sharing
for patients. However, doctors play a crucial role in convert-
ing the demand for better health from patients in a demand
for medical care. On the supply side, the availability of
different categories of surgeons, anaesthesists and other
staff involved in surgical procedures, as well as the supply
of the required medical and hospital equipment influence
surgical activity rates.
The measure used here focuses on waiting times from the
time that a medical specialist adds a patient to the waiting
list to the time that the patient receives the treatment. Both
the average waiting time and the median are presented.
Because some patients wait for very long times, the average
is usually greater than the median.
In 2013/14, the average waiting times for cataract surgery
was just over 30 days in the Netherlands, but much longer
in Chile, Estonia and Poland (Figure 7.11). In the United
Kingdom, the average waiting times for cataract surgery
was 72 days in 2013, slightly up from 66 days in 2007. In
Portugal and Spain, waiting times fell between 2007 and
2010, but has increased since then. In Finland and Estonia,
waiting times for cataract surgery has fallen steadily,
although the average waiting times remains high in
Estonia.
In 2013/14, the average waiting times for hip replacement
was just over 40 days in the Netherlands, but around
250 days in Estonia and over 300 days in Chile and Poland
(Figure 7.12). The median waiting times was around 40 days
in Denmark, 60 days in Israel, and between 75 and 90 days
in Hungary, the United Kingdom, Portugal, Canada and
New Zealand. It reached between 120 and 150 days in
Spain, Norway and Estonia, and over 200 days in Poland
and Chile. As is the case for cataract surgery, waiting times
for hip replacement fell in Portugal and Spain between 2007
and 2010, but has gone up since then.
Waiting times for knee replacement has comedown in recent
years in the Netherlands, Denmark, Finland and Estonia,
although it remains very long in Estonia (Figure 7.13).
Over the past decade, waiting time guarantees have
become themost common policy tool to tackle long waiting
times in several countries. This has been the case in Finland
where a National Health Care Guarantee was introduced in
2005 and led to a reduction in waiting times for elective
surgery (Jonsson et al., 2013). In England, since April 2010,
the NHS Constitution has set out a right to access certain
services within maximum waiting times or for the NHS to
take all reasonable steps to offer a range of alternative
providers if this is not possible (Smith and Sutton, 2013).
These guarantees are only effective if they are enforced.
There are two main approaches to enforcement: setting
waiting time targets and holding providers accountable for
achieving these targets; or allowing patients to choose
alternative health providers (including the private sector) if
they have to wait beyond a maximum amount of time
(Siciliani et al., 2013).
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Definition and comparability
There are at least two ways of measuring waiting
times for elective procedures: 1) measuring the waiting
times for patients treated in a given period; or
2) measuring waiting times for patients still on the list
at a point in time. The data reported here relate to the
first measure (data on the secondmeasure are available
in the OECD health database). The data come from
administrative databases (not surveys). Waiting times
are reported both in terms of the average and the
median. The median is the value which separates a
distribution in two equal parts (meaning that half the
patients have longer waiting times and the other half
lower waiting times). Compared with the average, the
median minimises the influence of outliers (patients
with very long waiting times).HEALTH AT A GLANCE 2015 © OECD 2015128
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Waiting times for elective surgeryInformation on data for Israel: http://oe.cd/israel-disclaimer
7.11. Cataract surgery, waiting times from specialist assessment to treatment, 2007 to 2014 (or 2013)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281097
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7.12. Hip replacement, waiting times from specialist assessment to treatment, 2007 to 2014 (or 2013)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281097
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7.13. Knee replacement, waiting times from specialist assessment to treatment, 2007 to 2014 (or 2013)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281097
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The statistical data for Israel are supplied by and under the responsibility of the relevant
Israeli authorities. The use of such data by the OECD is without prejudice to the status of
the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the
terms of international law.5 131
8. QUALITY OF CAREAvoidable hospital admissionsMost health systems have developed a “primary level” of
care whose functions include health promotion and disease
prevention, managing new health complaints, as well as
long-term conditions and referring patients to hospital-based
services when appropriate. A key aim is to keep people well,
by providing a consistent point of care over the longer-term,
tailoring and co-ordinating care for those with multiple
health care needs and supporting the patient in self-
education and self-management.
Asthma, chronic obstructive pulmonary disease (COPD)
and congestive heart failure (CHF) are three widely prevalent
long-term conditions. Both asthma and COPD limit the
ability to breathe: asthma symptoms are usually intermittent
and reversible with treatment, whilst COPD is a progressive
disease that almost exclusively affects current or prior
smokers. Asthma affects an estimated 235 million people
worldwide (WHO, 2013). More than 3 million people died of
COPD in 2012, which is equal to 6% of all deaths globally
that year (WHO, 2015). CHF is a serious medical condition
in which the heart is unable to pump enough blood to meet
the body’s needs. CHF is often caused by hypertension,
diabetes or coronary heart disease. Heart failure is estimated
to affect over 26million people worldwide resulting inmore
than 1 million hospitalisations annually in both the United
States and Europe.
Common to all three conditions is the fact that the evidence
base for effective treatment is well established andmuch of
it can be delivered at a primary care level. A high-performing
primary care system can reduce acute deterioration in people
living with asthma, COPD or CHF and prevent their admis-
sion to hospital.
Figure 8.1 shows hospital admission rates for asthma and
COPD together, given the physiological relationship
between the two conditions. Admission rates for asthma
vary 11-fold across countries with Italy, Switzerland and
Mexico reporting the lowest rates and Korea, United States
and the Slovak Republic reporting rates over twice the
OECD average. International variation in admissions for
COPD is 17-fold across OECD countries, with Japan and Italy
reporting the lowest rates and Hungary and Ireland the
highest rates. Combined, there is a lower 8-fold variation
across countries for the two respiratory conditions. Hospi-
tal admission rates for CHF vary 7-fold, as shown in
Figure 8.2. Mexico, United Kingdom and Korea have the
lowest rates, while the Slovak Republic, Hungary and
Poland report rates at least 1.8 times the OECD average.
The majority of countries report a reduction in admission
rates for CHF over recent years. This may represent an
improvement in the quality of primary care. The
approaches countries are taking to improve the quality of
primary care have been described in a series of country
reviews undertaken by OECD. Israel’s Quality Indicators for
Community Health Care program provides an example of how
publicly reported information on care is used to incentivise
providers to develop better services (OECD, 2012).
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Definition and comparability
The indicators are defined as the number of hospital
admissions with a primary diagnosis of asthma, COPD
and CHF among people aged 15 years and over per
100 000 population. Rates were age-sex standardised
to the 2010 OECD population aged 15 and over.
Disease prevalence may explain some, not all, varia-
tions in cross-country rates. Differences in coding
practices among countries and the definition of an
admission may also affect the comparability of data.
For example, while the transfer of patients from one
hospital to another is required to be excluded from
the calculations to avoid “double counting”, this cannot
be fully complied with by some countries. There is
also a risk that countries that do not have the capacity
to track patients through the system do not identify
all relevant admissions due to changes in diagnosis
coding on transfer between hospitals. The impact of
excluding admissions where death occurred has been
investigated, given these admissions are less likely to
be avoidable. The results reveal that while the impact
on the indicator rate varies across conditions (e.g. on
average, reduced asthma rates by less than 1%
whereas for CHF it was nearly 9%), the changes in the
variation of rates across countries for each condition
was minimal.HEALTH AT A GLANCE 2015 © OECD 2015132
8. QUALITY OF CARE
Avoidable hospital admissionsInformation on data for Israel: http://oe.cd/israel-disclaimer
8.1. Asthma and COPD hospital admission in adults, 2013 (or nearest year)
Note: Three-year average for Iceland and Luxembourg.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281105
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8.2. Congestive heart failure hospital admission in adults, 2008 and 2013 (or nearest years)
Note: Three-year average for Iceland.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281105
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8. QUALITY OF CAREDiabetes careDiabetes is a chronic disease that occurs when the body’s
ability to regulate excessive glucose levels in the blood is
lost. Across the OECD countries, diabetes is a leading cause
of cardiovascular disease, blindness, kidney failure, and
lower limb amputation. Globally it is estimated that over
380 million people had diabetes in 2014 and by 2035 it is
projected that close to 600 million people will have the con-
dition. Diabetes caused close to 5 million deaths in 2014
(IDF, 2014). Many countries have established comprehen-
sive approaches to diabetes care, but there are indications
that more can be done to prevent the disease (OECD, 2014).
Cholesterol-lowering drugs and medications to reduce
blood pressure are recommended in most national guide-
lines for the care of diabetes patients (see indicator “Pre-
scribing in primary care” in Chapter 8)
Poor control of the level of glucose in the blood over the
short term can lead to vomiting, dehydration and even
cause coma, whereas sustained high levels of blood glucose
over a number of years can result in serious diseases with
ongoing consequences for a person’s health and wellbeing.
For example, diabetes can cause nerve damage and poor
blood circulation over time. These problems make the feet
vulnerable to skin ulcers that can deteriorate quickly and
be difficult to treat. An ulcer that does not heal can cause
severe damage to tissues and bone over time and can even-
tually require amputation of a toe, foot or part of a leg.
Proper diabetes management and careful foot care can pre-
vent foot ulcers. Ongoing management of diabetes usually
involves a considerable amount of self-care, and therefore,
advice and education are central to the primary care of peo-
ple with diabetes. Effective control of blood glucose levels
through routinemonitoring, dietary modification and regu-
lar exercise can reduce the onset of serious complications
and the need for hospitalisation.
Figure 8.3 shows the avoidable hospital admissions for dia-
betes. The international variation in the rates is nearly 8-
fold, with Italy, Switzerland and Spain reporting the lowest
rates and Austria, Korea and Mexico reporting rates at least
two times that of the OECD average. Prevalence of diabetes
may explain some of the variation in diabetes admission
rates. A positive relationship can be demonstrated between
hospital admissions for the general population and diabe-
tes-related hospital admissions, providing some indication
that overall access to hospital care can also play a role in
explaining the level of hospital care among the diabetic
population (OECD, 2015).
Hospital admissions for major lower extremity amputation
(i.e. surgical removal of lower limb, including leg or foot)
reflect the long-term quality of diabetes care. Figure 8.4
shows the rates of major lower extremity amputation in
adults with diabetes. In the left panel the rates based on
the general population are presented. The international
variation in rates is over 14-fold, with Korea and Italy
reporting rates lower than 3 per 100 000 general population
and Israel, Slovenia and Portugal reporting rates above 10.
Rates based on the estimated diabetic population are pre-
sented in the right panel. The rates based on the diabetic
population are on average 9-fold higher than for the gen-
eral population and display differences in the ranking of
countries, providing an indication that differences in dis-
ease prevalence across countries may explain some, but
not all, cross-country variation.
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Definition and comparability
The indicator for diabetes hospital admission is
defined as the number of hospital admissions with a
primary diagnosis of diabetes among people aged
15 years and over per 100 000 population. The indica-
tor for major lower extremity amputation in adults
with diabetes is defined as the number of discharges
of people aged 15 years and over per 100 000 popula-
tion, for the general population and the estimated dia-
betic population. Rates for both indicators were age-
sex standardised to the 2010 OECD population aged 15
and over.
Differences in data definition and coding practices
between countries may affect the comparability of
data. For example, coding of diabetes as a principal
diagnosis versus a secondary diagnosis varies across
countries. This is more pronounced for diabetes than
other conditions, given that in many cases admission
is for the secondary complications of diabetes rather
than diabetes itself. Diabetes population estimates
used to calculate amputation indicator rates were
self-reported by countries. Subject to further data
development, the use of diabetes population estimates
to standardise the indicator rates will be considered in
the future.HEALTH AT A GLANCE 2015 © OECD 2015134
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Diabetes careInformation on data for Israel: http://oe.cd/israel-disclaimer
8.3. Diabetes hospital admission in adults, 2008 and 2013 (or nearest years)
Note: Three-year average for Iceland and Luxembourg.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281111
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8.4. Major lower extremity amputation in adults with diabetes, 2013 (or nearest year)
Note: Three-year average for Iceland and Luxembourg.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281111
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8. QUALITY OF CAREPrescribing in primary careBeyond consumption and expenditure information (see
Chapter 10), prescribing can be used as an indicator of
health care quality. Antibiotics, for example, should be pre-
scribed only where there is an evidence-based need, to
reduce the risk of resistant strains. Likewise, quinolones
and cephalosporins are considered second-line antibiotics
in most prescribing guidelines. Their use should be
restricted to ensure availability of effective second-line
therapy should first-line antibiotics fail. Total volume of
antibiotics prescribed, and second-line as a proportion of
total volume, have been validated as markers of quality in
the primary care setting. In May 2015, the World Health
Assembly endorsed a global action plan to tackle antimicro-
bial resistance (http://who.int/drugresistance/global_action_plan),
which is also reflected in several national strategies.
Figure 8.5 shows volume of all antibiotics prescribed in pri-
mary care, with volumes of second- line antibiotics embed-
ded within the total amount. Total volumes vary more than
four-fold across countries, with Chile, the Netherlands and
Estonia reporting the lowest volumes, and Turkey and
Greece reporting volumes much higher than the OECD aver-
age. Volumes of second-line antibiotics vary almost 16-fold
across countries. The Nordic countries, the Netherlands and
the United Kingdom report the lowest volumes of these
antibiotics, and Korea, the Slovak Republic and Greece the
highest.Variation is likely to be explained, on the supply side,
by differences in the regulation, guidelines and incentives
that govern primary care prescribers and, on the demand
side, by cultural differences in attitudes and expectations
regarding the natural history and optimal treatment of
infective illness.
In conjunction with additional indicators of the quality of
primary care for diabetes (see “Diabetes care”), Health at a
Glance is for the first time reporting two indicators related
to the quality of prescribing in primary care for diabetic
patients. In diabetic individuals with hypertension, angio-
tensin-converting enzyme inhibitors (ACE-I) or angiotensin
receptor blockers (ARB) are recommended in most national
guidelines as first-line medications to reduce blood pres-
sure, since they are most effective at reducing the risk of
cardiovascular disease and renal disease. Figures 8.6
and 8.7 suggest there is wide variability across countries in
prescribing practices for diabetes patients, with 27% of
diabetic patients in the Slovak Republic given prescriptions
for cholesterol-lowering medication, compared with 81% in
New Zealand. There is greater consistency in the proportion
of diabetic patients on antihypertensive agents with at
least one prescription for ACE-I or ARB, with the exception
of the Slovak Republic.
Benzodiazepines are often prescribed for elderly patients
for anxiety and sleep disorders, despite the risk of adverse
side effects such as fatigue, dizziness and confusion. A
meta-analysis suggests that the use of benzodiazepines in
elderly people is associated with more than double the risk
of developing such adverse effects compared with placebo
(Sithamparanathan et al., 2012). Figures 8.8 and 8.9 indicate
that, across the OECD, on average around 29 per
1 000 elderly patients receive long-term prescriptions for
benzodiazepines and related drugs ( 365 defined daily
doses in one year), and 62 per 1 000 have received at least
one prescription for a long-acting benzodiazepine or
related drugs within the year.
To reduce the potentially harmful overuse and misuse of
medicines, diagnostic tests and procedures, the Choosing
Wisely campaign was launched in 2012. Increasingly
international, the campaign comprises evidence-based
information for clinicians and patients on when medica-
tions and procedures may be inappropriate. Appropriate
use of antibiotics and benzodiazepines is addressed
(www.choosingwisely.org).
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Definition and comparability
Defined daily dose (DDD) is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. DDDs are assigned to each active
ingredient in a given therapeutic class by interna-
tional expert consensus. For instance, the DDD for
oral aspirin equals 3 grams, which is the assumed
maintenance daily dose to treat pain in adults. DDDs
do not necessarily reflect the average daily dose actually
used in a given country. DDDs can be aggregated
within and across therapeutic classes of the Anatomic
Therapeutic Classification (ATC). For more detail, see
www.whocc.no/atcddd.
In Figure 8.5, data for Chile include over the counter
(OTC) drugs. Data for Canada, Israel and Luxembourg
exclude drugs prescribed in hospitals, non-reimbursed
drugs and OTC drugs. Data for Iceland refer to all
sectors, not just primary care. Data for Portugal include
OTC and non-reimbursed drugs. Data for Australia
include non-reimbursed drugs. Data for Turkey refer
to outpatient health care.
Denominators comprise the population held in the
national prescribing database, rather than the general
population (with the exception of Belgian data on
benzodiazepines, which comes from a national
health survey).HEALTH AT A GLANCE 2015 © OECD 2015136
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Prescribing in primary careInformation on data for Israel: http://oe.cd/israel-disclaimer
8.5. Overall volume of antibiotics prescribed, 2013 (or nearest year)
1. Data refer to all sectors (not only primary care).
Source: European Centre for Disease Prevention and OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
 2 http://dx.doi.org/10.1787/888933281125
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8.6. People with diabetes with a prescription of
cholesterol lowering medication in the past year, 2013
(or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281125
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8.7. People with diabetes with a prescription
of recommended antihypertensive medication in the past
year, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281125
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8.8. Elderly people prescribed long-term benzodiazepines
or related drugs, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281125
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benzodiazepines or related drugs, 2013 (or nearest year)
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8. QUALITY OF CAREMortality following acute myocardial infarction (AMI)Mortality due to coronary heart disease has declined sub-
stantially since the 1970s (see indicator “Mortality from
cardiovascular diseases” in Chapter 3). Advances in the
prevention such as smoking (see indicator “Tobacco con-
sumption among adults” in Chapter 4) and treatment of
cardiovascular diseases outpaced those of many other dis-
eases (OECD, 2015a).
A good indicator of acute care quality is the 30-day AMI
case-fatality rate. This measure reflects the processes of
care, such as timely transport of patients and effective
medical interventions. The indicator is influenced by not
only the quality of care provided in hospitals but also dif-
ferences in hospital transfers, average length of stay and
AMI severity.
Figure 8.10 shows the case-fatality rates within 30 days of
admission for AMI when the death occurs in the same hos-
pital as the initial AMI admission. The lowest rate is found
inAustralia at 4.1% and the highest rate is in Mexico at 28.2%,
suggesting AMI patients do not always receive recommended
care. In Mexico, the quality of pre-hospital emergency
medical services is reportedly poor (Peralta, 2006), and the
high rates of uncontrolled diabetes may also be a contribut-
ing factor in explaining the highAMI case-fatality rates (see
indicator “Diabetes care” in Chapter 8) as patients with
diabetes have worse outcomes after AMI compared to
those without diabetes, particularly if the diabetes is poorly
controlled. In Japan, people are less likely to die of heart
disease overall, but are more likely to die once admitted
into hospital for AMI compared to other OECD countries.
One possible explanation is that the severity of patients
admitted to hospital with AMI may be more advanced
among a smaller group of people across the population, but
could also reflect underlying differences in emergency care,
diagnosis and treatment patterns (OECD, 2015b).
Figure 8.11 shows 30-day case fatality rates where fatalities
are recorded regardless of where they occur. This is a more
robust indicator because it records deaths more widely
than the same-hospital indicator, but it requires a unique
patient identifier and linked data which is not available in
all countries. The AMI case-fatality rate ranges from 7.1% in
Canada to 18.8% in Hungary and 19.1% in Latvia.
Case-fatality rates for AMI have decreased substantially
between 2003 and 2013 (Figures 8.10 and 8.11). Across the
OECD, case fatalities fell from 11.2% to 8.0% when consider-
ing same hospital deaths and from 14.3% to 9.5% when
considering deaths occurred in and out of hospital. The
rate of decline was particularly striking in the Slovak
Republic, the Netherlands andAustralia for the first indicator
and in Finland and Poland for the second indicator, with
more than 6% annual average reduction per year compared
to an OECD average of respectively 3 and 4 %. Better access
to high-quality acute care for heart attack, including timely
transportation of patients, evidence-based medical inter-
ventions and high-quality specialised health facilities such
as percutaneous catheter intervention-capable centres
have helped to reduce 30-day case-fatality rates (OECD,
2015a). For example, Korea had higher case-fatality rates
for AMI but in 2006 it has implemented a Comprehensive
Plan for CVD, encompassing prevention, primary care and
acute CVD care (OECD, 2012). Under the Plan, specialised
services were enhanced through a creation of regional
cardio and cerebrovascular centres throughout the country,
and average waiting time from emergency room arrival to
initiation of catheterisation fell from 72.3 in 2010 to
65.8 minutes in 2011, leading to a reduction in case-fatality
(OECD, 2015a).
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Definition and comparability
The case-fatality rate measures the percentage of
people aged 45 and over who die within 30 days
following admission to hospital for a specific acute
condition. Rates based on admission data refer to the
death occurred in the same hospital as the initial
admission. Admissions resulting in a transfer were
excluded for all countries except Australia, Belgium,
Denmark, Hungary, Ireland, Israel, Japan, Luxembourg,
Mexico, Netherlands, Slovak Republic and Sweden.
This exclusion generally increases the rate compared
with those countries which do not exclude these
transfers. Rates based on patient data refer to the
death occurred in the same hospital, a different hos-
pital, or out of hospital.
Rates are age-sex standardised to the 2010 OECD
population aged 45+ admitted to hospital for a specific
acute condition such as AMI and ischemic stroke.HEALTH AT A GLANCE 2015 © OECD 2015138
8. QUALITY OF CARE
Mortality following acute myocardial infarction (AMI)Information on data for Israel: http://oe.cd/israel-disclaimer
8.10. Thirty-day mortality after admission to hospital for AMI based on admission data, 2003 to 2013 (or nearest years)
Note: 95% confidence intervals represented by H. Three-year average for Iceland and Luxembourg.
1. Admissions resulting in a transfer are included.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281135
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8.11. Thirty-day mortality after admission to hospital for AMI based on patient data, 2003 to 2013 (or nearest years)
Note: 95% confidence intervals represented by H. Three-year average for Luxembourg.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281135
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8. QUALITY OF CAREMortality following strokeStroke and other cerebrovascular diseases accounted for
around 7% of all deaths in OECD countries in 2013. Isch-
emic stroke represented around 85% of all cerebrovascular
disease cases. It occurs when the blood supply to a part of
the brain is interrupted, leading to a necrosis (i.e. the cells
that die) of the affected part. Treatment for ischemic stroke
has advanced dramatically over the last decade. Clinical
trials have demonstrated clear benefits of thrombolytic
treatment for ischemic stroke as well as receiving care in
dedicated stroke units to facilitate timely and aggressive
diagnosis and therapy for stroke victims (Hacke et al., 1995;
Seenan et al., 2007).
Figure 8.12 shows the case-fatality rates within 30 days of
admission for ischemic stroke when the death occurred in
the same hospital as the initial stroke admission.
Figure 8.13 shows the case-fatality rate where deaths are
recorded regardless of where they occurred. This indicator
is more robust because it captures fatalities more compre-
hensively. Although more countries can report the more
partial same-hospital measure, an increasing number of
countries are investing in their data infrastructure and are
able to provide more comprehensive measures.
Across OECD countries 8.4% of patients in 2013 died within
30 days in the same hospital in which the initial admission
for ischemic stroke occurred (Figure 8.12). The case-fatality
rates were highest in Mexico (19.5%) and Latvia (18.4%).
Rates were less than 5% in Japan, Korea and the United
States. With the exception of Japan and Korea, countries
that achieve better results for ischemic stroke also tend to
report good case-fatality rates for acute myocardial
infarction (AMI). This suggests that certain aspects of acute
care may be influencing outcomes for both stroke and AMI
patients. By contrast, Japan reports the lowest rates for
ischemic stroke but high case-fatality rates for AMI. This
somewhat paradoxical result requires further investigation
but may be associated with the severity of disease in the
country that is not captured in the data (see indicator “Mor-
tality following acute myocardial infarction” in Chapter 8
for more details).
Across the 19 countries that reported in- and out-of-hospi-
tal case-fatality rates, 10.1% of patients died within 30-days
of being admitted to hospital for stroke (Figure 8.13). This
figure is higher than the same-hospital based indicator
because it captures deaths that occur not just in the same
hospital but also in other hospitals and out-of-hospital.
Between 2003 and 2013, case-fatality rates for ischemic
stroke have decreased substantially (Figures 8.12 and 8.13).
Across the OECD, case fatalities fell from 10.2% to 8.4%
when considering same hospital rates and from 12.7% to
10.1% when considering in- and out-of-hospital rates. The
United Kingdom and the Netherlands for the first indicator
and the United Kingdom, Estonia and Finland for the sec-
ond indicator were able to reduce their rates by an average
annual reduction of more than 6% compared to an OECD
average of respectively 2 and 2.5%. Better access to high-
quality stroke care, including timely transportation of
patients, evidence-based medical interventions and high-
quality specialised facilities such as stroke units have
helped to reduce 30-day case-fatality rates (OECD, 2015).
Despite the progress seen so far, there is still room to
improve implementation of best practice acute care for car-
diovascular diseases including stroke across countries. To
shorten acute care treatment time, targeted strategies can
be highly effective. But to encourage the use of evidence-
based advanced technologies in acute care, wider
approaches are needed. Adequate funding and trained pro-
fessionals should be made available, and health care deliv-
ery systems should be adjusted to enable easy access
(OECD, 2015).
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Definition and comparability
Case-fatality rates are defined in indicator “Mortality
following acute myocardial infarction” in Chapter 8.HEALTH AT A GLANCE 2015 © OECD 2015140
8. QUALITY OF CARE
Mortality following strokeInformation on data for Israel: http://oe.cd/israel-disclaimer
8.12. Thirty-day mortality after admission to hospital for ischemic stroke based on admission data, 2003 to 2013
(or nearest years)
Note: 95% confidence intervals represented by H. Three-year average for Iceland and Luxembourg.
1. Admissions resulting in a transfer are included.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281146
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8.13. Thirty-day mortality after admission to hospital for ischemic stroke based on patient data, 2003 to 2013
(or nearest years)
Note: 95% confidence intervals represented by H. Three-year average for Luxembourg.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281146
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8. QUALITY OF CAREWaiting times for hip fracture surgeryThe main risk factors for hip fracture are associated with
ageing – an increased risk of falling and loss of skeletal
strength from osteoporosis. With increasing life expec-
tancy across most OECD countries, it is anticipated that hip
fracture will become a more significant public health issue
in coming years.
In most instances following hip fracture, surgical interven-
tion is required to repair or replace the hip joint. There is
general consensus that early surgical intervention maxi-
mises patient outcomes and minimises the risk of compli-
cations. General agreement is that surgery should occur
within two days (48 hours) of hospitalisation. Guidelines
in some countries call for even earlier intervention. For
example, the National Institute for Health and Care
Excellence (NICE) clinical guidelines recommend hip fracture
surgery to be performed on the day of hospital admission
or the next day (National Institute for Health and Care
Excellence, 2014).
This is the first time Health at a Glance is reporting on the
time taken to initiate hip fracture surgery after hospital
admission. Timely surgery can be considered an indicator
of the quality of acute care received by patients with hip
fracture.
In 2013, on average across the OECD over 80% of patients
admitted for hip fracture underwent surgery within two
days (Figure 8.14). In Denmark, Iceland and the Netherlands,
the proportion was greater than 95%. Countries with the
lowest proportion of patients operated on within two days of
admission were Spain (43%), Italy (45%) and Portugal (45%).
Many patients were treated sooner than two days following
admission. In the Netherlands and the Czech Republic, for
example, over 40% of patients admitted for hip fracture
underwent surgery on the day of admission.
Figure 8.15 shows the proportion of hip-fracture repairs
occurring within two days of admission in OECD countries
between 2003 and 2013. The OECD average increased from
76% to 81% over that time. The greatest improvement was
observed in Italy, where the proportion increased from 28%
in 2008 to 45% in 2013, and in Israel, where it increased
from 70% in 2003 to 85% in 2013. A policy of comparative
public reporting of hospital indicators, including time to sur-
gery following hip fracture, implemented by Italian authori-
ties may partly explain the improvement observed in that
country. In Canada, the percentage of patients operated on
within the two day benchmark increased from 87% in 2008
to 92% in 2013, but there is considerable variation in this
indicator between provinces and hospitals (CIHI, 2015).
Portugal saw a decline of hip fracture repair within two
days of admission from 57% in 2008 to 45% in 2013.
Time to surgery for hip fracture patients is influenced by
many factors, including hospitals’ surgical theatre capacity,
flow and access. Improvement in timely surgery for patients
with a particular diagnosis or injury (e.g. hip fracture) may be
achieved at the expense of timeliness in others (e.g. hip or
knee replacements).
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Definition and comparability
This indicator is defined as the proportion of patients
aged 65 years and over admitted to hospital in a
specified year with a diagnosis of upper femur
fracture, who had surgery initiated within two
calendar days of their admission to hospital. Data are
also provided for the proportion of those patients who
had surgery within one day of their admission to
hospital, and for patients who had surgery on the
same day as their hospital admission. While the
capacity to capture time of admission and surgery in
hospital administrative data varies across countries,
most countries are able to distinguish between
patients who stay overnight and have surgery within
24 hours from patients who have surgery on the day of
admission. Some countries supplied results for surgery
within two calendar days only.HEALTH AT A GLANCE 2015 © OECD 2015142
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Waiting times for hip fracture surgeryInformation on data for Israel: http://oe.cd/israel-disclaimer
8.14. Hip fracture surgery initiation after admission to hospital, 2013 (or nearest year)
Note: Three-year average for Iceland.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281152
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8.15. Hip fracture surgery initiation after admission to hospital, 2003 to 2013 (or nearest years)
Note: Three-year average for Iceland.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281152
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8. QUALITY OF CARESurgical complicationsPatient safety remains one of the most prominent issues in
health policy and public debate. High rates of error during
the delivery of medical care have been demonstrated
repeatedly, including the landmark report by the Institute
of Medicine which estimated that more people die from
medical errors than from traffic injuries or breast cancer
(Kohn et al., 2000). Robust comparison of performance with
peers is fundamental to securing improvement. Two types
of patient safety event can be distinguished for this purpose:
never events, those events that should never occur, such as
failure to remove surgical foreign bodies at the end of a
procedure; and adverse events, such as post-operative sepsis,
which can not be avoided in all cases given the high-risk
nature of some procedures, although increased incidence at
an aggregate level may indicate a systemic problem.
Figure 8.16 shows rates for two related adverse events,
pulmonary embolism (PE) or deep vein thrombosis (DVT)
after hip or knee replacement surgery. These are high risk
procedures most commonly associated with postoperative
DVT and PE complications. PE and DVT cause unnecessary
pain and in some cases death, but can be prevented by anti-
coagulants and other measures before, during and after
surgery. Figure 8.17 shows rates for another adverse event,
sepsis after abdominal surgery. Abdominal surgery is also a
high risk procedure. Likewise, sepsis after surgery, which
may lead to organ failure and death, can in many cases be
prevented by prophylactic antibiotics, sterile surgical tech-
niques and good postoperative care. Figure 8.18 illustrates a
never event (events that should never occur), rates of foreign
body left in during procedure.Themost common risk factors
for this never event are emergencies, unplanned changes in
procedure, patient obesity and changes in the surgical
team; preventive measures include counting instruments,
methodical wound exploration and effective communica-
tion among the surgical team.
The left panel of Figures 8.16, 8.17 and 8.18. shows the rate
of the three respective postoperative complications based
on the surgical admission, the hospital admission when
the surgery took place. The right panel of these figures
shows rates based on the surgical admission and all subse-
quent re-admissions to hospital within 30 days, whether at
the same hospital or in another hospital. The use of a
unique patient identifier is required to calculate the indica-
tor rates in the right panel, which is currently not available
in some countries.
Caution is needed in interpreting the extent to which these
indicators accurately reflect international differences in
patient safety rather than differences in the way that coun-
tries report, code and calculate rates of adverse events (see
“Definition and comparability” box).
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Definition and comparability
Surgical complications are defined as the number of
discharges with ICD codes for complication in any
secondary diagnosis field for the “surgical admission”
and any diagnosis field for any subsequent related re-
admission within 30 days, divided by the total number
of discharges for patients aged 15 and older. Contrary
to the data presented in Health at a Glance 2013, the
indicator rates have not been adjusted by the average
number of secondary diagnoses, given a strong posi-
tive correlation between the number of secondary
diagnoses and indicator rates reported by countries
was not evident in the most recent data.
A fundamental challenge in international comparison
of patient safety indicators centres on the quality of
the underlying data. Variations in how countries
record diagnoses and procedures and define hospital
admissions can affect calculation of rates. For exam-
ple differences in the use of the present on admission
flag for diagnosis and disease (e.g. ICD-9-CM and ICD-
10-AM) and procedure classification systems are
known to affect data comparability. In some cases,
higher adverse event rates may signal more developed
patient safety monitoring systems and a stronger
patient safety culture rather than worse care. Recent
analysis of dispersion of postoperative PE or DVT rates
across hospitals within OECD countries revealed
extremely large variations in reported rates, including
implausibly high and low rates for hospitals in the
same country even after risk adjustment. Hence, dif-
ferences in the national rates presented here are likely
to reflect differences in coding and recording practices
both between and within countries and mask true
differences in care quality. There is a need for greater
consistency in reporting of patient safety events
across countries and significant scope exists for
improved data quality within national patient safety
programs.Wider analysis of coding comparability will
inform future strategies for improvement.HEALTH AT A GLANCE 2015 © OECD 2015144
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Surgical complicationsInformation on data for Israel: http://oe.cd/israel-disclaimer
8.16. Postoperative pulmonary embolism (PE) or deep vein thrombosis (DVT) in hip and knee surgeries, 2013
(or nearest year)
Note: Rates have not been adjusted by the average number of secondary diagnoses.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281167
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8.17. Postoperative sepsis in abdominal surgeries 2013 (or nearest year)
Note: Rates have not been adjusted by the average number of secondary diagnoses.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281167
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8.18. Foreign body left in during procedure, 2013 (or nearest year)
Note: Rates have not been adjusted by the average number of secondary diagnoses.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281167
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8. QUALITY OF CAREObstetric traumaPatient safety during childbirth can be assessed by looking
at potentially avoidable tearing of the perineum during
vaginal delivery. Tears that extend to the perineal muscles
and bowel wall require surgery. They are more likely to
occur in the case of first vaginal delivery, high baby birth
weight, labour induction, occiput posterior baby position,
prolonged second stage of labour and instrumental deliv-
ery. Possible complications include continued perineal pain
and incontinence.
These types of tears are not possible to prevent in all cases,
but can be reduced by employing appropriate labour man-
agement and high quality obstetric care. Hence, the propor-
tion of deliveries involving higher degree lacerations is a
useful indicator of the quality of obstetric care. Obstetric
trauma indicators have been used by the US Joint Commis-
sion as well as by different international quality initiatives
seeking to assess and improve obstetric care (AHRQ, 2006).
Episiotomy is a surgical incision of the perineum per-
formed to widen the vaginal opening for the delivery of an
infant. Wide variation in the use of episiotomy during vag-
inal deliveries currently exists across Europe, ranging from
around 70% of births in Portugal and Poland in 2010 to less
than 10% in Sweden, Denmark and Iceland (Euro-Peristat,
2013). The selective use of episiotomy to decrease severe
perineal lacerations during delivery is controversial, with
claims that there are currently inadequate data to properly
evaluate safety and effectiveness considerations (Lappen
and Gossett, 2010).
Obstetric trauma indicators are considered relatively reli-
able and comparable across countries, particularly given
they are less sensitive to variations in secondary diagnosis
coding practices across countries. Nevertheless, differ-
ences in the consistency with which obstetric units report
these complications may complicate international compar-
ison. Fear of litigation, for example, may cause under-
reporting; conversely systems that rely on specially trained
administrative staff to identify and code adverse events
from patients’ clinical records may produce more reliable
data.
Obstetric trauma with instrument refers to deliveries using
forceps or vacuum extraction. As the risk of a perineal lac-
eration is significantly increased when instruments are
used to assist the delivery, rates for this patient population
are reported separately. The average rate of obstetric
trauma with instrument (6.0 per 100 instrument-assisted
vaginal delivery) across 21 OECD countries in 2013 was
nearly 4 fold the rate without instrument (1.6 per
100 vaginal delivery without instrument assistance). The
rate of obstetric trauma after vaginal delivery with instru-
ment (Figure 8.19) shows high variation across countries.
Reported rates vary from below 2% in Poland, Slovenia, Italy
and Israel to more than 10% in the United States, Sweden,
Denmark and Canada.
Rates of obstetric trauma after vaginal delivery without
instrument (Figure 8.20) display equally large variation
across countries, ranging from 0.3% or less in Poland and
Slovenia to 2.8% or above in the United Kingdom, Sweden
and Canada.There is a strong relationship between the two
indicators, with Poland and Slovenia reporting the lowest
rates and Sweden and Canada reporting amongst the high-
est rates for both indicators.
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Definition and comparability
The two obstetric trauma indicators are defined as the
proportion of instrument assisted/non-assisted vagi-
nal deliveries with third- and fourth-degree obstetric
trauma codes in any diagnosis and procedure field.
Therefore, any differences in the definition of princi-
pal and secondary diagnoses have no influence on the
calculated rates. Several differences in data reporting
across countries may influence the calculated rates of
obstetric patient safety indicators. These relate pri-
marily to differences in coding practice and data
sources. Some countries report the obstetric trauma
rates based on administrative hospital data and oth-
ers based on obstetric register data. There is some evi-
dence that registries produce higher quality data and
report a greater number of obstetric trauma events
compared to administrative datasets (Baghestan et al.,
2007).HEALTH AT A GLANCE 2015 © OECD 2015146
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Obstetric traumaInformation on data for Israel: http://oe.cd/israel-disclaimer
8.19. Obstetric trauma, vaginal delivery with instrument, 2013 (or nearest year)
1. Based on registry data.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281174
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8.20. Obstetric trauma, vaginal delivery without instrument, 2013 (or nearest year)
1. Based on registry data.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281174
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8. QUALITY OF CARECare for people with mental health disordersThe burden of mental illness is substantial, affecting an
estimated one in four of the OECD population at any time,
and one in two across the life course (OECD, 2014a). High
quality, timely care has the potential to improve outcomes
and may help reduce suicide and excess mortality for indi-
viduals with psychiatric disorders.
High quality care for mental disorders in inpatient settings
is vital. Figure 8.21 shows rates of inpatient suicide
amongst all psychiatric hospital admissions. Inpatient sui-
cide is a ‘never event’, which should be closely monitored
as an indication of how well inpatient settings are able to
keep patients safe from harm. Most countries report rates
below 0.1 per 100 patients; Denmark and Estonia are excep-
tions with rates of 0.1 and 0.3 respectively. Steps to prevent
inpatient suicide include identification and removal of
likely opportunities for self-harm, risk assessment of
patients, monitoring and appropriate treatment plans.
Suicide rate after discharge can be an indicator of the qual-
ity of care in the community, and co-ordination between
inpatient and community settings. The risk of suicide in
the first year after discharge from psychiatric inpatient
care is much greater than for the general population. Sui-
cide rate amongst patients who had been hospitalised in
the previous year was 0.43 per 100 patients, compared to a
suicide rate of 0.01 per 100 for the general population in
2012 across OECD countries for which these data are avail-
able. Patients with a psychiatric illness are particularly at
risk immediately following discharge from hospital; in all
countries suicide within 30 days of discharge amounted to
at least one quarter of all suicides within the first year fol-
lowing discharge (Figure 8.22). Good discharge planning
and follow-up, and enhanced levels of care immediately
following discharge can help reduce suicide in the high-risk
days immediately following discharge (OECD, 2014a).
Individuals with a psychiatric illness have a higher mortal-
ity rate than the general population. An ‘excess mortality’
value that is greater than one implies that people with
mental disorders face a higher risk of death than the rest of
the population. Figures 8.23 and 8.24 show the excess mor-
tality for schizophrenia and bipolar disorder, which is
above two in all countries. A higher rate of physical illness
and chronic disease related to risk factors such as smoking,
drug and alcohol abuse, side effects of psychotropic treat-
ment and poor physical health care and increased risk of
suicide contribute to excess mortality. A multifaceted
disease-related approach is needed to reduce this excess
mortality, including primary care prevention of physical ill
health among people with mental disorders, better integra-
tion of physical and mental health care, behavioural inter-
ventions, and changing professional attitudes. For
example, Sweden monitors the use of inpatient physical
care for patients with a mental disorder diagnosis that
could have been avoided if primary care and/or primary or
secondary prevention was sufficient (OECD, 2014a; OECD,
2014b).
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Definition and comparability
The inpatient suicide indicator is composed of a
denominator of patients discharged with a principal
diagnosis or first two listed secondary diagnosis code
of mental health and behavioural disorders (ICD-10
codes F10-F69 and F90-99) and a numerator of the
number of patients who committed “suicide” (ICD-10
codes: X60-X84). There are often fewer than ten inpa-
tient suicides in a given year, meaning that reported
rates can vary. Where possible a 3-year average has
been calculated to give more stability to the indicator.
This was not possible for the Czech Republic, Portugal,
and Switzerland. The data should be interpreted with
caution due to a very small number of cases.
Suicide within 30 days and within one year of dis-
charge is established by linking discharge following
hospitalisation with a principal diagnosis or first two
listed secondary diagnosis code of mental health and
behavioural disorders (ICD-10 codes F10-F69 and
F90-99), with suicides recorded in death registries
(ICD-10 codes: X60-X84). In cases with several admis-
sions during the reference year, the follow-up period
starts from the last discharge.
For the excess mortality indicators the numerator is
the overall mortality rate for persons aged between 15
and 74 years old ever diagnosed with schizophrenia or
bipolar disorder. The denominator is the overall mor-
tality rate for the general population aged between 15
and 74 years old. The relatively small number of people
with bipolar disorder dying in any given year can
cause substantial variations from year to year in some
countries. The available data in most countries did
not allow the calculation of 2-year averages.
The data have been age-sex standardised to the 2010
OECD population structure, to remove the effect of
different population structures across countries.HEALTH AT A GLANCE 2015 © OECD 2015148
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Care for people with mental health disordersInformation on data for Israel: http://oe.cd/israel-disclaimer
8.21. Inpatient suicide amongst patients with
a psychiatric disorder, 2013 (or latest year)
Note: Three-year average for most countries.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281184
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8.22. Suicide following hospitalisation for a psychiatric
disorder, within 30 days and one year of discharge, 2012
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281184
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8.23. Excess mortality from schizophrenia, 2013
(or latest year)
Note: Excess mortality is compared to the mortality rate for the general
population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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8.24. Excess mortality from bipolar disorder, 2013
(or latest year)
Note: Excess mortality is compared to the mortality rate for the general
population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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8. QUALITY OF CAREScreening, survival and mortality for cervical cancerCervical cancer is highly preventable if precancerous
changes are detected and treated before progression
occurs. The main cause of cervical cancer, which accounts
for approximately 95% of all cases, is exposure to the
human papilloma virus (HPV) through sexual activity
(IARC, 2005).
Countries follow different policies with regards to the pre-
vention and early diagnosis of cervical cancer. About half of
OECD countries have cervical cancer screening organised
through population-based programmes but their periodicity
and target age groups vary (OECD, 2013). Some countries
with low cervical cancer incidence such as Israel and
Switzerland do not have an organised screening pro-
gramme but women in the eligible age group can have a
Pap smear test performed every three years for free. WHO
recommends HPV vaccinations as part of national immun-
isation programmes, primarily for girls aged 9-13 years, in
countries where the prevention of cervical cancer is a pub-
lic health priority, the introduction is feasible and finan-
cially sustainable, and cost-effectiveness has been
evaluated (WHO, 2014). Nowadays, most OECD countries
have HPV vaccination programmes.
Screening rates for cervical cancer ranged from 20.7% in
Mexico to 84.5% in the United States in 2013 and have
increased from 57.0% to 61.6% on average across OECD
countries over the past decade (Figure 8.25). The coverage
increase was particularly large in Korea where the screen-
ing programme was rolled out nationwide in the mid-
2000s. In about half of OECD countries, however, screening
coverage declined, which may be related to the introduc-
tion of HPV vaccinations, starting from the late 2000s
(OECD, 2013).
Cancer survival is one of the key measures of the effective-
ness of cancer care systems, taking into account both early
detection of the disease and the effectiveness of treatment.
Five-year relative cervical cancer survival ranges widely
from 45.3% in Chile to 81.2% in Norway in recent years
(Figure 8.26). Some countries with relatively high screening
coverage such as the United States, Austria, the United
Kingdom, New Zealand and Ireland have lower survival,
but four of the five countries have lowmortality. During the
past decade, five-year relative survival for cervical cancer
improved in many countries.
Mortality rates reflect the effect of cancer care over the past
years and the impact of screening, as well as changes in
incidence. The mortality rates for cervical cancer declined
in most OECD countries between 2003 and 2013
(Figure 8.27). In Greece, however, the mortality rate from
cervical cancer increased substantially by 47% during the
same period, although it is still below the OECD average.
The incidence is low and decreasing over time and it is
likely that Greece can control the increasing burden of cer-
vical cancer by providing more effective cervical cancer
treatment.
References
Allemani, C. et al. (2015), “Global Surveillance of Cancer
Survival 1995-2009: Analysis of Individual Data for
25 676 887 Patients from 279 Population-based Registries
in 67 Countries (CONCORD-2)”, The Lancet, Vol. 385,
pp. 977-1010.
IARC – International Agency for Research on Cancer (2005),
“Cervix Cancer Screening”, IARC Handbooks of Cancer Pre-
vention, Vol. 10, International Agency for Research on
Cancer, Lyon.
OECD (2013), Cancer Care: Assuring Quality to Improve Sur-
vival, OECD Publishing, Paris, http://dx.doi.org/10.1787/
9789264181052-en.
WHO (2014), “Human Papillomavirus Vaccines: WHO Posi-
tion Paper, October 2014”, Weekly Epidemiological Record,
No. 43, 89, 465–492, Geneva.
Definition and comparability
Screening rates are based on surveys or encounter
data, which may influence the results. Survey-based
results may be affected by recall bias. Programme data
are often calculated for monitoring national screening
programmes and differences in target population and
screening frequency may also lead to variations in
screening coverage across countries.
Relative survival is the ratio of the observed survival
experienced by cancer patients over a specified period
of time after diagnosis to the expected survival in a
comparable group from the general population in
terms of age, sex and time period. Survival data for
Chile, Germany and Italy are based on a sample of
patients. The number of countries which monitor and
report cancer survival has been increasing in recent
years and an international study (Allemani et al.,
2015) also shows that a wide range of countries have
cancer registries which enable international compari-
sons of cancer survival.
Countries use either period analysis or cohort analysis
to calculate cancer survival. Period analysis gives an
up-to-date estimate of cancer patient survival using
more recent incidence and follow-up periods than
cohort analysis which uses survival information of a
complete five-year follow-up period. The reference
periods for diagnosis and follow-up years vary across
countries.
Cancer survival presented have been age-standardised
using the International Cancer Survival Standard
(ICSS) population.
See indicator “Mortality from cancer” in Chapter 3 for
definition, source and methodology underlying cancer
mortality rates.HEALTH AT A GLANCE 2015 © OECD 2015150
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Screening, survival and mortality for cervical cancerInformation on data for Israel: http://oe.cd/israel-disclaimer
8.25. Cervical cancer screening in women aged 20-69,
2003 to 2013 (or nearest years)
1. Programme. 2. Survey. * Three-year average.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281196
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8.26. Cervical cancer five-year relative survival, 1998-2003
and 2008-2013 (or nearest periods)
1. Period analysis. 2. Cohort analysis. 3 Different analysis methods used
for different years. * Three-period average. 95% confidence intervals
represented by H.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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8. QUALITY OF CAREScreening, survival and mortality for breast cancerBreast cancer is the most prevalent form of cancer in
women across OECD countries. One in nine women will
have breast cancer at some point in their life and one in
thirty will die from the disease. Risk factors that increase a
person's chance of getting this disease include age, family
history of breast cancer, genetic predisposition, reproduc-
tive factors, oestrogen replacement therapy, and lifestyles
including obesity, physical inactivity, diet and alcohol con-
sumption.
Most OECD countries have adopted breast cancer screening
programmes as an effective way for detecting the disease
early, though the periodicity and population target groups
vary across countries (OECD, 2013). Due to recent progress
in treatment outcomes and concerns about false-positive
results, over-diagnosis and overtreatment, breast cancer
screening recommendations have been re-evaluated in
recent years. Taking account of recent research findings,
WHO recommends organised population-based mammog-
raphy screening if women are able to make an informed
decision based on the benefits and risks of mammography
screening (WHO, 2014).
Screening rates ranged from less than 20% in Mexico to
over 80% in Finland, Slovenia, Denmark and the United
States in 2013 (Figure 8.28). Screening coverage increased
substantially among countries with low rates a decade ago.
Mexico and Chile had an increase of more than ten-fold,
Korea an over four-fold increase, and the Slovak Republic
and Lithuania a three-fold rise. On the other hand, coun-
tries that had the highest screening rates in the early 2000s
experienced some reductions, including Finland, the
United States, the Netherlands, Ireland and Norway. In
Ireland, the screening programme, which was commenced
on a phased basis in 2000, completed its nationwide roll-
out in 2009, but it is still at a stage too early to evaluate the
coverage trend over time.
Breast cancer survival reflects early diagnosis as well as
improved treatments. All OECD countries have attained
five-year relative breast cancer survival of 80% except Esto-
nia, Poland and Chile (Figure 8.29). Relative survival of peo-
ple with cervical and colorectal cancers is also the lowest
for Poland and Chile (see indicators “Screening, survival
and mortality for cervical cancer” and “Survival and mor-
tality for colorectal cancer”). In both countries, access to
care is limited due to fewer numbers of cancer care centres
and radiotherapy facilities. In Chile, some cancer drugs and
other medical technologies are not widely available, and
there are not enough specialised professionals, resulting in
a long waiting time for cancer treatment (OECD, 2013).
Over the last decade, the five-year relative breast cancer
survival has improved in all OECD countries. Relative survival
has increased considerably in some Eastern European coun-
tries such as Estonia, the Czech Republic and Latvia,
although survival after breast cancer diagnosis is still
below the OECD average.The improvement may be related to
strengthening of cancer care governance in these countries.
For instance, the Czech Republic intensified its effort to detect
breast cancer patients early through the introduction of a
screening programme in 2002 and implemented a National
Cancer Control Programme in 2005 to improve the quality
of cancer care and cancer survival. Cancer care delivery
was reorganised by reducing the number of comprehensive
cancer centres while aiming to optimise the population
coverage of each centre, and skilled professionals and neces-
sary investment were allocated at each centre. The current
cancer care delivery model is considered to be well organised
and distributed adequately around the country, and, partly
due to the more equal access, variations in cancer survival
across regions have been reduced (OECD, 2013; OECD, 2014).
Mortality rates have declined in most OECD countries over
the past decade (Figure 8.30). The reduction is a reflection
of improvements in early detection and treatment of breast
cancer. Improvements were substantial in the Czech
Republic, Norway and the Netherlands with a decline of
over 20% in a decade. Denmark also reported a consider-
able decline, but its mortality rate was still the highest in
2013. On the other hand, in Korea, Turkey and Japan, the
mortality rate from breast cancer increased over the past
decade, although it remains the lowest among OECD coun-
tries, and the incidence of breast cancer has doubled or
more in the past decade.
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Definition and comparability
Screening rates and survival are defined in indicator
“Screening, survival and mortality for cervical cancer”
in Chapter 8. See indicator “Mortality from cancer” in
Chapter 3 for definition, source and methodology
underlying cancer mortality rates.HEALTH AT A GLANCE 2015 © OECD 2015152
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Screening, survival and mortality for breast cancerInformation on data for Israel: http://oe.cd/israel-disclaimer
8.28. Mammography screening in women aged 50-69,
2003 to 2013 (or nearest years)
1. Programme. 2. Survey. * Three-year average.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281202
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8.29. Breast cancer five-year relative survival, 1998-2003
and 2008-2013 (or nearest periods)
1. Period analysis. 2. Cohort analysis. 3 Different analysis methods used
for different years. * Three-period average. 95% confidence intervals
represented by H.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281202
0 20 40 60 80 100
1998-20032008-2013
Age-standardised survival (%)
Estonia3
Poland1
Chile2
Czech Rep.2
United Kingdom2
Ireland1
Austria2
Slovenia1
France2
Latvia2
OECD22
Netherlands2
Germany1
Italy1
Korea1
Belgium1
New Zealand
Denmark3
Iceland*2
Japan2
Canada2
Israel2
Portugal2
Australia1
Finland1
Norway1
United States2
Sweden2
8.30. Breast cancer mortality in women, 2003 to 2013 (or nearest years)
* Three-year average.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281202
0
5
10
15
20
25
30
35
40
45
2003 2013
Age-standardised rates per 100 000 women
Ko
rea
Tu
rke
y
Ja
pa
n
Me
xic
o
Co
lom
bia Ch
ile
Br
az
il
Co
sta
 R
ica
Sp
ain
No
rw
ay
Po
rtu
ga
l
So
uth
 Af
ric
a
Fin
lan
d
Sw
ed
en
Au
str
ali
a
Un
ite
d S
tat
es
Po
lan
d
OE
CD
34
Ca
na
da
Cz
ec
h R
ep
.
Lit
hu
an
ia
Gr
ee
ce
Sw
itz
erl
an
d
Au
str
ia
Ita
ly
La
tvi
a
Ru
ss
ian
 Fe
d.
Slo
va
k R
ep
.
Fra
nc
e
Es
ton
ia
Ne
w 
Ze
ala
nd
Lu
xe
mb
ou
rg*
Un
ite
d K
ing
do
m
Ge
rm
an
y
Isr
ae
l
Ne
the
rla
nd
s
Ice
lan
d*
Slo
ve
nia
Ire
lan
d
Be
lgi
um
Hu
ng
ary
De
nm
arkHEALTH AT A GLANCE 2015 © OECD 2015 153
8. QUALITY OF CARESurvival and mortality for colorectal cancerColorectal cancer is the third most commonly diagnosed
form of cancer after prostate and lung cancers for men, and
the second most common cancer after breast cancer for
women, across OECD countries. Colorectal cancer incidence
is high in Korea, the Slovak Republic, Hungary, Denmark and
the Netherlands at 40 or more cases per 100 000 population
while it is low in Mexico, Greece, Chile and Turkey at less
than half this rate. Incidence is significantly higher for men
than women across countries. There are several factors
that place certain individuals at increased risk for the dis-
ease, including age, ulcerative colitis, a personal or family
history of colorectal cancer or polyps, and lifestyle factors
such as a diet high in fat and low in fibre, lack of physical
activity, obesity, and tobacco and alcohol consumption.
Following screening for breast and cervical cancers,
colorectal cancer screening has become available, and an
increasing number of countries have introduced free pop-
ulation-based screening, targeting people in their 50s
and 60s (OECD, 2013). Partly because of uncertainties about
the cost-effectiveness of screening (Lansdorp-Vogelaar et
al., 2010), countries are using different methods (i.e. faecal
occult blood test, colonoscopy and flexible sigmoidoscopy).
Multiple methods are also available within the screening
programme in some countries. In most countries that
provide faecal occult blood test, screening is available every
two years.The screening periodicity schedule is less frequent
with colonoscopy and flexible sigmoidoscopy, generally
every ten years, making it difficult to compare screening
coverage across countries.
Advances in diagnosis and treatment of colorectal cancer
including improved surgical techniques, radiation therapy
and combined chemotherapy and their wider and timelier
access have contributed to increased survival over the last
decade. All OECD countries showed improvement in five-
year relative survival for colorectal cancer. On average, five-
year colorectal cancer survival improved from 55.8% to
62.2% for people with colorectal cancer during 1998-2003 to
2008-2013 respectively (Figure 8.31). Poland, Estonia and
the Czech Republic also had a considerable improvement,
but cancer survival in these countries is still the lowest
among OECD countries at less than 55%. Korea and Israel
had the highest survival at over 70%.
Inmost OECD countries, colorectal cancer survival is higher
for women but in Chile, Korea, Israel, Japan, Portugal, Austria
and the Netherlands, men have a slightly higher survival
(Figure 8.32). The gender difference is the largest in Estonia
with the five-year relative survival of 48.4% for males and
55.9% for females. Slovenia, Latvia and Sweden also have a
comparatively large difference.
Most countries experienced a decline in mortality of
colorectal cancer in recent years, with the average rate
across OECD countries falling from 27.4 to 24.2 deaths per
100 000 population between 2003 and 2013 (Figure 8.33).
The decline was particularly large in the Czech Republic,
Austria and Australia with a reduction of over 25%. The
main exceptions to this general trend were Turkey, Brazil,
Chile and Mexico where the mortality rate from colorectal
cancer increased by more than 10% over the last decade,
although the rate remains much lower than the OECD aver-
age. Despite some progress, Central and Eastern European
countries, particularly Hungary, the Slovak Republic, Slovenia
and the Czech Republic, continue to have higher mortality
rates than other OECD countries.
Across countries, colorectal cancer continues to be an
important cause of cancer death for both men and women
(see indicator “Mortality from cancer” in Chapter 8) and
countries will need to make further effort to promote not
only early diagnosis and effective treatment but also
healthy lifestyles to reduce its risk factors (see Chapter 8
“Non-medical determinants”).
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Definition and comparability
Survival and mortality rates are defined in indicator
“Screening, survival and mortality for cervical cancer”
in Chapter 8. See indicator “Mortality from cancer” in
Chapter 3 for definition, source and methodology
underlying cancer mortality rates. Survival and mor-
tality rates of colorectal cancer are based on ICD-10
codes C18-C21 (colon, rectosigmoid junction, rectum,
and anus).HEALTH AT A GLANCE 2015 © OECD 2015154
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Survival and mortality for colorectal cancerInformation on data for Israel: http://oe.cd/israel-disclaimer
8.31. Colorectal cancer, five-year relative survival,
1998-2003 and 2008-13 (or nearest periods)
1. Period analysis, 2. Cohort analysis. 95% confidence intervals
represented by H.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281219
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8.32. Colorectal cancer, five-year relative survival
by gender, 2008-13 (or nearest periods)
1. Period analysis. 2. Cohort analysis. 3 Different analysis methods used
for different years. * Three-period average. 95% confidence intervals
represented by H.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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8. QUALITY OF CAREChildhood vaccination programmeAll OECD countries have established vaccination pro-
grammes based on their interpretation of the risks and
benefits of each vaccine. Figures 8.34 and 8.35 show that
the overall vaccination of children against measles and
diphtheria, tetanus and pertussis (DTP) is high in OECD
countries. On average, 95% of children receive the recom-
mended DTP vaccination and 94% receive measles vaccina-
tions in accordance with national immunisation schedules.
Rates for DTP vaccinations are below 90% only in Indonesia,
Austria, Mexico, India and South Africa. Rates for measles
vaccinations are below 90% in Denmark, France, Mexico,
Indonesia, Austria, India and South Africa.
While national coverage rates are high in many countries,
some parts of the population remain exposed to certain
diseases. For example, theUnited States reported 189measles
cases between 1 January and 18 Septembre 2015. Most of
these cases were linked to an amusement park in
California. The Centers for Disease Control and Prevention
reported that most of the measles cases in 2015 were in
unvaccinated people. In the previous year, over 650 cases of
measles were reported in the United States, the highest
number of cases since measles elimination was docu-
mented in 2000. Many of the cases were associated with a
large outbreak that originated in the Philippines (Centers
for Disease Control and Prevention, 2015). In July 2015, the
first death related to measles since 2003 was reported in
the United States (Washington State Department of Health,
2015).
Parts of Europe also reported large number of measles
cases in 2015. During the 12 months to June 2015, more
than 4 000 cases were reported across 30 countries. More
than half the cases were in Germany, with over 400 cases
reported in Italy. The measles-related death of an
18-month toddler in Germany was reported in February
2015. Most of the cases across Europe were among unvacci-
nated people (European Centre for Disease Prevention and
Control, 2015). Catch-up programmes in older children may
be needed to avoid the risk of, or respond to, measles out-
breaks. Such a campaign was conducted in the United
Kingdom in 2013.
Figure 8.36 shows the percentage of children aged one year
vaccinated for hepatitis B. The hepatitis B virus is transmit-
ted by contact with blood or body fluids of an infected per-
son. A small proportion of infections become chronic, and
these people are at high risk of death from cancer or cirrhosis
of the liver. A vaccination has been available since 1982 and
is considered to be 95% effective in preventing infection
and its chronic consequences. Since a high proportion of
chronic infections are acquired during early childhood, the
WHO recommends that all infants should receive their first
dose of hepatitis B vaccine as soon as possible after birth,
preferably within 24 hours (WHO, 2015).
Most countries have followed theWHO recommendation to
incorporate hepatitis B vaccine as an integral part of their
national infant immunisation programme. Across the
OECD, the average immunisation coverage for hepatitis B
for children aged one year old is 92%. In countries such as
China, the Czech Republic and Korea, it reaches 99%. How-
ever, a number of countries do not require children to be
vaccinated, and consequently the rates for these countries
are significantly lower than other countries. For example,
in Denmark, Sweden and the United Kingdom, vaccination
against hepatitis B is not part of the general infant vaccina-
tion programme, but is provided to high-risk groups such as
children with mothers who are infected by the hepatitis B
virus. Other OECD countries that do not include vaccination
against hepatitis B in their infant programmes are Iceland,
Finland, Hungary, Japan, Slovenia and Switzerland. In
Canada, not all jurisdictions immunise infants against
hepatitis B, with some doing this at school age.
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Definition and comparability
Vaccination rates reflect the percentage of children
that receives the respective vaccination in the recom-
mended timeframe. The age of complete immunisation
differs across countries due to different immunisation
schedules. For those countries recommending the
first dose of a vaccine after age one, the indicator is
calculated as the proportion of children less than two
years of age who have received that vaccine. Thus,
these indicators are based on the actual policy in a
given country.
Some countries administer combination vaccines (e.g.
DTP for diphtheria, tetanus and pertussis) while oth-
ers administer the vaccinations separately. Some
countries ascertain vaccinations based on surveys
and others based on encounter data, which may influ-
ence the results.HEALTH AT A GLANCE 2015 © OECD 2015156
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Childhood vaccination programmeInformation on data for Israel: http://oe.cd/israel-disclaimer
8.34. Vaccination against diphteria, tetanus and
pertussis, children aged 1, 2013
Source: WHO/UNICEF.
1 2 http://dx.doi.org/10.1787/888933281226
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8.35. Vaccination against measles, children aged 1, 2013
Source: WHO/UNICEF.
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8.36. Vaccination against hepatitis B, children aged 1, 2013
Source: WHO/UNICEF.
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8. QUALITY OF CAREInfluenza vaccination for older peopleInfluenza is a common infectious disease affecting 5%-10%
of adults and 20%-30% of children. There are an estimated
3 to 5 million cases of severe influenza-related illness
worldwide each year, and 250 000 to 500 000 deaths (WHO,
2014). Influenza can also have a major impact on health
care systems. In the United States, it is estimated that each
year, more than 200 000 people are hospitalised for respira-
tory and heart condition illnesses associated with seasonal
influenza virus infections (Thompson et al., 2004). At certain
times of the year, influenza can place health systems under
significant stress. For example, in Ontario, Canada, the
average annual rate of emergency department visits
attributable to seasonal influenza is 500 per 100 000 popu-
lation. This rate increased to an estimated 1 000 per
100 000 population during the H1N1 pandemic in 2009
(Schanzer et al., 2013).
In 2003, countries participating in theWorld Health Assem-
bly committed to the goal of attaining vaccination coverage
against influenza of at least 50% of the elderly population
by 2006 and 75% by 2010. Figure 8.37 shows that in 2013, the
OECD average influenza vaccination rate for people aged 65
and over was 48%. Vaccination rates are as low as 1.1% in
Estonia, where influenza vaccination is recommended but
not free. Only four countries have attained the 75% target:
Mexico, Korea, Chile and the United Kingdom. Australia
came close to meeting the target.
Figure 8.38 indicates that between 2003 and 2013, the vacci-
nation rate against influenza among the elderly population
has remained stable on average among the group of OECD
countries that have trend data over this period, but with no
uniform trend across countries. In some countries, such as
New Zealand, Israel, Germany, Denmark, the Czech Republic
and the United Kingdom, the percentage of the population
aged 65 and over vaccinated against influenza has
increased, while it has come down in other countries such
as the Netherlands, Spain, France, the Slovak Republic and
Slovenia.
In June 2009, the WHO declared an influenza pandemic.
The H1N1 influenza virus (also referred to as “swine flu”)
infected an estimated 11% to 18% of the global population
(Kelly et al., 2011). Mexico was at the centre of the pan-
demic, being among the first countries where swine flu was
detected and also where mortality rates were reportedly
higher than those in many other countries. The high rate of
seasonal vaccinations that are still being observed in Mexico
may come as a result of the H1N1 experiences in that coun-
try. In other countries, however, the take-up rate of H1N1
vaccine was lower than expected, despite the vaccine being
included in most 2009-10 vaccination programmes. In part,
this may be due to the easing of concerns about the threat
of H1N1 amongst the general population by the time the
vaccine became available. Studies have shown that the
most important determinant for individuals to take-up
H1N1 vaccine was previous exposure to seasonal flu vaccine,
leading some researchers to argue that higher vaccination
rates for seasonal flu may help take-up during potential
future pandemics (Nguyen et al., 2011).
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Definition and comparability
Influenza vaccination rate refers to the number of
people aged 65 and older who have received an annual
influenza vaccination, divided by the total number of
people over 65 years of age. In some countries, the
data are for people over 60 years of age. The main lim-
itation in terms of data comparability arises from the
use of different data sources, whether survey or pro-
gramme, which are susceptible to different types of
errors and biases. For example, data from population
surveys may reflect some variation due to recall errors
and irregularity of administration.HEALTH AT A GLANCE 2015 © OECD 2015158
8. QUALITY OF CARE
Influenza vaccination for older peopleInformation on data for Israel: http://oe.cd/israel-disclaimer
8.37. Influenza vaccination coverage, population aged 65 and over, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281235
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8.38. Influenza vaccination coverage, population aged 65 and over, 2003 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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8. QUALITY OF CAREPatient experience with ambulatory careDelivering health care that is responsive and patient-centered
is playing a greater role in health care policy across OECD
countries. Measuring and monitoring patient experience
empowers patients and the public, involves them in deci-
sions on health care delivery and governance, and provides
insight into the extent to which they are health-literate and
have control over the treatment they receive. Across coun-
tries, using the health care user as a direct source of infor-
mation is becoming more prevalent for health system
monitoring, planning and decision making, and efforts to
measure andmonitor patient experiences have actually led
to health care quality improvements (Fujisawa and Klazinga,
forthcoming).
Since the mid-1990s, there have been efforts to institution-
alise measurement and monitoring of patient experiences.
In many countries, responsible organisations have been
established or existing institutions have been taking charge
of measuring and reporting patient experiences. They
developed survey instruments for regular collection of
patient experience data and standardised procedures for
analysis and reporting. An increasing number of countries
collect not only Patient-Reported Experience Measures
(PREMs) but also Patient-Reported Outcome Measures
(PROMs) which collect patients’ perception on their specific
medical conditions and general health, including mobility,
pain/discomfort and anxiety/depression, before and after a
specific medical intervention such as hip and knee replace-
ment.
A growing number of countries are using patient-reported
data to drive quality improvements in health systems.
Patient experience data are reported in periodic national
health system reports or on public websites, showing dif-
ferences across providers, regions and over time. Korea,
Norway, Sweden and the United Kingdom use patient expe-
rience measures in payment mechanisms or for fund allo-
cations to promote quality improvement and patient-
centred care, and Australia, Canada, the Czech Republic,
Denmark and France use them to inform health care regu-
lators for inspection, regulation and/or accreditation.
Patient-reported measures are also used in some Canadian
jurisdictions, Denmark, France and the Netherlands to pro-
vide specific feedback for providers’ quality improvement.
In England, PROMs and patients’ feedback about their
experience are used to inform patient choice and to incen-
tivise service improvement. For example, PROMs data for
patients undergoing some procedures such as hip and knee
replacement are used for benchmarking hospitals. The use
of PROMs can also enable the potential shift from a vol-
ume-based to a value-based model of health system
resource management (Canadian Institute for Health Infor-
mation, 2015).
Patients generally report positive experiences when it
comes to communication and autonomy in the ambulatory
health care system. Across countries, the majority of
patients report positive experiences with regards to time
spent with the doctor (Figure 8.39), easy-to-understand
explanations (Figure 8.40), opportunities to ask questions
or raise concerns (Figure 8.41), as well as involvement in
care and treatment decisions (Figure 8.42). For all four
aspects of patient experience, Belgium and Luxembourg
score high at above 95% of patients reporting positive expe-
riences. Poland has lower rates with fewer than one in two
patients reporting having been given the opportunity to ask
questions or been involved in their care and treatment dur-
ing consultation. The proportion of patients with positive
experience has decreased since 2010 in Australia, France,
the Netherlands and Switzerland, but countries with
lower rates such as Sweden and Poland have improved
some aspects of patient experiences in recent years (Com-
monwealth Fund, 2010).
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Definition and comparability
In order to measure and monitor general patient
experience in the health system, the OECD recom-
mends collecting data on patient experience with any
doctor in ambulatory settings. An increasing number of
countries have been collecting patient experience data
based on this recommendation through nationally rep-
resentative population surveys while Japan and Portugal
collect them through nationally-representative service
user surveys. Some countries, however, collect data
on patient experience with a regular doctor. For about
half the countries presented, the Commonwealth
Fund's International Health Policy Surveys 2010 and 2013
were used, even though there are critiques relating to
the sample size and response rates. Data from this
survey refer to patient experience with a regular doc-
tor rather than any doctor.
Rates are age-sex standardised to the 2010 OECD pop-
ulation, to remove the effect of different population
structures across countries.HEALTH AT A GLANCE 2015 © OECD 2015160
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Patient experience with ambulatory careInformation on data for Israel: http://oe.cd/israel-disclaimer
8.39. Doctor spending enough time with patient
in consultation, 2013 (or nearest year)
Note: 95% confidence intervals represented by H.
1. National sources. 2. Data refer to patient experienceswith regular doctor.
Source: Commonwealth Fund International Health Policy Survey 2013 and
other national sources.
1 2 http://dx.doi.org/10.1787/888933281241
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8.40. Doctor providing easy-to-understand explanations,
2013 (or nearest year)
Note: 95% confidence intervals represented by H.
1. National sources. 2. Data refer to patient experienceswith regular doctor.
Source: Commonwealth Fund International Health Policy Survey 2013
and other national sources.
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8.41. Doctor giving opportunity to ask questions or raise
concerns, 2013 (or nearest year)
Note: 95% confidence intervals represented by H.
1. National sources. 2. Data refer to patient experienceswith regular doctor.
Source: Commonwealth Fund International Health Policy Survey 2010
and other national sources.
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8.42. Doctor involving patient in decisions about care and
treatment, 2013 (or nearest year)
Note: 95% confidence intervals represented by H.
1. National sources. 2. Data refer to patient experienceswith regular doctor.
Source: Commonwealth Fund International Health Policy Survey 2013
and other national sources.
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9. HEALTH EXPENDITURE AND FINANCINGHealth expenditure per capitaThe amount that each country spends on health, for both
individual and collective services, and how this changes
over time can be the result of a wide array of social and eco-
nomic factors, as well as the financing and organisational
structures of a country's health system.
In 2013, the United States continued to outspend all other
OECD countries by a wide margin, with the equivalent of
USD 8 713 for each US resident (Figure 9.1). This level of
health spending is two-and-a-half times the average of all
OECD countries (USD 3 453) and nearly 40% higher than the
next biggest spender, Switzerland (adjusted for the differ-
ent purchasing powers – see “Definition and comparability”
box). Compared with some other G7 countries, the United
States spends around twice as much on health care per
person as Germany, Canada and France. Countries spend-
ing less than half the OECD average include many of the
central European members of the OECD, such as Hungary
and Poland, together with Chile. The lowest per capita
spenders on health in the OECD were Mexico and Turkey
with levels of less than a third of the OECD average. Outside
of the OECD, among the key partner countries, China and
India spent 13% and 4% of the OECD average on health in
per capita terms in 2013.
Figure 9.1 also shows the breakdown of per capita spending
on health into public and private sources (see the indicator
on “Financing of health care”). In general, the ranking
according to per capita public expenditure remains compa-
rable to that of total spending. Even if the private sector in
the United States continues to play the dominant role in
financing, public spending on health per capita is still
greater than that in all other OECD countries, with the
exception of Norway and the Netherlands.
Per capita spending on health across the OECD edged up
slightly in 2013 continuing a trend of recent years. This slow
rise comes after health spending growth ground to a halt in
the wake of the global financial and economic crisis. Between
2009 and 2013, average annual health spending growth across
the OECD was 0.6%, in contrast to the 3.4% in the period
between 2005 and 2009 (Figure 9.2). There has been a differ-
ence of health spending growth between Europe and the rest
of the OECD with some European countries facing dramatic
reductions in health spending from 2010 onwards.
There have been some significant changes in the annual
growth rates in health spending in the years before and
during the financial crisis in a number of countries. Annual
increases have been reversed in Greece (5.4% vs. -7.2%) and
Ireland (5.3% vs. -4.0%) and have slowed down in the vast
majority of OECD countries. Only six countries – Hungary,
Mexico, Switzerland, Israel, Japan and Chile – recorded
higher average growth following the crisis than pre-2009.
Chile, Korea and Turkey saw health spending increase by
more than 5% in real terms in 2013. For Chile and Korea,
this level of spending growth has been constant since 2009.
Preliminary estimates for 2014 point towards a slight slow-
down in health spending in Japan, after recent strong
growth.
In the United States, health spending grew by 1.5% in 2013,
less than half the average annual growth rate prior to 2009.
The latest forecasts from the Centers for Medicare and
Medicaid Services point to faster growth in 2014 as more
Americans gain health insurance coverage (Keehan et al.,
2015).
Canada has seen a sustained period of low growth since
2010. This is in contrast to the average 3.5% growth per year
between 2005 and 2009. With health spending growth esti-
mated to have continued below economic growth, health
spending as a share of GDP has also declined from a high of
10.6% in 2009 to 10.2% in 2013.
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Definition and comparability
Expenditure on health measures the final consump-
tion of health goods and services (i.e. current health
expenditure). This includes spending by both public
and private sources on medical services and goods,
public health and prevention programmes and
administration, but excludes spending on capital for-
mation (investments).
To compare spending levels between countries, per
capita health expenditures are converted to a com-
mon currency (US dollar) and adjusted to take account
of the different purchasing power of the national cur-
rencies. Economy-wide (GDP) PPPs are used as the
most available and reliable conversion rates.
For the calculation of growth rates in real terms, econ-
omy-wide GDP deflators are used. In some countries
(e.g. France and Norway) health-specific deflators
exist, based on national methodologies, but these are
not used due to limited comparability.
Note: Ireland is currently implementing a project to report
increased detail on health expenditure and financing data in
accordance with international guidelines. Data for 2013 is
therefore not available and revisions to this and the following
indicators will be made available on completion of the project.HEALTH AT A GLANCE 2015 © OECD 2015164
9. HEALTH EXPENDITURE AND FINANCING
Health expenditure per capitaInformation on data for Israel: http://oe.cd/israel-disclaimer
9.1. Health expenditure per capita, 2013 (or nearest year)
Note: Expenditure excludes investments, unless otherwise stated.
1. Includes investments.
2. Data refers to 2012.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888933281252
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9.2. Annual average growth rate in per capita health expenditure, real terms, 2005 to 2013 (or nearest years)
1. Mainland Norway GDP price index used as deflator. 2. CPI used as deflator.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281252
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9. HEALTH EXPENDITURE AND FINANCINGHealth expenditure in relation to GDPThe change in how much a country spends on healthcare
in relation to spending on all the other goods and services
in the economy can depend on both fluctuations in the rate
of health spending itself as well as growth in the economy
as a whole. The 2000s were characterised by a period of
health spending growth above that of the overall economy
so that health expenditure as a share of GDP rose sharply in
many OECD countries. However, the economic crisis that
took hold in 2008 resulted in an initial rise followed by a
reduction in the health spending to GDP ratio across many
OECD countries.
Health spending accounted for 8.9% of GDP (excluding
investment) on average across OECD countries in 2013,
unchanged from 2012 and up marginally from 8.8% in 2011
(Figure 9.3). Including capital spending (see the indicator
on “Capital expenditure in the health care sector”), expen-
diture on health as a share of GDP is estimated to have been
9.3% on average in 2013.
In 2013, the United States spent 16.4% of GDP on health,
remaining well above the OECD average and more than five
percentage points above a group of high-income countries all
at around 11%, which include the Netherlands, Switzerland,
Sweden, Germany and France. Almost half of OECD coun-
tries spend in a band between 8 and 10% of GDP on health
services. Among OECD countries, Mexico and Estonia
devoted around 6% of GDP to health – around two-thirds of
the OECD average, while Turkey reported the lowest share
at just over 5% of GDP. Among the key partner countries,
China and India spent 5.6% and 4.0% of GDP respectively
in 2013, while Brazil (9.1%) and South Africa (8.9%) spent
close to the OECD average (all including investment).
The health spending to GDP ratio jumped sharply in 2009 to
reach 9.0% on average – up from 8.3% in 2008 as overall eco-
nomic conditions rapidly deteriorated but health spending
continued to grow or was maintained in many countries.
In the subsequent context of reducing public deficits, the
subsequent reductions in (public) spending on health
have resulted in the share of GDP first falling and since
stabilising as health expenditure growth has become
aligned to economic growth in many OECD countries
(Figures 9.4, and 9.5).
The United States has seen its health spending to GDP ratio
remain consistent at 16.4% since 2009, in contrast to the
earlier steep rise whereby the share increased almost two
percentage points between 2005 and 2009. Canada also
experienced a steady rise through the second half on the
2000s to reach a peak in 2009. Since then, with health
spending growth lower than economic growth, the share of
GDP has gradually decreased. Japan, on the other hand, has
seen its health spending share of GDP rise steadily from the
OECD average in 2005 to continue increasing to more than
10% of GDP by 2013 as a result of a deliberate policy to
increase public spending on health.
In Europe, France and Germany also have seen their health
spending to GDP ratio stabilise since 2009 as health spend-
ing growth has aligned with economic growth. Other Euro-
pean countries, such as Portugal and Ireland saw health
spending growth decline much more than GDP, resulting in
a rapidly decreasing health spending to GDP ratio, after sig-
nificant increase prior to 2009, as health spending signifi-
cantly outpaced economic growth. Greece, where there
have been significant cuts in health spending, has seen the
health spending to GDP ratio fluctuate but overall remain at
a similar level to the mid-2000s as the overall economy has
suffered to the same extent.
Definition and comparability
See indicator “Health expenditure per capita” for a
definition of expenditure on health.
Gross domestic product (GDP) = final consumption +
gross capital formation + net exports. Final consump-
tion of households includes goods and services used
by households or the community to satisfy their indi-
vidual needs. It includes final consumption expendi-
ture of households, general government and non-
profit institutions serving households.
In countries, such as Ireland and Luxembourg, where
a significant proportion of GDP refers to profits
exported and not available for national consumption,
GNI may be a more meaningful measure than GDP.HEALTH AT A GLANCE 2015 © OECD 2015166
9. HEALTH EXPENDITURE AND FINANCING
Health expenditure in relation to GDPInformation on data for Israel: http://oe.cd/israel-disclaimer
9.3. Health expenditure as a share of GDP, 2013 (or nearest year)
Note: Excluding investments unless otherwise stated.
1. Data refers to 2012.
2. Including investments.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888933281263
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9. HEALTH EXPENDITURE AND FINANCINGHealth expenditure by functionSpending on inpatient care and outpatient care combined
covers the major part of health expenditure across OECD
countries – almost two-thirds of current health expendi-
ture on average in 2013 (Figure 9.6). A further 20% of health
spending was allocated to medical goods (mainly pharma-
ceuticals), while 12% went towards long-term care and the
remaining 6% on collective services, such as public health
and prevention services as well as administration.
Greece has the highest share of spending on inpatient care
(including day care in hospitals) among OECD countries: it
accounted for 42% of total health spending in 2013, up from
36% in 2009, as a consequence of larger decreases in spend-
ing for outpatient care and pharmaceuticals. In Poland,
France and Austria, the hospital sector also plays an impor-
tant role, with inpatient spending comprising more than a
third of total costs. While the United States consistently
reports the highest share of outpatient care (and by conse-
quence the lowest inpatient share), it should be noted that
this figure includes remunerations of physicians who inde-
pendently bill patients for hospital care. Other countries
with a high share of outpatient spending include Portugal
and Israel (48% and 46%).
The other major category of health spending is medical
goods. In the Slovak Republic and Hungary, medical goods
represent the largest spending category at 36% and 33% of
all health expenditure, respectively. With around 30%, the
share is also high in Greece and Mexico. In Denmark and
Norway, on the other hand, spending on medical goods
represents only 10-11% of total health spending.
There are also differences between countries in their
expenditure on long-term care (see the indicator on “Long-
term care expenditure” in Chapter 11). Countries such as
Norway, the Netherlands, Sweden and Denmark which
have established formal arrangements for the elderly and
the dependent population, allocate around a quarter or
more of total health spending to long-term care. In many
southern or central European countries with a more infor-
mal long-term care sector, the expenditure on formal long-
term care services accounts for a much smaller share of
total spending.
The slowdown in health spending experienced in many
OECD countries in recent years has affected all spending
categories, but to varying degrees (Figure 9.7). Expenditure
for pharmaceuticals has been cut annually by nearly 2%
after recording positive annual increases of 2% in the pre-
crisis years – still down on previously strong growth in phar-
maceutical spending in the 1990s and early 2000s (see the
indicator on “Pharmaceutical expenditure” in Chapter 10).
Despite initially ring-fencing and protecting public health
budgets, prevention spending turned negative in around
half of OECD since 2009. Overall, spending on preventive
care contracted by -0.3% on an annual basis, after recording
very high growth rates during the period 2005-09 (5.6%).
Part of the reversal in spending growth can be explained by
the H1N1 influenza epidemic, which led to significant one-
off expenditure for vaccination in many countries around
2009.
While spending on long-term, outpatient and inpatient
care have continued to grow, the rates have also signifi-
cantly reduced since 2009. Expenditure growth for outpa-
tient care was reduced by more than half overall (1.7% vs.
3.9%), but has still remained positive in three quarters of
OECD countries. Some governments decided to protect
expenditure for primary care and front-line services whilst
looking for cuts elsewhere in the health system. The
annual average growth rate for hospital care dropped to a
quarter of its previous growth rate, down from 2.4%, and
was negative between 2009 and 2013 in a dozen OECD
countries. Reducing wages in public hospitals, postponing
staff replacement and delaying investment in hospital
infrastructure were among the most frequent measures
taken in OECD countries to balance health budgets.
References
OECD (2000), A System of Health Accounts, OECD Publishing,
Paris, http://dx.doi.org/10.1787/9789264181809-en.
OECD, Eurostat andWHO (2011), A System of Health Accounts,
2011 Edition, OECD Publishing, Paris,
http://dx.doi.org/10.1787/9789264116016-en.
Definition and comparability
The System of Health Accounts (OECD, 2000; OECD,
Eurostat and WHO, 2011) defines the boundaries of
the health care system. Current health expenditure
comprises personal health care (curative care, rehabil-
itative care, long-term care, ancillary services and
medical goods) and collective services (prevention
and public health services as well as health adminis-
tration). Curative, rehabilitative and long-term care
can also be classified by mode of production (inpa-
tient, day care, outpatient and home care). Concern-
ing long-term care, only the health aspect is normally
reported as health expenditure, although it is difficult
in certain countries to separate out clearly the health
and social aspects of long-term care. Some countries
with comprehensive long-term care packages focus-
ing on social care might be ranked surprisingly low
based on SHA data because of the exclusion of their
social care. For example, an ongoing review of Japanese
long-term care boundaries concerning SHA will likely
lead to a significant increase in health spending based
on SHA2011 to be released in 2016. Thus, estimations
of long-term care expenditure are one of the main fac-
tors limiting comparability across countries.HEALTH AT A GLANCE 2015 © OECD 2015168
9. HEALTH EXPENDITURE AND FINANCING
Health expenditure by functionInformation on data for Israel: http://oe.cd/israel-disclaimer
9.6. Current health expenditure by function of health care, 2013 (or nearest year)
Note: Countries are ranked by curative-rehabilitative care as a share of current expenditure on health. * Refers to curative-rehabilitative care in
inpatient and day care settings. ** Includes home-care and ancillary services.
1. Inpatient services provided by independent billing physicians are included in outpatient care for the United States.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281277
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9. HEALTH EXPENDITURE AND FINANCINGFinancing of health careAcross all OECD countries, health care is financed by a mix
of public and private spending. In some countries, public
health spending is mostly confined to spending by the gov-
ernment using general revenues. In others, social insur-
ance funds finance the bulk of health expenditure. Private
financing of health care consists mainly of payments by
households (either as standalone payments or as part of
co-payment arrangements) as well as various forms of pri-
vate health insurance.
In nearly all OECD countries, the public sector is the main
source of health care financing. Around three-quarters of
health care spending was publicly financed in 2013
(Figure 9.8). In Denmark, Sweden and the United Kingdom,
central, regional or local governments financed more than
80% of all health spending. In the Czech Republic, France,
Luxembourg, Japan and Germany, social health insurance
financed 70% or more of all health expenditure. Only in
Chile and the United States was the share of public spend-
ing on health below 50%. In these countries, a great propor-
tion of health spending is financed either directly by
households (Chile) or by private insurance (United States).
Health care is competing for public resources with different
sectors such as education, defence and housing. The size of
the public budget allocated to health is determined by a
number of factors including the type of health and long-
term care system, the demographic composition of the
population and the relative budget priorities. On average,
15% of total government expenditure was dedicated to
health care in 2013 (Figure 9.9). There are, however, impor-
tant variations across OECD member states. Whereas a
fifth of government spending is allocated to health care in
countries such as New Zealand and Switzerland, this falls
to around 10% in Hungary and Greece.
Developments in overall health spending are largely driven
by the trends in public spending. Strong pre-crisis growth
resulted in average public expenditure on health increasing
at an annual rate of almost 4% (Figure 9.10). In 2010, growth
in public health spending came to a halt with reductions in
many countries. Since then spending growth has been very
slow, often in line with overall economic growth.
After public financing, the main source of funding tends to
be out-of-pocket payments. On average private households
directly financed 19% of health spending in 2013. The share
of out-of-pocket payments was above 30% in Mexico, Korea,
Chile and Greece and 10% or lower in France and the United
Kingdom. Out-of-pocket spending has continued to grow
since 2009, albeit at a slower rate, partly as a result of cost-
sharing measures introduced in a number of countries.
Measures taken include increasing co-payments and rais-
ing reimbursement thresholds for pharmaceuticals, reduc-
ing benefits for dental treatment, increasing user charges
for hospital care, introducing cost-sharing for certain activ-
ities in primary care and removing entitlements for public
coverage for particular groups of the population.
Private health insurance (PHI) can play different roles in
health systems. Whereas PHI provides primary health care
coverage for large population groups in the United States
and Chile, it complements or supplements public coverage
for the vast majority of the population in countries such as
France, Belgium and Slovenia. In other countries, such as
Australia and Ireland, it serves as duplicate insurance pro-
viding access to a larger group of providers. Spending for
PHI accounts for only 6% of overall health spending in the
OECD, but it represents a sizeable share in a number of
countries, particularly in the United States (35%) and Chile
(20%). While health spending growth through private
health insurance slowed down significantly in the period
2009-11, spending grew by 2.9% between 2011 and 2013 –
also as a response to some cost-shifting and loss of cover-
age in some countries.
References
OECD (2000), A System of Health Accounts, OECD Publishing,
Paris, http://dx.doi.org/10.1787/9789264181809-en.
OECD, Eurostat andWHO (2011), A System of Health Accounts,
2011 Edition, OECD Publishing, Paris, http://dx.doi.org/
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Definition and comparability
The financing of health care can be analysed from the
point of view of the sources of funding (households,
employers and the state), financing schemes (e.g.
compulsory or voluntary insurance) and financing
agents (organisations managing the financing
schemes). Here “financing” is used in the sense of
financing schemes as defined in the System of Health
Accounts (OECD, 2000; OECD, Eurostat andWHO, 2011).
Public financing includes expenditure by the general
government and social security funds. Private financ-
ing covers households’ out-of-pocket payments, pri-
vate health insurance and other private funds (NGOs
and private corporations). Out-of-pocket payments
are expenditures borne directly by patients. They
include cost-sharing and, in certain countries, estima-
tions of informal payments to health care providers.
Total government expenditure is used as defined in
the System of National Accounts and includes as
major components intermediate consumption, com-
pensation of employees, interest, social benefits,
social transfers in kind, subsidies, other current
expenditure and capital expenditure payable by cen-
tral, regional and local governments as well as social
security funds.HEALTH AT A GLANCE 2015 © OECD 2015170
9. HEALTH EXPENDITURE AND FINANCING
Financing of health careInformation on data for Israel: http://oe.cd/israel-disclaimer
9.8. Expenditure on health by type of financing, 2013 (or nearest year)
1. The Netherlands report compulsory cost-sharing in health care insurance and in Exceptional Medical Expenses Act under social security rather
than under private out-of-pocket, resulting in an underestimation of the out-of-pocket share.
2. Data refer to total health expenditure (= current health expenditure plus capital formation).
3. Social security reported together with general government.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281280
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9.9. Health expenditure as share of total government
expenditure, 2013 (or nearest year)
1. Data refer to total health expenditure (= current health expenditure
plus capital formation).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en;
OECD National Accounts; Eurostat Statistics Database; IMF World
Economic Outlook Database.
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9. HEALTH EXPENDITURE AND FINANCINGExpenditure by disease and ageAttributing health care expenditure by disease and age is
important for health policy makers in order to analyse
resource allocations in the health care system. This infor-
mation can also play a role in assessing the impact of pop-
ulation ageing and changing disease patterns on spending.
Furthermore, the linking of health expenditures by disease
to appropriate measures of outputs (e.g. hospital dis-
charges by disease) and outcomes (e.g. survival rates after
heart attack or cancer) helps in monitoring the perfor-
mance of health care systems at a disease-based level
(Heijink et al., 2006).
Figure 9.11 shows the distribution of hospital inpatient
expenditure according to seven main diagnostic categories.
These categories account for between 60% and 80% of all
inpatient acute care expenditure across the group of coun-
tries. Circulatory diseases account for the highest share of
inpatient spending in each of the countries except for
Korea and the Netherlands, where spending on cancer and
mental and behavioural disorders is the largest category,
respectively. The differences between countries can be
influenced by a number of factors, including demographic
structure and disease patterns, as well as institutional
arrangements and clinical guidelines for treating different
diseases. For example, in the Netherlands, mental and
behavioral disorders account for around 23% of all inpa-
tient spending – around twice the level as that of Germany,
Finland and Japan. This may be partly explained by the
large number of acute mental health hospitals with very
long average lengths of stay (OECD, 2015). Similarly, longer
than average lengths of stay in Japan for some of the spe-
cific circulatory diseases such as cerebrovascular disease
(stroke) might explain whymore than 22% of hospital inpa-
tient expenditures are allocated to the treatment of circula-
tory diseases. Discharges related to circulatory diseases
only account for 12% of all discharges in Japan – a propor-
tion similar to other countries.
Figure 9.12 compares expenditure by hospital discharge for
circulatory diseases and cancers. Generally, the cost per
discharge between these two main disease categories is
similar in all countries, apart from Japan where spending
per discharge for circulatory diseases is more than twice
that of cancer. Japan has the highest expenditure per dis-
charge compared to the other countries for circulatory dis-
ease, again due to the much longer lengths of stay, while
the Netherlands has the highest expenditure per discharge
for cancer treatment.
Different cost patterns can also be due partly to demographic
factors. The allocation of current health spending by age
group in the Czech Republic, Korea and the Netherlands in
Figure 9.13 shows that the share of spending increases with
age after an initial peak of spending linked to birth and
early childhood illnesses. The share of current health
spending remains relatively constant until around the 50 to
54 age group before increasing sharply as people grow
older. As a result, a significant share of current health
spending is consumed by elderly population. Those aged 65
and above consume around 60% of the current health
spending on average in all three countries. In addition, in
Korea and the Netherlands more than 20% of current
health spending is accounted for by those aged 85 years
and above, while in the Czech Republic the share is much
lower. This may be explained by a lower level of long-term
care spending in Czech Republic.
References
Heijink, R., M.A. Koopmanschap and J.J. Polder (2006), Inter-
national Comparison of Cost of Illness, RIVM, Bilthoven.
OECD (2015), Addressing Dementia: The OECD Response, OECD
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Definition and deviations
Expenditure by disease and age allocates current
health expenditure by patient characteristics. Guide-
lines developed propose disease categories according
to ICD-10. To ensure comparability between countries,
expenditures are also linked to the System of Health
Accounts (SHA) framework and a common methodol-
ogy is proposed advocating primarily a top-down allo-
cation of expenditures based on principal diagnosis.
The main comparability issues relates to the treat-
ment of non-allocated and non-disease-specific
expenditures. In the former case this is due to data
limitations (often in outpatient and pharmaceutical
expenditure) and in the latter case mainly prevention
and administration expenditure.
Note that the charts cover allocated spending only
and the following country limitations apply. Canada
excludes Quebec and mental health hospitals; the
Czech Republic refers to expenditure by the Health
Insurance Fund only; Germany refers to total hospital
expenditure; and the Netherlands refers to curative
care in general and specialty hospitals.HEALTH AT A GLANCE 2015 © OECD 2015172
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Expenditure by disease and ageInformation on data for Israel: http://oe.cd/israel-disclaimer
9.11. Share of hospital inpatient expenditures by main diagnostic category, 2011 (or nearest year)
Source: OECD Expenditure by Disease, Age and Gender Database.
1 2 http://dx.doi.org/10.1787/888933281298
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9. HEALTH EXPENDITURE AND FINANCINGCapital expenditure in the health sectorKnowing how much a health system is investing in hospi-
tals, medical technology and other equipment is very rele-
vant for policy making and analysis. Although health
systems remain a highly labour-intensive sector, capital
has been increasingly important as a factor of production
of health services over recent decades. This is illustrated,
for example, by the growing importance of diagnostic and
therapeutic equipment or the expansion of information,
computer and telecommunications technology in health
care over the last few years. The availability of statistics on
capital expenditure is essential to the analysis of the health
system’s production capacity (that is, whether capacity is
appropriate, deficient or excessive), which is needed in
turn to inform policy implementation (for example, if
excess capacity exists, the marginal cost of expanding cov-
erage will be lower than if the health care system is already
straining to fill current demand).
On average, OECD countries invested around 0.45% of their
GDP in 2013 in terms of capital spending in the health sec-
tor. This compares with 8.9% of GDP on average across the
OECD for current spending on health care services andmed-
ical goods (see the indicator on “Health expenditure in rela-
tion to GDP”). As with current spending, there are both
differences in the current levels of investment expenditure
between countries and in the recent trends observed.
At the higher end of the scale, Belgium spent more than
0.8% of GDP on capital investment in 2013, followed by a
group of countries, including France, Germany and the
United States, all spending more than 0.6% of GDP. Around
half the OECD countries are in a relatively narrow band of
plus or minus 25% of the average ranging from the United
Kingdom to Australia. At the lower end, Turkey, Chile and
Hungary spent around half the OECD average, while
Greece, Iceland and Mexico spent around 0.1% of GDP on
capital infrastructure and equipment in the health care
sector.
Data from National Accounts provides an idea of the type
of assets and capital spending. While capital spending can
fluctuate from year to year, overall in the health sector
there is an even split between spending on construction
(i.e. building of hospitals and other health care facilities)
and spending on equipment (medical machinery, ambu-
lances, as well as ICT equipment). Together they account
for 85% of capital expenditure. The remaining 15% is
accounted for by intellectual property products – the result
of research, development or innovation. This can vary sig-
nificantly between countries.
In parallel with current health spending, capital spending
has been affected by the global economic crisis with out-
lays on health system infrastructure and equipment
often being a prime target for reduction or postpone-
ment. Overall, capital spending grew strongly in the
period up to 2008 – annual capital expenditure was 22%
higher than in 2005 in real terms on average. During the
next three years, the annual outlay fell back by almost
15%. Since 2011, there has been a return to growth in capi-
tal spending (Figures 9.15 and 9.16).
The country differences also mirror the trends in current
spending. Outside of Europe, investment in the health sec-
tor has been generally less affected by the economic down-
turn. Australia and Korea, for example, report capital
spending more than 40% higher in 2013 compared with
2005.
A number of European countries have seen severe reduc-
tions in capital spending. Figures for Greece show that the
outlay was less than 40% of the 2005 level in 2013, with an
acceleration of the fall in 2010. Similarly, Spain experienced
a sharp reversal after 2008, with capital spending in 2012 at
half the level of 2005.
Definition and comparability
Gross fixed capital formation in the health care sys-
tem is measured by the total value of the fixed assets
that health providers have acquired during the
accounting period (less the value of the disposals of
assets) and that are used repeatedly or continuously
for more than one year in the production of health
services. The breakdown by assets includes infra-
structure (e.g. hospitals, clinics, etc.), machinery and
equipment (including diagnostic and surgical machin-
ery, ambulances, and ICT equipment), as well as soft-
ware and databases.
Gross fixed capital formation is reported by many
countries under the System of Health Accounts. It is
also reported under the National Accounts broken
down by industrial sector according to the Interna-
tional Standard Industrial Classification (ISIC) Rev. 4
using Section Q: Human health and social work activ-
ities or Division 86: Human health activities. The for-
mer is normally broader than the SHA boundary while
the latter is narrower.HEALTH AT A GLANCE 2015 © OECD 2015174
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Capital expenditure in the health sectorInformation on data for Israel: http://oe.cd/israel-disclaimer
9.14. Gross fixed capital formation in the healthcare sector as a share of GDP, 2013 (or nearest year)
1. Refers to gross fixed capital formation in ISIC 86: Human health activities (ISIC Rev. 4).
2. Refers to gross fixed capital formation in ISIC Q: Human health and social work activities (ISIC Rev. 4).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; OECD National Accounts Database.
1 2 http://dx.doi.org/10.1787/888933281305
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9.15. Gross fixed capital formation, selected
non-European countries, 2005-13
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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10. PHARMACEUTICAL SECTORPharmaceutical expenditurePharmaceuticals play a vital role in the health system and
policy makers must balance the access of patients to new
effective medicines with limited health care budgets, while
providing the right incentives to manufacturers to develop
new generations of drugs. After inpatient and outpatient
care, pharmaceuticals represent the third largest expendi-
ture item of health care spending and accounted for more
than a sixth (17%) of health expenditure on average across
OECD countries in 2013, not taking into account spending
on pharmaceuticals in hospitals.
The total retail pharmaceutical bill across OECD countries
was around USD 800 billion in 2013. However, there are
wide variations in pharmaceutical spending per capita
across countries, reflecting differences in volume, patterns
of consumption and pharmaceutical prices (Figure 10.1).
With more than USD 1 000 in 2013, the United States spent
far more on pharmaceuticals than any other OECD country
on a per capita basis, and double the OECD average. Japan
(USD 752), Greece (USD 721) and Canada (USD 713) also
spent significantly more on medicines than other OECD
countries. At the other end of the scale, Denmark (USD 240)
had relatively low spending levels, less than half the aver-
age across OECD countries. It is important to note that
these figures refer only to retail pharmaceuticals, that is,
pharmaceuticals dispensed directly to patients with a
medical prescription or over-the-counter purchases. Phar-
maceuticals can also be administered to patients when
they are in hospital, but these are not taken into account
here. Figures available for a small number of OECD coun-
tries suggest that this can add another 10-20% on average
to the retail spending, but can vary according to different dis-
pensing and budgetary practices (Belloni et al., forthcoming).
Around 80% of total retail pharmaceutical spending is for
prescribed medicines; the rest being spent on over-the-
counter (OTC) medicines. OTC medicines are pharmaceuti-
cals that can be bought without prescription and their costs
are generally borne by patients. In some cases, however,
OTC drugs can also be reimbursed by public payers.
Depending on country-specific legislation, OTC pharma-
ceuticals can be sold outside of pharmacies, for example, in
supermarkets, other retail stores or via the internet. In Aus-
tralia, Spain and Poland, the share of OTC medicines is rel-
atively high – in the latter case accounting for half of
pharmaceutical spending.
During the 1990s and early 2000s, increasing spending on
retail pharmaceuticals acted as a major contributor in driv-
ing up overall health expenditure (Figure 10.2). Average real
annual growth in pharmaceutical spending outpaced over-
all health spending growth – more than 5% on average each
year between 1990 and 2004, compared with average health
spending growth of less than 4% per year. However, in the
second half of the 2000s there was a significant drop in
average pharmaceutical spending growth which then
intensified following the global economic crisis. In this
period, policy makers in many OECD countries were con-
cerned about reining in public pharmaceutical spending in
an effort to limit total public spending (see Indicator
“Financing of pharmaceutical expenditure”). Thus, a num-
ber of countries introduced a series of measures: price cuts
(achieved through negotiations with the pharmaceutical
manufacturers, introduction of reference pricing, applica-
tion of compulsory rebates, decrease of pharmacy margins,
reductions of the value added tax applicable for pharma-
ceuticals), promoting the use of generics, reduction of
package sizes, reduction in coverage (excluding pharmaceuti-
cals from reimbursement) and increases in co-payments by
households.
References
Belloni, A., D. Morgan and V. Paris (forthcoming), “Pharma-
ceutical Expenditure and Policies: Past Trends and
Future Challenges”, OECD Working Paper, OECD Publish-
ing, Paris.
Definition and comparability
Pharmaceutical expenditure covers spending on pre-
scription medicines and self-medication, often
referred to as over-.the-counter products. In some
countries, other medical non-durable goods are also
included. Pharmaceuticals consumed in hospitals and
other health care settings are excluded. Final expendi-
ture on pharmaceuticals includes wholesale and retail
margins and value-added tax. It also includes phar-
macists’ remuneration when the latter is separate
from the price of medicines. Total pharmaceutical
spending refers in most countries to “net” spending,
i.e. adjusted for possible rebates payable by manufac-
turers, wholesalers or pharmacies.HEALTH AT A GLANCE 2015 © OECD 2015178
10. PHARMACEUTICAL SECTOR
Pharmaceutical expenditureInformation on data for Israel: http://oe.cd/israel-disclaimer
10.1. Expenditure on pharmaceuticals per capita, 2013 (or nearest year)
1. Includes medical non-durables (resulting in an over-estimation of around 5-10%).
2. Excludes spending on over-the-counter medicines.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281318
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10.2. Average annual growth in pharmaceutical and total health expenditure per capita, in real terms, average across
OECD countries, 1990 to 2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281318
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10. PHARMACEUTICAL SECTORFinancing of pharmaceutical expenditureIn all OECD countries, pharmaceuticals are financed by a
mix of public and private spending. Tax-funded schemes or
social health insurance cover a significant amount of pre-
scribed pharmaceuticals in most countries, sometimes
complemented by private health insurance. Patients typi-
cally have to cover some part of the cost of prescription
drugs themselves, although exemptions often exist for vul-
nerable segments of the population such as children, the
elderly and patients suffering from certain chronic ill-
nesses. Over-the-counter (OTC) pharmaceuticals are nor-
mally financed entirely by private households.
Pharmaceutical spending represents around 1.4% of GDP
on average across OECD countries ranging from 0.5% in
Denmark to 2.8% in Greece (Figure 10.3). Public funds repre-
sent slightly less than 60% on average – just under 1% of
GDP across OECD countries. However, this share is signifi-
cantly higher in Japan (1.5%) and Greece (1.9%) and much
lower in Denmark and Norway (both 0.3%). The proportion
of private expenditure in GDP is highest in Hungary and the
United States (both 1.3%), and also high in Canada (1.0%).
Public protection against the costs of pharmaceuticals is
not as developed as for other health services, such as inpa-
tient and outpatient care (Figure 10.4). On average across
OECD countries, the public sector covered a much higher
proportion of the costs of health services (79%) compared
with pharmaceuticals (57%) in 2013. This is true for all
countries with the exception of Greece where public cover-
age for pharmaceuticals is higher (67% vs. 64%). Public cov-
erage for pharmaceuticals is high in countries such as
France, Japan and Germany where coverage by public
financing schemes accounts for 70% or more of total costs.
Private sources have to cover more than half of the total
pharmaceutical bill in eight OECD countries, with public
coverage being the lowest in Poland (32%), the United
States (34%) and Canada (36%). However, in the United
States and Canada, private health insurance plays a signif-
icant role in covering parts of the pharmaceutical costs for
patients. Poland reports large spending on privately
financed OTC pharmaceuticals.
The growth in public spending on pharmaceuticals has
remained below total health spending growth over the last
decade (see Indicator “Pharmaceutical expenditure”) with
recent growth rates in sharp decline as compared to pre-
crisis years (Figure 10.5). Between 2009 and 2013, public
expenditure on pharmaceuticals dropped by 3.2% on aver-
age across OECD countries while it increased by 2.7% each
year in the 2005-09 period. The reduction was particularly
steep in Portugal (-11.1%), Denmark (-10.4%) and Iceland
(-9.9%). Greece and the Netherlands have also seen signifi-
cant reversals in growth of public pharmaceutical spending
following the crisis compared to the pre-crisis period. The
reduction in public spending on pharmaceuticals has not
been restricted to Europe. Public spending also came down
in Canada and Australia (both -2.1%). Japan, on the other
hand, continues to see substantial annual increases (4.9%).
Reduction of public pharmaceutical spending in most
OECD countries was achieved by a wide range of policy
measures (see Indicator “Pharmaceutical expenditure”),
including reforms that have aimed to shift some of the
burden of pharmaceutical spending away from the public
purse to private payers. These measures included the de-
listing of products (i.e. excluding them from reimbursement)
and the introduction or increase of user charges for retail
prescription drugs (Belloni et al., forthcoming). In recent
years, measures of this kind have been taken by around a
dozen OECD countries. Ireland, for example, introduced a
50-cent prescription fee for Medical Card holders in 2010
which was subsequently increased. At the same time, the
monthly drug reimbursement threshold was raised by 20%
to EUR 120 for non-Medical Card holders, followed by
subsequent increases. As a result of these policy measures,
the share of private financing of pharmaceuticals has
increased substantially in a number of countries. In Spain,
39% of pharmaceutical costs were covered out-of-pocket in
2013, up from 24% in 2009. In Greece and Iceland, the pro-
portion of pharmaceutical spending paid for by households
directly went up by 10 percentage points or more since
2009.
References
Belloni, A., D. Morgan and V. Paris (forthcoming), “Pharma-
ceutical Expenditure and Policies: Past Trends and
Future Challenges”, OECD Working Paper, OECD Publish-
ing, Paris.
Definition and comparability
See indicator on pharmaceutical expenditure for defi-
nition of what is included and possible limitations.
See indicator on financing of health care for definition
of “public” and “private” spending on health.
Health services refer to inpatient and outpatient care
(including day cases), long-term health care and
auxiliary services.HEALTH AT A GLANCE 2015 © OECD 2015180
10. PHARMACEUTICAL SECTOR
Financing of pharmaceutical expenditureInformation on data for Israel: http://oe.cd/israel-disclaimer
10.3. Expenditure on pharmaceuticals as a share of GDP,
2013 (or nearest year)
1. Includes medical non-durables.
2. Excludes spending on over-the-counter medicines.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281325
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10. PHARMACEUTICAL SECTORPharmacists and pharmaciesPharmacists assist people in obtaining medication and
ensuring that these are used in a safe and proper fashion.
The role of the pharmacists has changed over the recent
years.Although theirmain role is still to dispensemedications
in community pharmacies, pharmacists are increasingly
providing direct care to patients (e.g. flu vaccinations in
Ireland), both in community pharmacies and as part of inte-
grated health care provider teams.
OECD countries generally have between 50 and 130 pharma-
cists per 100 000 population. Japan has by far the highest
density of pharmacists, at twice the OECD average, while
the density of pharmacists is low in Turkey, Chile and the
Netherlands (Figure 10.6). Between 2000 and 2013, the num-
ber of pharmacists per capita has increased in nearly all
OECD countries, with the exception of Switzerland. It
increasedmost rapidly in Portugal, Ireland, Japan, Spain and
Hungary.
In Japan, the strong increase in the number of pharmacists
can be attributed to a large extent to government’s efforts to
separate more clearly drug prescribing from drug dispensing.
Traditionally, the vast majority of prescription drugs in
Japan were dispensed directly by doctors. Over the years,
the Japanese government has taken steps to encourage the
separation of drug prescribing from dispensing.The Medical
Service Law was first amended in 1997 and then in 2006 to
recognise community pharmacies as facilities providing
health goods and services. Following these amendments,
the percentage of prescriptions dispensed by pharmacists
rose from less than 40% of all prescriptions in 2000 to 67% in
2013, while the number of community pharmacies
increased from 48 252 to 57 071 (Japanese Pharmaceutical
Association, 2015).
Most pharmacists work in community pharmacies, but
some also work in hospital, industry, research and academia
(FIP, 2015). For instance, in Canada in 2012, more than
three-quarters of practising pharmacists worked in a com-
munity pharmacy while about 25% worked in hospitals and
other health care facilities (CIHI, 2013). In Japan, around
55% of pharmacists worked in community pharmacies in
2012, while around 20% worked in hospitals or clinics and
the other 25% worked in other settings (Japanese Pharma-
ceutical Association, 2015).
The number of community pharmacies varies widely
across OECD countries (Figure 10.7). This big variation can
be explained by the more or less active planning role of
governments and agencies; by the remuneration model
used in the country, as well as by different dispensing
channels of medicines. In addition to community pharma-
cies, medicines can be dispensed through hospital phar-
macies (serving both inpatients and outpatients) or can be
provided directly by doctors in a few countries. For example,
the relatively low number of community pharmacies in the
Netherlands may be explained partly by the fact that
patients can also purchase their prescription drugs directly
from some doctors (Vogler et al., 2012). There are about
400 GPs who are selling medicines in the Netherlands, pro-
viding access to drugs especially in rural areas where the
nearest pharmacy may be quite far away (RIVM, 2014).
Denmark has few, but large, community pharmacies
including branch pharmacies and supplementary phar-
macy units attached to the main pharmacy (Vogler et al.,
2012).
The range of products and services provided by the pharma-
cies varies across countries. In most European countries, for
example, pharmacies can also sell cosmetics, food supple-
ments, medical devices and homeopathic products and in a
few countries pharmacies can also sell reading glasses and
didactic toys (Martins et al., 2015). Depending on countries’
legislation, pharmacies can provide services such as vacci-
nation, medication use review, unit dose dispensing,
generic substitution, point of care testing, medication
administration, needle exchange programme, take back
medicines (disposal of medicines), etc.
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Definition and comparability
Practicing pharmacists are defined as the number of phar-
macists who are licensed to practice and provide direct
services to clients/patients. They can be either salaried
or self-employed, and work in community pharmacies,
hospitals and other settings. Assistant pharmacists and
the other employees of pharmacies are normally
excluded.
In Ireland, the figures include all pharmacists registered
with the Pharmaceutical Society of Ireland, possibly
including some pharmacists who are not in activity. In
addition they include assistant pharmacists, pharma-
ceutical assistants, and doctors who are dispensing
medication (approximately 140 in 2007), resulting in an
over-estimation compared with the data provided by
other countries. Assistant pharmacists are also
included in Iceland.
Community pharmacies are premises which in accordance
to the local legal provisions and definitions may operate
as a facility in the provision of pharmacy services in the
community settings. The number of community phar-
macies reported are the number of premises where
dispensing of medicines happened under the supervision
of a pharmacist.HEALTH AT A GLANCE 2015 © OECD 2015182
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Pharmacists and pharmaciesInformation on data for Israel: http://oe.cd/israel-disclaimer
10.6. Practising pharmacists, 2000 and 2013 (or nearest year)
1. Data include not only pharmacists providing direct services to patients, but also those working in the health sector as researchers, for
pharmaceutical companies, etc.
2. Data refer to all pharmacists licensed to practice (resulting in a large over-estimation of the number of practising pharmacists).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281337
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10. PHARMACEUTICAL SECTORPharmaceutical consumptionIn general, pharmaceutical consumption continues to
increase, partly driven by a growing demand for drugs to
treat ageing-related and chronic diseases and by changes
in clinical practice. This section examines consumption of
four categories of pharmaceuticals: antihypertensive, cho-
lesterol-lowering, antidiabetic and antidepressant drugs.
Consumption is measured in defined daily doses (DDD)
(see the box on “Definition and comparability”).
Consumption of antihypertensives has nearly doubled in
OECD countries between 2000 and 2013. It has more than
tripled in Estonia and quadrupled in Luxembourg
(Figure 10.8). It is highest in Germany and Hungary, almost
five-fold the level of Korea and Turkey. These variations
reflect both differences in the prevalence of high-blood
pressure and in clinical practice. In 2008, 16% of the Korean
population had high blood pressure, against 26% in
Germany and 37% in Hungary, while the average number of
DDD prescribed per patient with high blood pressure was
lower in Korea (0.5) than in Hungary (1.1) and Germany (1.2)
(OECD, 2015).
The use of cholesterol-lowering drugs has more than tri-
pled in OECD countries between 2000 and 2013 (Figure 10.9).
The Slovak Republic, the United Kingdom and Australia
had the highest consumption per capita in 2013, with levels
over 40% higher than the OECD average. Prescription clini-
cal guidelines for anti-cholesterol treatments have been
updated several times since the 1990s, recommending
wider screening, earlier treatments, and higher dosages.
This explains part of the high growth observed during the
period.
The use of antidiabetics has almost doubled in OECD coun-
tries between 2000 and 2013 (Figure 10.10). This growth can
be explained by a rising prevalence of diabetes, largely
linked to increases in the prevalence of obesity (see
indicator on overweight and obesity in Chapter 4), a major
risk factor for the development of type-2 diabetes. In 2013,
the consumption of antidiabetics was highest in Finland,
Germany and the United Kingdom.
Consumption of antidepressants has increased consider-
ably in most OECD countries since 2000 (Figure 10.11). This
might reflect some narrowing of the treatment gap for
depression. However, there is significant variation in con-
sumption of antidepressants between countries. Iceland
reported the highest level of consumption of antidepres-
sants in 2013, twice the OECD average, followed by Australia,
Portugal and Canada. Chile, Korea and Estonia reported low
consumption levels.
The level of antidepressants consumption depends on the
prevalence of depression in each country, and on how
depression is diagnosed and treated. This, in turn, depends
on other available therapies, local guidelines, and prescrib-
ing behavior (OECD, 2014; Moore et al., 2009). These factors
vary between countries. In England and in France, the
increase in antidepressants consumption has been associ-
ated with a longer duration of drug treatment (Grandfils
and Sermet, 2009; Moore et al., 2009).
Where antidepressants consumption is very low – Korea,
Chile, Estonia – there may be a case for addressing unmet
needs. In other countries with particularly high antidepres-
sants consumption, there is a need to assess the appropri-
ateness of prescribing patterns, and the availability of
alternative treatments for depression.
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Definition and comparability
Defined daily dose (DDD) is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. DDDs are assigned to each active
ingredient(s) in a given therapeutic class by interna-
tional expert consensus. For instance, the DDD for
oral aspirin equals 3 grams, which is the assumed
maintenance daily dose to treat pain in adults. DDDs
do not necessarily reflect the average daily dose actu-
ally used in a given country. DDDs can be aggregated
within and across therapeutic classes of the Anatomic-
Therapeutic Classification (ATC). For more detail, see
www.whocc.no/atcddd.
The volume of hypertension drugs consumption pre-
sented in Figure 10.8 refers to the sum of five ATC2
categories which can all be prescribed against hyper-
tension (antihypertensives, diuretics, beta-blocking
agents, calcium channel blockers and agents acting
on the renin-angiotensin system).
Data generally refer to outpatient consumption only,
except for the Czech Republic, Estonia, Italy and Sweden
where data also include hospital consumption. The
data for Canada relate to three provinces only (British
Columbia, Manitoba and Saskatchewan). The data for
Spain refer to outpatient consumption for prescribed
drugs covered by the National Health System (public
insurance). Data for Luxembourg are underestimated
due to incomplete consideration of products with
multiple active ingredients.HEALTH AT A GLANCE 2015 © OECD 2015184
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Pharmaceutical consumptionInformation on data for Israel: http://oe.cd/israel-disclaimer
10.8. Antihypertensive drugs consumption,
2000 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281342
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10. PHARMACEUTICAL SECTORShare of generic marketAll OECD countries see the development of generic markets
as a good opportunity to increase efficiency in pharmaceuti-
cal spending but many do not fully exploit the potential of
generics (Figure 10.12). In 2013, generics accounted for more
than three-quarters of the volume of pharmaceuticals sold in
the United States, the United Kingdom, Chile, Germany and
NewZealand,while they represented less than one-quarter of
the market in Luxembourg, Switzerland, Italy, and Greece.
Some of the differences in generic uptake can be explained by
market structures, notably the number of off-patent medi-
cines, and by prescribing practices, but generic uptake also
very much depends on policies implemented by countries
(EGA, 2011; Vogler, 2012). Several countries have expanded
their efforts to encourage generic uptake since the onset of
the economic crisis in 2008.
Prescribing in International Non-proprietary Name (INN) is
permitted in two-thirds of OECD countries and is mandatory
in a few countries (e.g. Estonia since 2010, Portugal and Spain
since 2011, and France since 2015). Similarly, pharmacists are
allowed to substitute brand-name drugs with generics in a
majority of OECD countries. While generic substitution is
mandatory in some countries (e.g., Denmark, Finland, Spain,
Sweden, Italy), New Zealand and the United Kingdom have
high generic penetration without any substitution mandate.
Financial incentives for physicians, pharmacists and patients
have been implemented to boost the development of generic
markets. For instance, France (in 2009 and 2012) introduced
incentives for GPs to prescribe generics through a pay-for-per-
formance schemewhile Japan (in 2012) increased the share of
generics in total prescribing leading to a bonus.
Pharmacies are often paid through mark-ups based on the
price of medicines. This disincentive to substitute a generic
for a more expensive drug has been addressed in some coun-
tries. France guarantees pharmacists an equivalent mark-up,
while in Switzerland, pharmacists receive a fee for generic
substitution. In several countries, pharmacists have the obli-
gation to inform patients about the possibility of a cheaper
alternative.
Patients have a financial interest to choose cheaper drugs
when their co-payment is lower for generic drugs than for its
equivalent. This is generally the case in all systems using
reference prices (or fixed reimbursement amount) for clusters
of products. In Greece, patients choosing originator over
generic drugs are now required to pay for the difference. In
France, since 2010, patients refusing generic substitution have
to pay in advance for their drugs and are reimbursed later.
These policies, associated with patent expiries of several
blockbusters in recent years, have contributed to the
increase in generic market share observed over the past
decade (Figure 10.13). In Portugal, the generic reimbursed
market grew from virtually zero in 2000 to 39% in volume
and 23% in value in 2013. In Spain, the generic reimbursed
market share reached 47% in volume and 21% in value in
2013, up from 3% in 2000. Beyond encouraging generic take-
up, it is also important to promote the lowest possible price
for generics. Figure 10.12 suggests, for instance, that the
differential price between brand-name and generic drugs is
much higher in the United Kingdom than in Germany.
One way to exert pressure on generic prices is tendering,
which has been used in New Zealand, the Netherlands and
Germanywith some success. Many countries, however, prefer
regulating the price of generics at market entry by reference
to the price of the originator (a practice known as “generic
price linkage”). Several countries have recently increased this
gap. In Canada, several provinces have introduced or reduced
the reimbursement prices of generics included in public
plans’ formularies since 2010. As a result, generic price caps
are around 25% of brand name products’ price (PMPRB, 2015).
France and Greece also increased the gap between originator
and generic prices to 40% and 60% respectively (Belloni et al.,
forthcoming).
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Definition and comparability
A generic is defined as a pharmaceutical product
which has the same qualitative and quantitative com-
position in active substances and the same pharma-
ceutical form as the reference product, and whose
bioequivalence with the reference product has been
demonstrated. Generics can be classified in branded
generics (generics with a specific trade name) and
unbranded generics (which use the international non-
proprietary name and the name of the company).
In many countries, the data cover all pharmaceutical
consumption. However, several countries provide data
covering only the community pharmaceutical market or
the reimbursed pharmaceutical market.
The share of generic market expressed in value can be
the turnover of pharmaceutical companies, the
amount paid for pharmaceuticals by third-party payers,
or the amount paid by all payers (third-party and
consumers). The share of generic market in volume
can be expressed in DDDs or as a number of packages/
boxes or standard units.HEALTH AT A GLANCE 2015 © OECD 2015186
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Share of generic marketInformation on data for Israel: http://oe.cd/israel-disclaimer
10.12. Share of generics in the total pharmaceutical market, 2013 (or nearest year)
1. Reimbursed pharmaceutical market.
2. Community pharmacy market.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281352
10.13. Trend in share of generics in the reimbursed pharmaceutical market, selected countries, 2000 to 2013
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281352
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10. PHARMACEUTICAL SECTORResearch and development in the pharmaceutical sectorThe pharmaceutical industry devotes significant resources
to research and development (R&D). In 2011, the industry
spent USD 92 billion on R&D (OECD, 2015). This represents
10-15% of industry revenues.
While pharmaceutical and biotechnology companies are
the greatest contributors to pharmaceutical R&D, pharma-
ceutical R&D financing is a complex mix of private and
public funding. The industry receives R&D tax credits in
many countries, and the development of medicines draws
heavily on knowledge and innovation derived from other
sectors including higher education and NGOs (Kezselheim
et al., 2015).
Worldwide, most pharmaceutical R&D activity takes place
in OECD countries. In 2011, the pharmaceutical industry
spent close to USD 50 billion for R&D in the United States,
11.5 billion in Japan, 5.2 in Germany and 3.7 in France. As a
share of GDP, pharmaceutical industry R&D spending is
highest in Switzerland (0.63%), Belgium (0.45%), Slovenia
(0.45%) and Denmark (0.36%) (Figure 10.14). In the United
States and Japan, the percentages were 0.30 and 0.26
respectively.
In some countries, pharmaceutical R&D accounts for one-
fourth to one-third of total private R&D expenditure,
reflecting a high degree of specialisation. This is the case in
Belgium (31%), Switzerland (30%), the United Kingdom
(28%), Hungary (26%) and Slovenia (25%). Sixteen and ten
per cent of private R&D was spent on pharmaceuticals in
the United States and Japan respectively.
Expenditure on R&D in the pharmaceutical industry in
OECD countries doubled in real terms between 2000 and
2011 (Figure 10.15). Expenditure growth was the highest in
the United States (+85%), followed by Japan (+76%) and
Europe (+38%). Outside the OECD, China has seen pharma-
ceutical R&D spending increase by 3.4-fold during that
time.
Is this increase in R&D spending associated with a higher
output or productivity? In the United States, the world’s
largest developer of pharmaceuticals, the annual number
of approved new drugs, formulations or indications has
more than doubled since 1970 (Figure 10.16). However,
when compared with R&D spending over that period
(adjusted for inflation), the number of approvals per
billion USD spent on R&D has reduced by a factor of 15
(Figure 10.16).
The reasons for this observation are likely to be complex.
Growing requirements to obtain regulatory approval have
increased development costs. Higher failure rates and an
ever-increasing “back catalogue” of effective drugs may
also be a factor. More fundamental problems with the cur-
rent R&D model and development pipeline have also been
suggested (Scannell et al., 2012). Risk-benefit decisions
made by industry regarding early R&D targets may also be
a function of the regulator, payer and the community
response to the eventual product. Of course, the downward
trend may reverse in the coming years due to changes in
the R&D model, or the emergence of new technology (e.g.
precision medicine).
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Definition and comparability
Business enterprise expenditure on R&D (BERD) cov-
ers R&D activities carried out in the private sector by
performing firms and institutes, regardless of the origin
of funding. This includes all firms, organisations and
institutions whose primary activity is the production
of goods and services for sale to the general public at
an economically significant price, and the private and
not-for-profit institutions serving them. BERD will
register in the country where the R&D activity took
place, not the country of origin of the organisations
funding the activity.
Data are provided by participating countries using a
survey. When assessing changes in BERD over time, it
is necessary to take account of changes in methods
and breaks in series, notably in terms of the extension
of survey coverage, particularly in the services sector,
and the privatisation of publicly owned firms. Identi-
fying new and occasional R&D performers is also a chal-
lenge and OECD countries take different approaches in
their BERD surveys.
Gross domestic product (GDP) = final consumption +
gross capital formation + net exports. Final consump-
tion of households includes goods and services used
by households or the community to satisfy their indi-
vidual needs. It includes final consumption expendi-
ture of households, general government and non-
profit institutions serving households. In countries,
such as Ireland and Luxembourg, where a significant
proportion of GDP refers to profits exported and not
available for national consumption, GNI may be a
more meaningful measure than GDP.HEALTH AT A GLANCE 2015 © OECD 2015188
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Research and development in the pharmaceutical sectorInformation on data for Israel: http://oe.cd/israel-disclaimer
10.14. Business expenditure on R&D (BERD) in pharmaceutical industry as a proportion of GDP and of total BERD, 2011
(or nearest year)
Source: OECD Main Science and Technology Indicators Database.
1 2 http://dx.doi.org/10.1787/888933281362
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10.15. Business expenditure on R&D in the pharmaceutical sector by region in 2000, 2005 and 2011 (or nearest years)
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Demographic trends
Life expectancy and healthy life expectancy at age 65
Self-reported health and disability at age 65
Dementia prevalence
Recipients of long-term care
Informal carers
Long-term care workers
Long-term care beds in institutions and hospitals
Long-term care expenditure
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities. The use of such data by the OECD is without prejudice to the status of the Golan
Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of
international law.5 191
11. AGEING AND LONG-TERM CAREDemographic trendsLonger life expectancies (see “Life expectancy” indicator in
Chapter 3) and declining fertility rates mean that older
people make up an ever-increasing proportion of the popu-
lations of OECD countries.
On average across OECD countries, the share of the popula-
tion aged over 65 years has increased from less than 9% in
1960 to 15% in 2010 and is expected to nearly double in the
next four decades to reach 27% in 2050 (Figure 11.1, left
panel). In about two thirds of OECD countries, at least one-
quarter of the population will be over 65 years of age by
2050. This proportion is expected to be especially large in
Japan, Korea and Spain where nearly 40% of the population
will be aged over 65 years by 2050. Population ageing will
also occur rapidly in China where the share of the popula-
tion over 65 is expected to triple between 2010 and 2050, to
reach a level just below the OECD average. Conversely,
Israel, the United States and Mexico will see a more gradual
increase in the share of the elderly population due to sig-
nificant inflows of migrants and higher fertility rates.
The growth in the share of the population aged 80 years
and over will be even more dramatic (Figure 11.1, right
panel). On average across OECD countries, 4% of the popu-
lation were 80 years old and over in 2010. By 2050, the per-
centage will increase to 10%. In Japan, Spain and Germany,
the proportion of the population aged over 80 is expected to
nearly triple between 2010 and 2050 (rising from 6% to 16%
in Japan and from 5% to 15% in Spain and Germany). The
rise will be even faster in Korea where the share of the pop-
ulation aged over 80 years will grow from 2% to 14% over
the next four decades. China will see similarly rapid ageing,
with the share of the population aged over 80 rising from
1% to 8%.
Population ageing is a phenomenon affecting most coun-
tries around the world, but the speed of the process varies
(Figure 11.2). The speed of population ageing is particularly
rapid in the European Union, where the share of the popu-
lation aged 80 years and over increased from 1.5% in 1960 to
nearly 5% in 2010, and is expected to rise to 11% by 2050.
The pace of population ageing has been slower in other
parts of the world, although it is expected to accelerate in
coming decades. In large partner countries including Brazil,
China, India, Indonesia and South Africa, only 2% of the
population was 80 years and over in 2010, but this share is
expected to reach around 5% by 2050.
Although the pressure that this growing proportion of peo-
ple aged 65 and 80 over will put on long-term care systems
will depend on the health status of people as they reach
these ages, population ageing is likely to lead to greater
demand for elderly care. As the share of the economically
active population is expected to decline, it will also affect
the financing of social protection systems and the potential
supply of labour in the economy. On average across OECD
countries, there were slightly more than four people of
working age (15-64 years) for every person 65 years and
older in 2012.This rate is projected to halve from 4.2 in 2012
to 2.1 on average across OECD countries over the next
40 years (OECD, 2013).
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Definition and comparability
Data on the population structure have been extracted
from the OECD Historical Population Data and Projec-
tions (1950-2050). The projections are based on the
most recent “medium-variant” population projections
from the United Nations, World Population Prospects
– 2012 Revision.HEALTH AT A GLANCE 2015 © OECD 2015192
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Demographic trendsInformation on data for Israel: http://oe.cd/israel-disclaimer
11.1. Share of the population aged over 65 and 80 years, 2010 and 2050
Source: OECD Historical Population Data and Projections Database, 2015.
1 2 http://dx.doi.org/10.1787/888933281371
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11. AGEING AND LONG-TERM CARELife expectancy and healthy life expectancy at age 65Life expectancy at age 65 has increased significantly for
both men and women over the past few decades in OECD
countries, rising by 5.5 years on average since 1970
(Figure 11.3). Some of the factors explaining these gains in
life expectancy at age 65 include advances in medical care
combined with greater access to health care, healthier life-
styles and improved living conditions before and after peo-
ple reach age 65.
Japan and Korea have achieved the highest gains in life
expectancy at age 65 since 1970, with an increase of almost
eight years. The gains have been much more modest in
Hungary, the Slovak Republic and Mexico, with an increase
of only about three years.
In 2013, people at age 65 in OECD countries could expect to
live another 19.5 years: 21 years for women and 18 years for
men (Figure 11.4). This gender gap of three years on aver-
age across OECD countries has been fairly stable over time.
In 2013, life expectancy at age 65 was highest in Japan for
women (24 years) and in Switzerland for men (nearly
20 years), followed by France in both cases. Among OECD
countries, it was lowest in Hungary for both women and
men.
Countries’ relative positions with respect to life expectancy
at age 65 mirror closely their relative positions with regard
to life expectancy at age 80. Life expectancy at age 80 in
2013 was highest in France and Japan for women (who can
expect to live an additional 11.5 years) and highest in
France and Spain for men (who can expect to live more
than 9 years).
Increased life expectancy at age 65 does not necessarily
mean that the extra years lived are in good health. In
Europe, an indicator of disability-free life expectancy
known as “healthy life years” is calculated regularly, based
on a general question about disability in the European
Union Survey of Income and Living Conditions (EU-SILC).
Given that this indicator has only recently been developed,
long-time series are not yet available and efforts continue
to improve its comparability.
Among European countries participating in the survey, the
average number of healthy life years at age 65 was almost
the same for women and men, at 9.5 years for women and
9.4 years for men in 2013 (Figure 11.5). The absence of any
significant gender gap in healthy life years means that
many of the additional years of life that women experience
relative to men are lived with some type of activity limita-
tion. Nordic countries (with the exception of Finland) had
the highest number of healthy life years at age 65 in 2013,
with women and men in Iceland and Norway expecting to
live an additional 15 years free from disability on average.
Life expectancy and healthy life expectancy at age 65 years
vary by educational status. For both men and women,
highly educated people are likely to live longer and in bet-
ter health. Differences in life expectancy by education level
are particularly large in Central and Eastern European
countries, especially for men. In the Czech Republic,
65-year-oldmenwith a high level of education could expect
to live seven years longer than those with a low education
level in 2012. By contrast, differences in life expectancy by
education level are much smaller (less than two years) in
Nordic countries (Denmark, Finland, Norway and Sweden)
and Portugal (Eurostat Database 2015).
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Definition and comparability
Life expectancy measures how long on average a per-
son of a given age can expect to live, if current death
rates do not change. However, the actual age-specific
death rate of any particular birth cohort cannot be
known in advance. If rates are falling, as has been the
case over the past decades in OECD countries, actual
life spans will be higher than life expectancy calcu-
lated using current death rates. The methodology
used to calculate life expectancy can vary slightly
between countries. This can change a country’s esti-
mates by a fraction of a year.
Disability-free life expectancy (or “healthy life years”)
is defined as the number of years spent free of activity
limitation. In Europe, this indicator is calculated
annually by Eurostat for EU countries and some EFTA
countries. The disability measure is the Global Activ-
ity Limitation Indicator (GALI) which comes from the
European Union Statistics on Income and Living Con-
ditions (EU-SILC) survey. The GALI measures limita-
tion in usual activities due to health problems. While
healthy life years is the most comparable indicator to
date, there are still problems with translation of the
GALI question, although it does appear to satisfacto-
rily reflect other health and disability measures
(Jagger et al., 2010).HEALTH AT A GLANCE 2015 © OECD 2015194
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Life expectancy and healthy life expectancy at age 65Information on data for Israel: http://oe.cd/israel-disclaimer
11.3. Life expectancy at age 65, 1970 and 2013 (or nearest years)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281383
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11.4. Life expectancy at age 65 by sex, 2013 (or nearest year)
Note: Countries are ranked in descending order of life expectancy for the whole population.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281383
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11. AGEING AND LONG-TERM CARESelf-reported health and disability at age 65Most OECD countries conduct regular health surveys which
allow respondents to report on different aspects of their
health. These surveys often include a question on self-per-
ceived health status, along the lines of: “How is your health
in general?”. Although these questions are subjective, indi-
cators of perceived general health have been found to be a
good predictor of future health care use and mortality
(DeSalvo, 2005; Bond et al., 2006). However, cross-country
differences may be difficult to interpret, as survey ques-
tions may differ slightly and cultural factors can affect
responses.
Keeping these limitations in mind, more than half of the
population aged 65 years and over report being in good
health in 13 of the 34 OECD countries (Figure 11.6). The
highest rates are in New Zealand, Canada and the United
States, where more than three-quarters of older people
report good health, but the response categories offered to
survey respondents in these three countries are different
from those used in most other OECD countries, introducing
an upward bias in the results (see box on “Definition and
comparability” below). Among European countries, older
people in Sweden, Switzerland, Norway and Ireland report
the best health status, with more than 60% assessing their
health to be good.
At the other end of the scale, less than 20% of over-65s in
Portugal, Hungary, Estonia, Poland, Turkey, the Slovak
Republic and Korea report being in good health. In nearly
all countries, men over 65 were more likely than women to
rate their health to be good. On average across OECD coun-
tries, 47% of men aged over 65 rated their health to be good
or better, while 41% of women did so.
The percentage of the population aged 65 years and over
who rate their health as being good or better has remained
fairly stable over the past 30 years in most countries where
long time series are available. There has been significant
improvement however in the United States, where the
share has increased from 65% in 1982 to 77% in 2013.
Measures of disability are not yet standardised across
countries, limiting the possibility for comparisons. In
Europe, based on the EU Statistics on Income and Living
Conditions survey, half of all over-65s reported that they
were limited either to some extent or severely in their usual
daily activities because of a health problem in 2013
(Figure 11.7). This ranged from a proportion of less than
25% in Norway and Iceland up to nearly 75% in the Slovak
Republic and close to 70% in Estonia. On average across
25 European OECD countries, most limitations reported
were moderate, 18% of the population aged 65 and over
reported severe limitations, which often correspond to
needs for long-term care.
Women were more likely than men to report severe activity
limitations due to a health problem in all European coun-
tries covered by this survey, with the exception of Poland.
The proportion of people aged 65 and over reporting some
severe activity limitations was highest in Greece and the
Slovak Republic, followed by Italy and Estonia (Figure 11.8).
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Definition and comparability
Self-reported health reflects people’s overall percep-
tion of their own health, including both physical and
psychological dimensions. Typically, survey respon-
dents are asked a question such as: “How is your
health in general? Very good, good, fair, poor, very
poor”. OECD Health Statistics provides figures related to
the proportion of people rating their health to be
“good/very good” combined.
Caution is required in making cross-country compari-
sons of perceived health status, for at least two rea-
sons. First, people’s assessment of their health is
subjective and can be affected by cultural factors. Sec-
ond, there are variations in the question and answer
categories used to measure perceived health across
surveys/countries. In particular, the response scale
used in Australia, Canada, New Zealand and the
United States is asymmetric (skewed on the positive
side), including the following response categories:
“excellent, very good, good, fair, poor”. The data
reported in OECD Health Statistics refer to respondents
answering one of the three positive responses (“excel-
lent, very good or good”). By contrast, in most other
OECD countries, the response scale is symmetric, with
response categories being: “very good, good, fair, poor,
very poor”. The data reported from these countries
refer only to the first two categories (“very good,
good”). Such difference in response categories biases
upward the results from those countries that are
using an asymmetric scale.
Perceived general disability is measured in the EU-
SILC survey through the question: “For at least the
past six months, have you been hampered because of
a health problem in activities people usually do? Yes,
strongly limited/Yes, limited/No, not limited”. Persons
in institutions are not surveyed, resulting in an under-
estimation of disability prevalence. Again, the mea-
sure is subjective, and cultural factors may affect sur-
vey responses.HEALTH AT A GLANCE 2015 © OECD 2015196
11. AGEING AND LONG-TERM CARE
Self-reported health and disability at age 65Information on data for Israel: http://oe.cd/israel-disclaimer
11.6. Perceived health status in adults aged 65 years and over, 2013 (or nearest year)
1. Results not directly comparable with other countries due to methodological differences (resulting in an upward bias).
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888933281398
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11.8. Strong limitations in daily activities in adults aged 65 years and over, European countries, 2013
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11. AGEING AND LONG-TERM CAREDementia prevalenceDementia describes a variety of brain disorders which pro-
gressively lead to brain damage and cause a gradual deteri-
oration of the individual’s functional capacity and social
relations. Alzheimer’s disease is the most common form of
dementia, representing about 60% to 80% of cases. There is
currently no cure or disease modifying treatment, but bet-
ter policies can improve the lives of people with dementia
by helping them and their families adjust to living with the
condition and ensuring that they have access to high qual-
ity health and social care.
According to WHO, 47.5 million people around the world
live with dementia in 2015. With populations ageing and
the effectiveness of preventive strategies still unclear, this
number is expected to rise to 75.6 million by 2030 and
almost triple by 2050, reaching 135.5 million (WHO, 2015).The
global cost of dementia was estimated at USD 604 billion in
2010 (Wimo et al., 2013) and as prevalence increases this
cost will grow.
In 2015, there were an estimated 18 million people living
with dementia in OECD countries, equivalent to more than
one in every 70 people. Although some people develop
early-onset dementia, the vast majority of those with
dementia are older people and across all OECD countries
more than one in every 16 people aged over 60 are living
with the condition. Prevalence varies between countries:
Italy, Japan and Germany all have more than 20 people with
dementia per 1 000 population, while the Slovak Republic,
Korea, Mexico andTurkey have fewer than ten (Figure 11.9).
Much of the variation in prevalence is due to the age struc-
tures of the populations in different countries, since demen-
tia is strongly linked to age.Across all OECD countries, around
1.3% of people aged 60-64 have dementia, compared to nearly
45% of those aged over 90 (Figure 11.10). Age-specific prev-
alence is similar across most countries, although studies in
Latin America have found higher rates than in other
regions (Prince et al., 2013).While this may be partly due to
differences in study design, it has also been suggested that
low educational levels among older people and high vascu-
lar risk could be contributing to increased rates of demen-
tia (Rizzi et al., 2014).
If the age-specific prevalence of dementia remains the
same, ageing populations mean that it will become more
common in the future. Prevalence will rise more quickly in
countries that are ageing rapidly. For example, the next
20 years will see prevalence in Japan rise from 21 to nearly
37 per 1 000 people; and in Korea prevalence will more than
double from 8 to 20 per 1 000 people (Figure 11.9). The over-
all number of people living with dementia in OECD coun-
tries will rise from 18 million in 2015 to nearly 31 million in
2035, with the oldest people (aged over 90) accounting for
an increasing share (Figure 11.11). However, there is some
evidence that the age-specific prevalence of dementia may
be falling in some countries (Matthews et al., 2013) and it
may be possible to reduce the risk of dementia through
healthier lifestyles and preventive interventions. If such
efforts are successful, the rise in prevalence may be less
dramatic than these numbers suggest.
There has recently been a renewed international focus on
tackling dementia and the OECD has been at the forefront
of this work, supporting countries to develop better poli-
cies. Finding a curemust be the long-term goal, but this will
require greater investment and a more collaborative
approach to research, harnessing the potential of big data.
However, any cure is likely to take several years to develop
and in the meantime countries need to act to improve the
lives of the millions of people living with dementia now.
This must include promoting timely diagnosis, delivering
high quality health and long-term care and providing sup-
port for families and carers (OECD, 2015).
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Definition and comparability
The prevalence estimates in Figure 11.9 are taken
from Prince et al. (2013), which is the latest and most
comprehensive systematic review of studies of
dementia prevalence around the world. Prevalence by
country has been estimated by applying these age-
specific prevalence rates for the relevant region of the
world to population estimates from the UN (World
Population Prospects: The 2012 Revision). Although
gender-specific prevalence rates were available for some
regions, the overall rates were used in this analysis.
Prevalence rates are assumed to be constant over
time.HEALTH AT A GLANCE 2015 © OECD 2015198
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Dementia prevalenceInformation on data for Israel: http://oe.cd/israel-disclaimer
11.9. Estimated prevalence of dementia per 1 000 population, 2015 and 2035
Source: OECD analysis of data from Prince et al. (2013) and the United Nations.
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11.10. Age-specific prevalence of dementia across all OECD countries, 2015
Source: OECD analysis of data from Prince et al. (2013) and the United Nations.
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11. AGEING AND LONG-TERM CARERecipients of long-term careAs people age, they are more likely to develop disabilities
and need support from family, friends and long-term care
(LTC) services. As a result, while LTC services are delivered
to younger disabled groups, the majority of LTC recipients
are older people. On average across the OECD, more than
half of all LTC recipients are aged over 80 and nearly four in
five are aged over 65 (Figure 11.12). Rising life expectancies
mean that older people make up an increasing proportion
of the populations of OECD countries. The risk of dementia
(see indicator on “Dementia prevalence”) and other debili-
tating conditions increases with age, so demand for LTC
services is likely to increase – although this effect may be
partially offset by improving health in old age. As a result,
the average proportion of the population receiving LTC in
OECD countries has risen from 1.9% in 2000 to 2.3% in 2013.
While population ageing is a significant driver of the
growth in LTC users over time, it explains relatively little of
the cross-country variation. For example, Portugal has a
relatively old population but only a small proportion receiv-
ing formal LTC. By contrast, Israel has one of the youngest
populations in the OECD but a greater than average propor-
tion receiving LTC. A more important driver is the availabil-
ity of publicly funded LTC services. Countries with strong
public provision, such as the Netherlands and Nordic coun-
tries, report the greatest number of LTC recipients as a
share of their populations, while countries with limited
public provision, such as the United States, Portugal and
Poland, report much smaller numbers. However, data for
people receiving care outside of public systems are more
difficult to collect andmay be underreported, meaning that
figures for countries that rely more heavily on privately-
funded care may be artificially low. Cultural norms around
the degree to which families look after older people may
also be an important driver of the utilisation of formal ser-
vices (see indicator on “Informal carers”).
In response to most people’s preference to receive LTC ser-
vices at home, many OECD countries have over the past
decade implemented programmes and benefits to support
home-based care, in particular for older people. In most
countries for which trend data are available, the propor-
tion of LTC recipients aged 65 and over receiving long-
term care at home has increased over the past ten years
(Figure 11.13), with particularly large increases in Sweden,
France and Korea. Often this is the result of specific poli-
cies: for example, Sweden has reduced its institutional care
capacity in an effort to encourage community care; while
France has adopted a multi-year plan to increase home
nursing care capacity to 230 000 by 2025 (Colombo et al.,
2011).
While the proportion of LTC recipients living at home has
increased over the past decade in most OECD countries, it
has declined from 69% to 60% in Finland. However, this
does not represent an increase in the use of traditional
institutions, but an increase in the use of “service housing”
– where older people move into specially adapted houses
where 24/7 care is available. This model of care allows peo-
ple with relatively severe needs to retain more indepen-
dence and autonomy than they would in a traditional care
institution.
References
Colombo, F. et al. (2011), Help Wanted? Providing and Paying
for Long-Term Care, OECD Publishing, Paris,
http://dx.doi.org/10.1787/9789264097759-en.
Definition and comparability
LTC recipients are defined as persons receiving long-
term care by paid providers, including non-profes-
sionals receiving cash payments under a social pro-
gramme. They also include recipients of cash benefits
such as consumer-choice programmes, care allow-
ances or other social benefits which are granted with
the primary goal of supporting people with long-term
care needs. LTC institutions refer to nursing and resi-
dential care facilities which provide accommodation
and long-term care as a package. LTC at home is
defined as people with functional restrictions who
receive most of their care at home. Home care also
applies to the use of institutions on a temporary basis,
community care and day-care centres and specially
designed living arrangements. Data for Iceland and
Canada are only available for people receiving care in
institutions, so the total number of recipients will be
underestimated.
Concerning the number of people receiving LTC in
institutions, the estimate for Ireland is under-
reported. Data for Japan underestimate the number of
recipients in institutions because hospitals also pro-
vide LTC. In the Czech Republic, LTC recipients refer to
recipients of the care allowance (i.e., cash allowance
paid to eligible dependent persons). Data for Poland
only refer to services in nursing homes. Data in Spain
only refer to a partial coverage of facilities or services.
In Australia, the data do not include recipients who
access the Veterans’ Home Care Program and those
who access services under the National Disability
Agreement, as it is currently unknown how many of
these people could be included in LTC recipients.
Australia collects data on users of aged care, but this
does not distinguish those using services on a long-
term basis, so the figures presented here are esti-
mated.With regard to the age threshold in chart 11.13,
data for France refer to people aged over 60.HEALTH AT A GLANCE 2015 © OECD 2015200
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Recipients of long-term careInformation on data for Israel: http://oe.cd/israel-disclaimer
11.12. Proportion of population receiving long-term care, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281419
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11.13. Share of long-term care recipients aged 65 years and over receiving care at home, 2000 and 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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11. AGEING AND LONG-TERM CAREInformal carersFamily and friends are the most important source of care
for people with LTC needs in OECD countries. Because of
the informal nature of care that they provide, it is not easy
to get comparable data on the number of people caring for
family and friends across countries, nor on the frequency
of their caregiving. The data presented in this section come
from national or international health surveys and refer to
people aged 50 years and over who report providing care
and assistance to family members and friends.
On average across OECD countries, around 15% of people
aged 50 and over provided care for a dependent relative or
friend in 2013 (Figure 11.14). There is significant variation
between countries, with nearly 20% of over-50s in Belgium
and Estonia providing informal care, compared to just over
10% in Israel and Australia. Rates of informal care are neg-
atively correlated with the proportion of older people
receiving formal services (see indicator on “Recipients of
informal care”) and the density of LTC workers (see indica-
tor on “Long-term care workers”). Countries such as Estonia
and the Czech Republic, with relatively few LTC workers and
recipients of formal services, have higher rates of informal
care; while countries such as Israel and Sweden, with large
number of LTCworkers andmany older people receiving LTC
services, have lower rates of informal care. The causality
here is not clear: it could be that strong public provision
means families do not have to care for older people with LTC
needs, or it could be that a strong tradition of family support
reduces the need for extensive public provision.
The majority of informal carers are women in all OECD
countries and on average more than 60% of carers are
women. This ranges from a high of 70% in Slovenia to a low
of 55% in Sweden (Figure 11.15).
On average across OECD countries, 74% of informal carers
provide care on a daily basis, while the remaining 26% pro-
vide care only on a weekly basis. However, there is wide
variation across countries in the intensity in caregiving
(Figure 11.16). In countries with comprehensive public
LTC systems, such as the Netherlands, Switzerland and
Nordic countries, family and friends provide less intensive
care. The highest intensity of care is reported in Spain,
Slovenia and Israel – although these countries actually
have relatively few people providing informal care
(Figure 11.14). Taking the total number of carers into
account, Estonia, Belgium, the Czech Republic and France
have greatest proportion of over-50s providing daily care to
family or friends, suggesting that informal care is particu-
larly important in these countries.
Intensive caregiving is associated with a reduction in
labour force attachment for caregivers of working age,
higher poverty rates, and a higher prevalence of mental
health problems. Many OECD countries have implemented
policies to support family carers with a view to mitigating
these negative impacts. These include paid care leave (e.g.,
Belgium), flexible work schedules (e.g., Australia and the
United States), respite care (e.g., Austria, Denmark and
Germany) and counselling/training services (e.g., Sweden).
Moreover, a number of OECD countries provide cash bene-
fits to family caregivers or cash-for-care allowances for
recipients which can be used to pay informal caregivers
(Colombo et al., 2011).
Declining family size, increased geographical mobility and
rising participation rates of women in the labour market
mean that there is a risk that fewer people will be willing
and able to provide informal care in the future. This could
have two consequences. Firstly, those that do provide infor-
mal care may be required to provide higher-intensity care.
This will make the support that they receive even more
important if negative health and employment outcomes
are to be avoided. Secondly, a reduction in the supply of
informal care would put increasing pressure on public LTC
systems. These systems will need adequate funding and
infrastructure in place to cope with increased demand, oth-
erwise people could be left without access to the services
they need.
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Definition and comparability
Family carers are defined as people providing daily or
weekly help to family members, friends and people in
their social network living in their household or out-
side of the household who require help for Activities
of Daily Living (ADL) and Instrumental Activities of
Daily Living (IADL). The data relate only to the popula-
tion aged 50 and over, and are based on national or
international health surveys. Survey results may be
affected by reporting biases or recall problems. Data
for Australia are limited to those providing assistance
with mobility, self-care, and communication, so may
be underestimated relative to other countries.HEALTH AT A GLANCE 2015 © OECD 2015202
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Informal carersInformation on data for Israel: http://oe.cd/israel-disclaimer
11.14. Population aged 50 and over reporting to be informal carers, 2013 (or nearest year)
Source: OECD estimates based on 2013 HILDA survey for Australia, 2012-13 Understanding Society survey for the United Kingdom and 2013 SHARE
survey for other European countries.
1 2 http://dx.doi.org/10.1787/888933281423
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11.15. Share of women among all informal carers aged 50 and over, 2013 (or nearest year)
Source: OECD estimates based on 2013 HILDA survey for Australia, 2012-13 Understanding Society survey for the United Kingdom and 2013 SHARE
survey for other European countries.
1 2 http://dx.doi.org/10.1787/888933281423
100
90
80
70
60
50
40
0
30
20
10
%
70.1
64.8 64.5 63.5 63.3 63.2 61.9 61.7 61.5 61.1 61.0 60.0 59.0 58.5 57.9 56.1 55.9 54.8
Slo
ve
nia
Es
ton
ia
Sw
itz
erl
an
d
Au
str
ali
a
Fra
nc
e
Ita
ly
Sp
ain
Un
ite
d K
ing
do
m
Isr
ae
l
Cz
ec
h R
ep
.
OE
CD
17
Lu
xe
mb
ou
rg
Ge
rm
an
y
Au
str
ia
Ne
the
rla
nd
s
Be
lgi
um
De
nm
ark
Sw
ed
en
11.16. Frequency of care provided by informal carers, 2013
Source: OECD estimates based on 2013 SHARE survey.
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11. AGEING AND LONG-TERM CARELong-term care workersLong-term care (LTC) is a labour-intensive service. Formal
LTC workers are defined as paid staff, typically nurses and
personal carers, providing care and/or assistance to people
limited in their daily activities at home or in institutions,
excluding hospitals. Formal care is complemented by infor-
mal, usually unpaid, support from family and friends,
which accounts for a large part of care for older people in
all OECD countries (see indicator on “Informal carers”).
Relative to the population aged 65 and over, Sweden and
the United States have the most LTC workers and Turkey
and Portugal the least (Figure 11.17). In all countries except
for Israel, Japan, Estonia and Korea, the majority of LTC
staff work in institutions, even though the majority of
recipients usually receive care at home (see indicator on
“Care recipients”). This reflects the fact that those in insti-
tutions often have more severe needs and require more
intensive care.
Most LTC workers are women and work part-time. Over
90% of LTC workers are women in Canada, Denmark, the
Czech Republic, Ireland, Korea, New Zealand, the Slovak
Republic, the Netherlands, Norway and Sweden. Foreign-
born workers also play an important role in LTC provision,
although their presence is uneven across OECD countries.
While Germany has very few foreign-born LTC workers,
nearly one in four care workers in the United States is for-
eign-born (Colombo et al., 2011). The recruitment of for-
eign-born workers can help respond to growing demand for
LTC, but growingmigrant inflows have raised issues around
the management of irregular migration, and paid work
which is undeclared for tax and social security purposes.
The LTC sector represents a small but growing share of
total employment in OECD countries, averaging just over
2%. This share has increased over the past decade in many
countries, with the broadening of public provision and
increased demand for services. In Japan, the number of LTC
workers has more than doubled since 2001, following the
implementation of a universal LTC insurance programme
in 2000 and government policies to professionalise LTC
work, while there was a slight decrease in total employ-
ment over this period. Similarly, LTC employment in
Germany has outstripped the growth in total employment
since 2001. In contrast, LTC employment in Sweden and the
Netherlands – countries which already had comprehensive
LTC systems and high employment in the sector in the
early 2000s – has roughly followed trends in overall employ-
ment (Figure 11.18).
On average, around 30% of LTC workers are nurses and the
other 70% are personal care workers (also referred to
as nursing aides, health assistants in institutions or home-
based care assistants) with less formal training. Since qual-
ity of care depends on all staff having appropriate skills,
many OECD countries have set educational and training
requirements for personal care workers, although these
vary substantially, especially where home-based care is
concerned (OECD/European Commission, 2013).
Increasing demand for LTC services and a possible decline
in the availability of family caregivers mean that demand
for LTC workers is likely to rise. Responding to increasing
demand will require policies to improve recruitment (e.g.
encouraging more unemployed people to consider training
and working in the LTC sector); improve retention (e.g.
enhancing pay and work conditions); and increase produc-
tivity (e.g. through reorganisation of work processes and
more effective use of new technologies) (Colombo et al.,
2011; European Commission, 2013).
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Definition and comparability
Long-term care workers are defined as paid workers
who provide care at home or in institutions (outside
hospitals). They include qualified nurses and personal
care workers providing assistance with ADL and other
personal support. Personal care workers include dif-
ferent categories of workers who may be called under
different names in different countries. They may have
some recognised qualification or not. Because per-
sonal care workers may not be part of recognised
occupations, it is more difficult to collect comparable
data for this category of LTC workers across countries.
LTC workers also include family members or friends
who are employed under a formal contract either by
the care recipient, an agency, or public and private
care service companies. They exclude nurses working
in administration. The numbers are expressed as
head counts, not full-time equivalent.
The data for Italy exclude workers in semi-residential
long-term care facilities. The data for Japan involve
double-counting (as some workers may work in more
than one home). The data for Ireland refer only to the
public sector. The data for Australia are estimates
drawn from the 2011 National Aged Care Workforce
Census and Survey, and underrepresent the numbers
of people who could be considered LTC workers.HEALTH AT A GLANCE 2015 © OECD 2015204
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Long-term care workersInformation on data for Israel: http://oe.cd/israel-disclaimer
11.17. Long-term care workers per 100 people aged 65 and over, 2013 (or nearest year)
1. In Sweden, Spain and the Slovak Republic, it is not possible to distinguish LTC workers in institutions and at home.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281433
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11.18. Trends in long-term care employment and total employment, selected OECD countries, 2001-13
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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11. AGEING AND LONG-TERM CARELong-term care beds in institutions and hospitalsThe number of beds in long-term care (LTC) institutions
and in LTC departments in hospitals provides a measure of
the resources available for delivering LTC services to indi-
viduals outside of their home.
On average across OECD countries, there were 45 beds in
LTC institutions and five beds in LTC departments in hospi-
tals per 1 000 people aged 65 and over in 2013 (Figure 11.19).
Belgium had the highest number of LTC beds in 2013, with
around 72 beds per 1 000 people aged 65 and over in LTC
institutions. On the other hand, there were fewer than
20 beds per 1 000 people aged 65 and over in LTC institu-
tions or in hospitals in Italy and Poland.
On average across all OECD countries, there has been a slight
increase in the number of LTC beds per 1 000 population
over 65 since 2000 (Figure 11.20). This increase consists
entirely of beds in LTC institutions, with the number of
hospital beds remaining constant on average. However, this
masks a lot of variation. At one extreme, some countries
with well-established, comprehensive LTC systems have
been reducing residential LTC capacity. Sweden has
reduced the number of LTC beds by 2.4 per year per 1 000
population over 65, as part of a drive to move LTC out of
residential facilities and into the community (Colombo et
al., 2011). The Netherlands, Denmark and Norway have also
made significant reductions in the number of beds avail-
able. At the other end of the scale, Korea has seen a mas-
sive increase in capacity since 2000, adding 4.5 beds per
year per 1 000 population over 65, with the increase partic-
ularly marked since the introduction of a public LTC insur-
ance scheme in 2008. In contrast to many other countries, a
significant proportion of the LTC beds added in Korea are in
hospitals. Spain has also increased its number of LTC beds
significantly, although all of the additional beds are in LTC
institutions rather than hospitals.
While most countries allocate very few beds for LTC in hos-
pitals, others still use hospital beds quite extensively for
LTC purposes. Despite recent increases in the number of
beds in LTC institutions in Korea, the majority of LTC beds
are still in hospitals. In Japan many hospital beds are used
for long-term care, but recently the number has been
decreasing. Some European countries, such as Finland,
Hungary and Estonia, still have a significant number of LTC
beds in hospitals, but in general there has been a move
towards replacing hospital beds with institutional facilities,
which are often cheaper and provide a better living envi-
ronment for people with LTC needs. Finland, France and
Iceland have all seen significant increases in LTC beds in
institutions and decreases in hospital LTC beds since 2000 –
although in the case of Iceland, this is partly due to
changes in how beds are categorised.
Providing LTC in institutions can be more efficient than
community care for people with intensive needs, due to
economies of scale and the fact that care workers do not
need to travel to each person separately. However, from the
point of view of public budgets, it often costs more, since
informal carers make less of a contribution and LTC sys-
tems often pick up board and lodging costs as well as care
costs. Moreover, LTC users generally prefer to remain at
home and most countries have taken steps in recent years
to support this preference and promote community care
(see Figure 11.13). However, depending on individual cir-
cumstances, a move to LTC institutions may be the most
appropriate option, for example for people living alone and
requiring round the clock care and supervision (Wiener et
al., 2009) or people living in remote areas with limited
home-care support. It is therefore important that countries
retain an appropriate level of residential LTC capacity, and
that care institutions develop and applymodels of care that
promote dignity and autonomy.
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Definition and comparability
Long-term care institutions refer to nursing and resi-
dential care facilities which provide accommodation
and long-term care as a package. They include spe-
cially designed institutions or hospital-like settings
where the predominant service component is long-
term care for people with moderate to severe functional
restrictions. Beds in adapted living arrangements for
persons who require help while guaranteeing a high
degree of autonomy and self-control are not included.
For international comparisons, they should not
include beds in rehabilitation centers.
However, there are variations in data coverage across
countries. Several countries only include beds in pub-
licly-funded LTC institutions, while others also
include private institutions (both profit and non-for-
profit). Some countries also include beds in treatment
centers for addicted people, psychiatric units of gen-
eral or specialised hospitals, and rehabilitation cen-
ters. Australia does not collect data on the numbers of
beds provided for LTC. Data on Australian LTC beds in
institutions are estimated from aged care database.HEALTH AT A GLANCE 2015 © OECD 2015206
11. AGEING AND LONG-TERM CARE
Long-term care beds in institutions and hospitalsInformation on data for Israel: http://oe.cd/israel-disclaimer
11.19. Long-term care beds in institutions and hospitals, 2013 (or nearest year)
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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11.20. Trends in long-term care beds in institutions and in hospitals, 2000-13 (or nearest year)
Note: The OECD average includes only countries with data for both institutions and hospitals.
1. Australia, Germany, Luxembourg, the Netherlands, Norway and Switzerland do not report any long-term care beds in hospital.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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11. AGEING AND LONG-TERM CARELong-term care expenditureLong-term care (LTC) expenditure has risen over the past
few decades in most OECD countries and is expected to rise
further in the coming years, with population ageing leading
to more people needing ongoing health and social care, ris-
ing incomes leading to higher expectations of quality of life
in old age, the supply of informal care potentially shrinking
and productivity gains difficult to achieve in such a labour-
intensive sector (De La Maisonneuve and Oliveira Martins,
2013).
A significant share of LTC services is funded from public
sources. Total public spending on LTC (including both the
health and social care components) accounted for 1.7%
of GDP on average across OECD countries in 2013
(Figure 11.21). The highest spender was the Netherlands,
where public expenditure on long-term care was two and a
half times greater than the OECD average, at 4.3% of GDP. At
the other end of the scale, the Slovak Republic, Greece,
Estonia, Hungary, the Czech Republic, Poland and Israel
allocated less than 0.5% of their GDP to public provision of
long-term care. This variation partly reflects differences in
population structure, but mostly the development of for-
mal LTC systems, as opposed to more informal arrange-
ments based mainly on care provided by unpaid family
members. Despite the problems of underreporting, pri-
vately-funded LTC expenditure plays a relatively large role
in Switzerland (0.6% of GDP), Germany (0.6%) and Belgium
(0.4%). As a share of total spending on LTC (including pri-
vate and public health and social components), private
spending accounts for more than a third in the United
States (43%), Germany (37%) and Spain (36%). Most private
spending is out-of-pocket, since private LTC insurance does
not play an important role in any country.
The boundaries between health and social LTC spending
are still not fully consistent across countries, with some
reporting particular components of LTC as health care,
while others view it as social spending. The Netherlands,
Sweden, Norway and Denmark spend over 2% of GDP on
the health part of LTC, which is double the OECD average.
Finland has the highest level of public spending on social
LTC, reaching 1.6% of GDP, much higher than the OECD
average of 0.5%. The Netherlands and Japan spend more
than 1% of GDP on social LTC, but this accounts for less
than 0.1% of GDP in Korea, Spain and Luxembourg.
Public spending on LTC has grown rapidly in recent years in
some countries (Figure 11.22). The annual growth rate in
public expenditures on LTC was 4.0% between 2005 and
2013 across OECD countries, which is above the growth in
health care expenditures over the same period. Countries
such as Korea and Portugal have implemented measures to
expand the comprehensiveness of their LTC systems in
recent years and so have among the highest public spend-
ing growth rates since 2005, although spending in both
countries remains relatively low as a share of GDP.
Many OECD countries have expanded the availability of
home care services in order to allow people receiving LTC to
remain more independent and part of their community.
Between 2005 and 2013, the annual growth rate of public
spending on home care matched spending growth for care in
institutional care settings – at 4.3% per year (Figure 11.23).
However, there were significant increases in home care
spending of more than 7% per year in Korea, Estonia, Japan
and France.
Projection scenarios suggest that public resources allocated
to LTC as a share of GDP could double or more by 2060
(Colombo et al., 2011; De La Maisonneuve and Oliveira
Martins, 2013). One of the main challenges in many OECD
countries in the future will be to strike the right balance
between providing appropriate social protection to people
with LTC needs and ensuring that this protection is fiscally
sustainable.
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Definition and comparability
LTC spending comprises both health and social sup-
port services to people with chronic conditions and
disabilities needing care on an on-going basis. Based
on the System of Health Accounts (SHA), the health
component of LTC spending relates to nursing and
personal care services (i.e. assistance with activities of
daily living (ADL)). It covers palliative care and care
provided in LTC institutions or at home. LTC social
expenditure primarily covers assistance with instru-
mental activities of daily living (IADL). Countries’
reporting practices between the health and social
components of LTC spending may differ. In addition,
publicly-funded LTC expenditure is more suitable for
international comparisons as there is significant vari-
ation in the reporting of privately-funded LTC expen-
diture across OECD countries.
Data for the United States refer to institutional care
only, so underestimate the total amount of public
spending on long-term care services.HEALTH AT A GLANCE 2015 © OECD 2015208
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Long-term care expenditureInformation on data for Israel: http://oe.cd/israel-disclaimer
11.21. Long-term care public expenditure (health and social components), as share of GDP, 2013 (or nearest year)
Note: The OECD average only includes the eleven countries that report health and social LTC.
1. Figures for the United States refer only to institutional care.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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Additional information on demographic and economic
context, and health expenditure and financing
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities.The use of such data by the OECD is without prejudice to the status of the Golan Heights,
East Jerusalem and Israeli settlements in theWest Bank under the terms of international law.211
ANNEX A. ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.1. Total population, mid-year, 1970 to 2014
Thousands
1970 1980 1990 2000 2010 2011 2012 2013 2014
Australia 12 507 14 695 17 065 19 028 22 032 22 340 22 724 23 132 23 524
Austria 7 467 7 549 7 678 8 012 8 363 8 392 8 430 8 479 8 503
Belgium 9 656 9 859 9 967 10 251 10 896 11 048 11 128 11 183 11 284
Canada 21 745 24 518 27 691 30 687 34 127 34 484 34 880 35 317 35 540
Chile 9 570 11 174 13 179 15 398 17 094 17 248 17 403 17 557 17 819
Czech Republic 9 858 10 304 10 333 10 255 10 474 10 496 10 511 10 514 10 527
Denmark 4 929 5 123 5 141 5 340 5 548 5 571 5 592 5 615 5 597
Estonia 1 360 1 477 1 569 1 397 1 331 1 327 1 323 1 318 1 316
Finland 4 606 4 780 4 986 5 176 5 363 5 388 5 414 5 439 5 460
France 50 772 53 880 56 709 59 062 62 918 63 223 63 514 63 790 64 360
Germany1 61 098 61 549 63 202 82 212 81 777 81 798 80 426 80 646 80 925
Greece 8 793 9 643 10 157 10 917 11 153 11 103 11 037 10 948 11 381
Hungary 10 338 10 711 10 374 10 211 10 000 9 972 9 920 9 893 9 843
Iceland 204 228 255 281 318 319 321 324 327
Ireland 2 957 3 413 3 514 3 805 4 560 4 577 4 587 4 598 4 610
Israel 2 958 3 878 4 660 6 289 7 624 7 766 7 910 8 057 8 186
Italy 53 822 56 434 56 719 56 942 59 277 59 379 59 540 60 234 60 789
Japan 103 721 117 061 123 613 126 927 128 058 127 799 127 515 127 296 127 083
Korea 32 241 38 124 42 869 47 008 49 410 49 779 50 004 50 220 50 424
Luxembourg 339 364 382 436 507 518 531 543 556
Mexico 50 628 66 737 87 065 100 896 114 256 115 683 117 054 118 395 119 713
Netherlands 13 039 14 150 14 952 15 926 16 615 16 693 16 755 16 804 16 858
New Zealand 2 828 3 170 3 390 3 858 4 366 4 404 4 433 4 472 4 388
Norway 3 876 4 086 4 241 4 491 4 889 4 953 5 019 5 080 5 137
Poland 32 664 35 574 38 111 38 259 38 043 38 063 38 063 38 040 38 037
Portugal 8 680 9 766 9 983 10 290 10 573 10 558 10 515 10 457 10 375
Slovak Republic 4 538 4 980 5 299 5 389 5 391 5 398 5 408 5 413 5 416
Slovenia 1 725 1901 1998 1989 2049 2053 2057 2060 2062
Spain 33 815 37 439 38 850 40 263 46 577 46 743 46 773 46 620 45 943
Sweden 8 043 8 311 8 559 8 872 9 378 9 449 9 519 9 600 9 699
Switzerland 6 181 6 319 6 716 7 184 7 825 7 912 7 997 8 089 8 188
Turkey 35 294 44 522 56 104 67 393 73 142 74 224 75 176 76 148 76 903
United Kingdom 55 663 56 314 57 248 58 893 62 766 63 259 63 700 64 107 64 091
United States 205 052 227 225 249 623 282 162 309 326 311 583 313 874 316 129 318 892
OECD (total) 870 967 965 259 1 052 204 1 155 498 1 236 028 1 243 502 1 249 052 1 256 518 1 264 123
Partners
Brazil 96 078 118 563 146 593 171 280 193 253 194 933 196 526 198 043 199 492
China (People’s Rep.) 814 423 984 122 1 165 429 1 280 429 1 359 822 1 368 440 1 377 065 1 385 567 1 393 784
Colombia .. .. 34 130 40 296 45 510 46 045 46 582 47 121 47 662
Latvia 2 359 2 512 2 663 2 368 2 098 2 060 2 034 2 013 1 994
Lithuania 3 140 3 413 3 698 3 500 3 097 3 028 2 988 2 958 3 163
India 555 064 698 721 868 891 1 042 262 1 205 625 1 221 156 1 236 687 1 252 140 1 267 402
Indonesia 114 080 145 510 178 633 208 939 240 677 243 802 246 864 249 866 252 812
Russian Federation 130 392 138 655 147 969 146 597 142 849 142 961 143 207 143 507 143 787
South Africa 22 502 29 077 36 793 44 846 51 452 51 949 52 386 52 776 53 140
1. Population figures for Germany prior to 1991 refer toWest Germany.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
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ANNEX A. ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.2. Share of the population aged 65 and over, 1970 to 2014
1970 1980 1990 2000 2010 2011 2012 2013 2014
Australia 8.3 9.6 11.1 12.4 13.6 13.8 14.2 14.4 14.7
Austria 14.0 15.5 14.8 15.4 17.6 17.6 17.8 18.0 18.3
Belgium 13.3 14.3 14.8 16.7 17.1 17.0 17.3 17.5 17.7
Canada 7.9 9.4 11.3 12.6 14.2 14.5 14.9 15.2 15.6
Chile 5.0 5.5 6.1 7.2 9.0 9.3 9.5 9.8 10.0
Czech Republic 12.0 13.6 12.5 13.8 15.3 15.6 16.2 16.8 17.3
Denmark 12.1 14.3 15.6 14.8 16.3 16.8 17.3 17.8 18.3
Estonia 11.6 12.5 11.6 14.9 17.5 17.5 17.7 18.1 18.4
Finland 9.0 11.9 13.3 14.8 17.0 17.5 18.1 18.7 19.3
France 12.8 14.0 13.9 16.0 16.8 16.9 17.3 17.7 ..
Germany 13.0 15.5 15.2 16.2 20.7 20.6 21.0 21.1 20.8
Greece 11.1 13.0 13.6 16.4 19.0 19.3 19.8 20.2 19.7
Hungary 11.5 13.5 13.2 15.0 16.6 16.8 16.9 17.2 17.6
Iceland 8.7 9.8 10.5 11.5 12.0 12.3 12.6 12.9 13.1
Ireland 11.1 10.7 11.4 11.1 11.2 11.5 11.9 12.2 12.6
Israel 6.7 8.6 9.1 9.8 9.9 10.0 10.3 10.7 10.9
Italy 10.7 13.1 14.7 18.1 20.4 20.5 20.8 21.0 21.4
Japan 7.1 9.1 12.1 17.4 23.0 23.3 24.1 25.1 26.0
Korea 3.1 3.8 5.1 7.2 11.0 11.4 11.8 12.2 12.7
Luxembourg 12.4 13.6 13.3 14.2 13.8 13.7 13.8 13.8 14.1
Mexico 4.6 4.3 4.3 5.2 6.2 6.3 6.4 6.5 6.7
Netherlands 10.1 11.4 12.7 13.5 15.3 15.5 16.2 16.8 17.3
New Zealand 8.4 9.7 11.2 11.8 13.0 13.3 13.8 14.2 14.8
Norway 12.8 14.6 16.3 15.2 14.8 15.0 15.3 15.6 15.8
Poland 8.2 10.1 9.9 12.1 13.6 13.6 14.0 14.4 14.9
Portugal 9.2 11.1 13.2 16.0 18.3 18.7 19.1 19.4 19.3
Slovak Republic 9.1 10.5 10.2 11.4 12.4 12.6 12.8 13.1 13.5
Slovenia 9.5 11.3 10.6 13.8 16.5 16.5 16.8 17.1 17.5
Spain 9.5 10.8 13.4 16.7 16.8 17.1 17.4 17.7 18.4
Sweden 13.5 16.2 17.7 17.3 18.0 18.4 18.7 19.0 19.3
Switzerland 11.2 13.8 14.5 15.2 16.7 16.8 17.1 17.3 17.5
Turkey 4.3 4.7 4.2 5.3 7.0 7.2 7.3 7.5 7.7
United Kingdom 12.9 14.9 15.7 15.8 16.2 16.4 16.7 17.1 17.6
United States 9.8 11.3 12.5 12.4 13.1 13.3 13.7 14.1 14.5
OECD34 9.8 11.4 12.0 13.4 15.0 15.2 15.5 15.9 16.2
Partners
Brazil 3.5 4.0 4.4 5.4 6.8 7.0 7.2 7.4 7.6
China (People’s Rep.) 4.0 5.1 5.8 6.9 8.4 8.5 8.7 8.9 9.1
Colombia .. .. 5.0 5.7 6.7 6.9 7.0 7.2 7.3
India 3.3 3.6 3.9 4.4 5.1 5.1 5.2 5.3 5.4
Indonesia 3.3 3.6 3.8 4.7 5.0 5.1 5.1 5.2 5.3
Latvia 11.9 13.0 11.8 14.9 18.3 18.5 18.7 18.9 18.7
Lithuania 9.9 11.3 10.8 13.8 17.6 18.0 18.2 18.3 17.2
Russia 7.7 10.2 10.0 12.4 12.8 12.7 12.9 13.0 13.3
South Africa 3.4 3.1 3.2 3.4 5.2 5.3 5.4 5.5 5.6
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888933281523HEALTH AT A GLANCE 2015 © OECD 2015 213
ANNEX A. ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.3. GDP per capita in 2013 and average annual growth rates, 1970 to 2013
GDP per capita in
USD PPP
Average annual growth rate per capita, in real terms
2013 1970-80 1980-90 1990-2000 2000-10 2010-2013
Australia 44 976 1.3 1.5 2.4 1.6 1.3
Austria 45 082 3.5 2.1 2.2 1.1 0.9
Belgium 41 573 3.2 1.9 2.0 0.9 -0.2
Canada 42 839 2.8 1.4 1.8 0.8 1.1
Chile 22 178 .. .. 5.0 3.1 4.5
Czech Republic 28 739 .. .. 0.6 3.0 0.0
Denmark 43 782 1.9 2.0 2.3 0.3 -0.4
Estonia 25 823 .. .. .. 3.9 5.2
Finland 39 869 3.4 2.7 1.9 1.3 -0.5
France 37 671 3.0 2.0 1.7 0.6 0.4
Germany1 43 887 2.8 2.1 1.3 1.0 1.8
Greece 25 854 3.6 0.2 1.7 1.5 -5.9
Hungary 23 336 .. .. .. 2.2 1.0
Iceland 42 035 5.2 1.6 1.6 1.5 1.8
Ireland 45 677 3.2 3.3 6.3 0.6 0.6
Israel 32 502 .. 1.9 2.9 1.4 1.6
Italy 35 075 3.3 2.3 1.6 -0.1 -1.8
Japan 36 236 3.2 4.1 0.9 0.7 1.2
Korea 33 089 7.4 8.6 6.0 3.9 2.4
Luxembourg 91 048 1.9 4.5 3.6 1.1 -0.8
Mexico 16 891 3.7 -0.9 2.0 0.6 1.9
Netherlands 46 162 2.3 1.7 2.5 0.9 -0.6
New Zealand 34 899 1.0 1.2 1.7 1.3 1.5
Norway 65 640 4.1 1.2 4.0 0.9 1.6
Poland 23 985 .. .. 3.7 4.0 2.7
Portugal 27 509 3.5 3.0 2.6 0.5 -2.1
Slovak Republic 26 497 .. .. .. 4.8 1.8
Slovenia 28 859 .. .. 1.9 2.4 -1.2
Spain 33 092 2.6 2.6 2.4 0.7 -1.3
Sweden 44 646 1.6 1.9 1.8 1.5 0.4
Switzerland 56 940 1.0 1.6 0.5 1.0 0.5
Turkey 18 508 .. .. 1.8 3.0 3.6
United Kingdom 38 255 2.0 2.7 2.1 1.1 0.6
United States 53 042 2.1 2.4 2.2 0.7 1.3
OECD 38 123 2.9 2.3 2.4 1.6 0.7
Partners
Brazil 16 192 .. -0.6 0.8 2.4 1.9
China (People's Rep.) 11 661 .. 7.7 9.3 9.9 7.7
Colombia 12 695 .. 1.5 1.0 2.8 4.0
Costa Rica 13 872 .. .. .. 2.6 3.0
India 5 406 .. 3.3 3.5 5.9 4.8
Indonesia 10 023 .. 3.4 2.6 3.9 4.4
Latvia 22 958 .. .. .. 5.2 6.1
Lithuania 25 715 .. .. . 5.4 6.0
Russian Federation 25 247 .. .. .. 5.1 2.8
South Africa 12 553 .. -0.8 -0.1 1.9 1.0
1. Data prior to 1991 refers toWestern Germany.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en. International Monetary Fund, World
Economic Outlook Database, April 2015.
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ANNEX A. ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.4. Health expenditure per capita in 2013, average annual growth rates,
2009 to 2013
Health expenditure
per capita in USD
PPP
Annual growth rate per capita in real terms1
2013 2009/10 2010/11 2011/12 2012/13 2005-13
Australia2 3 866 -0.6 3.8 2.9 .. 2.5
Austria 4 553 1.5 0.5 2.3 -0.3 1.6
Belgium 4 256 -0.8 2.7 0.1 0.1 1.8
Canada 4 351 2.0 -1.3 0.3 0.1 1.9
Chile3 1 606 6.0 5.1 6.1 8.3 5.9
Czech Republic 2 040 -3.1 2.5 -0.1 -0.2 2.5
Denmark 4 553 -1.4 -1.4 0.2 -0.5 1.3
Estonia 1 542 -4.3 0.8 .. 4.4 3.9
Finland 3 442 1.6 2.3 0.8 0.2 1.5
France 4 124 0.8 .. 0.6 1.2 1.2
Germany 4 819 3.0 0.8 2.7 1.7 2.4
Greece 2 366 -10.9 -2.8 -12.2 -2.5 -2.3
Hungary 1 719 4.4 1.9 -2.2 -0.6 -0.8
Iceland 3 677 -6.1 0.1 1.3 3.4 0.0
Ireland2 3 663 -8.7 -4.1 1.1 .. 1.2
Israel 2 428 3.1 2.9 5.7 2.8 2.7
Italy 3 077 1.1 -0.9 -3.0 -3.5 -0.6
Japan 3 713 5.2 4.9 3.0 .. 3.7
Korea 2 275 8.1 4.0 4.4 5.3 7.2
Luxembourg2 4 371 -2.2 -5.8 -5.0 .. -2.1
Mexico 1 048 1.3 -2.1 5.9 2.0 1.7
Netherlands 5 131 2.3 1.7 3.2 -0.3 2.5
New Zealand 3 328 0.4 0.8 2.7 -1.3 2.4
Norway4 5 862 -0.1 2.6 1.9 0.6 1.6
Poland 1 530 .. 2.0 1.2 3.8 5.8
Portugal 2 514 1.1 -4.8 -5.0 -3.2 -0.9
Slovak Republic 2 010 .. -2.4 4.4 0.0 6.7
Slovenia 2 511 0.9 0.1 -0.8 -1.4 1.4
Spain 2 898 -0.1 -0.6 -2.4 -3.8 1.0
Sweden 4 904 -0.3 .. 1.4 2.0 1.4
Switzerland 6 325 .. 2.1 3.5 1.9 1.9
Turkey 941 -1.2 1.2 -0.7 5.4 3.0
United Kingdom 3 235 -1.3 -0.1 0.3 0.6 1.7
United States 8 713 1.9 1.0 1.6 1.5 1.9
OECD 3 453 0.1 0.6 0.8 0.9 2.0
Partners
Brazil5 1 471 7.7 2.4 .. .. 4.2
China (People's Rep.)5 649 6.1 12.3 12.5 .. 12.0
Colombia5 864 -1.0 1.9 7.4 .. 5.9
Costa Rica5 1 380 .. .. .. .. ..
India5 215 .. .. .. .. ..
Indonesia5 293 9.2 3.8 11.8 5.3 6.2
Latvia 1 216 -1.8 -1.8 2.5 3.7 1.7
Lithuania 1 573 -3.7 3.4 1.9 1.3 4.9
Russian Federation 5 1 653 -4.0 1.4 -0.3 1.8 6.3
South Africa5 1 121 1.9 2.0 5.3 1.3 2.1
1. Using national currency units at 2005 GDP price level.
2. Latest year 2012.
3. CPI is used as deflator.
4. GDP deflator refers to Mainland Norway.
5. Including investment.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
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ANNEX A. ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.5. Expenditure on health, percentage of GDP, 1980-2013
1980 1990 2000 2010 2011 2012 2013
Australia 5.8 6.5 7.6 8.5 8.6 8.8 e ..
Austria 7.0 | 7.7 9.2 10.1 9.9 10.1 10.1
Belgium 6.2 7.1 | 8.0 | 9.9 10.1 10.2 10.2 e
Canada 6.6 8.4 8.3 10.6 10.3 10.2 10.2
Chile .. .. 6.4 6.7 6.7 7.0 7.3
Czech Republic .. 3.8 | 5.7 | 6.9 7.0 7.1 7.1
Denmark 8.4 8.0 8.1 | 10.4 10.2 10.4 10.4
Estonia .. .. 5.2 6.1 5.7 | 5.8 6.0
Finland 5.9 7.2 | 6.7 8.2 8.2 8.5 8.6
France 6.7 8.0 | 9.5 | 10.8 | 10.7 10.8 10.9
Germany 8.1 8.0 | 9.8 11.0 10.7 10.8 11.0
Greece .. 6.0 7.2 9.2 e 9.7 e 9.1 e 9.2 e
Hungary .. .. | 6.8 | 7.7 7.6 7.5 7.4
Iceland 5.8 7.4 9.0 8.8 8.6 8.7 8.7
Ireland 7.5 5.6 5.6 8.5 8.0 8.1 ..
Israel 7.0 6.6 6.8 7.0 7.0 7.4 e 7.5 e
Italy .. 7.0 | 7.6 8.9 8.8 8.8 8.8
Japan 6.4 5.8 7.4 9.5 10.0 10.1 10.2 e
Korea 3.5 3.7 4.0 6.5 6.5 6.7 6.9
Luxembourg .. .. 5.9 7.2 6.8 6.6 ..
Mexico .. 4.3 | 4.9 | 6.2 5.9 6.1 6.2
Netherlands 6.6 7.1 | 7.0 | 10.4 10.5 11.0 11.1
New Zealand 5.7 6.7 7.5 | 9.7 e 9.7 e 9.8 e 9.5 e
Norway 5.4 7.1 | 7.7 | 8.9 8.8 8.8 8.9
Poland .. 4.3 5.3 | 6.5 6.3 6.3 6.4
Portugal 4.8 5.5 | 8.3 9.8 9.5 9.3 9.1
Slovak Republic .. .. 5.3 | 7.8 7.5 7.7 7.6
Slovenia .. .. 8.1 | 8.6 8.5 8.7 8.7
Spain 5.0 6.1 | 6.8 | 9.0 9.1 9.0 8.8
Sweden .. 7.3 | 7.4 | 8.5 | 10.6 10.8 11.0
Switzerland 6.6 7.4 | 9.3 | 10.5 10.6 11.0 11.1
Turkey 2.4 2.5 | 4.7 5.3 5.0 5.0 5.1
United Kingdom 5.1 5.1 6.3 8.6 8.5 8.5 8.5
United States 8.2 11.3 12.5 16.4 16.4 16.4 16.4
OECD 6.1 6.5 7.2 8.8 8.8 8.9 8.9
Partners
Brazil1 .. .. 7.0 8.7 8.7 8.9 9.1
China (People's Rep.)1 .. .. 4.6 5.0 5.1 5.4 5.6
Colombia1 .. .. 5.9 6.8 6.5 6.8 6.8
Costa Rica1 .. .. 7.1 9.7 10.2 10.1 9.9
India1 .. .. 4.3 3.8 3.9 3.9 4.0
Indonesia1 .. .. 1.8 2.7 2.7 2.9 2.9
Latvia .. .. .. 6.1 5.6 5.4 5.3
Lithuania .. .. .. 6.8 6.5 6.3 6.1
Russian Federation1 .. .. 5.4 6.9 6.7 6.5 6.5
South Africa1 .. .. 8.3 8.7 8.6 8.9 8.9
| Break in series.
e: Preliminary estimate.
1. Including investment.
Source: OECD Health Statistics 2015, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
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